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3Abstract
Impaired uterine blood flow (UBF) leads to fetal growth restriction (FGR),
one of the most challenging obstetric complications. FGR is associated with
stillbirth, long-term neurological impairment and adult onset cardiovascular
disease; there is no treatment currently available.
Previously, it was shown that sustained local over-expression of Vascular
Endothelial Growth Factor (VEGF) in the uterine arteries (UAs) of pregnant
sheep using an adenoviral vector results in increased UBF as measured by
Doppler sonography, reduced vascular contractility and increased vascular
relaxation 4-7 days after administration. The aim of this thesis is to examine the
long-term effects on UBF, UA vascular reactivity, and the possible mechanism of
action.
Telemetric transit-time flow probes were implanted around the UAs of
mid-gestation pregnant sheep (n=10), and a telemetric blood-pressure sensitive
catheter was inserted in the maternal (n=5) or fetal (n=4) carotid arteries. After
obtaining baseline values for 7 days, we injected adenovirus vectors (5x1011
particles) encoding the VEGF-A165 gene (Ad.VEGF) into one UA, and a reporter
β-galactosidase gene (Ad.LacZ), contra-laterally. UBF and maternal 
haemodynamics were measured daily until term, when the UAs were harvested
and their vascular reactivity studied. There was a significant increase in UBF in
the Ad.VEGF transduced side (36.53% v/s 20.08%, p=0.02), a reduction in UA
contractility but no difference in relaxation. A significantly greater number of
adventitial blood vessels were observed in the Ad.VEGF treated UA. There were
no significant changes in maternal or fetal blood pressure post-injection. Similar
effects were observed with injection of an adenovirus encoding another member
of the VEGF gene family, VEGF-DΔNΔC (n=5).
4Endothelial cells (ECs) were isolated from the UAs of control mid-
gestation pregnant sheep, cultured and infected with Ad.VEGF or Ad.LacZ
vector. Protein extracted from UAECs infected ex vivo was assayed for eNOS and
phosphorylated eNOS (Ser1177) levels by Western blotting. eNOS and phospho-
eNOS levels increased with rising Ad.VEGF concentrations in UAECs; Ad.LacZ
vector transduction had no effect.
Local over-expression of VEGF effects a long-term increase in UBF by
upregulation of eNOS, with neovascularization of the adventitia and reduced UA
contractility. These changes may benefit pregnancies complicated by severe FGR.
With clinical translation in mind, the last section of this thesis describes the
optimization of a technique of gene targeting to the utero-placental circulation of
growth-restricted guinea pigs, using a thermo-sensitive pluronic gel. Having
optimized this technique, VEGF over-expression in the uteroplacental circulation
is now being tested in this animal model of FGR.
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Chapter 1
Introduction
Fetal growth restriction (FGR) is defined as a condition in which the fetus
does not achieve its genetically determined growth potential (Figure 1.1). The
term is often used inter-changeably with small for gestational age (SGA) infants,
though the two are different and they describe different conditions. SGA infants
fall below the 10th percentile for a given gestational age. Approximately 50 to
70% of SGA babies are growth restricted. A substantial number however are not
growth restricted, but are just small for gestational age when compared with the
general population. Customised centile charts that take into consideration the
genetic background of the neonate are very helpful in distinguishing SGA from
FGR. Using the mother’s height, weight, ethnicity and the sex of the neonate, the
birthweight centile is adjusted to provide a more accurate centile (Gardosi J et al.,
1992;McCowan LM et al., 2005). A typical birthweight centile chart commonly
found in obstetric wards is represented in Figure 1.2. It is important to distinguish
SGA from FGR, since SGA babies that are not growth restricted thrive and they
have a lower morbidity and mortality when compared to their FGR counterparts .
FGR is a major problem for obstetricians, neonatologists, parents and
society in general. It afflicts up to 7% of all pregnancies in the UK, and is severe
in 1:500 cases (Romo A et al., 2009). FGR fetuses have higher incidences of
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morbidity and mortality, and an increased pre-disposition to cardiovascular
disorders and neurological handicaps (Bernstein IM et al., 2000;Romo A et al.,
2009). The causes of FGR are manifold, some of which are described below.
Figure 1.1 – Picture of a neonate that is appropriately growth for gestational
age (right) and another neonate that suffered fetal growth restriction (FGR,
left).
The FGR neonate is smaller, with less fat deposition, and with dry wrinkly skin.Both these babies
were born at the same gestational age. (Picture courtesy: Dr. A.L. David, UCL).
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Figure 1.2 – A centile chart representing birthweight
These charts indicate the birthweight of a child in comparison with children of the same age and
maturity who have shown optimum growth. The centile lines on the chart show the expected range
of weights; each represents the proportion of children to be expected below that line. The points
marked on the chart above are representative of a child that has grown (A) appropriately for its
gestational age; (B) small for gestational age; or (C) developed severe fetal growth restriction.
(Picture obtained from UK-WHO growth charts:early years; Royal College of Paediatrics and
Child Health)
The FGR infant at birth may be symmetrically or asymmetrically small.
The former are characterized by reduced weight, length and head circumference at
birth. The etiological factors associated with symmetric growth restriction include
intra-uterine infections, chromosomal abnormalities and intra-uterine toxins such
as alcohol and smoking. The asymmetrically growth-restricted infants, seen most
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commonly in instances of utero-placental vascular insufficiency, show sparing of
head growth relative to weight and length.
1.1 Maternal Factors resulting in FGR
1.1.1 Maternal Hypertensive Conditions
Hypertensive disorders are present in 30-40% of pregnancies characterized
by FGR. These disorders include pre-eclampsia, chronic hypertension with or
without superimposed pre-eclampsia, autoimmune disorders, chronic severe
nephropathy, and pregestational diabetes complicated with vasculopathy. The
underlying cause of restricted fetal growth is believed to be constriction of the
utero-placental blood vessels, thereby limiting perfusion. It has been observed that
the worse the severity of pre-eclampsia and the earlier the onset of the disease, the
more growth-restricted is the fetus (Maulik D, 2006a). According to one report,
the decline in birth weight was 5% in mild pre-eclampsia, 12% with severe
disease and 23% with early onset disease (Long PA et al., 1980). Unfortunately,
maternal anti-hypertensive therapy does not improve fetal growth and some
commonly prescribed β-blockers like atenolol may even exacerbate the condition. 
This is because the fetus is dependent on a higher pressure circulation and
reducing it can precipitate hypoxia. This is sometimes seen in clinical practice
when women with a very high BP are given a large dose of antihypertensive
drugs, which results in fetal distress.
1.1.2 Maternal Autoimmune Disorders
Maternal autoimmune disorders, especially those that involve the vascular
system, are associated with poor perinatal outcomes. Pregnant women with
antiphospholipid (aPL) antibody syndrome have increased incidences of
idiopathic recurrent fetal loss. For pregnant women with systematic lupus
erythematosus, the risk of miscarriage is about 40% when aPL antibodies are
positive compared to a risk of 15% when they are absent (McNeil HP et al.,
1991). The presence of aPL antibodies is also correlated with adverse fetal
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growth. In a prospective study, 24% of fetuses with birth weight below the 10th
centile had positive aPL antibodies (Polzin WJ et al., 1991). In another
prospective study, the relative risk of FGR with positive aPL antibodies was
found to be significantly enhanced (Yasuda M et al., 1995). The correlation
between positive aPL antibodies and the onset of FGR is not very well
understood, and many authors have put forth different theories in an attempt to
provide an explanation. One such study has reported that aPL antibodies suppress
the production of prostacyclins in murine aortic endothelial cells, and may induce
the production of thromboxane A2, a potent vasoconstrictor and inducer of platelet
aggregation, which in turn could lead to the formation of thrombi (Carreras LO et
al., 1981). It is also possible that aPL antibodies may exert a direct toxic effect on
the trophoblasts, independent of any thrombus formation (Yasuda M et al., 1995);
or may disturb the intricate signaling transduction processes that are essential for
the maintenance of normal pregnancy (Gleicher N et al., 1992).
1.1.3 Maternal Lifestyle
Maternal use of various recreational agents and narcotic substances is
associated with FGR. For instance, maternal cigarette smoking leads to decreased
fetal weight (Kramer MS, 1987). The effect is primarily mediated by carbon
monoxide generation, which in turn reduces fetal oxygenation. In addition, the
vasoconstrictive properties of nicotine also have a detrimental effect on utero-
placental perfusion. In a prospective cohort study, it was found that there was an
average birth weight reduction of 6% when smoking continued throughout
gestation compared with only 1.7% when smoking was stopped after the first
trimester. The effect is dose-dependent (Cliver SP et al., 1995).
Use of cocaine during pregnancy has been associated with significant
maternal and fetal risks, including maternal stroke, hypertension, placental
abruption, fetal brain injury and stillbirth. A multicentre study conducted by the
National Institute of Child Health and Human Development Neonatal Research
Network has demonstrated that exposure to cocaine in utero can retard fetal
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growth symmetrically (Bada HS et al., 2002). The growth parameters most
affected included birth weight, body length and head circumference.
Alcohol consumption in pregnancy has been associated with fetal alcohol
syndrome or fetal alcohol spectrum disorders. Characterized by dysmorphic
features and retardation of mental growth, FGR remains a central feature of these
conditions (Sokol RJ et al., 2003). Current scientific opinion suggests that there is
no conclusive evidence that very small amounts of alcohol consumption during
pregnancy are harmful to the mother and baby. At the same time, there is
uncertainty on the threshold of safe alcohol consumption during this period for
pregnant women. For this reason, the Royal College of Obstetricians and
Gynecologists (RCOG) has consistently stated that women should avoid drinking
excessive amounts of alcohol when pregnant but there is no evidence that
drinking 1 to 2 units once or twice a week is harmful
(http://www.rcog.org.uk/what-we-do/campaigning-and-opinions/statement/rcog-
statement-nice-guidelines-alcohol-consumption-dur)
1.1.4 Therapeutic Agents
Some commonly used therapeutic agents have been implicated in causing
FGR. These include antineoplastic medication, anti-convulsants such as
phenytoin, β-blockers (particularly atenolol) and steroids (Maulik D, 2006a). The 
underlying cause of the growth restriction associated with many of these drugs is
unclear. Chemotherapeutic agents are known to inhibit rapidly dividing cells,
which are richly abundant in the placenta and fetus and thus result in FGR. There
is strong evidence that administration of a single course of steroids before 34
weeks of gestation induces fetal lung maturity in preterm labor. However, a
number of animal and human studies suggest that administration of multiple doses
leads to retardation of fetal somatic growth and neurodevelopmental handicap
(Spinillo A et al., 2004).
1.1.5 Malnutrition
Maternal malnutrition characterized by an extremely low caloric intake
can limit the supply of substrates to the developing fetus, and hence retard its
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growth. The effect may span generations. During the harsh Dutch famine of 1944-
1945, the average daily caloric intake was below 1500 kcal for many women
during the third trimester. This was associated with significant reductions in fetal
weight and size, as well as a possible intergenerational effect resulting in low fetal
and neonatal weights (Stein Z and Susser M, 1975).
1.1.6 Environmental Pollution
Even relatively low concentrations of gaseous pollutants such as sulphur
dioxide, nitrogen dioxide, carbon monoxide and ozone can have profound effects
on retarding fetal growth (Liu S et al., 2003). One of the recent disasters which
provided evidence for effects of environmental pollution on fetal growth has been
the World Trade Centre (WTC) disaster. The WTC dust comprised pulverized
cement, glass fibers, asbestos, lead, polycyclic aromatic hydrocarbons,
polychlorinated biphenyls, polychlorinated furans and dioxins. A follow-up study
of 182 pregnant women who were within 1 mile of the disaster on September 11,
2001 revealed a two-fold increase in infants whose growth had been compromised
(Landrigan PJ et al., 2004;Perera FP et al., 2005).
1.1.7 Uterine and placental vascular insufficiency
Utero-placental vascular insufficiency is one of the most common causes
of FGR. This thesis deals with FGR caused only by utero-placental vascular
insufficiency. Hence, it has been discussed in greater detail in a separate section
(1.3).
1.2 Fetal Factors resulting in FGR
1.2.1 Aneuploidy
Chromosomal abnormalities are strongly associated with FGR, which is
commonly symmetrical and early onset. Traditionally, about 7% of FGR cases
have been attributed to aneuploidy (abnormal number of chromosomes).
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Approximately, 90% of the fetuses with trisomy 18 will develop FGR compared
with only 30% of those with trisomy 21 (Snijders RJ et al., 1993b). Fetuses with
aneuploidy have an increased incidence of multiple malformations and stillbirth
(Maulik D, 2006a). A majority of the triploid fetuses are lost during the first
trimester because of spontaneous abortions. The few that survive into the second
trimester are characterized by profound anatomical defects and severe
asymmetrical FGR (Doshi N et al., 1983).
1.2.2 Genomic Imprinting and Uniparental Disomy
Uniparental Disomy (UPD) is the inheritance of both homologs of a
chromosome from a single parent. This condition, even though quite rare, has
been implicated in FGR, the most commonly found example being maternal UPD
of chromosome 16 (Maulik D, 2006a) and chromosome 14 (Sanlaville D et al.,
2000).
Genomic imprinting is a developmental process which gives rise to
differential expression of maternal or paternal genes or chromosomal regions
because of the suppressed expression of either the maternal or paternal alleles,
although both are present (Wutz A and Barlow DP, 1998). There are as many as
100 genes that are imprinted in mammals, and many of these are involved in fetal
growth. According to the genetic conflict theory, paternally expressed imprinted
genes are believed to enhance the availability of nutrients to the developing fetus,
and hence enhance fetal growth. On the contrary, maternally expressed imprinted
genes have a tendency towards conservation of maternal nutritional resources
(Haig D, 1993;Haig D, 1997). This concept finds support in gene knockout
animal models of paternally or maternally expressed growth factors such as the
insulin-like growth factor. At the insulin-like growth factor 2 (Igf2) locus, only
the paternal allele is expressed, and it produces a polypeptide (IGF-2) that
promotes the transfer of substrates from the mother to the fetus. At the insulin-like
growth factor 2 receptor (Igf2r) locus, the pattern of imprinting is reversed. The
paternal allele is silent while the maternal allele encodes for a receptor that
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degrades the IGF-2 peptide. Igf2r binds to and internalizes IGF-2, and transports
it to intra-cellular compartments (early endosomes and lysosomes) where it is
degraded. Knockout experiments have proven that normal fetal development
depends on a balance between these two reciprocally imprinted genes; knockout
of the Igf2 alleles brings about a 40% reduction in birthweight (DeChiara TM et
al., 1990), whereas knockout of the Igf2r gene in fetuses results in offspring that
are oversized and ultimately nonviable (Lau MM et al., 1994).
It may appear paradoxical for a maternal allele to limit the supply of
substrates to the fetus. A female mouse maximizes her reproductive success by
producing a number of litters. If she invests too much of her resources in her
current fetuses, she risks compromising her prospects for future progeny.
However, because there can be different paternity amongst litters, paternal interest
is best served by promoting nutrient transfer beyond what would be optimum for
the mother.
Such genetic trends have evolved in humans as well, and they play an
important role in regulating fetal development. The dominance of the maternally
imprinted genes over paternally imprinted genes restricts fetal growth in utero
(Haig D, 1993;Hitchins MP and Moore GE, 2002), as seen in cases of Prader-
Willi syndrome, where there is loss of function of imprinted genes on the paternal
allele of region 15q11-13 (Holm VA et al., 1993).
1.2.3 Fetal Malformations
The Centre for Disease Control and Prevention (CDC) found that
approximately 22% of the infants with birth defects are growth-restricted (Khoury
MJ et al., 1988). Some of the fetal malformations that are commonly associated
with FGR or SGA infants include cardiac defects (tetralogy of Fallot, endocardial
cushion defect, hypoplastic left heart, pulmonary stenosis, and ventricular septal
defects), anencephaly and abdominal wall defects. A single umbilical artery
(instead of the normally two present) is also associated with FGR. Thus, a
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defective organ system/circulation appeared to be restricting the normal growth of
the fetus.
1.2.4 Perinatal infections
Protozoan and viral infections are also known to commonly cause FGR.
The viral pathogens that are commonly implicated in FGR include rubella,
cytomegalovirus, human immunodeficiency virus, and varicella-zoster (Maulik D,
2006a). Protozoan infections that have been associated with FGR include malaria
and toxoplasmosis. In Sub-Saharan Africa, about 40% of FGR cases are
attributable to pregnancy-associated malaria (PAM). The malaria parasite,
Plasmodium falciparum, expresses proteins called P. falciparum erythrocyte
membrane protein-1 (PfEMP-1) on the surface of infected red blood cells (RBCs).
These proteins cause the infected RBCs to sequester and block small blood
vessels in the placenta, and hence limit the supply of substrates and oxygen to the
growing fetus. The fact that PfEMP-1 is subject to a high level of antigenic
variation has made the development of a vaccine for PAM difficult (Bir N et al.,
2006).
1.2.5 Preterm birth
There is a strong association between spontaneous preterm birth and FGR
(Tamura RK et al., 1984). In a case controlled study, it was determined that 30%
of the fetuses born spontaneously before 35 weeks were growth-restricted
compared to only 4.5% of those born at 37 weeks or later (Bukowski R et al.,
2001). The onset of growth restriction not only precedes but also signals the
premature onset of parturition, suggesting an adaptive response to in utero stress
(Gardosi JO, 2005). Preterm delivery can also be iatrogenic, when doctors
intervene to deliver a fetus prematurely in an attempt to prevent irreparable
damage to the fetus or even stillbirth if the pregnancy were allowed to continue.
This generally occurs when FGR is suspected and there is a high risk of intra-
uterine demise.
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1.3 Utero-placental vascular insufficiency
The provision of adequate nutrients and oxygen to the conceptus is a basic
requirement for normal growth and development. The maternal vascular tree is
able to provide all substrates and oxygen essential for the development of the
fetus. During pregnancy uterine perfusion increases dramatically from 50ml/min
in week 10 of human pregnancy to as much as 1300 ml/min at term as a result of
increased maternal cardiac output and trophoblast-driven modification of the
uterine spiral arteries (Lang U et al., 2003). Failure of this normal physiological
process leads to preeclampsia (PET) and fetal growth restriction (FGR). The re-
modelling of human utero-placental blood vessels in pregnancy is described
below.
1.3.1 Development of human uteroplacental vessels
During the first half of human pregnancy, the uteroplacental (spiral)
arteries undergo a series of pregnancy-specific changes to create the
uteroplacental circulation, which include: (i) apparent replacement of endothelium
and medial smooth muscle cells by invasive trophoblast; (ii) loss of elasticity; (iii)
dilation to wide, non-contractile vessels; and (iv) loss of vasomotor control
(Kaufmann P et al., 2003).
This remodelling of the spiral arteries reduces maternal blood flow
resistance and increases uteroplacental perfusion to meet the requirements of the
fetus (Figure 1.3). The loss of contractility and maternal vasomotor control
ensures maternal blood supply to the placenta, irrespective of maternal attempts to
regulate the blood distribution within the body. Local loss of vasomotor control
also allows the fetus to gain control over the maternal blood flow resistance and
blood flow distribution within the intervillous space. The extent and depth of
trophoblast invasion is less in FGR compared with normal pregnancy which
results in an inadequate re-modelling of the uterine spiral arteries (Figure 1.3).
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This is the primary cause of uteroplacental insufficiency and the adverse fetal
outcomes that are seen in affected pregnancies.
Figure 1.3: A comparison between non-pregnant (uninvaded), normal
pregnant and pathological (FGR) pregnant uterine arteries.
The extent and depth of trophoblast invasion is less in pathological compared with normal
pregnancy, with inadequate re-modelling of the myometrial spiral arteries in FGR. This results in
reduced blood flow to the feto-placental unit, which manifests as fetal growth restriction. (Moffett-
King A, 2002).
1.3.2 Uterine blood flow in normal human pregnancies
As discussed above, in normal human pregnancy the action of invasive
trophoblasts on the maternal spiral arteries leads to the development of a low
resistance uteroplacental circulation which facilitates the marked increase in
blood flow seen in these vessels at term. Thaler et al evaluated low risk
pregnancies by transvaginal duplex Doppler ultrasound (n = 24), and compared
them to non-pregnant women (n = 27) (Thaler I et al., 1990). A steady increase in
volume flow rate in the left ascending uterine artery from a mean of 94.5 mL/min
before pregnancy to 342 mL/min in late gestation was observed, reflecting a 3.5-
Non-pregnant PregnantFGR
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fold increase. The mean diameter of the uterine artery in the non-pregnant state
was 1.6 mm, and this increased to 3.7 mm towards term.
1.3.3 Uterine blood flow in pregnancies affected by
uteroplacental insufficiency
Studies have shown that FGR is associated with abnormalities of the
uteroplacental, umbilical and fetal circulations (Divon MY and Hsu HW, 1992).
It is useful to look at some of the differences of two types of abnormal
pregnancies, FGR and PET, which are proposed to be a result of uteroplacental
insufficiency.
1.3.3.1 Fetal growth restriction due to uteroplacental
insufficiency
Normal fetal growth is determined by the genetically predetermined
growth potential modulated by maternal, fetal, placental, and external factors.
FGR is a failure to reach this potential and is clinically suspected if sonographic
estimates of fetal weight, size, or symmetry are abnormal. FGR is usually
diagnosed when the fetus is at or below the tenth percentile for their estimated
fetal weight (EFW) at a given gestational age. Cases of FGR are often considered
to be severe when the EFW falls below the fifth percentile. Such examples are
often first detected at the 20-week fetal ultrasound scan and are associated with
asymmetric growth restriction.
In cases of FGR or severe FGR (SFGR) due to uteroplacental
insufficiency there is defective trophoblast invasion and an inadequate
development of maternal placentation. The uteroplacental circulation remains in
a state of high resistance, which causes generalised endothelial cell injury
(Papageorghiou AT et al., 2004). The local production of vasoactive substances
such as prostaglandins, endothelins and nitric oxide is impaired and this leads to
vasospasm in the small arterioles of the uteroplacental compartments as well as of
other systemic vascular beds. Consequently there is an abnormal increase in the
systemic vasopressor responses and this in turn may cause hypertension by
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impairing renal function and increasing total peripheral resistance. Activated or
injured endothelial cells lose their ability to maintain vascular integrity, which
leads to an increase in capillary permeability, platelet thrombosis and increased
vascular tone. Subsequent damage to the vascular wall promotes an atherosis-like
process in the small arteries. The result of these processes is a local ischemia.
High resistance notched uterine artery Doppler waveforms have been
observed in human pregnancies that go on to develop either PET or severe FGR
(Papageorghiou AT et al., 2004). Konje JC et al quantified the reduction in
uterine blood flow (UBF) in pregnancies complicated by FGR when compared to
normal pregnancy: 12.5% reduction was observed at 20 weeks and 36.7% from 24
weeks of gestation until delivery. In absolute terms, the UBF in normal
pregnancies at 20 weeks gestation was 328+159 ml/min v/s 287+117 ml/min in
FGR pregnancies. At 38 weeks, the corresponding values were 830+284 ml/min
and 534+332 ml/min, respectively (Konje JC et al., 2003).
Sheep studies have demonstrated an almost linear positive correlation
between UBF and fetal size (Lang U et al., 2003), suggesting that this may be a
useful non-clinical model to evaluate the efficacy of new treatments for FGR.
Gelfoam embolisation of the proximal uterine arteries in sheep reduce UBF by
50% results in FGR and produces high resistance notched uterine artery Doppler
waveforms similar to those seen in human FGR pregnancy (Ochi H et al., 1998).
1.3.3.2 Pre-eclampsia
Pre-eclampsia (PET) is a major cause of maternal mortality (15 – 20% in
developing countries) and morbidities (acute and long-term), perinatal death and
pre-term birth (Sibai B et al., 2005). It is characterised by an abnormal response
to placentation that is associated with increased systemic vascular resistance,
enhanced platelet aggregation, activation of the coagulation system and
endothelial dysfunction. Typically after the uterus has been delivered of the fetus
and placenta, the disease resolves. It is believed that one of the underlying causes
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of PET is associated with defects in extravillous trophoblast invasion and failure
to establish the maternal circulation correctly, resulting in uteroplacental hypoxia.
PET may manifest as early onset or late onset disease. Early onset disease,
before 33 weeks gestation is generally associated with FGR and adverse
pregnancy outcomes, including increased incidence of maternal and fetal
morbidity and mortality. In contrast, maternal and perinatal outcomes are
generally favourable in women with mild PET developing beyond 36 weeks
gestation. It is believed that the pathophysiology of the disorder leading to early
onset disease may differ from that of late onset disease (Sibai B et al.,
2005;Steegers EA et al., 2010).
The traditional diagnosis of PET, based on new onset of both hypertension
and proteinuria after 20 weeks gestation, is applicable to most women.
Hypertension is defined as a blood pressure of at least 140 mmHg (systolic) or 90
mmHg (diastolic) on at least two separate occasions 4-6 hours apart in previously
normotensive women. Proteinuria is defined as excretion of at least 300mg of
protein every 24 hours. However, in some women, there may only be gestational
hypertension without proteinuria, which is associated with a high rate of maternal
and fetal morbidity. Additionally, both hypertension and proteinuria may be
absent in 10-15% of women who develop haemolysis, elevated liver enzymes,
and low platelet counts (HELLP syndrome) and in 38% of women who develop
eclampsia. Both of these are associated with significantly higher rates of adverse
pregnancy outcomes than mild PET (Sibai BM, 2004;Douglas KA and Redman
CW, 1994).
1.3.3.3 Histological and morphological differences of human
PET and FGR
The underlying abnormality in FGR and PET is a failure of oxygen
transport from the intervillous space to the umbilical vein. Hypoxia can be present
at any of three stages across the placenta: pre-placental, uteroplacental and post-
45
placental (Kingdom JC and Kaufmann P, 1997). In each case the placentae show
very different histological structures.
Pre-placental hypoxia occurs in the presence of maternal anaemia or
pregnancy at high altitude. The terminal placental villi are characterized by
increased capillary volume fraction and increased capillary branching. The
amount and proliferation of villous cytotrophoblasts is also increased. Because the
hypoxia in this case is present before the placenta, it affects the entire organ
resulting in uniform distribution of histological features (Kingdom JC and
Kaufmann P, 1997). Concomitant with an increase in villous capillary density,
there is also an increased secretion of vascular endothelial growth factor (VEGF)
and erythropoietin (Zamudio S et al., 2006;Zamudio S et al., 2007). This is
followed by reprogramming of the metabolic machinery, to augment energy
supply by anaerobic pathways. In the placenta, this occurs by an increase in
glucose consumption and lactate production, along with upregulation of various
key elements of the glycolytic pathway (Illsley NP et al., 1984). Another
characterisitic response triggered by hypoxia is termed “demand reduction”,
which consists of attenuation of energy-expensive processes not essential for
survival, such as fetal movements (Hooper SB, 1995). At the tissue level, this is
manifested as inhibition of transcription and translation and related processes
dependent on protein synthesis, such as cell growth and proliferation (Hochachka
PW and Lutz PL, 2001). Although the mechanisms of demand reduction are not
yet understood in the placenta, they are believed to result in the development of
pathological pregnancies, as seen in FGR and PET, where placental and fetal
growth are compromised in response to a low O2 environment (Illsley NP et al.,
2010).
Uteroplacental hypoxia occurs where normal oxygenated maternal blood
has a restricted access to the uteroplacental circulation. This is seen in cases of
utero-placental vascular insufficiency. Placentae derived from FGR pregnancies
with abnormal but still preserved end-diastolic flow (PEDF) in the umbilical
arteries, irrespective of whether complicated by PET or not, are classified under
this category, and show a similar histological structure to that described for pre-
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placental hypoxia (Kingdom JC and Kaufmann P, 1997). Placentae from this
group display villi with elevated capillary volume fractions, amounts of
cytotrophoblast and levels of syncytiotrophoblast knot formation. The capillaries
grow by branching angiogenesis and vascular impedance is reduced. Neonates of
such pregnancies are generally dehydrated and have elevated hematocrits, the
placentae are thin, appear dark on sectioning and the villi are small and composed
primarily of capillaries.
Post-placental hypoxia is where maternal oxygenated blood enters the
intervillous space at a normal or reduced rate, but there is a major defect in
fetoplacental perfusion (Kingdom JC and Kaufmann P, 1997). This form of
hypoxia is seen in cases of severe FGR characterized by absent or reversed end
diastolic flow (AREDF). The histopathological findings are homogeneous, but
dissimilar to those observed in specimens from pre-placental or utero-placental
hypoxia (Kingdom JC and Kaufmann P, 1997). The most characterisitic features
are those of “terminal villi deficiency” where the villous placenta fails to transfer
oxygen to the fetus despite normally oxygenated blood entering the intervillous
space (Mayhew TM et al., 2003;Macara L et al., 1996;Kingdom J et al., 2000).
Mayhew TM et al (2003) quantified differences in placental morphology
in PET, FGR, and PET with FGR pregnancies with particular focus on the
dimensions and composition of peripheral (intermediate and terminal) villi.
Placentae were sampled randomly. Fetal weights were reduced in all pregnancies
complicated by PET, with or without FGR. However, only pregnancies
complicated by FGR had a significantly smaller placenta. PET was not associated
with any major effects on placental morphology (except for trophoblast
thickness). In contrast, FGR was associated with placentae with reduced volumes
of intervillous space as well as all types of villi (stem, intermediate and terminal)
The impedance of growth of peripheral villi affected all tissues (trophoblast,
stroma, capillaries) and was accompanied by smaller exchange areas and a thicker
trophoblastic epithelium (Mayhew TM et al., 2003).
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In another study, it was reported that that in cases of PET not accompanied
by FGR, the placentae were morphologically very similar to control placentae in
the volumes of parenchymal components, number of nuclei and the exchange
areas of villi and capillaries (Teasdale F, 1985). This contrasts with the data from
cases of PET accompanied with FGR (Teasdale F, 1987). Placentae were
evaluated in this study: five from patients who suffered from severe PET and
FGR and five age-matched controls. There was a decrease observed in the
volumes of villi and intervillous space in the PET/FGR group. These findings
were similar to alterations, which are observed with FGR alone, suggesting the
main effects are due to FGR alone and not to interactions between PET and FGR.
Similar findings have been reported following comparison of twenty FGR
placentae (ten at 20 – 22 weeks and ten at 23 – 25 weeks) with twenty aged
matched controls. Placental and fetal weights in the FGR groups were smaller
than in the controls. Poor vascularisation and immaturity of the villous tree were
found in many FGR cases. The thickness of the placental membranes was
increased from 10.74 ± 0.09 mm at 20 – 22 weeks and 10.92 ± 0.09 mm at 23-25
weeks in control groups, to 11.62 ± 0.1 mm and 11.87 ± 0.12 mm, respectively
(Reshetnikova O et al., 2002).
Macara et al, (1996) evaluated the villous ultrastructure and
immunohistochemistry in FGR pregnancies (n = 16, with absent end-diastolic
flow velocity in the umbilical artery) and age-matched controls (n = 16). They
found that the terminal villi from FGR cases were smaller in diameter, and had a
reduced villous tissue per placental area (density of all classes of villi). This
suggests that the cross-sectional area of terminal villi and the degree of
vascularisation are reduced in FGR pregnancies with reduced umbilical artery
perfusion. The number of cytotrophoblast cells, identified by the presence of
nuclei, was reduced in the FGR group. These cells proliferate and fuse to form
the syncytiotrophoblast layer, which might indicate a reduction in the turnover of
the trophoblast layer in FGR.
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In summary, differences between PET, FGR, and PET with FGR can be
clearly seen when histological and morphological evaluations are performed. In
general, the surface area of the syncytiotrophoblast is reduced whereas the
thickness of the exchange barrier formed by the trophoblast and fetal capillary
endothelium is increased in FGR (Sibley CP et al., 2005;Mayhew TM et al.,
2003).
1.4 Diagnosis and Management of pregnancies
complicated by FGR
The most important step in management of pregnancies complicated by
FGR is an accurate diagnosis of the condition, along with the underlying
etiological factor. This is often quite difficult, and easy to get wrong.
FGR caused by utero-placental insufficiency can be detected at the 24
week fetal ultrasound scan as a notched uterine artery waveform, the notch being
indicative of increased resistance to the flow of blood in the uterine arteries
(Figure 1.4). An increased pulsatility index (PI) and resistance index (RI) at this
time point can also indicate uteroplacental circulatory resistance. Even at the 11-
14 week scan, a notched uterine artery waveform and a raised PI can indicate that
a pregnancy is at risk of developing FGR, although the sensitivity and specificity
of these parameters are too poor to support their use in clinical risk prediction.
Ultrasonography is also useful in identifying the restriction of body weight and
length of long bones, with a relative “head sparing” effect. There may be reduced
amniotic fluid around the fetus reflecting poor renal perfusion. (Ott WJ,
2006;Miller J et al., 2008)
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Figure 1.4 – Notched uterine artery waveform in pregnancies characterized
by FGR.
The notch is indicative of high resistance to the flow of blood in the myometrial spiral arteries.
EDF = End diastolic flow. (Picture courtesy: Dr. A.L. David, UCL)
Severely affected FGR fetuses weighing around 500 g or less have a high
morbidity, and over 50% die postnatally. If fetal growth ceases completely in
mid-pregnancy and the fetal weight remains below 500 g, the only management
options currently available to parents are (i) to terminate the pregnancy, (ii) to
await inevitable fetal death, or, (iii) to deliver the fetus by caesarean section if it
weighs at least 450 - 500 g, in the knowledge that there is a high chance of
postnatal death or disability. Small improvements in fetal growth and gestational
age at delivery are associated with major improvements in survival and morbidity.
A multi-centre observational study of severely growth restricted neonates showed
a drop in major morbidity from 56.6% to 10.5% as gestational age advanced from
24 weeks to 32 weeks, and median survival gained per day in utero was 2%
(range 1.1 – 2.6) between 24 and 27 weeks of gestation (Baschat AA et al., 2007).
The principal aim of fetal surveillance is the timely recognition of fetal
stress and compromise so that delivery can be timed appropriately to prevent
irreparable fetal damage or even demise. The risks of early delivery to the neonate
need to be carefully balanced with the risks to the fetus of continuing intrauterine
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life. Faced with the stresses of a compromised supply of nutrients and oxygen, the
fetus mobilizes a number of adaptive responses that include preferential fetal
growth over placental growth, deceleration of the fetal growth rate, reduction in
fetal movements to conserve energy, increased number of red blood cells to
improve the oxygen carrying capacity of fetal blood, and blood flow redistribution
to vital organs (like the brain and heart) at the expense of less critical tissues and
organs. Fetal surveillance tests aim to reflect this sequence of events and to
deliver the fetus before irreparable damage has been done.
The most important fetal surveillance tests include Doppler sonography of
the umbilical arteries and other fetal vascular beds, the biophysical profile (BPP),
sonographic estimation of amniotic fluid volume, and the cardiotocograph (CTG)
(Maulik D, 2006b).
Numerous studies have demonstrated the value of umbilical artery
Doppler indices in predicting adverse outcomes in pregnancies complicated by
FGR (Maulik D, 2006b). The absence of end-diastolic flow (AEDF) in the
umbilical artery waveform is known to be associated with high incidences of
morbidity and mortality (Karsdorp VH et al., 1994). Reversal of end-diastolic
flow (REDF) is associated with an even worse prognosis. When used in a well
defined high-risk pregnancy and combined with an appropriate plan of
management, umbilical artery dopplers have been shown to be clinically useful as
a predictive test for fetal/neonatal compromise (Morris RK et al., 2011)
The CTG is a non-invasive test during which the heartbeat of the fetus is
measured while it is at rest, and during movement or kicking. Interpretation of the
CTG test is relatively simple as it depends solely on the presence or absence of
fetal heart rate accelerations which occur in response to fetal movements. The
usual duration of a CTG is 20 minutes, during which observation of a minimum
two accelerations of at least 15 bpm above baseline lasting at least 15 seconds
need to be seen to classify the test as ‘reactive’ or normal. A non-reactive CTG
can be associated with detrimental perinatal outcomes; however, more often than
not it is related to the fetus sleep cycle or maternal sedation (Maulik D, 2006b).
The CTG is used in conjunction with Doppler sonography of the umbilical
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arteries to predict when is best to deliver a severely growth restricted fetus.
However, it is considered to be of limited value as a stand alone test to monitor
fetal condition.
Assessment of amniotic fluid volumes including the single deepest pocket
and the amniotic fluid index (AFI), a measurement of the deepest pools of
amniotic fluid in four uterine quadrants are considered useful in monitoring fetal
condition. Oligohydramnios is associated with adverse perinatal outcome, and is
highly prevalent in FGR. Its occurrence is therefore an important finding which
signals the need to increase fetal monitoring (Chamberlain PF et al., 1984;Bastide
A et al., 1986). The cause of oligohydramnios is believed to be a reduced renal
blood flow, due to blood flow redistribution and decreased urine output (Arduini
D and Rizzo G, 1991).
The biophysical profile (BPP) test is carried out to determine the health of
the baby during pregnancy usually in combination with assessment of fetal blood
flow (by Doppler) and fetal growth. The number and type of fetal movements,
changes in the fetal heart rate with movement, muscle tone, breathing rate and
AFI are combined to give a score which indicates the overall health of the fetus. A
declining BPP score reflects deteriorating fetal condition and may indicate
delivery to avoid fetal demise. Similar to CTG, the BPP is of limited value as a
stand-alone test but useful when used in conjunction with other fetal surveillance
tests.
As fetal condition deteriorates, the fetus adapts by dilatation of the fetal
cerebral arteries, termed “brain sparing” which can be picked up on a Doppler
scan of the middle cerebral artery (MCA) as an increased pulsatility index
(Maulik D, 2006b;Baschat AA et al., 2001). In sheep fetuses, redistribution of
blood in favour of the brain has been shown to be an effect of hypoxaemia
(Peeters LL et al., 1979). Both in humans and sheep, this adaptation can be
reversed temporarily by maternal hyperoxygenation (Goetzman BW et al.,
1984;Arduini D et al., 1988). The CTG and BPP may also be improved using
maternal oxygen administration, but there is a temporary impairment of the fetal
heart rate pattern and increase in heart rate decelerations after discontinuation of
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oxygen (Bekedam DJ et al., 1991). An important limitation of oxygen therapy is
that it needs to be administered continuously without interruption.
The guidelines for managing FGR caused by utero-placental insufficiency
are well established. Once other factors like chromosomal abnormalities, fetal
structural abnormalities or maternal/fetal infections have been ruled out, Doppler
assessment of the uterine arteries is performed at 22-24 weeks. A raised PI with a
notched waveform is confirmatory of FGR caused by utero-placental
insufficiency. It is then important to monitor the growth of the fetus serially by
ultrasound examination every two weeks. Once the fetal growth velocity slows,
scans are performed more frequently for assessment of umbilical artery Dopplers,
fetal growth and AFI. Once fetal growth has ceased, abnormalities in the
umbilical artery and middle cerebral blood flow are common and CTG
montitoring can be instigated every few days. The mother is prescribed a course
of steroids to mature the fetal lungs, and delivery is planned in liaison with the
neonatal unit (Maulik D, 2006b).
The presence of umbilical artery AEDF or an abnormal CTG after 34
weeks would require immediate delivery. In a pregnancy less than 34 weeks, the
administration of steroids to enhance fetal lung maturity is recommended. A
recent multicentre randomized-controlled trial, the Growth Restriction
Intervention Trial, compared the effects of delivering within 48 hours of steroid
administration and delaying for as long as the fetal health in utero permitted. It
found no difference in the still birth rate between the two groups (Walker DM et
al., 2011).
If pregnancy is less than 28 weeks, the best plan of management of FGR
remains uncertain and depends largely on the judgements of the obstetrician and
neonatologist. If the fetal status dictates emergency delivery, it should be
performed by caesarean section. However, delivery at this stage of gestation has a
high morbidity and poor neonatal outcomes.
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1.5 Perinatal Consequences of Fetal Growth Restriction
As has been described so far, fetal growth is dependent on multiple
factors. These include the pre-determined genetic potential, the ability of the
mother to provide sufficient nutrients, the ability of the placenta to transfer
nutrients, intra-uterine hormones, and growth factors. An infant who fails to attain
his growth potential in utero is described as growth-restricted. Some of the long-
term and short-term consequences of FGR are described below:-
1.5.1 Mortality
The rates of perinatal mortality are markedly higher in FGR infants,
irrespective of whether they are symmetrically or asymmetrically growth-
restricted. One study reported a 5 to 6-fold increase in perinatal mortality in both
pre-term and term FGR infants (Lackman F et al., 2001), while another reported a
10-fold rise in the death rate of FGR infants at term (McIntire DD et al., 1999). A
higher number of fetal deaths are reported in those pregnancies characterized by
AREDF on antenatal Doppler velocimetry (Hackett GA et al., 1987).
Additionally, many stillbirths are undetected cases of FGR, when other causes
have been ruled out.
1.5.2 Prematurity and Associated Complications
FGR fetuses are often not able to complete their in utero development
until term and need to be delivered prematurely. FGR coupled with prematurity
gives rise to a number of perinatal complications, which include respiratory
distress syndrome (Tyson JE et al., 1995), chronic lung disease (Regev RH et al.,
2003;Aucott SW et al., 2004), higher rates of necrotizing enterocolitis (Bernstein
IM et al., 2000;Aucott SW et al., 2004) and intraventricular hemorrhage (Simchen
MJ et al., 2000). It is believed that a non-favourable and hypoxic intra-uterine
environment resulting from vascular placental insufficiency, results in a delay in
metabolic adaptation responses and postnatal reperfusion injury, which manifests
as prolonged lung disease.
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1.5.3 Hypothermia
FGR infants have lower adipose tissue stores, resulting in less physiologic
defenses against hypothermia. If thermally stressed, the FGR infant will increase
caloric expenditure in order to maintain normothermia, which may result in
acidosis and poor growth (Doctor BA et al., 2001).
1.5.4 Hypoglycemia
FGR infants are at elevated risk of hypoglycaemia after birth as they
transition from a continuous supply of glucose to an intermittent one. Metabolic
adaptations such as decreased glycogen and adipose tissue stores, increased
insulin levels, altered insulin:glucagon ratios, impaired gluconeogenesis and
ketogenesis all contribute to the inability of the FGR infant to maintain fasting
glucose homeostasis (Pallotto EK and Simmons RA, 2002).
1.5.5 Polycythemia
One of the characteristic features of FGR is chronic in utero hypoxemia
which leads to increased levels of erythropoietin, and consequent increase in RBC
numbers (polycythemia) (Snijders RJ et al., 1993a). This may eventually
exacerbate placental vascular dysfunction. Under the circumstances of
hypoxemia-stimulated extramedullary hematopoiesis, the risk for
thrombocytopenia may increase 10-fold; and increased blood viscosity, decreased
erythrocyte pliability, as well as platelet aggregation worsen intra-placental blood
flow dynamics further (Trudinger B et al., 2003).
1.5.6 Immune Deficiency and Sepsis
FGR infants generally have a compromised humoral and cellular immune
system, which contributes to increased sepsis. They show a decrease in IgG
concentrations, phagocytic index, lysozymes and neutrophil numbers, all of which
explain their higher susceptibility to post-partum infections (Snijders RJ et al.,
1993a;Chandra KR and Matsumura T, 1979).
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These perinatal consequences of utero-placental insufficiency illustrate the
multisystemic effects of FGR, and how detrimental it can be for neonatal health.
1.6 Long-term consequences of Fetal Growth Restriction
There is now strong evidence that FGR infants have an increased pre-
dispostion to many adult onset disorders. These include cardiovascular disorders,
type II diabetes and many neurological handicaps.
It is intriguing to consider how an adverse in utero environment can be an
etiologic factor for diseases in adult life. The answer may lie in the developmental
origins hypothesis. This hypothesis states that increased allocation of energy to
any one trait during development, such as brain growth, would reduce allocation
of resources to the other traits, such as tissue repair processes (Barker DJ, 2006).
This makes such individuals more vulnerable to adult-onset disease in three ways.
(i) They have diminished functional capacity in key organs, like the kidney. It is
believed that hypertension is initiated by the reduced number of glomeruli found
in people who are small at birth (Brenner BM and Chertow GM, 1993).
(ii) They have altered hormonal levels and metabolism. Insulin resistance, which
is often associated with low birth weight and FGR, may be viewed as persistence
of a fetal adaptive response to maintain blood glucose concentrations for the
benefit of the brain, but at the expense of glucose transport into muscles for
general growth (Phillips DI, 1996).
(iii) It is believed that people who were born with smaller birth weights are more
vulnerable to adverse environmental influences in later life. Animal experiments
have proven that the environment faced by an individual in utero has a profound
effect on shaping his responses to environmental stresses encountered in later life
(Barker DJ, 2006).
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Some of the diseases that afflict FGR infants early on in adulthood are
discussed below.
1.6.1 Coronary Heart Disease
To exemplify the third point described above, a recent study conducted in
Helsinki found that men with low taxable incomes had higher incidences of
coronary heart disease (CHD) (Barker DJ et al., 2001). Furthermore, this
association between low income and CHD was confined to men who had slow
fetal growth and who were thin at birth, defined by a ponderal index
(birthweight/length3) of less than 26 kg/m3. Men who were not small at birth
showed no association of CHD with income, which suggests they were resilient to
the effects of low income. It is believed that perceptions of low status and lack of
success are associated with changes in neuroendocrine pathways that manifest as
disease. People who were born SGA are believed to have elevated serum cortisol
concentrations in response to stress, resulting in CHD (Phillips DI et al., 2000).
1.6.2 Type II Diabetes
A number of studies have found that differences in insulin sensitivity
prevalent in individuals who are born small are associated with increased
susceptibility to type II diabetes compared to individuals who are appropriately
grown for gestational age (Hales CN et al., 1991;Lithell HO et al., 1996;Newsome
CA et al., 2003).
One such study was conducted on a cohort of men who were born in
Hertfordshire, UK from 1911 onwards and had their birth weight and weight at 1
year age recorded (Hales CN et al., 1991). Blood samples were collected from
them when they were 59-70 years old and analysed for plasma glucose and insulin
levels. The study revealed that there was a three-fold difference in the prevalence
of diabetes and impaired glucose tolerance in men with the lowest (2.495 kg) and
highest (4.309 kg) early weights.
The mechanisms which associate low fetal and infant weights with adult-
onset diabetes and glucose intolerance are still not very well understood. It is
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known that in humans, much of the development of Islets of Langerhans occurs
between the 12th intra-uterine week and 5th post-natal month. FGR human babies
have reduced numbers of cells in their organs (Widdowson EM et al., 1972). In
some instances, this limitation in cell number may be directly associated with
limitation in function. Experiments in rats fed a low protein diet during pregnancy
demonstrated reduced numbers of β-cells and associated reduction in insulin 
secretion (Snoeck A et al., 1990). Similarly, growth-restricted human neonates
may have fewer β-cells and a diminished capacity for insulin secretion (van 
Assche FA and Aerts L, 1979).
It is interesting to note that in pigs and rats, cell numbers increase most
rapidly after birth, rather than before, and the animal can therefore recover to
some extent from the effects of a malnourished in utero environment. Humans, on
the other hand, accomplish a greater proportion of their growth before birth than
do pigs. It has been calculated that the fertilized human ovum goes through
approximately 42 rounds of cell division before birth (Milner RDG, 1989), whilst
after birth there need be only a further five cycles of division. In humans, the
effects of intra-uterine growth failure are therefore relatively more severe
(Widdowson EM, 1971).
1.6.3 Hypertension
A strong association has also been found between low birthweight and
hypertension. A one kg difference in birthweight is associated with around 3 mm
Hg difference in systolic pressure (Barker DJ, 2006). This effect may appear
small at first; however, the lesions that accompany poor fetal growth which tend
to elevate blood pressure, and which may include a reduced number of glomeruli
(oligonephropathy) have a marginal influence on blood pressure within the
normal range as counter-regulatory mechanism maintain homeostasis. The lesions
progress via hyperfiltration of the reduced number of glomeruli and the
consequent glomerulosclerosis makes it difficult to maintain homeostasis. This
leads to increased blood pressure, which initiates a cycling cascade that further
deteriorates the lesions (Brenner BM and Chertow GM, 1993).
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Histological examination of the kidneys of people killed in road accidents
revealed that there were larger but fewer number of glomeruli in the kidneys of
those being treated for hypertension (Keller G et al., 2003).
Another study found that there was more than 20 mmHg diference
between the systolic pressures of hypertensive patients who weighed less than
2500g at birth and those who weighed more than 4000g at birth. This is consistent
with the fact that those individuals with detrimental in utero development have a
greater pre-disposition to develop clinical hypertension by the time they reach old
age, which does not respond well to treatment (Barker DJ, 2006;Yliharsila H et
al., 2003).
To conclude, associations between low birth weight and later diseases
have been extensively replicated in studies in different countries. The associations
between low birth weight and chronic disease are thought to be consequences of
developmental plasticity, the phenomenon by which a single genotype can give
rise to a range of different phenotypes in response to different environmental
conditions during development. Poor nourishment during the in utero period, as in
disorders like FGR make the individual highly susceptible to CHD, type II
diabetes and hypertension later on in life.
1.7 Prenatal Therapies for FGR caused by utero-placental
insufficiency
The choice of prenatal therapies for FGR depends on the nature of the
etiological insult. Treatment of poor lifestyle habits (like stopping of cigarette
smoking, alcohol use, and illicit drugs) may be of benefit. It is also important to
rule out FGR caused by chromosomal disorders or perinatal infections before
finalizing an appropriate management plan for FGR caused by vascular placental
insufficiency. A number of antenatal treatments have been proposed such as
maternal oxygen administration (hyperoxia) (Say L et al., 2003), low dose aspirin
(Leitich H et al., 1997) and sildenafil citrate (Villanueva-Garcia D et al., 2007);
however none have shown evidence of benefit on neonatal outcome. Some of
these treatments are briefly described below.
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1.7.1 Bed rest
Bed rest either at home or in the hospital has been widely proposed,
particularly with the legs slightly elevated, with the aim of improving utero-
placental perfusion by decreasing peripheral blood flow, preventing venocaval
compression, increasing venous return and cardiac output (Figueroa R and Maulik
D, 2006). Unfortunately, extended bed rest can have detrimental consequences for
the mother such as an increased risk of thromboembolism, muscle atrophy,
heartburn, constipation, a prolonged postpartum recovery period, and increased
stress for the mother and her family (Kovacevich GJ et al., 2000;Heaman M and
Gupton A, 1998). In addition, a review of the randomized trials to assess the
benefits of extended bed rest at the hospital for women with FGR did not come to
any conclusive evidence for bed rest to be beneficial over ambulation
(Gulmezoglu AM and Hofmeyr GJ, 2000).
1.7.2 Oxygen supplementation
Maternal oxygen supplementation has been proposed since hypoxemia is a
characteristic feature of many FGR pregnancies. In addition lowered oxygen
tensions at high altitudes is associated with significantly lower birth weights than
at sea level, probably because of reduced oxygen delivery (Giussani DA et al.,
2007). Say and colleagues compared the therapeutic effects of maternal oxygen
therapy with no oxygen therapy in suspected FGR cases (Say L et al., 2003).
Their investigations included three studies with 94 women. The oxygen groups
received 55% or 40% humidified oxygen at 8L/min by face mask, 24hours/day
until delivery. Oxygenation compared with no oxygenation was associated with a
reduction in the perinatal mortality rate (relative risk 0.50, 95% confidence
interval 0.32-0.81) and a significant improvement in birthweight. However, two
of these randomized trials did not involve a placebo. Moreover, the higher
gestational age in the oxygen groups may have accounted for the difference in
improved perinatal outcomes. Thus, there is not sufficient data to support the
benefits of maternal oxygen administration on impaired fetal growth, and further
investigations into this field are warranted.
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Maternal oxygen supplementation has been associated with detrimental
consequences in some FGR animal models and stopping the therapy in mid-
gestation resulted in even poorer fetal oxygenation than the pre-therapy levels
(Harding JE et al., 1992). Furthermore, prolonged oxygen supplementation is
likely to result in maternal pulmonary dysfunction (Johanson R et al., 1995). The
therapy is also difficult to administer. Thus, it is believed that maternal oxygen
supplementation should not be used in cases of suspected FGR (Say L et al.,
2003).
1.7.3 Aspirin
Low-dose aspirin has been used from mid-gestation to prevent the
development of pre-eclampsia in women at high risk. Even though the underlying
causes of pre-eclampsia and FGR are not well understood, biochemical studies
have suggested there may be an imbalance in vasodilators such as prostacyclins
and vasoconstrictors such as thromboxane. Low dose aspirin inhibits the
cyclooxygenase-1 mediated synthesis of thromboxane-A2 in the platelets
(Kawabe J et al., 2010), without affecting prostacyclin synthesis. This alters the
prostacyclin to thromboxane ratio and is believed to vasodilate the utero-placental
vascular bed, thereby improving perfusion (Figueroa R and Maulik D, 2006).
Leitich and colleagues (1997) performed a meta-analysis that showed that
the use of low-dose aspirin resulted in a significant reduction in FGR and a non-
significant reduction in perinatal mortality. Their analysis revealed that aspirin
was effective at doses of 50-80 mg/day. The preventive effect was further
improved at higher doses between 100-150 mg/day. Importantly, aspirin was only
effective if started before week 17 of gestation (Leitich H et al., 1997).
It is therefore important that pregnant women who are likely to benefit
from low-dose aspirin should be carefully identified and started on the treatment
early on in gestation, before 17 weeks (Leitich H et al., 1997). The majority of
severe FGR cases occur in the first pregnancy, and thus once it is diagnosed,
usually by 20 -24 weeks at the earliest, low dose aspirin is unlikely to be of
benefit.
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1.7.4 β-adrenergic receptor agonists 
β-adrenergic receptors agonists or betamimetics relax the smooth muscle
cells of the vasculature and myometrium, thereby dilating the utero-placental
vascular bed and increasing placental perfusion. In addition, they also enhance
blood glucose levels. Both these effects may relieve the detrimental effects of
utero-placental vascular insufficiency to some extent. Betamimetics however, are
able to cross the placenta and reach the fetal circulation, where they may cause
adverse effects by altering fetal glucose levels and vasodilating the fetal
vasculature (Figueroa R and Maulik D, 2006). In a randomized placebo controlled
trial on betamimetic therapy in women with suspected FGR, no difference was
found between the treatment group and control group, when comparing
birthweight or neonatal morbidity and mortality. Thus, at the moment there is no
evidence for their clinical usefulness in FGR (Gulmezoglu AM and Hofmeyr GJ,
2001).
1.7.5 Viagra
Some of the recent work aimed at mitigating FGR resulting from utero-
placental insufficiency has included investigating the role of sildenafil citrate
(Viagra). In ex vivo experiments, Viagra significantly reduced vasoconstriction
and enhanced vasodilatation of myometrial small arteries from women whose
pregnancies were complicated by FGR (Wareing M et al., 2005). It was therefore
hypothesized that Viagra may offer a potential therapeutic strategy to improve
uteroplacental blood flow in FGR pregnancies. Administration of Viagra as an
intravenous bolus unexpectedly decreased uterine blood flow in pregnant ewes
carrying either healthy or growth-restricted fetuses. It is believed that sildenafil
results in a systemic reduction in vascular resistance and consequent blood flow
“steal” from the uteroplacental circulation to the systemic vascular circuit (Miller
SL et al., 2009). This indicates that sildenafil may be an inappropriate therapy for
pregnancies complicated by FGR and should be used only with caution during
pregnancy because of its detrimental effects. Furthermore a randomized control
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trial of sildenafil citrate did not prolong gestation in pregnancies complicated by
severe PET (Samangaya RA et al., 2009). Contrary to these results, a recent study
demonstrated that oral silenafil therapy was associated with an improvement in
the rate of fetal abdominal circumference growth in women with severe early-
onset FGR (von Dadelszen P et al., 2011). This study is however limited by
patient numbers (n=10), and a more detailed investigation into the benefits of
sildenafil citrate therapy, including improvement in perinatal outcomes, if any, is
warranted.
1.7.6 Growth Factor treatment
Transamniotic Fetal Feeding (TAFF) is the continuous infusion of
hormones or nutrients into the amniotic fluid. As fetal swallowing occurs in utero,
the enriched amniotic fluid is ingested and used for fetal anabolism.
Transamniotic administration of recombinant human (rh)-IGF-1 by continuous
infusion over a 7-day period towards the end of gestation in FGR rabbits
enhanced serum IGF-1 levels and resulted in an increase in both fetal and
placental weights in infused v/s sham catheterized but non-infused contra-lateral
controls (Skarsgard ED et al., 2001). TAFF using Epidermal growth factor (EGF)
also led to significant improvements in fetal weight and normalized neonatal birth
weights equivalent to that of appropriately grown fetuses (Cellini C et al., 2004).
Though proven to be beneficial in pre-clinical studies, the clinical translation of
this methodology is unlikely. This is because chronic catheterization of the human
amniotic cavity, particularly in high-risk pregnancies is not feasible.
It has been demonstrated that site-specific placental gene transfer of
Angiopoietin-2 using an adenoviral vector resulted in a significant increase in
fetal weights in normal pregnant mice, compared to control untreated mice. Other
transgenes evaluated in the same study (Ang-1, bFGF, hepatocyte growth factor,
IGF-1, PlGF, PDGF-B and VEGF-A121) had no effect on fetal weight. The
authors plan further experiments in models of placental vascular insufficiency,
such as the naturally occurring FGR model in rabbits to assess the potential
efficacy of these growth factors (Katz AB et al., 2009).
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1.7.7 Treatment with melatonin and vitamin C
In a recent study, the potential of melatonin and vitamin C to increase
umbilical blood flow was explored (Thakor AS et al., 2010). A fetal intra-venous
infusion of melatonin and vitamin C significantly improved umbilical blood flow,
via NO-dependent vasodilatation. The effects appeared to last for a short duration
of time however, suggesting that chronic administration may be needed for any
potential therapeutic benefit on fetal growth to be realized.
Work done by the same group in an FGR rat model, created by maternal
nutrient restriction, has shown that administration of melatonin maternally in
drinking water restores pup birthweight to that of control non growth-restricted
pups. Interestingly, the fetal weights at day 20 were not significantly different
between the undernourished group treated with melatonin and undernourished
controls. This suggests that melatonin has a profound effect on enhancing
neonatal birthweight only in the last 2 days of pregnancy (rat gestation = 22-23
days). It is believed that the beneficial effects of melatonin are mediated by an
improvement in placental efficiency (Richter HG et al., 2009).
1.7.8 Nitric oxide donors
Studies in an FGR sheep model created by maternal under-feeding
demonstrated that NO donors like L-arginine may be of potential benefit in
ameliorating FGR (Lassala A et al., 2010). L-arginine is a nutritionally essential
amino acid for fetal development (Wu G et al., 2009), and a precursor of NO
biosynthesis (Wu G and Morris SM, Jr., 1998). Hence, it is believed that Arginine
may play a critical role in placental development, utero-placental perfusion and
transfer of nutrients from the mother to the fetus (Wu G et al., 2006).
In human patients, administration of L-arginine (3 g daily orally for 20
days) was found to have beneficial effects in ultrasound-diagnosed cases of FGR
(cases of chromosomal abnormality, maternal diabetes, drug and alcohol use were
excluded). There was a significant increase in estimated fetal weight in the treated
group compared to control group, which received no treatment. The neonatal
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weights were also significantly improved in the treated group (2823+85 g v/s
2495+147 g). The percentage of FGR neonates in the treatment group was
significantly lesser than the control group (29% v/s 73%). (Sieroszewski P et al.,
2004). The mechanism behind these effects is believed to be the enhanced
production of NO, which improves utero-placental blood flow not only by
vasodilatation, but also because of its anti-aggregative effects on platelets.
1.7.9 Pravastatin
Studies in a murine model of PET, created by lentiviral-mediated over-
expression of sFlt-1 in the placenta, have demonstrated that statins may be of
potential benefit in ameliorating PET (Kumasawa K et al., 2011). Statins have
conventionally been used for the treatment of hypercholesterolemia, but it has
recently been reported that they have a protective effect on vascular endothelial
cells (Ludman A et al., 2009). Administration of pravastatin in pre-eclamptic mice
(5µg/day intra-peritoneally; equivalent to a human therapeutic dose of 10mg/day)
daily from embryonic day (E) 7.5 onwards resulted in significant improvements in
maternal hypertension at E16.5 and later timepoints. There were also
improvements in glomerular endotheliosis and proteinuria, concomitant with
significant reduction in the levels of circulating sFlt-1 and significant increase in
levels of mouse PlGF. VEGF levels remained unaltered (Kumasawa K et al.,
2011). As PET and FGR commonly overlap with each other, statins may be of
potential benefit for treating FGR too, even though this was not evaluated in the
current study. The potential of pravastatin to treat PET in the clinics is currently
under investigation in clinical trials, one of which is the StAmP trial (Statins for
Amelioration of Pre-eclampsia), being conducted at University College London
Hospitals.
1.7.10 Japanese Herbal Medicine
The traditional Japanese herbal medicine Toki-shakuyaku-san was found
to have beneficial effects in a rat model of PET and FGR, caused by sub-
cutaneous infusion of L-NAME (inhibitor of NO synthase activity).
Administration of Toki-shakuyaku-san (1g/kg, 2g/kg) by gavage from day 14 of
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gestation onwards brought about a reduction in maternal blood pressure.
Furthermore, there was also improvement in fetal weight, when treated with the
higher dose (2g/kg). Treatment with L-arginine, with the amount present in Toki-
shakuyaku-san, was found to have no therapeutic effects. Additionally, there was
no significant change in the serum levels of NO following treatment with Toki-
shakuyaku-san. This suggests that the beneficical effects of Toki-shakuyaku-san
on hypertension and fetal weight in this rat model of PET and FGR were NO-
independent. (Takei H et al., 2004)
As has been discussed in this section, there is currently no treatment
available which may convincingly ameliorate FGR and reliably reduce morbidity
and mortality rates in the clinic, though several pre-clinical studies to develop a
treatment are in progress. This thesis describes a novel gene therapy based
approach that may be of potential therapeutic benefit in severe FGR caused by
utero-placental insufficiency. The aim was to decrease the severity of FGR by
adenovirus-mediated local over-expression of VEGF in the uterine arteries of
pregnant sheep.
1.8 Types of placentation
In order to select the most appropriate animal models required to support
the local administration of adenovirus-VEGF (Ad.VEGF) to pregnant women in
their second trimester, it is useful to compare key aspects of human placentation
to those found in animal models.
The maternofetal barrier refers to the tissue layers separating maternal and
fetal circulations in the placenta. There is significant variation amongst different
species in the completeness of this placental barrier depending on the extent of
trophoblast invasion (Figure 1.5). This has been reviewed in detail by Kaufmann
P (1981).
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Figure 1.5 : Tissue layers of the maternofetal barrier according to the
Grosser classification.
a-maternal blood (red dots); b-maternal endothelium (red); c-endometrial connective tissue (red);
d-endometrial epithelium (red); e-trophoblast (blue); f-fetal connective tissue (black); g-fetal
endothelium (black); h-fetal blood (black dots). The fetal components of the placental barrier (e –
g) are collected under the term chorion. Maternal components are reduced step by step until the
chorion comes into direct contact with the maternal blood (r, red dots). The trophoblast (blue)
may be covered on one side (haemodichorial) or on both sides (haemotrichorial) by
cytotrophoblast (Kaufmann P, 1981).
1.8.1 Epitheliochorial placenta
At one end of the spectrum the fetal chorion directly faces the intact
endometrial epithelium. The blastocyst does not invade the endometrium, only
remaining attached to it. Six tissue layers separate maternal and fetal blood:
maternal capillary endothelium, maternal endometrial connective tissue and
maternal endometrial epithelium and three layers of fetal origin - trophoblast,
chorionic connective tissue, and fetal endothelium. From the six layers, the
epithelio - chorial syndesmo - chorial endothelio - chorial
hemo - trichorial hemo - dichorial hemo - monochorial
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trophoblast or the maternal epithelium may fuse syncytically. This kind of
placentation is seen in sheep.
1.8.2 Syndesmochorial placenta
The stepwise removal of maternal tissue layers as a result of further
blastocyst invasion results in destruction of the uterine epithelium. This placenta
is found in camels.
1.8.3 Endotheliochorial placenta
Deeper invasion of trophoblasts and corresponding removal of
endometrial connective tissue results in the development of endotheliochorial
placenta. This placental barrier is characteristic for all carnivores.
1.8.4 Haemochorial placenta
The final step of trophoblast invasion results in erosion of the maternal
vessels, which are finally completely destroyed. The trophoblastic surfaces now
face the maternal blood directly (Enders AC, 1965). Depending on the number of
trophoblastic epithelial layers a more detailed subdivision has been proposed:
haemotrichorial (rat: Enders AC, 1965), haemodichorial (rabbit: Enders AC,
1965; human in the first trimester: (Hamilton WJ and Boyd JD, 1970), and
haemomonochorial (guinea pig: (Kaufmann P and Davidoff M, 1977); human
placenta at term Hamilton WJ and Boyd JD, 1970).
1.9 Animal Models of FGR
FGR can be artificially created in animal models by adopting a variety of
strategies that affect the maternal, fetal or placental environments. In selecting an
animal model of FGR, it is necessary to consider the size of the animal, its
characteristic placentation, intra-uterine growth trends and gestational period. The
commonly adopted experimental approaches to create FGR are described below.
Notably, about three quarter of all experiments using models of FGR have
been performed in two rodent species, rats and mice (Schroder HJ, 2003).
Advantages of the mouse include its small size and short generation time.
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Additionally, the availability of murine embryonic stem cells facilitates gene
targeting and the development of transgenic lines. The small size of mice, which
make their maintenance easier compared to other species, may actually be a
potential disadvantage for functional studies. The mouse placentation is quite
different to human placentation. In contrast to humans, trophoblast invasion in the
mouse is shallow. Uterine natural killer cells play a more important role than
trophoblast in arterial remodelling in mice. The interhaemal barrier between the
maternal and fetal circulations in mice consists of three trophoblast layers, outer
one cellular and inner two syncytial, compared to only a single layer of syncytial
trophoblast in humans. This difference is important when investigating the overall
exchange of substrates across the placenta between the uterine and umbilical
circulations.
The placental endocrine functions in the two species differ significantly.
In mice, ovarian progesterone production is required throughout the length of
gestation (3 weeks), and maintenance of the corpus luteum is dependent on
pituitary prolactin and placental lactogen. In humans, maintenance of the corpus
luteum is dependent on human chorionic gonadotropin (hCG) produced by the
trophoblast. Furthermore, from 8 weeks of gestation, progesterone produced by
the syncytiotrophoblast is sufficient to maintain pregnancy, even after
ovariectomy (Schroder HJ, 2003).
One of the other drawbacks of working with mouse and rat models is their
high rate of genetic mutation. This is believed to be on account of their shorter
generation times, and consequently higher mutation rates, or possibly less
accurate DNA replication systems. It is therefore suggested that murid rodents
like mice, rats and hamsters are inappropriate models for most research on human
conditions.
In contrast to mice and rats, the rabbit placentation (haemodichorial) and
guinea pig placentation (haemomonochorial) is closer to the human situation, as
discussed above.
The advantage of working with guinea pigs over rabbits though, is that
being a smaller animal, they are easier to maintain. More importantly, they have a
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longer gestation (~65 days) compared to the rabbit (~31 days). For our study, this
is an advantage as it gives us the opportunity to intervene (by injecting gene
therapy vectors) at mid-gestation, and be able to study the effects of the therapy
for over a month.
While no animal truly recapitulates human pregnancy, the pregnant sheep
has been extensively used over the past 40 years to study fetal physiology. The
ovine fetus has a good tolerance to in utero manipulations allowing the surgical
placement of catheters in both the maternal and fetal vasculature (Jellyman JK et
al., 2004;Abi-Nader KN et al., 2011) and a consistent gestation period of 145
days, which is approximately half that of the human. As in humans, the
gestational age of the fetus can be accurately determined by ultrasound using fetal
measurements similar to those used in clinical practice (Barbera A et al., 1995).
Ultrasound is routinely used in farming practice to check for multiple pregnancy
early in gestation (Aiumlamai S et al., 1992). Considerable insights into placental
oxygen and nutrient utilization and transfer has been obtained from pregnant
sheep, and confirmed in humans once appropriate technology became available
(Barry JS and Anthony RV, 2008). There are some important similarities and well
as differences between human and sheep placentae.
In human pregnancy, the conceptus truly invades the uterine wall, which
does not occur in ovine pregnancy. The sheep placenta consists of spot-like
regions of maternofetal interdigitations (placentomes) containing a tuft of fetal
villi, called a cotyledon, attached to 60-150 endometrial thickenings called
caruncles. The placentomes are spread throughout the uterine cavity. The sheep
cotyledon is anatomically very similar to the human placenta, and the vasculature
within both is also very similar. Undoubtedly, the sheep placenta is far from being
a perfect model for the human; nevertheless, the similarity in fetal placental
vascular structure, relatively long duration of gestation, size and weight of the
fetus make the sheep an appropriate model for human pregnancy (Meschia G et
al., 1965;Battaglia FC et al., 1968).
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The manifestations of FGR pregnancy in human and sheep are also very
similar. Placental structural abnormalities that have been associated with FGR
include reductions in placental villous number, diameter and surface area; along
with reductions in villous arterial number, diameter and degree of branching
(Krebs C et al., 1996;Macara L et al., 1996;Barry JS and Anthony RV, 2008).
Severe early-onset FGR is associated with altered umbilical artery Doppler
waveforms which are indicative of increased placental vascular resistance
(described above). In incidences of ovine FGR as well (induced by hyperthermia),
there is modification of placental vasculature in a similar fashion to that of the
human FGR condition (Regnault TR et al., 2002). The near term uterine and
umbilical blood flows are reduced, while umbilical artery Doppler velocimetry
measures demonstrate increased pulsatility and resistance indices (Galan HL et
al., 2005). Furthermore, fetal cotyledon VEGF levels are reduced in near term
sheep FGR pregnancies (Regnault TR et al., 2003), which is very similar to what
is observed in the human clinical setting (Lyall F et al., 1997).
The increase in uterine blood flow that occurs through the latter half of
gestation is also very similar for humans and sheep. It increases two and a half
times in humans (from 0.3 to 0.8 L/min) while in sheep, this increase is three fold
(0.4 to 1.2 L/min) (Konje JC et al., 2003;Meschia G, 1984). This is concomitant
with an increase in the supply of substrates and oxygen to the conceptus, failure
of which manifests as asymmetric FGR. The rates of oxygen and glucose
consumption in both near-term sheep and human fetuses are also similar (Barry JS
and Anthony RV, 2008).
Based on the similarities between sheep and human pregnancy and the
ability to place maternal and fetal catheters in pregnant sheep, it may be
concluded that the pregnant sheep is an appropriate animal model to study human
pregnancy.
Some of the specific methods used to create FGR in animal models are
described below:-
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1.9.1 Naturally occurring models
The rabbit is a useful species in which to investigate FGR. It provides a
naturally occurring model of FGR which parallels the human situation in three
ways: (a) the onset occurs in the third trimester; (b) brain sparing is seen; and (c)
the underlying cause is vascular insufficiency via a “watershed region” between
the vaginal and uterine arterial blood supplies. The bicornuate uterus carries
multiple fetuses within individual amniotic cavities/gestational sacs. At term, the
weight ratio of the growth-retarded fetus (third from ovarian end) to the favored
fetus (closest to ovarian end) in each horn is consistently 0.85. The advantage of
the bicornuate uterus is that there are two IUGR fetuses per litter, which enables
comparative studies between the runt pairs, with one serving as the other’s control
(Skarsgard ED et al., 2001;Thakur A et al., 2000).
1.9.2 Dietary manipulation
FGR may be created in animal models by either maternal nutrient
restriction or maternal overnourishment. Both of these conditions are discussed
below:-
1.9.2.1 Maternal undernutrition
One of the most commonly used strategies to create FGR is maternal
nutrient restriction, particularly in rodents. In this thesis, we have worked with
one such animal model of FGR-the maternal nutrient restricted guinea pig
(Roberts CT et al., 2001a). Restricting maternal nutrition 4 weeks before and
during pregnancy is a well-recognized method of creating FGR in small animals.
In the guinea pig this impairs placental functional development, reduces the
placental exchange and trophoblastic surface, and increases the thickness of the
exchange barrier (Roberts CT et al., 2001a). Such actions are thought to be
mediated by decreasing levels of the IGFs, which are important modulators of
placental growth and differentiation (Roberts CT et al., 2001b;Roberts CT et al.,
2002), and which are implicated in human FGR.
The maternal nutrient restriction model has also been created in other
rodents by under-feeding the mother for different lengths of time during
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gestation, reviewed in (Haugaard CT and Bauer MK, 2001). Woodall et al
developed an FGR model in rats by nutrient restricting pregnant females by 30%
of the ad lib intake, throughout gestation. After birth, all pups were cross-fostered
by an ad lib intake mother. The mean fetal weight at late gestation, neonatal
weight, placental weight as well as postnatal body weight at 18 weeks of age were
all significantly lower in the undernourished group compared to the control group.
Circulating IGF-I was significantly reduced in the restricted group from day 22 of
gestation until postnatal day 9, but not at later time points (Woodall SM et al.,
1996;Woodall SM et al., 1999).
1.9.2.2 Over-nourishment in adolescent pregnant sheep
Paradoxically, when adolescent sheep are over-nourished during
pregnancy, fetal and placental weights are distinctly reduced from as early as 95
days of gestation and birth weight is significantly reduced (Wallace JM et al.,
2004). There is also a reduction in both the uterine and umbilical blood flows. The
decrease in placental weight is due to a reduction in both the number and weight
of placentomes, though placental function is not altered. Furthermore, the fetus is
hypoxic and exhibits brain sparing. There is an attenuated uptake of oxygen,
glucose and amino acids by the umbilical circulation.
The etiology is believed to be the increased insulin and IGF-1 levels in
maternal plasma, that are characteristic of over-nourishment, which provide a
sustained anabolic stimulus for growth of maternal tissues that is so powerful that
it shifts the supply of nutrients away from the feto-placental unit (Schroder HJ,
2003). In other words, the mother grows in size and weight at the expense of the
fetus, which becomes growth-restricted.
1.9.3 Uterine artery ligation
Another commonly adopted strategy is uterine artery ligation, first
demonstrated in rats (Wigglesworth JS, 1964). This reduces the blood flow in the
uterine artery, and thereby limits the supply of nutrients and oxygen to the fetus.
The model was originally designed to demonstrate the importance of uterine
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blood supply as a controlling factor in fetal growth. One of the drawbacks with
this model is the high incidence of fetal death and resorption among the fetuses in
the manipulated horn.
In guinea pigs, the maternal side of the placentae is supplied with blood
from an arcade between the uterine and ovarian artery. Ligation of this arcade
between the uterine and ovarian arteries consistently results in growth restriction
by about 50% compared to controls and there is no post-natal ‘catch up’ growth.
However, the fetal mortality on the experimental side was found to be as high as
30% (Carter AM, 1993;Lafeber HN et al., 1984).
Tanaka et al mimicked a phenomenon called “postischemic
hypoperfusion” of utero-placental circulation to create an FGR model with low
mortality and favourable reproducibility. Instead of ligating the uterine artery,
they used two small artery clamps to occlude the uterine artery vessels for a
period of 5-60 minutes on day 17 of gestation. The fetuses were delivered by
cesarean section on day 21. The fetuses on the ischemic side were found to be
significantly lighter than control non-ischemic fetuses. Furthermore, they had
significantly lowered liver:body weight ratios and significantly increased
brain:body weight ratios compared to controls. Fetal mortality on the ischemic
side was 14% (Tanaka M et al., 1994).
In large species like sheep, an adjustable occluder with exteriorized
controller has been placed around the maternal common iliac artery which allows
the operator to regulate uterine blood flow (Clark KE et al., 1982). Reduction in
uterine blood flow is associated with significant reductions in fetal and placental
weights (Lang U et al., 2003). Alternatively, the technique of embolizing the
utero-placental vasculature with microspheres has been employed to create FGR
in sheep (Clapp JF, 3rd et al., 1981;Creasy RK et al., 1972). Though successful in
limiting fetal growth by reducing utero-placental perfusion, one of the main
criticisms of this technique has been the simultaneous necrosis of placental tissue.
Hence, the effects of a compromised uteroplacental circulation on fetal growth
cannot be distinguished from those caused by a reduced placental exchange
capacity for nutrients and substrates.
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1.9.4 Single umbilical artery ligation
Single umbilical artery ligation (SUAL) has also been used to create FGR
in the sheep fetus. At 108-119 days of pregnancy, one umbilical artery is isolated
and ligated close to the fetal abdomen. Although this model was developed in the
late 1960s (Emmanouilides GC et al., 1968), it is prevalent even currently in FGR
studies (Miller SL et al., 2009). A reduced umbilical blood flow limits the supply
of substrates and oxygen from the ewe to the fetus (Oh W et al., 1975), resulting
in asymmetric growth restriction. The SUAL fetuses are characterized by
relatively greater brain and adrenal weights, compared to control fetuses
(Morrison JL, 2008). There is a significant reduction in fetal and placental
weights. Furthermore, gross and microscopic examination of the placenta
revealed evidence of infarction of about one-half of its surface (Oyama K et al.,
1992).
1.9.5 Placental injury or reduction
Experimentally induced thermal placental injury causes FGR in pregnant
rabbits. The optimum exposure to create the FGR condition was determined to be
15mA direct current for 40 seconds, which created growth-restriction in 71% of
all treated fetuses and relatively low abortion rates. The fetuses and placentae
showed reductions in weight of about 31% and 41% respectively relative to
controls, and brain:liver weight ratio was increased in the FGR group compared to
controls (Rosati P et al., 1995). The basis of this model is interference with the
placental exchange function by creating a wide area of ischemic tissue.
Likewise, growth restriction has been created in the sheep by surgical
reduction in the number of endometrial caruncles from the uterus of the non-
pregnant ewe prior to mating. During pregnancy, the maternal caruncles are in
close apposition with the fetal cotyledons, and the two together form placentomes.
Reducing the number of caruncles leads to a reduction in placental weight, which
clearly influences fetal weight (Alexander G, 1964;Robinson JS et al., 1979)
because there is reduced placental exchange area and function. The removal of
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100 uterine caruncles before mating has been shown to reduce lamb birthweight
by about 17% (Mellor DJ et al., 1977). These placentally restricted fetuses also
show evidence of redistribution of cardiac output and brain sparing, a common
manifestation of asymmetric FGR.
1.9.6 Hypoxia
A number of FGR models have been created by exposing the pregnant rat
to low oxygen tension in the last half of gestation. In the rat, even brief
intermittent episodes of hypoxia for 1-2 hours/day acutely decrease fetal oxygen
delivery, and this can have deleterious consequences on fetal growth (Schwartz JE
et al., 1998).
More recently, the importance of fetal oxygenation for prenatal growth
was demonstrated in the chicken model (Giussani DA et al., 2007). Incubation of
fertilized eggs laid by sea level hens at high altitude markedly reduced fetal
growth. However, this growth restriction could be completely prevented by
oxygen supplementation to the fertilized eggs during incubation at high altitude,
thereby proving that oxygen was the limiting factor resulting in growth
retardation. These growth restricted embryos were also characterized by an
increased relative brain weight, expressed as a percentage of fetal body mass.
Interestingly, incubation at high altitude of fertilized eggs laid by high altitude
hens also restricted fetal growth, albeit to a lesser extent than sea level hens.
1.9.7 Hyperthermia
A high ambient temperature in the first trimester of pregnancy is
associated with lower birth weight (Lawlor DA et al., 2005). The underlying
physiological mechanisms of this relationship have been explored in the sheep.
This model can be created in pregnant ewes by raising the ambient temperature to
40°C for 12 hours and then to 35°C for 12 hours of each 24-hour period, with
relative humidity maintained at 30-40%, from 45 days of gestation onwards.
Under this regimen, the maternal core body temperature is raised by 0.6-1.0°C
within 7 days, which decelerates fetal growth (Wallace JM et al., 2005). Placental
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and fetal weights are reduced by as much as 50% in FGR fetuses of hyperthermic
ewes at 135 days gestation (Thureen PJ et al., 1992).
Maternal hyperthermia results in smaller placentomes with a diminished
capacity for the transfer of oxygen and substrates (like glucose) to the fetus. The
fetal adaptations cause a slowing of fetal growth to match the placental substrate
supply. The uterine and umbilical blood flows are also reduced (Bell AW et al.,
1987). FGR created by exposing pregnant ewes to hyperthermia is also
characterized by relative sparing of the fetal heart, and an increase in the ratio of
brain to liver weight, which is evident as early as 55 days of gestation.
1.9.8 Transgenic models
There are a number of transgenic mouse models of FGR available. One of
them is the placental-specific Igf2-knockout mouse. As mentioned previously
(Section 1.2.2.), the Igf2 gene is paternally expressed in the fetus and placenta,
and promotes the transfer of nutrients from the mother to the fetus. Deletion of
this gene from the labyrinthine trophoblast of the mouse placenta has been shown
to reduce the nutrient transfer functions and growth of the placenta, and result in
FGR. Fetuses from the knockout animals were found to weigh only 78% of wild
type fetuses at E19 (Constancia M et al., 2002).
Mice in which the gene for eNOS had been knocked out also showed
evidence of FGR and reduced placental development at E17, as well as a slower
growth trajectory postnatally. The etiology is believed to be a compromised utero-
placental circulation, on account of reduced production of NO by the endothelium
(Hefler LA et al., 2001). Prolonged blockade of nitric oxide synthesis in pregnant
rats, by continuous infusion with L-nitro-arginine, results in chronic maternal
hypertension and substantial FGR, reducing weights of newborn pups by as much
as 40% (Molnar M et al., 1994).
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1.10 Adenovirus mediated gene therapy: background and
considerations for treatment of FGR
This thesis discusses the potential of local administration of recombinant
therapeutic adenoviruses to reverse utero-placental vascular insufficiency. To
appreciate the potential hazards of intra-arterial injection of an adenovirus
encoding for VEGF, it is necessary to briefly review the nature and background
history of adenovirus infections. A concise account is provided by (Russell WC,
1998).
1.10.1 Natural history of adenoviral infections
Adenoviruses are frequent causes of spontaneous, short-lived infections of
the respiratory and gastrointestinal tracts and ocular infections in humans of all
ages, which commonly result in brief pyrexia (fever) and signs of temporary
inflammation and epithelial damage in the affected tissues. Systemic infection,
such as meningoencephalitis, is very uncommon. Infection normally occurs via
aerosol spread. Natural infectivity is low because adenoviruses are frequently
found in the atmosphere, whereas people rarely develop a clinically apparent
infection. Recovery is considered to be due to clearance of the virus and infected
cells by humoral and cellular mechanisms (Russell WC, 1998;O’Riordan C,
2002;Trapnell BC and Shanley TP, 2002).
Adenoviruses do not integrate into the host genome (Russell WC,
1998;Evans JD and Hearing P, 2002). For that reason, and because of the efficacy
of the immune response, active adenoviral infection is short-lived and chronic
infection does not occur in people with a normal immune system. Serotype 5
adenovirus infections commonly occur in children in the community, so
antibodies are often found in young people and in most adults (Russell WC,
1998).
There is limited data on adenovirus infection during pregnancy and the
association of adenovirus with miscarriage and FGR (Reddy UM et al.,
2005;Montone KT et al., 1995). However the evidence is only circumstantial and
78
there is none to confirm adenovirus infection to be the etiological factor for
abnormal pregnancies. Infact, the presence of viral infection in amniotic fluid
samples (collected at amniocentesis) was found to be not significantly associated
with postamniocentesis pregnancy loss (Wenstrom KD et al., 1998). The
adenovirus-VEGF construct used in the studies described in this Ph.D. has been
genetically modified by deletion of E1 and partial deletion of E3, the former
making it replication deficient, which is a major defence against any disease in
humans (Figure 1.6)
Figure 1.6 – Recombinant adenoviral construct used in the experiments
described in this thesis.
The adenoviral backbone has been modified by deletion of E1 and partial deletion of E3, the
former resulting in the construct becoming replication incompetent. ITR = Inverted terminal
repeats; ψ = packaging signal. 
1.10.2 Infection with replication deficient adenoviruses
Adenovirus virions normally infect susceptible species (e.g. humans, pigs,
and cotton rats) by entering cells via attachment to Coxsackie and Adenovirus
Receptor (CAR), followed by binding to integrins 3 and 5 which promote
virus internalization (Bergelson JM et al., 1997;Tomko RP et al., 1997;Nemerow
GR and Stewart PL, 1999). They become uncoated in the cytoplasm, transported
to the nucleus and divert the cell’s synthetic mechanisms to produce more viral
DNA, proteins etc, which are assembled into further virons that are subsequently
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released and are available to infect other cells and organisms (Russell WC,
1998;Evans JD and Hearing P, 2002;Nemerow GR, 2002). The adenoviral DNA
remains episomal and is not integrated into the host genome (Evans JD and
Hearing P, 2002).
It has been demonstrated that expression of CAR on trophoblast cells
varies with gestational age and trophoblast phenotype (Koi H et al., 2001). CAR
was found to be continuously expressed in invasive cytotrophoblast (fetal side)
but not in syncytiotrophoblast (outermost fetal component), thus rendering the
syncytiotrophoblast resistant to adenoviral infection and limiting transplacental
transmission. The ability of adenoviruses to infect trophoblasts is also related to
the state of trophoblast differentiation (MacCalman CD et al., 1996;Parry S et al.,
1998). Recombinant adenoviruses efficiently transduce the inner cytotrophoblast,
but there is a significant reduction in the transduction efficiency of these vectors
after the terminal differentiation of the mononucleated cytotrophoblast into the
multinucleated syncytiotrophoblast.
These reports (MacCalman CD et al., 1996;Parry S et al., 1998;Koi H et
al., 2001) and others (Nemerow GR, 2002) do suggest that species susceptibility
to adenovirus infection is related to the absence or scarcity of appropriate CAR
receptors. Based on these reports, it is evident that administration of adenoviral
vectors into the utero-placental vasculature is likely to limit fetal transmission
because of the placental barrier, which is refractory to infection. However, it is
important to note that this hypothesis relies on assays of CAR in tissue culture,
which can itself alter expression of the virus receptor and may not fully reflect
events in vivo. ‘Susceptibility’ may be only a relative state as there are
experimental and clinical results showing adenoviral infection of cells and
animals of non-susceptible species after exposure to high concentrations of wild-
type and modified viruses to become gene therapy agents (Evans JD and Hearing
P, 2002;Kim M et al., 2002;Batra RK and Sharma SWL, 2002).
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To conclude, it is important to be aware that there are now experimental
and clinical results showing that adenoviral vectors may infect cells from animals
of so-called ‘non-susceptible’ species, and the details of expression and the
metabolic activities of the viral and imported transgenes in these circumstances
are not yet clear. Thus, in the context of developing a safe gene therapy candidate
for treatment of FGR, the potential for transplacental transmission needs to be
thoroughly investigated to assess the safety of administration.
1.11 Rationale for use of Adenovirus-vegf and mechanism
of action
Vascular Endothelial Growth Factor (VEGF, especially VEGF-A) is
essential in several processes during embryonic development, including
vasculogenesis, whereby primordial vessels arise from blood islands and
endothelial cell progenitors undergo differentiation; and angiogenesis, which is
the formation of new blood vessels (capillaries) from pre-existing ones (Carmeliet
P, 2003;Sadler TW, 2004) (Figure 1.7).
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Figure 1.7 - Embryonic blood vessel formation involves two major processes:
vasculogenesis (top), in which vessels arise from blood islands, and
angiogenesis (bottom), in which new vessels sprout from existing ones.
During vasculogenesis, fibroblast growth factor 2 (FGF-2) binds to its receptor on subpopulations
of mesoderm cells and induces them to form hemangioblasts. Then under the influence of VEGF
acting through two different receptors, these cells become endothelial and coalesce to form
vessels. Angiogenesis is also regulated by VEGF, which stimulates proliferation of endothelial
cells at points where new vessels will sprout from existing ones (Sadler TW, 2004).
Several groups have suggested that VEGF gene or protein therapy may be
therapeutically useful in local perivascular applications by stimulating vascular
protective endothelial functions (Zachary I et al., 2000) and as a potential
treatment for ischaemic heart disease (Simons M et al., 2000;Yla-Herttuala S and
Martin JF, 2000;Khurana R et al., 2001). Importantly, VEGF has been found to
cause vasodilatation and an increase in blood flow in diverse animal blood vessels
and vascular beds (Ku DD et al., 1993;Takeshita S et al., 1998). These effects are
mediated partly through its ability to stimulate endothelial production of nitric
oxide (NO) and prostacyclin (PGI2) (Laitinen M et al., 1997;Wheeler-Jones C et
al., 1997;Horowitz JR et al., 1997).
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Several studies have shown VEGF production and secretion in the human
placental and fetal membranes. VEGF is expressed in the syncytiotrophoblast,
chorionic and amniotic membranes and decidua (Ahmed A et al., 1995), secreted
by villous fibroblasts (Anthony FW et al., 1994), and the villous trophoblasts
(Lash GE et al., 2002). The fall in uteroplacental resistance in normal pregnancy
is mediated by interstitial extravillous trophoblast secretion of angiogenic and
vasodilator signals such as VEGF to promote local blood flow to the uterus
(discussed in Section 1.13.5). In FGR and PET, there is decreased depth and
density of trophoblast invasion (Naicker T et al., 2003;Reister F et al., 2001), and
myometrial small arteries show increased vasoconstriction and decreased
endothelium-dependent vasodilatation (Ong SS et al., 2005;Wareing M et al.,
2005).
In PET, placental derived soluble (s) Flt-1, an antagonist (decoy receptor)
for VEGF is upregulated, and is thus proposed to cause lowered circulating
concentrations of free VEGF and endothelial dysfunction (Sibai B et al.,
2005;Ahmad S and Ahmed A, 2004). Analysis of supernatants from pre-
eclamptic placental villous explant cultures revealed a four-fold rise in sFlt-1
compared to normal pregnancies. Conditioned medium from normal villous
explants induced endothelial cell migration and in vitro tube formation, both of
which were attenuated by pre-incubation with sFlt-1. Endothelial cells treated
with pre-eclamptic conditioned medium showed substantially reduced
angiogenesis compared with normal conditioned (P < 0.001) medium, which was
not further decreased by the addition of exogenous sFlt-1, indicating a saturation
of the soluble receptor (Ahmad S and Ahmed A, 2004).
Similarly, maternal serum concentrations of VEGF have been found to be
significantly diminished in pregnancies complicated by FGR (Bersinger NA and
Odegard RA, 2005). Another study found that women with established FGR have
significantly elevated levels of sFlt-1, but importantly, the increase in sFlt-1 does
not precede the clinical onset of FGR, as it does in PET. The same study showed
that VEGF levels in cases of established FGR were significantly lower than in
normal pregnant women (Savvidou MD et al., 2006).
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For several years, there have been suggestions that placental angiogenic
and vasoactive factors might serve as therapeutic targets in compromised
pregnancies in humans (Reynolds LP et al., 2006;Ahmad S and Ahmed A, 2004).
I have carried out experiments in this thesis to test this hypothesis in pregnant
sheep.
1.12 Vascular Endothelial Growth Factor (VEGF)
VEGF is a vascular endothelial cell-specific mitogen, initially called
vascular permeability factor because of its ability to render microvessels
hyperpermeable to plasma proteins at sites where it was over-expressed along
with its receptors (Leung DW et al., 1989;Dvorak HF et al., 1991). Its role as a
potent endothelial mitogen was confirmed only a few years later. Since these
initial findings it has been shown that VEGF-A165, the substance characterized in
these early studies, is a member of a wider family encompassing a number of
related genes, which have multiple effects on endothelial and other cells, and play
a pivotal role in vascular development. The pro-angiogenic role of VEGF has
attracted clinical interest for its possible uses in gene therapy to improve the blood
supply to ischaemic tissues (therapeutic angiogenesis) and as a target for anti-
angiogenic drugs that prevent tumour vascularization. In addition to its role in
blood vessel development during embryogenesis and post-natal growth, VEGF
also has roles in adult angiogenesis during wound healing, the menstrual cycle
and exercise-induced muscle enlargement, and in vascular maintenance (Maharaj
AS and D'Amore PA, 2007;Ferrara N, 1999).
The VEGF family of growth factors comprises a group of homodimeric
glycoproteins and belongs to a super-family of growth factors also comprising the
Platelet derived growth factors (PDGFs). Both growth factors consist of
antiparallel homodimers covalenly linked by two interchain disulphide bonds and
possessing a characteristic cysteine knot structure that confers important binding
properties (Keyt BA et al., 1996).
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The VEGF family includes VEGF-A, -B, -C, -D, the related placental
growth factor (PlGF), the orf virus-encoded factor VEGF-E, and VEGF-F found
in snake venom. The human VEGF-A gene is organized in eight exons, separated
by seven introns (Tischer E et al., 1991), and is localized in chromosome 6p21.3
(Vincenti V et al., 1996). Alternative exon splicing of a single VEGF-A gene
results in the generation of at least five different molecular species, having
respectively 121, 145, 165, 189, and 206 amino acids, following signal sequence
cleavage (VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206) (Figure 1.8). The
different VEGF-A isoforms have different biochemical and physical properties
due to the presence or absence of the C-terminal domains, encoded by exons 6
and 7. VEGF165 is deficient in the residues encoded by exon 6, while VEGF121
lacks the residues encoded by exons 6 and 7. VEGF165 is the predominant and
most potent molecular species produced by a variety of normal and transformed
cells. Native VEGF165 is a basic, heparin-binding, homodimeric glycoprotein of
45 kDa (Ferrara N and Henzel WJ, 1989). Transcripts encoding VEGF121 and
VEGF189 have been detected in a majority of cells and tissues which express the
VEGF-A gene, whilst VEGF206 is a rare form (Houck KA et al., 1991). VEGF121
is a freely diffusible protein. VEGF165 is also secreted, although a significant
fraction remains bound to the cell surfaces and extracellular matrix (ECM) on
account of its affinity to heparan sulphate, while VEGF189 and VEGF206 are
almost completely sequestered in the ECM (Park JE et al., 1993). The heparin
binding activity of VEGF-A is due to the presence or absence of exons 6 and/or 7
that encode for heparin binding domains (Robinson CJ and Stringer SE, 2001).
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Figure 1.8 – VEGF-A isoforms result from alternative splicing
VEGF-A isoforms are generated by alternative splicing from a single gene, and are 121, 145, 165,
189 and 206 amino acids long. The larger isoforms contain a heparin binding domain which
mediates binding to the extracellular matrix (ECM), Neuropilin-1 and HSPG. Domains 1 to 5 are
conserved between all VEGF-A isoforms and constitute the VEGFR-1 and VEGFR-2 binding
domains. Figure adapted and modified from (Eming SA and Krieg T, 2006).
The physiological importance of VEGF-A is discussed in Section 1.13.
VEGF-B is expressed in a wide range of tissues and particularly in the
heart and skeletal muscle. VEGF-B knockout mice are healthy and fertile
(Bellomo D et al., 2000;Aase K et al., 2001). Both of these studies performed in
knockout mice noted that VEGF-B appears to have a role in cardiac development,
but the reported phenotypes differed. Bellomo et al (2000) reported that one-
month old VEGF-B-null mice have smaller hearts than wild-type mice, while
Aase et al (2001) reported that the electrocardiogram PQ interval was slightly
extended, which they attributed to an atrial conduction defect.
VEGFs-C and D are believed to play an important role in the development
of the lymphatic system. VEGF-C-/- mice die during late embryogenesis due to a
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defect in lymph vessel formation (Karkkainen MJ et al., 2001). In contrast,
VEGF-D-/- mutant mice are viable and do not display any abnormal phenotype
(Baldwin ME et al., 2005), suggesting that any key developmental roles of
VEGF-D are compensated by another molecule, possibly VEGF-C. However,
VEGF-D may play an important role in lymphangiogenesis, as ectopic expression
of VEGF-D in the skin of transgenic mice under the control of the keratin 14 gene
promoter induced the growth of lymphatic vessels in the dermis, whereas blood
vessels were unaffected (Veikkola T et al., 2001). It may also be possible that
VEGF-D may be less important in mice than humans, given that mouse VEGF-D
lacks VEGFR2 binding capacity.
VEGF-E is encoded in the Orf virus, a parapox virus infecting sheep,
goats and sometimes humans and inducing a transient angiogenesis in the skin
(Lyttle DJ et al., 1994).
1.13 Physiological significance of VEGF
Hereafter VEGF denotes VEGF-A. VEGF is a potent biological molecule,
which plays an important role in several physiological and disease-related
functions. These include angiogenesis, vasodilatation, vascular permeability,
vascular protection and endothelial cell survival, which in turn have been
implicated in developmental and pathological roles.
1.13.1 Angiogenesis
VEGF is known to play a critical role in embryonic vasculogenesis and
angiogenesis. Loss of a single VEGF allele in mice is known to result in
embryonic lethality between day 11 and 12. The VEGF+/- heterozygous embryos
are growth retarded and exhibit a number of developmental abnormalities such as
under-development of the fore-brain region, malformation of the outflow region
of the heart, rudimentary dorsal aortae and reduced thickness of the ventricular
wall. The yolk sac revealed a markedly reduced number of nucleated red blood
cells within the blood islands. There were significant defects in the vasculature of
a number of tissues and organs, including the placenta and nervous system
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(Ferrara N et al., 1996;Carmeliet P et al., 1996). All these defects are believed to
result directly or indirectly from the reduced levels of VEGF.
The effects of VEGF on post-natal development have also been assessed.
Partial inhibition of VEGF achieved by inducible Cre-loxP-mediated gene
ablation resulted in increased mortality, stunted body growth, and impaired organ
development, primarily of the liver (Gerber HP et al., 1999). Administration of a
soluble VEGF receptor chimeric protein, mFlt(1-3)-IgG, which achieves a greater
level of VEGF inhibition (than the conditional Cre-loxP-mediated gene ablation
strategy), resulted in a nearly complete arrest of somatic growth and lethality
within 4-6 days, when administered soon after birth. The primary cause of death
in these mice appeared to be liver and renal failure. On isolation, endothelial cells
from the liver exhibited increased apoptotic index, thereby suggesting that VEGF
is required not only for proliferation but also survival of endothelial cells.
However, the dependence on VEGF was gradually lost after the fourth postnatal
week, after which time VEGF inhibition did not result in any serious defects
(Gerber HP et al., 1999).
In a fully grown animal, VEGF is primarily required for processes
dependent on active angiogenesis, such as corpus luteum formation and wound
healing. The development and endocrine functions of the ovarian corpus luteum
are dependent on the growth of new capillary vessels (Bassett DL, 1943). VEGF
mRNA is temporally and spatially upregulated during the proliferation of blood
vessels in the rat, mouse and primate ovary and the rat uterus, suggesting that
VEGF mediates the cyclical growth of blood vessels in the female reproductive
tract (Ravindranath N et al., 1992;Cullinan-Bove K and Koos RD, 1993).
The angiogenic role of VEGF is also important for wound healing, as re-
vascularisation of injured/damaged tissue is essential for repair. It is believed that
VEGF also increases the permeability of capillaries surrounding wounds. This
leads to fibrin deposition in the damaged tissue, which in turn acts as a substrate
for tissue regrowth, including angiogenesis. The regulation of VEGF expression
and angiogenesis is disturbed in abnormally healing wounds (Bates DO and Jones
RO, 2003).
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However, not all angiogenesis mediated by VEGF is beneficial. Many
tumour cell lines secrete VEGF in vitro, suggesting that this molecule is an
important mediator of tumour vascularisation. Without attracting blood vessel
growth, many tumours are unable to grow to dangerous sizes due to the
limitations of obtaining nutrients via diffusion. In situ hybridisation studies have
demonstrated that VEGF mRNA is up-regulated in many human tumours,
including lung, breast, ovary, kidney and cancers of the gastrointestinal tract
(Ferrara N, 1999). The discovery of the involvement of VEGF in tumour
vascularisation and progression launched a huge effort to develop anti-VEGF
therapies for the treatment of cancer, including anti-VEGF antibodies and VEGF
receptor tyrosine kinase inhibitors. Bevacizumab (Avastin), a humanised anti-
VEGF-A monoclonal antibody, received FDA approval in 2004 for the treatment
of colorectal cancer. A phase III trial showed that Bevacizumab slowed tumour
growth and improved survival when used in combination with other
chemotherapeutic agents (Hurwitz H et al., 2004), and other trials have shown
varying degrees of efficacy of Bevacizumab with different cancers (Jain RK et al.,
2006).
VEGF-mediated angiogenesis is also involved in eye disease.
Inappropriate blood vessel growth in the eye often interferes with vision, leading
to visual impairment. A common cause of blindness in older people is wet age-
related macular degeneration whereby blood vessels grow into the eye with
advancing age, particularly in the retinal region around the optic nerve (the
macula). VEGF is synthesized by retinal epithelial cells (Adamis AP et al., 1993),
and is over-expressed in retinopathies in, for example, diabetes (Aiello LP et al.,
1994). Anti-VEGF therapies Pegaptanib (Macugen) and Ranibizumab (Lucentis)
are FDA-approved for the treatment of age-related macular degeneration, working
in part by preventing VEGF-stimulated blood vessel growth in the retina (Ciulla
TA and Rosenfeld PJ, 2009). In clinical trials, both Pegaptanib and Ranibizumab
have been shown to slow the onset of macular degeneration and in some patients
improve visual performance (Gragoudas ES et al., 2004;Rosenfeld PJ et al.,
2006;Brown DM et al., 2006;Ciulla TA and Rosenfeld PJ, 2009).
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VEGF-reducing therapies may suffer from a number of unwanted side-
effects however, due to loss of VEGF-dependent vascular protection, including
bleeding, oedema, clotting and hypertension (Kamba T and McDonald DM,
2007).
In some other pathologies, a pro-angiogenic strategy may be beneficial.
Atherosclerosis leads to build-up of plaques in artery walls, narrowing the lumen
and increasing the likelihood of plaque rupture and thrombosis. Atherosclerosis of
the coronary or cerebral arteries may lead to life-threatening events such as
myocardial infarction or stroke. Stimulation of collateral vessel growth to bypass
a narrowing vessel has been of major interest in treating conditions such as angina
and peripheral vascular disease, and preventing future heart attacks. VEGF may
have a role in collateral growth under normal and ischaemic conditions (Rissanen
TT et al., 2005;Clayton JA et al., 2008) and adenovirus-mediated over-expression
of VEGF has beneficial effects in animal models of peripheral and cardiac
ischaemia (Zachary I et al., 2000), though so far convincing therapeutic effects
have not been demonstrated in clinical trials (Zachary I and Morgan RD, 2011).
1.13.2 Vasodilatation
VEGF increases endothelial production of the vasoactive molecules NO
and PGI2 (Laitinen M et al., 1997;Wheeler-Jones C et al., 1997). The importance
of both these molecules in vasodilatation is discussed in greater detail below
(Section 1.16). VEGF induces sustained eNOS activation in endothelial cells
(ECs) via Phosphoinositide 3-kinase (PI3K) dependent Akt-catalysed
phosphorylation of eNOS at Ser1177, the same site phosphorylated in response to
shear stress (Dimmeler S et al., 1999). Phosphorylation of this site renders eNOS
active at resting Ca2+ concentrations. PI3Ks are a family of enzymes which play
an important role in cellular physiology, particularly cell growth, proliferation,
differentiation, motility, survival and intracellular trafficking. They mediate these
functions in response to the binding of different growth factors to cell surface
receptors (Vanhaesebroeck B et al., 2010).
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VEGF also promotes long-term NO production by inducing expression of
both eNOS and the highly active isoform iNOS (Kroll J and Waltenberger J,
1998). Short-term (less than 10 minutes after VEGF administration) NO
production is independent of PI3K, and may involve VEGF-stimulated Ca2+
mobilisation (Gelinas DS et al., 2002). VEGF-stimulated PGI2 production in ECs
involves PKC- and ERK-mediated activation of cytosolic phospholipase 2, and
also requires intracellular Ca2+ (Gliki G et al., 2001;Wheeler-Jones C et al., 1997).
1.13.3 Vascular and Neuro-protection
It has been proposed that low levels of VEGF protect the adult vasculature
partly via NO and prostacyclin production (Zachary I et al., 2000). Common side
effects for anti-VEGF therapies (such as Bevacizumab) include bleeding, oedema,
unwanted clotting and hypertension (Kamba T and McDonald DM, 2007). Mice
with an endothelial-specific VEGF knockout survive to birth but show
progressive endothelial degeneration, with 50% of them dying before 25 weeks of
post-natal life (Lee S et al., 2007). Interestingly, exogenous VEGF administration
is unable to compensate for loss of endothelial-produced VEGF in endothelial
survival, suggesting that an intracellular VEGF signalling loop may be important.
A role for VEGF in neuroprotection (and other aspects of the nervous
system including axonal outgrowth) has been noted (Sondell M et al., 2000).
While this may partially occur via regulation of neural vascularisation or
maintenance of the neural vasculature, VEGF acts as a direct pro-survival factor
for cultured neurons (Oosthuyse B et al., 2001). In addition, loss of VEGF
isoforms showed a defect similar to that observed in patients with amyotrophic
lateral sclerosis (ALS), an adult-onset motor neuron disease. Virus-mediated
over-expression of VEGF in muscles of mice with experimental ALS reduced
disease symptoms and improved survival (Azzouz M et al., 2004), suggesting that
VEGF-dependent neuroprotection is biologically relevant.
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1.13.4 Endothelial cell migration
VEGF also plays important roles in modulating endothelial cell migration
and vascular permeability. Such effects are important for processes like wound
healing. VEGF mediates endothelial cell migration by activating proteins
involved in chemotaxis. As the ECM plays an essential role in stabilising blood
vessels through interactions with endothelial cells and vascular smooth muscle
cells (VSMCs) sheathed in a basement membrane, breakdown of the latter is a
pre-requisite for endothelial cell migration and formation of new vessels during
development and disease (Zachary I, 2005). This is triggered by the induction of
matrix-degrading metalloproteinases (MMPs). MMP-2 and MMP-9 appear to
play an important role in promoting angiogenesis and are upregulated along with
VEGF and VEGFR2 in angiogenic lesions in a model of tumour angiogenesis
(Bergers G et al., 2000).
1.13.5 Physiological re-modelling of spiral arteries in
pregnancy
In humans, the fall in utero-placental vascular resistance that occurs in
pregnancy, is mediated by local factors including VEGF. For example,
leucocyte/trophoblast cell interactions result in substantial increases in both
VEGF and PlGF (Zhou Y et al., 2003b). The human cytotrophoblast cells secrete
angiogenic and vasodilator signals (Zhou Y et al., 2003a) that affect local blood
flow to the uterus and mediate the normal maternal response to pregnancy, which
includes vasodilatation in the utero-placental vascular circuit and increased
maternal cardiac output and blood volume. As already described, in PET,
placental-derived sFlt, an antagonist of VEGF and PlGF, is upregulated resulting
in lowered circulating concentrations of free VEGF and PlGF and endothelial
dysfunction (Sibai B et al., 2005). Trophoblast expression of various vasodilatory
and anticoagulative factors such as VEGF is related to the depth of invasion by
trophoblast giant cells (Hemberger M et al., 2003). Invading cytotrophoblasts
secrete VEGF to regulate their acquisition of an endothelial-like phenotype which
allows them to replace the maternal cells that line the uterine vessels (Zhou Y et
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al., 2002). These cells are also dependent on VEGF for their maintenance and
growth (Zhou Y et al., 2003a).
1.14 Regulation of VEGF gene expression
Upregulation of VEGF-A by hypoxia is mediated via the binding of
hypoxia inducible facor-1 (HIF-1) to the hypoxia response element (HRE) in the
VEGF promoter. HIF-1 is composed of a 120 kDa HIF-1α subunit complexed 
with a HIF-1β subunit. Under physiological conditions (in normoxia), HIF-1α 
undergoes rapid degradation. Two key prolines within its oxygen degradation
domain (ODD) are hydroxylated by one of a three member family of prolyl-
hydroxylase domain-containing proteins (PHDs 1-3), the activity of these
enzymes being oxygen dependent (Semenza GL, 2001). Their actions allow HIF-
1α interaction with ubiquitin ligase thus promoting the formation of a larger 
complex which is rapidly destroyed by proteasome activity. Under hypoxic
conditions, the hydroxylation of HIF-1α is reduced, preventing degradation and 
allowing HIF-1α to accumulate and to combine with HIF-1β at nuclear HREs of 
target genes such as VEGF, thereby allowing gene transcription. Not only is
hypoxia able to increase the production of VEGF, it also allows stabilization of its
mRNA (Ikeda E et al., 1995). These two mechanisms provide a system by which
ischemic tissues can increase VEGF production and secretion, so attracting the
growth of new blood vessels (Shweiki D et al., 1992).
In a study investigating the role of HIF-1α in tumour growth, Ryan et al 
showed that HIF-1α inactivation led to a dramatic reduction of tumorigenesis and 
increased apoptosis, concomitant with reduced hypoxia-induced expression of
VEGF (Ryan HE et al., 1998).
1.15 VEGF Receptors
VEGFs bind to three major receptor tyrosine kinases (RTK): VEGFR-
1/Flt-1 (fms-like tyrosine kinase-1), VEGFR2/KDR/Flk-1 (fetal liver kinase-1)
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and VEGFR-3/Flt-4. In addition, heparan sulphate proteoglycans (HSPGs) and
Neuropilins (NRPs) are also able to bind VEGF isoforms in an isoform-specific
manner.
VEGFR-1 and VEGFR-2 comprise an extracellular domain of seven
immunoglobulin-like (Ig-like) domains containing ligand binding activity, a
single hydrophobic transmembrane domain and a cytoplasmic region, containing
a bipartite tyrosine kinase domain divided into two parts by an inert sequence.
VEGFR-3 is slightly different from the structures of VEGFR-1 and VEGFR-2
because the fifth Ig-like domain (in VEGFR-3) is cleaved into disulfide-linked
subunits (Iljin K et al., 2001). Analysis of mutant and chimeric forms of VEGFR1
and VEGFR2 have shown that ligand binding occurs primarily to the second and
third Ig-like domains (Barleon B et al., 1997b;Davis-Smyth T et al., 1996). Figure
1.9 (Page 98) summarises the interactions between the different VEGF isoforms
and their receptors. Briefly, VEGF-A165 binds to VEGFR1 and VEGFR2 (Neufeld
G et al., 1999). VEGF-C and –D also recognize VEGFR2 but with lower affinity
and bind to a third receptor, VEGFR3. PlGF and VEGF-B bind with high affinity
only to VEGFR1, and VEGF-E only binds to VEGFR-2. VEGFR-1 has a 10-fold
higher affinity for VEGF-A165 than VEGFR-2 (Petrova TV et al., 1999).
Nevertheless, VEGFR-1 undergoes little detectable phosphorylation and weak
signaling when bound to VEGF-A165, whereas, VEGF-A165 binding to VEGFR-2
results in autophosphorylation on several major sites and is followed by the
activation of multiple downstream signaling pathways (Waltenberger J et al.,
1994). All three VEGF receptors possess a similar overall structure, the tyrosine
kinase domains being 80% identical at the amino acid level in the three receptors.
1.15.1 VEGFR-1
VEGFR-1 is a 180kDa protein which binds VEGF and can be alternatively
spliced to generate a soluble, secreted form, sFlt-1. VEGFR-1 null mice die in
utero, apparently from a vascular defect, with lethality occurring around E8.5
(Fong GH et al., 1995). Endothelial cells are present, but these are not correctly
assembled into functional vascular channels. This indicates that while VEGFR-1
94
is not required for endothelial cell differentiation, it may be necessary for vascular
organization. Blood cells were also formed. This is in contrast to the defect in
VEGFR-2 mice, where endothelial and blood cells were lacking (Shalaby F et al.,
1995). The lack of vessel formation in VEGFR-1 null mice has been associated
with an abnormally high number of endothelial precursor cells, due to increased
commitment of mesenchymal stem cells to the hemangioblast lineage (Fong GH
et al., 1999). Using chimeric mice generated from mixtures of VEGFR-1 null and
wild-type embryonic stem cells in various proportions, the same study showed
that when diluted, the VEGFR-1 null EC progenitors formed apparently normal
vascular channels. This indicates that the vascular disorganization observed in
VEGFR-1 null mice is because of a dramatic increase in the number of
endothelial progenitors. It also suggests that endothelial expression of VEGFR1
may not be a pre-requiste for an EC to participate normally in vessel formation.
VEGFR-1 tyrosine kinase activity is not essential for normal vascular
development. Hiratsuka et al deleted exons encoding the C-terminus of VEGFR-1
in mice, so preserving the extracellular and transmembrane regions but removing
the intracellular tyrosine kinase domain. Mice homozygous for the deletion were
viable and fertile, and blood vessel development was unaffected (Hiratsuka S et
al., 1998).
Overall, this suggests that VEGFR-1 may act as a negative regulator
(decoy receptor) of VEGF function during embryonic development which
sequesters this ligand, rendering it less available to VEGFR-2 and preventing
excessive VEGF signaling through the latter. Soluble VEGFR-1, lacking either
the tyrosine kinase domain or the transmembrane domain, can still sequester
VEGF away from VEGFR-2, allowing normal vascular development.
The pathological role of sFlt-1 in the etiology of PET has already been
discussed above.
Even though VEGF signaling through VEGFR-1 is not essential in ECs; it
is very important in some non-endothelial cells. Both monocytes and
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macrophages require the tyrosine kinase signaling activity of this receptor for
chemotaxis in response to VEGF and PlGF (Barleon B et al., 1996;Clauss M et
al., 1996).
1.15.2 VEGFR-2
VEGFR-2, also known as kinase domain receptor (KDR) in humans or
fetal liver kinase-1 (Flk-1) in mice, binds VEGF-A165 resulting in phosphorylation
of its tyrosine residues (Millauer B et al., 1993;Quinn TP et al., 1993). VEGFR-2
binds to VEGF-A, fully processed VEGFs C and D, and VEGF-E.
VEGFR-2 is expressed in endothelial cells and their progenitors (Millauer
B et al., 1993;Quinn TP et al., 1993;Yamaguchi TP et al., 1993), and was thought
to be specific for endothelial cells, but has more recently been identified on other
cell types including neurons and their progenitors (Yang X and Cepko CL,
1996;Nishijima K et al., 2007).
VEGFR-2 null mice die in utero at E8.5-9.5 due to a massive defect in
vasculogenesis, whereas heterozygous mice were fertile and apparently normal
(Shalaby F et al., 1995). In knockout animals, no blood vessels were observed in
either the embryo or yolk sac, and yolk sac blood islands were not formed.
VEGFR-2 null mice contained cells expressing early endothelial markers
including VEGFR3 and tie2, but not the later endothelial marker tie1, and no
recognizable endothelial cells were present, indicating an essential early role of
VEGFR2 in endothelial differentiation. Interestingly, VEGF-A knockout mice do
form some endothelial cells, showing that some roles of VEGF-A in endothelial
development can be compensated to some extent by another VEGFR-2 ligand,
such as VEGF-C. VEGFR-2 null mice also developed few committed
haematopoietic progenitor cells, indicating a role for VEGFR2 in blood
development. VEGFR2 has been reported as a marker which defines the
haemangioblast (Yamaguchi TP et al., 1993), the blood island precursor which
forms endothelial and blood cells in the yolk sac, explaining the association
between absence of blood and endothelial cells in VEGFR-2 deficient mice.
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Porcine aortic endothelial cells which lack endogenous VEGF receptors,
display chemotaxis and mitogenesis in response to VEGF when transfected with a
plasmid coding for KDR. On the contrary, transfected cells expressing Flt-1 lack
such responses (Waltenberger J et al., 1994). While VEGFR-2/Flk-1/KDR is
known to undergo strong ligand-dependent tyrosine phosphorylation in intact
cells, Flt-1 undergoes only a weak or undetectable response (Seetharam L et al.,
1995;Waltenberger J et al., 1994). Furthermore, VEGF mutants which bind
selectively to VEGFR-2, are fully active EC mitogens (Keyt BA et al., 1996) and
VEGFR-2 activation is required for antiapoptotic effects of VEGF for human
umbilical vein endothelial cells (HUVECs) in serum-deprived conditions (Gerber
HP et al., 1998). Thus, it is suggested that the major signaling receptor for VEGF,
mediating most of its biological activities in ECs (such as migration, proliferation,
survival and changes in permeability) is VEGFR-2.
1.15.3 VEGFR-3
VEGFR-3 is expressed only in venous endothelial cells in the embryo, and
is confined to the lymphatic system in the adult (Iljin K et al., 2001). It has roles
in cardiovascular development in the embryo, particularly lymphangiogenesis,
and binds to VEGF-C and VEGF-D. In VEGFR-3 deficient mice, large vessels
become abnormally organized with defective lumens, leading to fluid
accumulation in the pericardial cavity and cardiovascular failure at embryonic day
9.5 (Dumont DJ et al., 1998).
1.15.4 Neuropilins
Neuropilins (NRPs), [reviewed by (Pellet-Many C et al., 2008)] are
transmembrane glycoproteins that bind some VEGFs, and class 3 semaphorins
(mainly sema3A), the latter being secreted proteins involved in directing the
growth cones of growing axons. Two neuropilin genes are known, NRP1 and
NRP2, which like VEGFR1 can produce either a transmembrane receptor or, by
alternative splicing, can result in soluble forms (sNRP1 and 2) composed of part
of the extracellular region only. NRP1 binds to some isoforms of VEGF-A
(including VEGF-A165) (Soker S et al., 1998), VEGFs B-E and PlGF2 (and mouse
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PlGF), whereas NRP2 binds to some VEGF-A isoforms (including VEGF-A165),
and VEGFs C and D (Gluzman-Poltorak Z et al., 2000;Karpanen T et al., 2006).
Both NRP1 and NRP2 are expressed in vascular endothelial cells, but in the adult
vasculature NRP1 is mainly expressed by arterial ECs, whereas NRP2 is
expressed by venous and lymphatic ECs (Yuan L et al., 2002).
NRPs have no known signaling role acting alone, but are believed to act as
co-receptors for VEGF and semaphorins. When co-expressed in cells with KDR,
NRP1 enhanced the binding of VEGF-A165 to KDR and VEGF-A165-mediated
chemotaxis. Conversely, inhibition of VEGF-A165 binding to NRP-1, inhibits its
binding to KDR and its mitogenic activity for endothelial cells (Soker S et al.,
1998). These findings suggest that neuropilin-1 binding of VEGF and its
complexation with KDR enhances KDR signaling, causing increased migratory
and proliferative effects of VEGF-A165. The potentiation of VEGF-stimulated cell
signaling by NRP-1 could occur via a number of mechanisms, such as
stabilization of the VEGF/VEGFR-2 signaling complex at the cell surface so
increasing the duration of VEGFR-2 signaling, or by transducing signals directly
(e.g. via the NRP-1 associated molecule synectin) which feed in to VEGFR-2
signaling.
NRP-1 null mice die in utero around E12.5-13.5. Multiple cardiovascular
defects are seen with sparse capillaries in the yolk sac and some major vessels in
the brachial region incorrectly branched, incomplete or not formed at all
(Kawasaki T et al., 1999). Neurogenic defects are also observed, with nerves
following incorrect paths, probably due to a blockade of semaphorin 3-mediated
signaling (Kitsukawa T et al., 1997). The vascular and neural functions of NRP-1
were further delineated by producing mice deficient in NRP-1 specifically in the
endothelium, or mice expressing mutant NRP-1 specifically unable to bind
Sema3A but able to bind VEGF-A165 (Gu C et al., 2003). Endothelial-specific
NRP-1 null mice died in utero, displaying abnormalities in major arteries and
reduced vessel branching at E12.5. In contrast, mice expressing a mutant NRP-1
which binds VEGF-A165 but not Sema3A, are born alive, but exhibit nervous
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system defects and die soon after birth. Together these data indicate that
endothelial expression of NRP-1 but not Sema3A binding to NRP-1, is required
for normal vascular development, while Sema3A binding to NRP-1 plays a
restricted role in neurogenesis. However, the precise contribution of VEGF
binding to NRP-1 in vascular development is not yet known.
NRP-2 null mice are viable, with no apparent cardiovascular defects but a
reduced number of small lymphatic vessels (Chen H et al., 2000;Yuan L et al.,
2002). The major defect appears to be neural, with abnormal guidance of cranial
and spinal nerves. NRP-1/NRP-2 double knockout mice die in utero at E8, earlier
than for single NRP-1 null mice (Takashima S et al., 2002), suggesting that NRP-
2 may compensate to a certain extent for NRP-1 during early cardiovascular
development. NRP-1/NRP-2 double-null mice display a severe cardiovascular
abnormality with large avascular areas in the yolk sac and embryo, and reduced
connections between blood vessel sprouts. This severe phenotype, similar to that
observed for VEGF-A null and VEGFR-2 null mice, may reflect insufficient
VEGF-A/VEGFR-2 signalling as NRP-mediated potentiation of the VEGF-A
signal is lost.
1.15.5 Heparan sulphate proteoglycans
Several VEGF isoforms, including VEGF-A165, contain a heparin binding
domain, and so are able to bind to HSPGs. HSPGs are transmembrane proteins
abundant on the surface of endothelial cells, where the covalently-linked heparan
sulphate moiety, similar to the mast cell-produced polysaccharide mixture,
heparin, binds to the plasma protein antithrombin III. This binding accelerates the
action of antithrombin III to inactivate thrombin, so limiting the extent of
thrombus formation during the clotting cascade. HSPGs are highly negatively
charged, and bind to strongly positive regions on a variety of secreted growth
factors including VEGFs (Bernfield M et al., 1992).
The heparin binding domain of VEGF-A is not present in some isoforms
such as VEGF-A121 and differences in heparin binding, as well as NRP1 binding,
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have been suggested to account for some of the differences in, for example,
biological activity between VEGF-A splice variants. Even though heparin binding
itself does not appear essential for VEGF biological activity, at least in cell based
studies, a complete loss of heparin-binding ability may have more dramatic
effects. Heparin has been reported to affect the interaction of VEGF-A165 with
VEGFR-2 (Tessler S et al., 1994), and to increase VEGF-A165-stimulated
tubulogenesis (Ashikari-Hada S et al., 2005).
Figure 1.9 – Family of VEGF ligands and their receptors.
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1.16 Pathways of endothelium-dependent vascular
relaxation
There are three characterized pathways of endothelium-dependent
relaxation – production of Nitric oxide, Prostacyclins and Endothelial derived
hyperpolarizing factor. These are discussed below.
1.16.1 Nitric oxide
Nitric oxide (NO) is a gas produced by the NO synthase (NOS) family of
proteins. There are three cognate forms of NOS, neuronal NOS (nNOS), inducible
NOS (iNOS) and endothelial NOS (eNOS). eNOS and nNOS are expressed
constitutively, dependent on Ca2+ and calmodulin, and generate relatively small
amounts of NO for maintenance of vascular tone and neurotransmission,
respectively. On the other hand, iNOS is an inflammation-inducible, high activity,
Ca2+ independent enzyme that liberates large amounts of NO (Sessa WC,
2009;Valdes G et al., 2009)
NO serves as a second messenger in diverse physiological responses in the
cardio-vascular system, particularly vasodilatation, anti-coagulation, vascular
remodeling and angiogenesis. NO is known to be the most potent vasodilator in
large blood vessels. In the aorta and carotid arteries of eNOS knockout mice,
endothelium-dependent vasodilatation is completely eliminated (Sessa WC,
2009;Huang PL et al., 1995;Faraci FM et al., 1998). Furthermore, it has been
shown that these mice exhibit a hypertensive phenotype (Huang PL et al., 1995)
whereas transgenic mice which chronically over-express eNOS are characterized
by hypotension (Ohashi Y et al., 1998).
An effector cell, such as an endothelial cell gets stimulated by a chemical
mediator like VEGF, acetylcholine, bradykinin or physical force like shear stress
(frictional force generated by blood flow against endothelium). These stimuli
activate eNOS to promote the conversion of L-arginine to nitric oxide by
increasing the intracellular calcium (Vane JR, 1994). The nitric oxide then acts
upon the guanylate cyclase of the same cell or diffuses to another cell such as a
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smooth muscle cell to increase the cyclic (c) GMP (by the guanylate cyclase
reaction) and bring about vascular relaxation (Griffith TM et al., 1985) (Figure
1.10). As NO is soluble in water, there are no barriers to its diffusion. Hence, one
can visualize arterial endothelial cells releasing small amounts of NO each time
they are stretched by the pulsations of the heart (Vane JR, 1994), resulting in a
small degree of vascular relaxation.
When L-arginine is metabolized by NOS to form NO, L-citrulline is
formed (Palmer RM and Moncada S, 1989). This reaction is inhibited by NG-
mono-methyl-L-arginine (L-NMMA), a commonly used inhibitor of NOS activity
in pharmacology studies. L-citrulline is very quickly recycled through arginine
succinate back to L-arginine, so that the endothelial cells have a mechanism for
maintaining intracellular L-arginine concentrations (Hecker M et al., 1990). This
is important for the maintenance of vascular tone.
It has been demonstrated that VEGF not only upregulates but also
mediates some of its biological effects by upregulation of reactive oxygen species,
particularly hydrogen peroxide. This generation of reactive oxygen species by
VEGF is dependent upon the activity of PI-3 kinases (Colavitti R et al., 2002).
These reactive oxygen species have relevance for vascular biology as they
decrease the bioavailability of NO. Both superoxide and hydrogen peroxide are
highly reactive with NO and form peroxynitrites as the major product. Even
though peroxynitrites can cause vasodilatation, the concentrations required to do
so are far in excess of the effective vasorelaxant concentrations of NO. There is
now an increasing amount of evidence suggesting that a large number of
cardiovascular diseases stem from the increased generation of reactive oxygen
species, which impair the physiological functions of eNOS. These include
hypercholesterolemia, hypertension, CHD and diabetes (Kojda G and Harrison D,
1999).
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Figure 1.10 – Role of nitric oxide (NO) signaling in angiogenesis, vascular
tone and haemostasis
VEGF binding to its receptor VEGFR2 on endothelial cells activates endothelial nitric oxide
synthase (NOS3, eNOS) to produce the diffusible signaling molecule NO. NO plays an important
role in a number of physiological processes. It diffuses into vessel walls, and brings about an
increase in cyclic GMP (via the guanylate cyclase pathway) in vascular smooth muscle cells
(VSMCs), resulting in vascular relaxation and increase in blood flow. NO also stimulates
endothelial cell growth and motility, which leads to angiogenesis. VEGF signaling through NO
contributes to increased vascular permeability. In addition, NO also prevents thrombosis by
inhibiting platelet adhesion and aggregation. Figure adapted from (Isenberg JS et al., 2009).
1.16.2 Prostacyclins (PGI2)
Prostacyclin is one member of the prostaglandin family of lipid mediators
derived from arachidonic acid, of which there are now close to 90 members.
Arachidonic acid is an unsaturated constituent of the phospholipid bilayer in cell
membranes. It is metabolized by constitutive cyclooxygenases (COX-1) and
inducible COX-2 into prostaglandins and related compounds (Dubois RN et al.,
1998). COX-2 is the key enzyme involved in synthesis of PGI2, particularly in
response to treatment with growth factors (Kawabe J et al., 2010).
PGI2 is a major vasodilator within the prostaglandin cascade and
synthesized predominantly by the endothelium (Gryglewski RJ, 2008). Its main
effects are mediated either directly (through activation of soluble adenylate
cyclase, which increases cyclic AMP levels), or by opposing the vasoconstrictor
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and pro-aggregating effects of platelet-derived thromboxane-A2 (TXA2), which is
also an intermediate produced during arachidonic acid metabolism (by COX-1
enzyme). The ability of the large vessel wall to synthesize PGI2 is greatest at the
intimal surface and progressively decreases towards the adventitia (Moncada S et
al., 1977).
Prostacyclins relax isolated vascular strips and are strong hypotensive
agents on account of their property to induce vasodilatation in all vascular beds
studied, including the pulmonary and cerebral circulations. The vasorelaxant
effects of prostacyclin have been reviewed in detail (Moncada S and Vane JR,
1978).
During normal pregnancy, the urinary metabolites of prostacyclin increase
progressively to up to 5-fold above their original levels during the last month of
pregnancy (Ylikorkala O et al., 1986). A large scale prospective study showed
that women afflicted by PET had lower urinary levels of prostacyclin metabolites
as early as weeks 13-16 (but no change in levels of TXA2), which yielded a higher
TXA2/PGI2 ratio (Mills JL et al., 1999). This imbalance in favour of the
vasoconstrictive and pro-coagulant TXA2 is believed to be the underlying cause of
the main features that charcterize PET, including hypertension, platelet
aggregation and reduced utero-placental perfusion (Wang YP et al., 1991).
Following this discovery that the levels of prostacyclins and thromboxane were
perturbed in PET pregnancies, the use of low-dose aspirin as a therapeutic
strategy has been tested in a number of clinical trials. The rationale behind this
was that COX inhibitors, like aspirin at low doses, could prevent or ameliorate
PET by reducing platelet thromboxane production while sparing endothelial PGI2
production. However, this strategy was of limited therapeutic benefit, indicating
that there is more to PET than an alteration in levels of PGI2 and thromboxane
(CLASP, 1994).
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1.16.3 Endothelial derived hyperpolarizing factor (EDHF)
Endothelium-dependent relaxation/vasodilatation in response to chemical
agonists and physical forces such as shear stress exerted by the flow of blood, are
generally attributed to the release of NO and/or PGI2. However, in a number of
vascular beds, these responses cannot be completely explained by these two
mediators only. The relaxation observed in the presence of NOS and COX
inhibitors has been associated with hyperpolarization of vascular smooth muscle
(VSMCs) and an endothelium derived hyperpolarizing factor or EDHF has been
postulated (Feletou M and Vanhoutte PM, 2009). The hyperpolarization of
VSMCs has been attributed to an increase in conductance to K+ ions. Increased K+
ion efflux from a cell results in a more negative resting membrane potential and
thus hyperpolarization, which is followed by relaxation (Feletou M and Vanhoutte
PM, 2005).
Selective K+ channel inhibitors have been used in vitro to characterize the
types of potassium channel involved in the EDHF response. The channels that
most commonly appear to mediate EDHF responses are charybdotoxin-sensitive
large conductance Ca2+ activated potassium channels and apamin-sensitive small
conductance Ca2+ activated potassium channels (Edwards G et al., 1998).
The identity of EDHF is a topic of much heated debate. Some of the
compounds that have been proposed as potential candidates include
epoxyeicosatrienoic acids, hydrogen peroxide, K+ ions, C-type natriuretic peptide,
hydrogen sulphide, carbon monoxide, etc. The exact identity of EDHF may differ
in different vascular beds (Feletou M and Vanhoutte PM, 2009).
Electrophysiological and pharmacological investigations in human arteries
have demonstrated that there appears to be a larger contribution of EDHF in the
microvessel circulation than in large arteries (Urakami-Harasawa L et al., 1997).
The generation of double-knockout mice, which lack both eNOS and COX-1, i.e.,
the “EDHF mouse” has facilitated the assessment of contribution of EDHF in
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endothelium-dependent relaxation in resistance arteries (COX-2 expression was
found to be absent in the resistance vessels of these mice). In these mice, males
become hypertensive while females are normotensive. Furthermore, the
endothelium-dependent relaxation was intact in the resistance arteries of female
mice (and associated with vascular smooth muscle hyperpolarization) but greatly
attenuated in vessels from male mice. This suggests that EDHF may be more
important in female arteries to confer endothelium-dependent dilatation, while
NO and PGI2 may play an important role in male arteries (Scotland RS et al.,
2005).
A previously published study investigated the role of EDHF from
myometrial blood vessels in non-pregnant, normotensive and PET women. The
relative contributions of NO, PGI2 and EDHF were investigated by using
inhibitors of all three alone and in combination. The vessels from non-pregnant
and PET women showed minimal residual relaxation in the presence of L-NAME,
suggesting that NO is the prinicipal mediator of endothelium dependent relaxation
in these vessels. COX and EDHF inhibitors had no effect on relaxation. On the
contrary, normal pregnant vessels were able to compensate and relax via either a
NO or EDHF dependent mechanism. Hence, normal pregnancy is associated with
the development of parallel EDHF and NO pathways in the myometrial bed,
ensuring that if one of the pathways is functioning poorly, there is a compensatory
back-up mechanism in place. This ‘back-up’ system is lacking in PET pregnancy,
with the endothelium-dependent relaxation solely being mediated via NO (Kenny
LC et al., 2002).
Thus, endothelium-dependent relaxation of blood vessels is primarily
mediated through three different pathways of relaxation – NO, PGI2 and EDHF.
The relative contribution of these different pathways of relaxation varies in
different species and different vascular beds. These three pathways may be
selectively blocked by the addition of inhibitors such as L-NAME, NG,NG-
Dimethylarginine dihydrochloride (for NOS); Indomethacin or NS-398 (for
PGI2); and, Apamin and Charybdotoxin (which inhibit the effects of EDHF)
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(Figure 1.11). While Indomethacin is a non-selective inhibitor of both the COX-1
and COX-2 pathways, NS-398 specifically inhibits the COX-2 pathway.
Figure 1.11 – Pathways of endothelium-dependent relaxation.
Bradykinin acts on endothelial cells, stimulating the release of nitric oxide (NO), prostacyclins
(PGI2) and Endothelium-derived hyperpolarizing factor (EDHF). These molecules act on the
vascular smooth muscle layer of a blood vessel and bring about relaxation. The action of either of
these pathways may be blocked by treatment with specific inhibitors. L-NAME is an inhibitor of
the NOS pathway, Indomethacin/NS-398 blocks the synthesis and effects of PGI2, and Apamin
inhibits the effects of EDHF.
1.17 Biology of Endothelial Cells (ECs)
In this study, I have attempted to understand the mechanism of action of
VEGF by carrying out ex vivo experiments on sheep uterine artery endothelial
cells. The ECs form a monolayer lining called the endothelium, in all of the blood
vessels of our circulation. Initially, they were thought to act as a dialysis
membrane allowing nutrients from the blood stream to diffuse through to the
underlying tissue without letting proteins or blood cells escape. It is now known
that these highly sophisticated cells are virtually in control of the blood
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circulation, and have been appropriately referred to as the ‘maestro’ of blood
circulation (Vane JR, 1994).
1.17.1 Structure
Being composed of a single layer of flat scale-like cells that are all in
contact with a basement membrane, the endothelium is described as a squamous
epithelium. ECs are very flat, between 20-50 μm in diameter and up to 5μm in 
depth (Limaye V and Vadas M, 2007). The cytoplasm is relatively simple with
few organelles, mostly concentrated in the perinuclear zone. Another prominent
feature of ECs is the presence of many pinocytotic vesicles which are involved in
the process of transport of substances from one side of the cell to the other.
1.17.2 Cell junctions and basement membrane
ECs are connected to one another by three types of junctions commonly
found in other epithelia: tight, adherens and gap (Dejana E, 2004). All junction
types consist of a trans-membrane protein on one cell, interacting homotypically
with another molecule of the same protein on an adjacent cell. Other proteins bind
the cytoplasmic tail of the transmembrane molecule, linking it directly or
indirectly to the actin cytoskeleton.
Tight junctions form a belt around the endothelial cell, the zona occludens,
and act as a barrier to the transport of substances across the endothelium via the
paracellular route (between cells). Tight junctions also have fence-like properties,
restricting the diffusion of membrane components and allowing the maintenance
of differing compositions of the apical and basolateral plasma membrane.
Adherens junctions also form a belt around endothelial cells, the zonula
adherens, and provide mechanical strength to cell-cell contacts but are also
involved in signaling EC-EC contact. Cadherins, the key transmembrane proteins
involved, are indirectly linked to the actin cytoskeleton by binding to intracellular
catenins. All ECs express vascular endothelial (VE)-cadherin, which is the main
cadherin present in endothelial cell adherens junctions (Vestweber D, 2008). VE-
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cadherin associates with vascular endothelial growth factor receptor 2 (VEGFR2)
in confluent cells, regulating endothelial cell survival (Carmeliet P et al., 1999).
Catenins, including β-catenin, plakoglobin/γ-catenin and p-120, are able to 
bind to the cytoplasmic tail of VE-cadherin, and link it to the actin cytoskeleton.
Catenins can translocate to the nucleus, and regulate transcription, allowing EC-
EC contact to influence gene expression. Sequestering of β-catenin by VE-
cadherin in juxtaposed endothelial cells is thought to be involved in contact
inhibition of cell growth (Gumbiner BM and McCrea PD, 1993).
Gap junctions do not form a belt, but exist as fluid-filled channels
(connexons) which form direct links between the cytoplasm of adjacent ECs,
allowing the passage of ions and small molecules, so aiding cell-cell
communication. Connexons are composed of individual protein subunits called
connexins (Cx) – ECs express Cx43, Cx40 and Cx37, forming channels around
20nm in diameter. ECs also form gap junctions with underlying smooth muscle
cells.
Platelet endothelial cell adhesion molecule (PECAM, also known as
CD31), a transmembrane immunoglobulin-like molecule which can participate in
homophilic or heterophilic interactions, is concentrated at EC-EC junctions.
Although not part of a defined junctional complex, PECAM is important in EC-
EC adhesion. PECAM staining is often used as a marker for endothelium in
immunohistochemistry.
The endothelium, as for other epithelia, rests on a basement membrane
produced by the endothelial cells themselves (Kramer RH et al., 1984). The
basement membrane is usually continuous but may be discontinuous, and
encloses ECs in a sheath in intact vessels. Pericytes are enclosed within the
basement membrane, smooth muscle cells are not. All basement membranes
consist primarily of type IV collagens, laminins, nidogens (entactins) and HSPGs
such as perlecan, with lower amounts of other components such as
thrombospondin, fibronectin and vitronectin (Hallmann R et al., 2005). The
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basement membrane may influence cell behaviour by binding growth factors such
as VEGF (via HSPGs), and through the binding of integrins to components such
as laminins.
1.17.3 Function
Endothelial cells are involved in many aspects of vascular biology,
including:
*Vasoconstriction and vasodilatation, and hence the control of blood flow and
blood pressure
*Coagulation
*Atherosclerosis
*Formation of new blood vessels (angiogenesis)
*Inflammation and oedema
*Filtering and trafficking functions, particularly in the renal glomerulus and in the
blood-brain barrier to allow transit of white blood cells in and out of the
bloodstream.
Some of these essential functions will be briefly reviewed below.
1.17.3.1 Control of blood flow and blood pressure
ECs regulate basal vasomotor tone, and therefore vascular blood flow and
blood pressure, by the tightly controlled release of vasodilators like NO, PGI2 and
EDHF as well as vasoconstrictors like endothelins and thromboxane A2 as
discussed in detail in a preceding section.
The endothelins (ETs) are a family of 21 amino acid peptides, of which
ECs and smooth muscle cells produce mainly the ET-1 isoform. Production of
ET-1 is induced by hypoxia, ischaemia and shear stress, which induce the
110
transcription of ET-1 mRNA, with rapid secretion of ET-1 within minutes. The
majority of ET-1 secretion is towards the abluminal side of the EC and thus it acts
in a paracrine manner by binding to ETA receptors on smooth muscle cells, to
cause vasoconstriction. It also has some autocrine effects through the ETB
receptors on endothelial cells, activation of which causes NO and prostacyclin
release (Rosendorff C, 1997).
1.17.3.2. Coagulation
The quiescent endothelium possesses anticoagulant activity by providing
an anti-thrombotic surface which inhibits the coagulation cascade. One of the
major strategies used by ECs to maintain anticoagulant activity is to prevent
activation of thrombin. Activated thrombin converts soluble fibrinogen into
insoluble strands of fibrin, which stimulates coagulation by causing platelet
activation and the activation of several coagulation factors (Limaye V and Vadas
M, 2007). ECs express HSPGs, which along with glycosaminoglycans in the
ECM, are able to stimulate antithrombin-III (Rosenberg RD, 1985). They also
express tissue factor pathway inhibitor (TFPI) that prevents thrombin formation,
and express thrombomodulin (Dielis AW et al., 2008). Therefore, in the healthy
endothelium, the balance is towards the expression of anticoagulant factors to
ensure smooth uninterrupted blood flow in the vessels.
1.17.3.3. Angiogenesis
Angiogenesis is the formation of new blood vessels from pre-existing
ones. This process involves the degradation of ECM by ECs, as well as their
migration, proliferation and the formation of tubes in association with mural cells.
In the process of vessel formation, it is essential for ECs to carry out efficient cell-
matrix attachments and cell-cell contacts.
Attachments between the EC and surrounding ECM are mediated by the
integrin family of cell surface adhesion molecules. Integrins provide adhesive and
signaling functions between ECs and the ECM, and this interaction is critical in
maintaining the EC polarity and alignment along the vasculature. The integrins
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link the cell with the ECM at focal adhesion points and interact with the actin
cytoskeleton. This interaction stimulates cell contraction, thus allowing cell
movement on adhesive contacts (Silva R et al., 2008).
In addition to interaction with the ECM, ECs must form cell-cell contacts
in order to produce a viable capillary like network. This cell-cell adhesion is
mediated by molecules like VE-cadherin and PECAM-1, as described above.
1.17.3.4. Inflammation and oedema
Endothelial cells are responsive to local agents such as histamine, which is
released when local tissues are damaged. As a result, the intercellular junctions
between endothelial cells allow the passage of large amounts of fluid from blood
plasma into the extravascular space, so that the surrounding tissues become
engorged with fluid and swollen, a condition called oedema.
The endothelium also plays a critical function in regulating the trafficking
of leucocytes from the intravascular space to extravascular sites of inflammation.
The first step in leucocyte transmigration is the arrest of leucocytes and contact
with the ECs. This is mediated by the selectins, which allow the rolling and
docking of the leucocyte on the endothelium (Vestweber D, 2007). During the
second step of the transmigration process, the leucocytes flatten and migrate along
the endothelium, a process known as diapedesis. Finally, extravasation occurs by
leucocyte migration through EC junctions and their subsequent
attachment/migration on ECM components (collagen and fibronectin) (Vestweber
D, 2007). The main families of molecules involved in this trafficking process are
the selectins, integrins, immunoglobulin supergene family and variants of the
CD44 family (Limaye V and Vadas M, 2007).
1.18 Previous work from our lab which has led up to this
project
Some of the previous experiments from our lab which laid the foundation
for the research described in this Ph.D. are discussed below.
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The hypothesis proposed was that local over-expression of VEGF in the
uterine arteries of normal pregnant sheep would increase uterine blood flow, and
alter vascular reactivity. The first experiments were analysed at a short term time
point after adenovirus gene transfer, to determine firstly whether local VEGF
over-expression was occurring and secondly what effect it might have. First
generation (E1, E3-deleted) replication-deficient adenovirus vectors (5 x 1011 viral
particles in 10 mL Phosphate buffered saline) containing the VEGF-A165 gene
(Ad.VEGF-A165) or the nuclear localising beta-galactosidase reporter gene
(Ad.LacZ, the same dose) as a control, were injected into the uterine arteries of
pregnant sheep (n = 5) at 88 – 102 days of gestation (term = 145 days). Uterine
blood flow was quantified using Doppler sonography just before vector injection.
The operators were unaware as to which side had received the Ad.VEGF-A165
vector.
Between 4 to 7 days after adenovirus injection, the ewe was re-
anaesthetised, and uterine blood flow and umbilical artery Doppler measurements
were repeated. When compared with measurement of blood flow before vector
injection, uterine artery blood flow increased by over three-fold (mean ± SD
increased from 233 ± 156 mL/min to 753 ± 415 mL/min) in Ad.VEGF-A injected
vessels and this increase was significant (Figure 1.12).
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Figure 1.12 - Changes in uterine blood flow (UBF) 4 - 7 days after injection of
Ad.VEGF-A165 or Ad.LacZ.
UBF was determined in mid-gestation pregnant sheep by Doppler ultrasonography, just prior to
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries contralaterally (n=5). 4-7
days later, UBF was again measured in the injected animals under terminal anaestheia. There was
a dramatic and significant three-fold increase in UBF in the Ad.VEGF-A165 transduced uterine
arteries. Blood flow increased in the Ad.LacZ transduced uterine arteries as well, though this
increase was not significant (David AL et al., 2008).
Post-injection uterine blood flow was also higher than pre-injection levels
in the Ad.LacZ injected vessels but the increase was not significant (mean uterine
blood flow pre-injection was 320 ± 160 mL/min and post-injection was 430 ± 110
mL/min). There were no significant changes in the umbilical artery diameter, PI,
resistance index (RI) or fetal heart rate 4 – 7 days after injection of adenoviral
vectors. Cross-flow of vector from injection in one uterine artery on one side to
the other uterine artery on the contra-lateral side is unlikely to have taken place.
The uterine arteries supply only one uterine horn each and we believe the volume
of injection (10 mL) is only sufficient to reach the uterine artery branches and
maternal villi on that side of injection. No evidence of vector spread to the
contra-lateral artery was detected using RT-PCR analysis for vector expression or
ELISA analysis for transgenic protein expression in uterine arteries samples.
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Furthermore, the transduced vessels harvested at post-mortem examination
were examined on an organ bath set-up to investigate changes in vascular
reactivity. A significant reduction in the contractile response and significant
increase in relaxation was observed in Ad.VEGF-A165 transduced uterine arteries
relative to Ad.LacZ transduced vessels. The endothelium-dependent relaxation
was also studied in the presence of different inhibitors of relaxation, and it was
found that the major contributors to relaxation in pregnant sheep uterine arteries
were the NOS and EDHF pathways (David AL et al., 2008).
To conclude, local administration of Ad.VEGF-A165 into the uterine artery
of pregnant sheep increases uterine blood flow short term, as measured in a
blinded fashion by Doppler ultrasonography. This increase in UBF is concomitant
with a diminished contractile response and enhanced relaxation response of
Ad.VEGF-A165 transduced vessels.
1.19 Aims of the thesis
With the aim of developing a treatment for FGR, the aim of this thesis is to
investigate the effect of local VEGF gene therapy on the uteroplacental
circulation, particularly :
1) To study the effects of local VEGF over-expression on the uterine arteries
of pregnant sheep.
2) To study the effects of local VEGF over-expression on eNOS, phospho-
eNOS and iNOS levels in uterine artery endothelial cells from pregnant
sheep
3) To optimize a technique of gene targeting to the utero-placental circulation
of pregnant guinea pigs, with the aim of using this technique to study the
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effects of VEGF gene transfer on fetal growth in an FGR model of guinea
pig pregnancy.
.
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Chapter 2
Methods
2.1 Care of Sheep and Animal Husbandry
Sheep of Romney breed were used. Each ewe was ear tagged twice with
an identification number and the sheep flock was vaccinated against Toxoplasma,
Chlamydia and Clostridium annually. All procedures on animals were conducted
in accordance with the UK Home Office regulations and the Guidance for the
Operation of Animals (Scientific Procedures) Act (1986) under Project Licence
number 70/6546 titled ‘Fetal gene therapy in utero’. All animal surgeries were
under general anaesthesia and conducted by personal licencees (Anna David,
Donald Peebles, Khalil Abi-Nader, Vedanta Mehta, Steven Shaw and Michael
Boyd).
2.2 Timed Mating of Ewes
All experiments were conducted on time-mated sheep to ensure the
gestational age of fetus was consistent. Tupping of sheep was begun in early
autumn during the sheep breeding season and approximately 20 sheep were
tupped each year. To enable timed mating of sheep, Chronogest® sponges
(Flugestone acetate) containing 30mg of progesterone were placed in the vagina
of ewes for 2 weeks to induce ovulation. Forty-eight hours after removal of the
progesterone sponges, ewes were placed in a pen with the ram overnight. The
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abdomen of the ram had been marked beforehand with Ram Raddle®, a coloured
powder mixed with liquid paraffin that permanently marks the fleece on the back
of the ewe once she has been tupped. Ewes that had been marked the next
morning were presumed to have been successfully tupped. Two weeks later ewes
were placed back in with the ram overnight in case of unsuccessful tupping the
first time. A different coloured Ram Raddle was used to be able to differentiate
the two tupping dates. Ewes were scanned by the technical staff at the Royal
Veterinary College at approximately 60 days of gestation to confirm pregnancy.
Non-pregnant ewes were re-sponged and re-tupped a month later. The success
rate of sheep pregnancy on tupping was 85%.
2.3 Transport of tupped sheep and housing
Pregnant ewes were sent from the Royal Veterinary College (RVC)
Hawkshead Campus to the Biological Services Unit (BSU), RVC Camden
Campus in a lorry one week before use to allow acclimatization. At the BSU in
Camden, they were housed together in pairs in specially designed sheep pens at
ambient temperature. The floor of the pens was covered with straw and the ewes
had ad lib access to hay and running water and were given a daily portion of
Super Ewe and Lamb 6mm pencils compound feed (Appendix 1). The feed is a
concentrated source of oil, protein and vitamins and the amount given to sheep
was increased as gestation progressed or when there was more than one fetus.
This ensures adequate nutrition for the ewe and reduces the risk of toxaemia
caused by the large late gestation fetus compressing the rumen and reducing the
ability of the ewe to digest enough hay for nutrition.
The straw bedding was changed and the room thoroughly washed weekly.
The room dimensions exceeded the guidelines of the UK Home Office, to ensure
that the animals were comfortable and not distressed. A picture of the sheep pen
with all the dimensions is shown in Figure 2.1.
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Figure 2.1 – Diagram of sheep enclosure
The monitoring space consisted of an animal enclosure room adjacent to a computer room. The
two receivers, which were fixed at 53cm above ground level on the inside of the enclosure, were
arranged in a way to maximize free animal movement in the space available while maintaining a
good signal. The green line indicates the area of the enclosure in which the sheep were free to
roam. Cables ran from each receiver to the computer outside the sheep enclosure and above the
height of the ewe to avoid damage.
2.4 Confirmation of pregnancy and gestational age using
ultrasound
All pregnant sheep were scanned the day after arrival at the BSU, Camden
to confirm pregnancy, fetal number and gestational age. Ewes were caught, turned
up and held in a sitting position for scanning by an experienced animal technician.
The fleece was then clipped from the abdomen. Using gel (Ultragel Vete,
Transpharma Sas, Italy) applied to the suprapubic area and lower abdomen, an
experienced fetal medicine specialist (Anna David, Khalil Abi-Nader, Steven
Shaw) scanned the uterus using an Acuson 128 XP10 ultrasound scanner
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(Siemens, Bracknell, United Kingdom) with a C3 3.5 MHz curvilinear transducer.
Fetal number was checked and the gestational age of the fetuses was confirmed
by comparing the biparietal diameter (BPD) and occipito-snout length (OSL) with
published data. (Barbara A et al 1995, Kelly RW and Newnham JP, 1989).
Figure 2.2 - Acuson 128 XP10 ultrasound machine (Siemens, Bracknell,
United Kingdom) used to scan pregnant sheep and guinea pigs.
2.5 Sheep anaesthesia and preparation for surgery
Prior to surgery, the sheep were starved overnight on wood chip bedding
with free access to water. During this fasting period, a companion animal was also
placed and fasted with the sheep that had to undergo surgery the next morning to
prevent distress. The overnight fasting was to prevent bloating which may occur
when sheep under anaesthesia are unable to belch (eructate) normally and release
methane gas, which is a by-product of the fermentation of their food.
(Wolfensohn S and Lloyd M, 1998).
On the morning of surgery, the sheep was run down the corridor to the
theatre room where she was ‘turned’ and restrained. The wool was clipped from
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her neck, the jugular vein was cannulated using a 19 Gauge butterfly winged
perfusion set (Terumo Europe NV, Leuven, Belgium) and general anaesthesia was
induced with thiopental sodium 20mg/kg intravenously (IV, Thiovet, Novartis,
Animal Health UK Ltd., Hertfordshire, UK). Once asleep, the ewe was lifted onto
the operating table and intubated supine with a 9.0 mm cuffed endotracheal tube
(Portex, UK) using a laryngoscope (Penlon, UK) to visualize the vocal cords. A
cuff was inflated on the endotracheal tube to prevent inhalation of regurgitated
ruminal contents and the ewe’s head was lowered to allow drainage of saliva and
ruminal fluid (Taylor PM, 1991). Because access to the whole abdomen was
needed for procedures, the animals were kept in dorsal recumbency. Anaesthesia
was maintained with 2%-2.5% Isoflurane in oxygen (Isoflurane-vet, Merial
Animal Health Ltd., Essex, UK) using a Magill circuit (Medishield ventilator,
Manley Serovent).
The induction and maintenance of general anaesthesia was performed by
Mr. Michael Boyd, Theatre Manager, Biological Services Unit, RVC Camden.
Once anaesthetized, the wool was clipped from the ewe’s abdomen and a
detailed ultrasound examination of the uterus and its contents was performed
using a 3.5MHz probe as before. Fetal measurements were collected, namely
biparietal diameteter, occipito-snout length, abdominal circumference, femur
length and umbilical artery Doppler pulsatility and resistance indices.
Ultrasound examination was performed by Dr. Anna David, Dr. Khalil
Abi-Nader, Vedanta Mehta and Dr. Steven Shaw.
The abdominal surface, right flank and the neck area of the ewe was
scrubbed with ‘Hibiscrub’ (Chlorhexidine gluconate 4% w/v, Regent Medical,
Manchester, UK) followed by ‘Povidone’ (1% w/w Iodine solution, Vetasept
Animal Care Ltd., York, UK). The neck and abdomen were exposed with sterile
drapes.
A pulse oximeter (5250 RGM, Ohmeda) placed on the ewe’s ear was used
to monitor oxygen saturation and pulse rate during general anaesthesia and this
data was documented every 15 minutes together with respiration rate, isoflurane
concentration and level of anaesthesia. Maternal blood was taken for pre-
121
operative haematological and biochemical analysis. Blood was collected into BD
Vacutainer tubes (BD Vacutainer systems, Plymouth, UK) containing 0.105 M
sodium citrate for plasma (9C, blue topped bottle), silica clot activator polymer
gel for serum (yellow top bottle) and potassium EDTA (K3EDTA) for whole
blood (purple top bottle).
2.6 Insertion of Blood pressure catheter to monitor
maternal haemodynamics
The blood pressure in the ewe was measured by inserting a blood pressure
sensitive catheter into the carotid artery. The instrument used was a TA11 PA-
D70 device (Data Sciences International, Tilburg, Netherlands), which has a
35cm long catheter connected to a transmitter (Figure 2.3) that can be switched
on/off with a magnet waved 3-4 cm over the skin surface. The tip of the catheter
is filled with a bio-compatible gel, to prevent coagulation of blood.
Figure 2.3 – A PA-D70 implant (Data Sciences International, Tilburg,
Netherlands) used to measure maternal blood pressure and heart rate in
pregnant sheep.
In preparation for the BP catheter insertion surgery, the transmitter was
switched ‘on’ with the magnet and confirmed to be ‘on’ by bringing it close to a
radio tuned into 530 KHz AM. When the transmitter is on, it is reflected on a
‘tuned’ radio as a characteristic humming sound. A metallic receiver RMC-1
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(Data Sciences International, USA) was placed under the operating table, to catch
the signal from the transmitter during the surgery.
The skin of the ewe’s neck to the right of the trachea in the midline was
incised longitudinally for 5cm with a number 11 blade (Swann-Morton, Sheffield,
UK) and exposed to reveal the trachea and the strap (infrahyoid) muscles. The
muscles were gently pushed aside to the midline to expose the carotid artery,
which was dissected free of underlying connective tissue. Two 1-0 sterile silk
vessel ties (Ethicon, New Jersey, USA) were placed around the carotid artery,
about 1 cm apart. The upper vessel tie was tied tightly around the vessel to
occlude it, the lower suture was loosely tied. The carotid artery between the two
ties was raised slightly to suspend the vessel between the ties and occlude it. A
small incision was made at an angle in the suspended vessel wall with scissors.
Using a fine forceps the vessel incision was opened and the tip of the catheter was
gently inserted into the carotid artery lumen, and pushed towards the heart until a
clean blood pressure waveform could be observed on the computer placed nearby.
The lower vessel tie was then tied tightly around the vessel and catheter to keep it
in place. A further tie was placed around the vessel and catheter within to secure
it.
The body of the transmitter was placed in a cavity made between the
subcutaneous neck tissue and underlying neck muscles. The subcutaneous tissue
was closed with continuous 2-0 Vicryl (Johnson & Johnson Intl, St. Stevens-
Woluwe, Belgium). The skin incision was closed with continuous 2-0 vicryl
suture. Terramycin antibiotic (3.92% cutaneous spray containing oxytetracycline
hydrochloride; Pfizer, Kent, UK) was sprayed over the incision.
2.7 Implantation of flow probes around uterine arteries
A 6mm 6-PS transit-time flow probe (Transonic Systems Inc, New York),
which can measure blood flow within a +10% limit of error was used to measure
blood flow in the uterine arteries. Flow probes were placed around the main
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uterine artery on either side where they measured the real time flow
measurements. Data was telemetrically transmitted to a computer located in the
adjacent room using Bluetooth technology. Before implantation, the flow probes
were tested by shaking their reflection bracket in a container full of water, and
observing if there was any change in the waveform on the acquisition computer.
A midline lower abdominal incision was made in the skin using a number
11 blade from just below the umbilicus to the pubic bone. The rectus sheath was
carefully incised avoiding any vessels, and the peritoneal cavity was opened
carefully. The ruminant bowel was packed to one side using sterile lap sponges.
The disassembled flow probes were sterilized by placing in Vetguard cold
sterilant (Steritech, Cheltenham, UK) for 15 minutes after which the flow probes
were reassembled just before placement. A trocar and cannula were passed from
the peritoneal cavity through the skin to exit at the right flank of the ewe. The
sterilized flow probes were then internalized by passing them through the cannula
into the maternal peritoneal cavity. The lower lateral aspect of each uterine horn
was exposed to observe each main uterine artery as it passed over the anterior
wall of the uterus within its mesometrium (a picture of the uterine artery tree of
pregnant sheep is shown in Figure 2.14). The visceral peritoneum was dissected
to expose the uterine artery 5cm from its most lateral aspect, and to free a short
loop segment from its underlying connective tissue.
A flow probe was placed around each main uterine artery and secured in
place using the screws provided with the kit (Figure 2.4). The overlying visceral
peritoneum was closed using 4-0 Prolene suture (Ethicon, Edinburgh, UK). The
lap sponges were removed from the abdomen and intra-muscular Penstrep 3ml
(200mg/ml procaine penicillin and 250mg/ml dihydrostreptomycin; Norbrook
Laboratories Ltd., County Down, UK), intra-peritoneal Crystapen 3g (Sodium
benzylpenicillin G, Schering-Plough, Uxbridge, UK) + gentamicin 80mg
(Geneticin Injectable, Roche Products Ltd., Hertfordshire, UK) were administered
for antibiotic prophylaxis. The abdomen was closed in layers. The rectus sheath
was closed with continuous 6mm nylon tape (Johnson and Johnson, Belgium) to
prevent herniation of the abdominal contents. The subcutaneous tissue and the
124
skin were closed with 1-0 PDS and 1-0 Vicryl (Ethicon, Norderstedt, Germany)
respectively.
Figure 2.4 – A transit-time flow implanted around the main uterine artery
for telemetric measurement of uterine artery blood flow.
The ewe was turned slightly more to the left side to allow access. The skin
buttons were tunneled under the skin a further 10cm higher up and brought out
onto the maternal right flank. The opening into the abdomen was closed with 1-0
PDS (Ethicon, Norderstedt, Germany) for the sheath and 1-0 Vicryl (Ethicon,
Norderstedt, Germany) for the skin. The skin buttons were sutured in place with
1-0 PDS (Figure 2.5).
Figure 2.5 – The skin buttons sutured on the maternal right flank of the
sheep.
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(Continued from overleaf) The physiometer system was connected with flow probes implanted
around the uterine arteries through the skin buttons. Once connected, the flow probes beamed the
real-time uterine artery blood flow measurements to an acquisition computer in close proximity by
bluetooth technology.
Terramycin was sprayed over the abdominal incision and the flank
incisions. Analgesia (0.1 mg/ml IM buprenorphine) was administered to the ewe.
The ewe was then allowed to recover, extubated and placed in its pen under
observation. Early standing (within 1 hour) was encouraged to prevent bloating.
2.8 Vector Injection
Approximately 1 week (range 6 to 10 days) after the probe placement
surgery, the ewe was re-anaesthetized and the mid-line laparatomy scar was
reopened. The location of the transonic flow probes was checked. A short section
of the main uterine artery, just proximal to the flow probe was cleared of the
surrounding visceral peritoneum and the vessel was stabilized using a 45 cm
vessel loop (Bard UK, London) (Figure 2.6). The vessel was digitally occluded,
while vector (5x1011 viral particles in 10ml PBS in a 10ml syringe) was injected
into the lumen, just distal to the site of occlusion using a 23 gauge butterfly needle
(Figure 2.7). Blood was first withdrawn into the butterfly cannula to ensure the
needle was inside the uterine artery lumen and then, the vector was slowly
injected over one minute. The butterfly needle was removed and the vessel was
digitally occluded over the injection site as well. The vessel occlusion was
maintained for a further four minutes giving a total occlusion time of 5 minutes.
This ensured there was sufficient time for the adenovirus to infect the
endothelium of the uterine artery vessel and branches locally and to prevent
excessive systemic spread of the vector.
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Figure 2.6 – Isolation of the proximal part of the uterine artery before vector
injection.
Before vector injection, a short section of the main uterine artery, just proximal to the flow probe
was cleared of the surrounding visceral peritoneum and the vessel was stabilized using a 45 cm
vessel loop. This enabled the vector to be injected into the vessel more reliably.
Figure 2.7 - Injection of vector into the occluded uterine artery
The vector (5x1011 viral particles in 10 ml PBS) was injected slowly into the lumen of the uterine
artery just distal to the site of occlusion but proximal to the flow probe, over a period of one
minute. Following vector injection, the vessel occlusion was maintained for a further four minutes
to ensure sufficient time for the adenovirus to infect the endothelium of the uterine artery vessel
and branches locally.
The occlusion was then released, the vessel loops were removed and the
site of injection was carefully observed for any signs of bleeding. The peritoneum
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was again sutured over the exposed section of the uterine artery using a 4-0
Prolene suture (Ethicon, Norderstedt, Germany).
Antibiotics were administered and the body wall was closed as described
above. Intra-muscular analgesia was given as before, and the sheep was allowed
to recover in its pen.
2.9 Insertion of blood pressure catheter to monitor fetal
haemodynamics
The animals were prepared for surgery and anaesthetized as described in
previous sections. Laparotomy was performed using a midline incision as before
and the abdomen was opened in layers. A 6PS transit-time flow probe (Transonic
Systems Inc., NY, USA) was then placed around each main uterine artery on both
sides to measure uterine artery blood flow. The flow probe cables were then
exteriorised on the upper right flank of the ewe. This procedure is described in
greater detail in the preceding section (Section 2.7).
In preparation for the fetal BP catheter insertion surgery, the transmitter
was switched ‘on’ with the magnet and confirmed to be ‘on’ by bringing it close
to a radio tuned into 530 KHz AM. A metallic receiver RMC-1 (Data Sciences
International, USA) was placed under the operating table, to catch the signal from
the transmitter during the surgery.
Following this the uterus was palpated and the fetal parts identified. In an
area of myometrium away from placentomes, a 5cm uterine incision was made
just above the fetal head using a No21 blade (Swann-Morton, Sheffield, UK).
The fetal head was exteriorized through the uterine incision and Babcock clamps
were used to compress the amniotic membrane against the uterine wall in order to
minimize bleeding (Figure 2.8). A 3cm longitudinal incision was made in the fetal
neck 1cm to the right of the trachea and the right common carotid artery was
identified and mobilized from beneath the strap muscles. Two 3-0 silk ties
(Mersilk, Ethicon Ltd, Edinburgh, UK) were passed under the vessel proximally
and distally and held without tying using Kelly clamps. The right common carotid
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artery was then elevated under tension from the two sides to prevent excessive
bleeding, while an incision was made in the vessel wall using a fine-tipped
scissors until the lumen could be identified. A fine-tipped curved forceps was
inserted into the arterial lumen and the jaws were held apart to maintain luminal
patency. One of the hemodynamic catheters of the telemetric D70-PCTP device
(Data Sciences International, Tilburg, Netherlands) was inserted into the arterial
lumen and threaded upstream towards the aorta for a distance of around 5-7cm
until a clear signal to the nearby receiver could be obtained. The silk lines were
then tied, one to occlude the vessel distally and one to secure the catheter within
the vessel proximally. The neck skin was closed over the catheter using 2-0
Vicryl (Ethicon, St. Stevens-Woluwe, Belgium). The fetal head was returned to
the amniotic cavity. The other hemodynamic catheter was inserted into the
amniotic cavity to record background pressure. The uterine incision was closed in
two layers using 2-0 PDS (Ethicon, St. Stevens-Woluwe, Belgium) in a running
fashion with the catheters passing through the incision at a distance from the
angles. While the first layer incorporated the whole thickness of the uterine wall
along with the amniotic membrane, the second layer buried the first to provide a
water-tight seal. The transmitter was then attached to the inner surface of the
abdominal wall slightly lateral to the laparotomy incision using 3-0 Prolene
(Ethicon, Norderstedt, Germany). This step is necessary to allow easy
accessibility since an external magnet is needed to turn the transmitter On and
Off. A 3ml intramuscular injection of Penstrep (200mg/ml procaine penicillin
and 250mg/ml dihydrostreptomycin; Norbrook Laboratories Ltd., County Down,
UK) and a 75% intraperitoneal/25% intrauterine injection of sodium
benzylpenicillin G 3g (Crystapen, Schering-Plough, Uxbridge, UK ) + gentamicin
80mg (Genticin Injectable, Roche Products Ltd, Hertfordshire, UK) were given at
the end of the procedure for infection prophylaxis. The abdomen was then closed
in layers and buprenorphine 0.01mg/kg IM (Vetergesic, Alstoe Animal Health,
York, UK) was administered every 6-12 hrs for analgesia during the first 48-72
hours after the operation and the ewe was allowed to recover.
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Figure 2.8 – Implantation of blood pressure sensitive catheter in the fetal
carotid artery to monitor haemodynamics.
A D70-PCTP telemetric device (Data Sciences International, Tilburg, Netherlands) was used to
measure blood pressure and heart rate in the fetal sheep. The device has two pressure sensitive
catheters, one of which was inserted into the fetal carotid artery to measure fetal haemodynamics,
while the other was inserted into the amniotic cavity to record background pressure. A –
Exteriorization of fetal head to expose the fetal carotid artery after making a longitudinal incision
in the neck. B – Insertion of blood pressure sensitive catheter into the fetal carotid artery. C –
Attachment of the body of the implant to the inner surface of the abdominal wall.
The surgeries described above were performed by Dr. Anna David, Prof.
Donald Peebles, Dr. Khalil Abi-Nader, Vedanta Mehta and Dr. Steven Shaw.
2.10 Haemodynamic monitoring
Between the probe placement and vector injection surgeries, the blood
pressure and uterine blood flow of the sheep were monitored every day. The
uterine artery flow probe gave a signal once the amplitude of the detected blood
flow rose above 35%. This depended on how rapidly a fluid interface developed
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between the probe and the vessel, a function of vessel size and took between 48-
72 hours.
In order to monitor the uterine blood flow, the rechargeable battery packs
and physiometer (Transonic Systems Inc, NY, USA, Figure 2.9) were placed in a
back pack attached to the wool on the sheep’s back. The physiometer was
connected to the flow probes via the skin buttons on the upper right flank of the
sheep. Once connected, the flow probes transmitted the real time uterine blood
flow measurements to an acquisition computer located in close proximity by
wireless Bluetooth technology. The data was acquired using the Physioview
software (Transonic Systems Inc, NY, USA). A sample uterine artery blood flow
waveform is represented in Figure 2.10. The wireless communication equipment
operates at a worldwide available standard 2.4 GHz frequency band. The real time
pulsatile flow was sampled at a frequency of 128 Hz.
Figure 2.9 – Battery pack and Physiometer
In order to monitor uterine artery blood flow in pregnant sheep, cables from the physiometer were
attached to the skin buttons on the right flank of the ewe. This enabled the real-time blood flow
data from the flow probes around the uterine arteries to be transmitted to an acquisition computer
in close proximity, by bluetooth technology.
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Figure 2.10 – Sample uterine artery blood flow waveform acquired using
Physioview software
The uterine blood flow was monitored for 6-7 hours daily for 3 days
before and 7 days after the vector injection surgery in a sub-set of the sheep. This
was to investigate whether the administration of the vector had any short-term
effects on the diurnal rhythm of uterine artery blood flow (UABF). Thereafter, the
monitoring was reduced to one hour daily (till the day of post-mortem) at the
same time everyday to eliminate the effect of any diurnal variation on uterine
blood flow. The uterine artery waveforms were exported to Notepad (Microsoft
Inc, NY, USA) and analysed in AcKnowledge 3.9.1 (Acknowledge Inc,
Somerville, MA, USA) to derive an average value and standard deviation for each
hour of monitoring.
For every sheep monitored, a baseline UABF was established for each of
the two uterine arteries by averaging the values of UABF recorded for three
consecutive days immediately before the administration of the vector. Each
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subsequent daily reading of UABF was then compared with this baseline and
converted into a percentage increase in blood flow from baseline. The latter was
plotted on a line graph (MS Office Excel, Microsoft Inc, NY, USA) and the
slope/gradient of increase in UABF for each uterine artery was calculated. The
gradient of increase of blood flow in the uterine arteries transduced with
Ad.VEGF (-A165 or D) and Ad.LacZ were compared using the General Linear
Model Test (Minitab 5.1) to determine statistical significance.
The blood pressure signal was immediately available from the time of
catheter placement. The blood pressure and heart rate were monitored
continuously round the clock for 3-5 days before and ~7 days after the
administration of the vector. This was to investigate if the administration of the
vector had any acute detrimental effects on systemic blood pressure. Thereafter,
the blood pressure was monitored for one hour daily (till the day of post-mortem)
at the same time each day to eliminate the effect of diurnal variation on blood
pressure.
When the blood pressure of a sheep needed to be monitored, the
transmitter placed in the maternal or fetal neck was switched on with a magnet.
The turned on transmitter beamed the real time blood pressure signal to the
metallic receivers RMC-1 (Data Sciences International, USA) which further
relayed it to an acquisition computer placed in close proximity (Figure 2.11). At
the end of the monitoring period, the transmitter was turned off by swiping the
magnet over the skin of the neck.
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Figure 2.11 – A sheep being monitored for uterine artery blood flow and
blood pressure.
In order to monitor blood pressure, the transmitter implanted in the ewe’s neck was switched on
with a magnet. Once ‘on’, the transmitter beamed the blood pressure signal to two metallic
receivers (visible in picture), which further relayed the signal to an acquisition computer. To
monitor UABF, the battery pack and physiometer were placed in back packs hooked on to the
sheep’s fleece, and connected to the skin buttons on the flank. Once connected to the flow probes
(via skin buttons), the physiometer telemetrically transmitted the real time blood flow data to an
acquisition computer by bluetooth technology.
The real time blood pressure waveforms were acquired using the software
‘Acquisition’ (Data Sciences International, USA, Figure 2.12). The acquired
traces were opened up in another program ‘Analysis’ (Data Sciences
International, USA) on which plots for Diastolic blood pressure, Systolic blood
pressure and Heart Rate were constructed from the original BP waveform. These
plots were exported into Microsoft Office Excel and further analysed to derive an
average value of Diastolic blood pressure, Systolic blood pressure and Heart Rate
for each hour of monitoring. The Mean Arterial Pressure (MAP) for each hour of
monitoring was calculated from the analysed data using the formula;-
Mean Arterial Pressure = 2xDiastolic pressure + Systolic pressure
3
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Figure 2.12 – Sample blood pressure waveform acquired using Dataquest
Acquisition Software (DSI, Tilburg, Netherlands)
Statistical analysis was performed by comparing the MAP values before
and after the administration of the vector (at the same time of the day) using
paired t-test.
2.11 BrdU infusion for assessment of cell division
A sub-set of sheep received an intravenous infusion of BrdU 48 hours
before their scheduled post-mortem examination in order to assess endothelial cell
proliferation. Normal saline was warmed to 40-50°C and BrdU (B5002, Sigma
Aldrich, Gillingham, Dorset, UK) was slowly dissolved in it by gentle vortexing
to yield a final concentration of 20mg/ml. Once completely dissolved, the BrdU
injection solution was allowed to cool down to room temperature (22-25°C).
The weight of the sheep was taken using special scales designed for large
animals. Half an hour before the infusion, the sheep was administered Diazepam
(1 mg/kg, Hameln Pharmaceuticals, Gloucester, UK) sub-cutaneously and
restrained in a crate. The fleece on her ear was shaved with an electric clipper,
cleaned with 70% ethanol, followed by the application of EMLA cream
(Lidocaine/prilocaine mixture in 5% oil-in-water emulsion) for at least 30 minutes
to provide local anaesthesia. A 21-gauge butterfly needle was then inserted into
the marginal vein of the ear. Blood was withdrawn to confirm the placement of
the needle in the vein. The catheter and needle were flushed with heparinised
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saline, and the needle was secured in its position by wrapping it up in tape. The
sheep’s head was supported during the procedure to prevent her pulling the needle
out.
A total of 20mg BrdU/kg of body weight was slowly infused into the
venous catheter over 20 to 25 minutes (Figure 2.13). The needle was then
withdrawn from the vein, and the injection site was digitally compressed for a
minute to achieve hemostasis. The sheep was released from the crate and returned
to her pen at the end of the procedure.
Figure 2.13 – Infusion of BrdU into the marginal vein of the ewe’s ear.
The endothelial cell proliferation in uterine arteries of pregnant ewes in response to over-
expression of VEGF was examined by BrdU immunohistochemistry. The animals received an
intravenous BrdU infusion (20 mg/kg bodyweight) into the marginal vein of the ear after
application of EMLA cream for local anaesthesia. The infusion was carried out 48 hours before
post-mortem examination.
The BrdU infusion was carried out by Mr. Michael Boyd, Dr. Anna David
and Vedanta Mehta.
2.12 Post-mortem examination
The post-mortem examination was performed approximately five days
before the expected date of delivery (range 3 to 7 days, delivery usually at 145
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days of gestation). The ewe was anaesthetized as before, and fetal measurements
and umbilical artery Doppler examination were recorded by ultrasound. The post-
mortem was performed under terminal anaesthesia to maintain perfusion to the
uterine arteries during clearing. This was essential to prevent any endothelial
damage that occurs rapidly after death.
Maternal blood was sampled for biochemistry and haematological
analysis. The abdomen was reopened using the previous scar. The uterine arteries
were stripped gently of their surrounding serosa and two loose ties were placed
around the proximal segment of each uterine artery, just below the flow probe,
which was then removed. The uterine arteries were then gently cleared of the
surrounding serosa down to the third branch (Figure 2.14). Once the vessels had
been cleared, the ewe was put down by injecting 40ml of Euthatal (sodium
pentobarbitone, Rhône Merieux, Essex UK) into the carotid vein. Once the
cessation of heart beat was confirmed, the proximal tie was tied securely round
the uterine arteries which were then divided distally. The entire uterine artery tree
to the third branch was then removed gently in one piece and placed immediately
into cold Kreb’s buffer (K0507, Sigma Aldrich, Gillingham, Dorset, UK). The
uterine arteries were further cleared in cold Kreb’s buffer and the branches were
separated.
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Figure 2.14 – The branches of the uterine artery dissected out at post-
mortem examination.
The different braches of the uterine artery (main branch, 1st branch, 2nd branch and 3rd branch)
were dissected out under terminal anaesthesia. Samples were taken from each of the branches for
RNA extraction, protein extraction, histology, immunohistochemistry and organ bath
pharmacology.
The uterus was opened and amniotic fluid was collected and snap frozen.
The umbilical cord was tied and cut and the fetal sheep was removed from the
uterine cavity. Fetal blood was sampled from the umbilical veins for VEGF
ELISA, biochemistry and haematological analysis. Maternal and fetal organs
were sampled widely according to a standard proforma, organs were weighed and
measurement of fetal parameters was undertaken (Appendix IV).
Samples from each tissue were snap-frozen in liquid nitrogen for future
nucleic acid/protein extraction. One sample from each tissue was placed in a
histology cassette and dropped into 4% paraformaldehyde (pH 7.4) overnight
before transfer into 70% ethanol.
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2.13 Organ Bath Studies
2.13.1 Principle:
Organ bath is an in vitro technique that allows us to examine functional
responses and vascular reactivity of isolated arterial or venous segments. In organ
bath experiments, a blood vessel is cleared of surrounding fat and connective
tissue and mounted between two L-shaped pins in physiological medium. The
medium is bubbled with oxygen and maintained at 37°C. The contractility and
relaxation of the vessel is examined by subjecting it to increasing doses of
agonists. A force transducer calculates the tension changes in response to different
agents under isometric conditions, i.e, the vessel diameter is kept constant and
displays this information as a real-time trace on a computer (Figure 2.15).
Figure 2.15 – Principle of organ bath analysis
A small segment of a blood vessel is suspended between two L-shaped pins in an organ bath
chamber. The chamber is filled with Kreb’s buffer through which carbogen gas (95% O2, 5% CO2)
is constantly bubbled. The solution in the chamber is maintained at 37°C using a water
thermocirculator. Agonists added directly into the organ bath chamber cause the vessel ring to
either contract or relax. The change in the tension of the vessel is measured by a force transducer
and recorded on an acquisition computer as a real-time trace.
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2.13.2 Method:
The uterine arteries were transported from the BSU Camden to the Rayne
Institute, UCL in freshly made Kreb’s buffer within 1 hour of retrieval from the
ewe. Their pharmacologic responses were analysed on an 8 chambered organ bath
set-up. Under a microscope, the branches were cleared of surrounding connective
tissue within a petri-dish containing Kreb’s buffer and cut into 3mm long rings.
Each ring was carefully mounted between the two L-shaped pins of a 25ml organ
bath, ensuring the endothelium was not damaged. The composition of the Kreb’s
buffer used is described in Appendix II. The Kreb’s buffer was bubbled with
carbogen gas (95% oxygen, 5% carbon dioxide) to maintain a physiological pH of
7.4, and the temperature was maintained at 37°C with a water thermocirculator.
Following mounting, the vessels were allowed to equilibrate for one hour,
with washing every 15 minutes. During this time, the basal tension was also
gradually increased to 1.0g in small steps, to allow the vessels to generate their
optimum response to the agonists in future steps.
After one hour, the vessels were challenged with 48mM Potassium
chloride (KCl) to test for viability and also to determine the maximum
contractility. They were then washed 3 times with Kreb’s buffer, and challenged
again after 20 minutes. In all, they were challenged 3-4 times with KCl, till the
maximum contractile response generated was equal to the previous response
(+5%). A contractile response greater than 1.5g was considered viable.
After the KCl stimulation, the vessels were again allowed to rest for 30
minutes, during which time they were washed 3 times with Kreb’s buffer. Then, a
dose response curve to L-phenylephrine (L-1286 Sigma Aldrich) was generated
(10-9 to 3x10-5M). The next higher dose was added only after the contraction
induced by the previous dose had stabilized.
The vessels were again allowed to rest for 30 minutes, during which they
were washed 4-5 times with Kreb’s buffer, until they attained the basal tone. After
attaining the basal tone, they were pre-contracted with phenylephrine, until they
achieved an absolute contraction between 2-4 grams. Once the contraction had
stabilized, they were made to relax to bradykinin (B-3259, Sigma Aldrich, 10-11 to
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3x10-7M). After the bradykinin dose-response curve, the vessels were washed and
different inhibitors of relaxation were added to the organ bath chamber. Following
appropriate incubation times; 20 minutes for L-NAME, (3x10-4 M, N5751, Sigma
Aldrich, a NOS inhibitor), 20 minutes for Indomethacin/NS-398, (10-5 M,
I7378/N-194, Sigma Aldrich, a COX inhibitor), and 30 minutes for Apamin, (10-6
M, A-1289, Sigma Aldrich, an inhibitor of the EDHF pathway), the vessels were
again pre-contracted and then relaxed exactly as described previously. The
contractility of the vessels to L-phenylephrine in the presence of L-NAME was
also examined.
The real-time traces were analysed using Chart Wizard 4.2.1. The
extracted data was plotted in the form of a points-graph with non-linear regression
using GraphPad Prism 5.0, and statistical significance was assessed using two-
way ANOVA.
2.14 Histology of tissues and determination of intima/media
ratios
Tissues samples were fixed in 4% paraformaldehyde overnight,
transferred to 70% ethanol the next day and processed into paraffin in cassettes
using a Thermo Shandon Pathfinder Histology processor (Thermo Scientific,
Surrey, UK). The paraffinised tissue blocks were cut into 3-micron thick sections
using a microtome, and the ribbon was floated in a water bath (37°C) until it had
completely stretched. The stretched paraffin ribbon was placed in the centre of a
glass slide and air dried. The slides used were coated with Polylysine (631-0107
VWR, Leuven, Germany) to ensure that the tissue stuck firmly and did not fall off
during subsequent immunohistochemistry steps.
One slide of each section was used for H&E staining to look for
pathological changes. H&E staining was performed by immersing the slide in
hematoxylin solution made up in PBS pH 7.2 for 5 minutes and washed 3 times in
PBS before being immersed in 1% eosin counterstain solution made up in PBS
pH 7.2 for 5 seconds and washed 3 times in PBS. Sections were processed
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through an increasing alcohol gradient into xylene and then mounted in DPX
mounting medium. A coverslip was placed over the section and the slide was
allowed to dry. Slides were analysed under normal light microscopy with the
assistance of Dr. Elizabeth Benjamin, Department of Pathology and Institute for
Women’s Health, University College London.
H&E stained sections of the uterine arteries were photographed under 10x
magnification on a microscope (Nikon Eclipse E600, Amstelveen, Netherlands),
and the photomicrographs were imported into Image J (National Institute of
Health, USA) for further analysis. The relative thicknesses of the intimal and
medial layers were determined using the ‘Track and Trace’ Function to calculate
the intima/media ratios.
2.15 Adventitial Vessel enumeration
One of the important functions of VEGF is angiogenesis or formation of
new blood vessels. In order to confirm this, the number of adventitial blood
vessels was assessed in ovine uterine arteries that been transduced with either
Ad.VEGF-A165 or Ad.LacZ.
The number of adventitial blood vessels was first counted in H&E stained
sections by light microscopy. However, it was considered more appropriate and
informative to perform this count on immunohistochemically stained sections,
using an antibody that specifically stains the endothelium. Hence, the uterine
artery sections of pregnant sheep were stained with two antibodies that are
commonly used to stain the endothelium – anti-von Willebrand Factor (vWF) and
anti-CD31.
2.15.1 Principle of Immunohistochemistry
Immunohistochemistry (IHC) refers to the process of localizing antigens
(proteins) in cells of a tissue section exploiting the fundamental principle of
antibodies binding specifically to antigens in biological tissues. Visualising an
142
antibody-antigen interaction can be accomplished in a number of ways. In the
most common instance, an antibody is conjugated to an enzyme, such as
peroxidase, that can catalyse a colour-producing reaction on addition of an
appropriate substrate. Alternatively, the antibody can also be tagged to a
fluorophore, such as fluorescein. rhodamine or alexafluor (this is known as
immunofluorescent staining).
The advantage of IHC over techniques like Enzyme-linked Immunosorbent Assay
(ELISA) or Western blotting (which function on the same principle) is the ability
to identify and locate specific proteins within the tissue structure, which adds a
whole new dimension to the technique. The target immunogens may sometimes
be physically “hidden” from the antibody, because of protein folding or formation
of cross-linking methylene bridges during ‘fixation’. An antigen retrieval step,
where enzymes or heat are used to re-model the protein structure and break down
methylene bridges, may be required to visualise some antigens.
2.15.2 Method
Paraffin sections on slides were dewaxed and hydrated, by sequentially
passing through the following steps: xylene (3 min, BDH), xylene (3 min), xylene
(3 min), absolute ethanol (2 min, BDH), absolute ethanol (2 min), 95% ethanol (1
min), 95% ethanol (1 min), 70% ethanol (2 min), 70% ethanol (2 min), distilled
water (5 min). Endogenous peroxidase activity was blocked by immersing the
slide in 0.6% Hydrogen peroxide (Sigma Aldrich) for 15 minutes. The slide was
then rinsed in tap water. A boundary was made around the tissue section using a
DAKO pen (DAKO, Glostrup, Denmark). Antigen retrieval was performed by
trypsin digestion to unmask the antigen sites that may have become cross-linked
during fixation. A fresh solution of 0.1% trypsin (Difco Trypsin-250, 215240, BD
Biosciences, Oxford, UK) and 0.1% calcium chloride was prepared in 0.005M
Tris buffered saline at 37°C, pH 7.8. Slides were immersed for 10 minutes and
then rinsed in PBS.
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Non-specific antibody binding to proteins in tissue preparations was
prevented by applying 5% non-immune goat serum (X0907, Dako, Glostrup,
Germany) to each slide for 30 minutes at room temperature, the serum being from
the species which provided the second layer antibody. The primary antibody
rabbit anti-human von Willebrand factor (anti-vWF, A0082, Dako) was diluted in
PBS with 0.1% BSA (PBS/BSA) at varying concentrations (1:50, 1:100, 1:200,
1:400 and 1:800) and pipetted on the tissue sections within the boundary (~200
μl). The slides were then placed at 4°C overnight in a humidified chamber. 
Negative controls were obtained by omitting the incubation with primary
antibody.
Next morning, secondary goat anti-rabbit biotinylated IgG (E0432, Dako,
Glostrup, Denmark) was diluted 1:100 in PBS/BSA and added to the slides after
washing with PBS/BSA. The slides were kept at room temperature for one hour.
During the last half hour of incubation, the ABC Solution (PK 4000, Vector
Laboratories, Peterborough, UK) was prepared as per manufacturer’s protocol,
and allowed to stand at room temperature for at least 30 minutes.
The slides were then washed with PBS/BSA (1 wash), followed by PBS (2
washes). The ABC solution was then added to the tissue sections after gently
drying off the excess buffer. The slides were further incubated at room
temperature for 1 hour.
Towards the end of incubation, the 3-3’diaminobenzidine (DAB) substrate
solution (D5905, Sigma Aldrich) was prepared. 25mg of DAB were added to 50
ml of PBS and the solution was vigorously vortexed and filtered. The slides were
rinsed with PBS. Just before use, 16.7μl of 30% Hydrogen peroxide was added to 
the DAB solution which was mixed and transferred to a cuvette. The slides were
transferred into the solution and allowed to stain for about 15 minutes, before the
reaction was stopped by transferring the slides to water.
The stained sections were counterstained with Mayer’s haematoxylin
solution (51275, Fluka, USA), differentiated in Scott’s tap water and destained in
acid alcohol. The slides were then dehydrated by passing through an ascending
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alcohol gradient, followed by 3 changes in xylene. They were finally mounted in
DPX and covered with a cover slip.
The appropriate primary antibody concentration was determined, and all
remaining slides were stained using this concentration. The blood vessels in the
perivascular adventitia were observed under a microscope (Nikon Eclipse E600,
Amstelveen, Netherlands). The number of positively stained vessels with a
distinct lumen was counted in duplicate sections and compared between the
uterine arteries from both the Ad.VEGF and Ad.LacZ injected sides. The
statistical significance was determined using unpaired t-test.
2.16 Immunohistochemistry for VEGF receptors
The paraffinised tissue sections were dewaxed and hydrated as described
above. Antigen retrieval was performed by treating the tissue sections in Pronase
(10165921001, Roche Diagnostics, Germany) for 15 minutes at room temperature
(for Neuropilin-1 staining) or boiling in Citrate buffer pH 6.0 for 20 minutes (for
VEGFR-1 and VEGFR-2). The sections were then treated with 3% Hydrogen
peroxide for 15 minutes to block endogenous peroxidases, washed with PBS and
permeabilized by treating in PBS with 0.1% Tween-20 (PBST) for 15 minutes.
The slides were washed again and blocked in rabbit serum (X0902, Dako) (for
Neuropilin-1 and VEGFR-2) or goat serum (for VEGFR-1). A goat polyclonal
neuropilin-1 (1:50, sc-7239 Santa Cruz Biotechnology USA), rabbit polyclonal
VEGFR-1 (1:50, sc-316 Santa Cruz Biotechnology) or mouse monoclonal
VEGFR-2 (1:50, sc-6251 Santa Cruz Biotechnology) primary antibody was
applied to the tissue sections overnight at 4°C in a humidified chamber.
Next morning, the slides were washed and the appropriate secondary
antibody was applied at 1:400 dilution, polyclonal rabbit anti-goat biotinylated
IgG (E0466 Dako Glostrup Denmark) for neuropilin-1, polyclonal rabbit anti-
mouse biotinylated IgG (E0464 Dako Glostrup Denmark) for VEGFR-2 and
polyclonal goat anti-rabbit biotinylated IgG (E0432 Dako Glostrup Denmark) for
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VEGFR-1. The slides were then stained and fixed as has been described for anti-
vWF staining.
2.17 Immuno-Fluorescence Double Labeling for BrdU and
vWF
Uterine arteries from sheep that had been infused with BrdU were fixed,
processed, paraffin embedded and sectioned as has been described previously.
The tissue sections were used for double labeling with anti-BrdU antibody (a cell
proliferation maker) and anti-vWF antibody (an endothelial marker) to
specifically identify proliferating endothelial cells.
The dewaxing, blocking of endogenous peroxidases, antigen retrieval
(with trypsin), blocking of non-specific binding sites with pre-immune serum and
application of primary anti-vWF were performed as has been described previously
(Section 2.15.2). The only difference is that in place of non-immune goat serum,
non-immune donkey serum (D9663, Sigma Aldrich) was used for the blocking
step (as donkey is the species in which both the secondary and tertiary antibodies
had been raised).
Next morning, the slides were rinsed with PBS/BSA, followed by a one
hour room temperature incubation with biotinylated donkey anti-rabbit secondary
antibody (1:100, 711-065-152, Jackson ImmunoResearch, West Grove, PA,
USA). The slides were then rinsed with PBS, and the sections were incubated for
another one hour with the avidin-biotinylated horseradish peroxidase complex
(ABC, PK 4000, Vector Laboratories, Peterborough, UK). The deposited ABC
Complex was detected via covalent conjugation of biotinylated tyramide (1:1000
in PBS, Dupont, UK), reacted in the presence of 0.01% Hydrogen peroxide in
PBS for 10 minutes at room temperature (Werner A et al., 1998). This treatment
with biotinylated tyramide allowed us to transform an initially noncovalent form
of biotin labeling into a covalent one, to allow the label to withstand the post-
treatment with 2N Hydrochloric acid (HCl) for 45 minutes at room temperature
needed to expose the BrdU antigen (by dissociating the histones and partially
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denaturing DNA). The HCl-treated sections were briefly washed in PBS, exposed
for 30 minutes to 0.1M boric acid/sodium borate buffer (pH 8.5), washed in PBS
again, pre-incubated with 0.5% Triton X-100 and 5% donkey serum in PBS and
then incubated with the primary mouse antibody against BrdU (1:100 Dako,
Glostrup, Germany M0744) overnight at 4°C. This step was followed by a one
hour incubation with a secondary Alexafluor-488 conjugated goat anti-mouse IgG
(1:200, 11001, Invitrogen, Paisley, UK) and then enhanced with a tertiary
Alexafluor-488 conjugated donkey anti-goat antibody (1:200, 11055, Invitrogen,
Paisley, UK), in combination with Texas Red Streptavidin (016-070-084, Jackson
Immunoresearch) for one hour at room temperature. The sections were covered
with mounting medium with DAPI (H-1200, Vector Laboratories, UK) and stored
in the dark at 4°C before use. Negative controls were obtained by not exposing
the tissue section to either of the primary antibodies.
This analysis was performed by Vedanta Mehta and Panicos Shangaris.
2.18 Confocal Microscopy
For visualizing the immuno-fluorescence double labeling, digital
micrographs of the Alexafluor-488 for the BrdU staining and Texas red
fluorescence for vWF were taken representing an area of 1mm x 1mm (1024
pixels x 1024 pixels; grayscale 0-255) with a Leica TCS 4D confocal laser
microscope using a 20X objective (Milton Keynes, UK). The fluorescence was
excited using low ArKr laser power (0.25V) at wavelengths of 488 nm for
Alexafluor-488, 568 nm for Texas Red and 358 nm (ultraviolet) for DAPI, and
detected using the BP-FITC filter for Alexafluor-488, the LP590 filter for Texas
Red and the LP360 filter for DAPI, respectively. Nine consecutive, equidistant
levels were recorded and condensed to a single bitmap using the MaxIntens
algorithm.
Confocal Microscopy was performed by Vedanta Mehta under the
supervision of the technical staff at the Imaging Facility, Rockefeller Building,
UCL.
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2.19 RT-PCR
To determine the extent of vector expression, Reverse-Transcription (RT)-
PCR was performed on a number of maternal and fetal samples (maternal uterine
arteries, uterus and placentomes; maternal and fetal gonad, adrenal, lung, liver,
kidney, spleen, brain and thymus) obtained at post-mortem examination.
For RT-PCR, total RNA was isolated from 30-40mg of snap-frozen tissues
using the Qiagen RNeasy Mini Kit (74104, Qiagen Ltd, Crawley, West Sussex,
UK) as per manufacturer’s instructions, with an additional proteinase-K (19131,
Qiagen) digestion step (following homogenization) at 55°C for 10 minutes. The
yield and purity of RNA was estimated on a spectrophometer by measuring the
A260/A280 ratio, and considered to be suitable for analysis if the ratio was 1.80-
1.95.  Total RNA (1μg) was reverse transcribed to cDNA using the QuantiTect 
Reverse Transcription Kit (205311, Qiagen). The RT step was carried out at 42°C
for 30 minutes.
PCR was performed on the cDNA generated using the Taq PCR Master
Mix Kit (201443, Qiagen). For Ad.VEGF-A165 detection, the forward primers
used (Table 2.1) were designed to span the vector transgene boundary (Viita H et
al., 2008) to ensure that the reaction was sensitive only for the transgenic vegf,
and not endogenous vegf. In all cases, a PTC-100 Thermocycler (MJ Research
Inc., Watertown, MA, USA) was used and the PCR final reaction volume was 20
μl. Each reaction contained 10 μl Taq PCR Master Mix, 6 μl sterile double 
distilled water, 1 μl forward primer (to yield a final concentration of 1 μM), 1 μl 
reverse primer (to yield a final concentration of 1 μM) and 2 μl cDNA. The PCR 
cycle was 94°C for 4 minutes, followed by 30 cycles of denaturation at 94°C for 1
minute, annealing at 64°C for 1 minute and extension at 72°C for 1 minute,
followed by a final extension step of 72°C for 10 minutes.
The RT-PCR, described as above was further sensitized by following it
with a semi-nested approach. 2 μl of the first round reaction product was 
transferred to a fresh tube and used as the template for the second round PCR
step. The second round forward primer was identical to the first round forward
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primer, but the reverse primer bound to the template at a site more internal than
the complementary binding site of the first round reverse primer (Table 2.1,
Figure 2.16). The annealing temperature was kept at 54°C. All other thermocyling
steps were identical to the first round reaction protocol. The primer sequence and
thermocycling protocol for both the first round and second round PCR is
described in Table 2.1. The optimization of the semi-nested PCR has been
described in the Results Section.
Table 2.1 – Primer sequence and protocol to determine Ad.VEGF-A165
expression in ovine maternal and fetal samples
Primer Sequence Annealting
Temperature
and Time
Expected
Product size
1st round
Forward
Primer
5`-TCAGATCCATGAACTTTCTGC-
3`
64°C for 60
seconds
1st round
Reverse Primer
5`-TCTCTCCTATGTGCTGGCCT-3` 64°C for 60
seconds
366 base
pairs
2nd round
Forward
Primer
5`-TCAGATCCATGAACTTTCTGC-
3`
54°C for 60
seconds
2nd round
Reverse Primer
5`-GATCCGCATAATCTGCATGGT-
3`
54°C for 60
seconds
330 base
pairs
Figure 2.16 – Sites of primer binding for first round and second round of
semi-nested RT-PCR to determine Ad.VEGF-A165 expression
Ψ = packaging signal, ITR = Inverted terminal repeats, CMV = Cytomegalovirus promoter 
As a positive control to show the presence of sheep cDNA in the reverse
transcribed samples, primers to endogenous sheep sequences (kindly provided by
Dr. Jill Maddox, University of Melbourne) were tested for specificity. These
primers were designed from cattle sequences and amplified sheep sequences of
transcription factor COUP-TF1 (COUPTF1, GenBank ref AJ249440), TATA box
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binding protein (TBP, GenBank ref L47974) and scavenger receptor class B type
1 (SRB1, GenBank ref AF019384). The TBP primer was found to be the most
specific for sheep DNA and the one that gave no non-specific amplification signal
with adenovirus alone (David AL, 2005, Ph.D. Thesis). It was thus used as a
positive control for sheep cDNA in future investigations. The reaction conditions
for the amplification of the TBP gene are summaried in Table 2.2.
Table 2.2 – PCR conditions for Tatabox binding protein in sheep tissues.
Product size 127 base pairs
Forward primer 5`-TCTGTCTATTCTGGAGGAGCAGCAAC-3`
Reverse primer 5`-TGCCTGCTGGGACGTCGACT-3`
Annealing temperature 65°C
All products of PCR amplification were subjected to electrophoresis
alongside a 1kb+ DNA ladder on a 1% agarose gel containing ethidium bromide
(10mg/ml) at 80V for 1 hour. The gel was visualized on an ultra-violet
transilluminator and photographed on Gel Documentation System (Syngene,
Cambridge, UK). For the Ad.VEGF-A165 PCR, RNA samples from uninjected
sheep, non-infected HUVECs and a water blank were used as negative controls;
while RNA from HUVECs or sheep uterine artery endothelial cells transduced
with Ad.VEGF-A165 was used as a positive control. For the TBP PCR, water
blank was used as a negative control. Each tissue was subjected to PCR analysis
twice.
Analysis was performed by Vedanta Mehta and assisted by Gemma Petts.
2.20 Blood Investigations
Analysis of blood count, biochemistry, liver function and bile acids was
performed on maternal and fetal blood samples at the Royal Veterinary College
pathology department (Clinical Sciences Division), Hawkshead Campus, Potters
Bar. Maternal samples were analysed before vector injection and at post-mortem,
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while fetal samples could only be analysed at post-mortem. An optimum data set
for blood analysis was investigated (Table 2.3, David AL, 2005, Ph.D. Thesis)
Table 2.3 – Blood analysis performed on samples from experimental
maternal and fetal sheep
Haematological analysis Serum biochemistry Liver function tests
White blood cell count Total protein conc. Glutamate dehydrogenase
Neutrophil count and % Albumin conc. Aspartate transaminase
Lymphocyte count and % Globulin conc. Gamma-
glutamyltransferase
Monocyte count and % Sodium conc. Creatine kinase
Eosinophil count and % Potassium conc. Total bilirubin conc.
Basophil count and % Chloride conc. Bile acids
Red blood cell count Bicarbonate conc.
Haemoglobin conc. Anion gap
Haematocrit Calcium conc.
Mean red cell volume
and haemoglobin conc.
Inorganic phosphorous
conc.
Platelet count Urea conc.
Creatinine conc.
conc.:concentration
2.21 Isolation of primary uterine artery endothelial cells
(UAECs)
The uterine arteries from mid-gestation pregnant sheep (approximately 90-
100 days, n=6) were dissected free of surrounding connective tissue and cleared
right from their origin at the internal iliac artery up to the level of the 2nd division,
under terminal anaesthesia, as previously described. The ewe was then put down
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with an overdose of intravenous pentobarbitone (40ml, Euthatal, Rhône, Merieux,
Essex, UK) and the uterine arteries were ligated at the two ends using 1-0 silk ties
and removed as a single piece (which included the main, first and second
branches). They were transported from the BSU to the tissue culture laboratory in
UCL in falcon tubes containing Endothelial Cell Basal Medium (EBM, CC3124,
Lonza, Walkersville, USA) supplemented with 1.5μg/ml Fungizone (15290-026, 
Invitrogen, Paisley, UK).
The uterine arteries were then placed in a petri-dish in a sterile laminar
flow hood and cleared further of surrounding connective tissue and blood clots.
At the proximal end of the uterine arteries, a 23 gauge butterfly needle was
introduced and secured tightly with a haemostat. About 50ml of M-199 (41150-
020, Invitrogen, Paisley, UK) was flushed through the vessel to remove all blood
clots. The distal end of the vessel was then tied off and it was inflated with EBM
containing 5mg/ml collagenase (11088815001, Roche Diagnostics, Mannheim,
Germany) and 0.5% bovine serum albumin (BSA) (A4503, Sigma Aldrich, UK)
to help dissociate endothelial cells from the vessel wall. The inflated vessel was
placed in the 37°C incubator for varying lengths of time, either 15 minutes or 55
minutes (Bird IM et al., 2000;Grummer MA et al., 2009). The distal tie was then
cut and the contents of the vessel were flushed into a falcon tube using
Endothelial Cell Growth Medium (EGM, described in Appendix III). The
contents of the falcon were centrifuged at 1000rpm for eight minutes two times to
concentrate the endothelial cell fraction. After each cycle, the supernatant was
removed and the pellet was re-suspended in EGM to remove all debris.
The freshly isolated cells were considered to be at passage 0 and plated in
4 wells of a 6-well plate (140675, Nunc, Roskilde, Denmark) in EGM containing
10% Fetal bovine serum, 1% penicillin-streptomycin (15140-122, Invitrogen,
Paisley, UK). All cell surfaces on which endothelial cells were cultured were
treated with gelatin (G1393, Sigma Aldrich) to enhance adhesion to the surface.
Cells were grown for approximately 6 days and passaged (passage 1) to T-25
flasks (136196, Nunc). To passage the UAECs, they were first rinsed with EBM
(containing no serum) as serum is known to inhibit the action of trypsin. The cells
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were then treated with 0.25% trypsin (25200-056, Invitrogen) and kept in the
incubator for 2 minutes. Detachment of cells from the culture dish surface was
confirmed under the microscope. If a large number of cells were still adherent, the
incubation time with trypsin was prolonged. Following this, the reaction with
trypsin was quenched by the addition of EGM. This medium containing free
floating cells was transferred to a falcon tube for centrifugation. After two washes
in EGM, cells were plated to new dishes (T-25 flasks).
Cells were then grown to 70% confluence in T-25 flasks and then
passaged (passage 2) to T-75 flasks (178905, Nunc). Cells were again grown to
approximately 70% confluence and passaged once more (passage 3) to T-175
flasks (178883, Nunc). Once ready for passage, the cells were passaged (passage
4) to 6-well plates for adenovirus infection experiments. The number of cells
seeded per well was 3.5x105, as determined by a haemocytometer-based
automated cell counter (Adam-MC Cell Counter, Digital Bio, Korea).
For immunofluorescent staining, a gelatinized cover slip was placed at the
bottom of the 6-well plate before seeding the cells.
2.22 Experiments to confirm identity of uterine artery
endothelial cells
To ensure that isolated and cultured cells were of endothelial origin, three
experiments were performed.
2.22.1 Immunofluorescent staining
3.5x105 cells/well were seeded on a gelatinized cover-slip in a 6-well plate
and allowed to grow until completely confluent (usually overnight). Next
morning, the medium was aspirated and 4% formaldehyde was added gently
along the edge of each well to fix the cells. The plate was kept on a shaking
platform for 15 minutes, after which the formaldehyde was discarded and the cells
were washed twice with PBS. 0.1% Triton X-100 (diluted in PBS) was then added
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to each well to permeabilize the cell membrane. The solution was aspirated after
10 minutes and the cells were washed twice with PBS.
Primary antibodies were prepared in PBS containing 0.1% Tween-20 and
1% BSA. The antibodies used are outlined in the Table 2.4. After the addition of
the primary antibody, the plate was left overnight at 4°C on the shaking platform.
Next morning, the cells were washed three times in PBS. The appropriate
secondary antibodies (Table 2.4) were prepared in the same solution and added to
the cells for one hour at room temperature. The wells were again washed three
times with PBS. The coverslip was then gently lifted up and flipped over a drop of
4’,6-diamidino-2-phenylindole (DAPI) solution on a glass slide (with the cell
adhering surface of the coverslip facing down). After five minutes, the slides
were observed under a fluorescent microscope and subsequently photographed on
a confocal microscope. Negative controls were obtained by omission of the
primary antibody.
Table 2.4 – Antibodies used for detecting sheep uterine artery endothelial
cells
Target antigen for immuno-staining Primary and secondary antibodies
vWF 1° = polyclonal rabbit anti-human vWF
(1:400, A0082, Dako, Glostrup,
Germany)
2° = Alexafluor-488 donkey anti-rabbit
IgG (1:1000, A21206, Invitrogen,
Paisley, UK)
β-catenin 1° = rabbit monoclonal anti- β-catenin 
(1:2000, C2206, Sigma Aldrich,
Gillingham, Dorset, UK)
2° = Alexafluor-488 donkey anti-rabbit
IgG (1:1000, A21206, Invitrogen,
Paisley, UK)
VE-cadherin 1° = mouse monoclonal anti-VE
cadherin (1:500, sc9989, Santa Cruz
Biotechnology, Heidelberg, Germany)
2° = Alexafluor-488 goat anti-mouse
IgG
(1:1000, A11001, Invitrogen, Paisley,
UK)
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2.22.2 Acetylated LDL analysis
Endothelial cells internalize and degrade Acetylated Low Density
Lipoprotein (Ac-LDL) 7-15 faster than smooth muscle cells via the “scavenger
cell pathway” of LDL metabolism. This has enabled the identification of
endothelial cells distinctly from smooth muscle cells based on their increased
metabolism of Ac-LDL (Voyta JC et al., 1984).
The UAECs were incubated with Ac-LDL tagged with Alexafluor-488 to
confirm their endothelial identity (L-23380, Invitrogen, UK). Ac-LDL was added
directly to cells growing in culture in 1 ml EBM (serum-free) to yield a final
concentration of 10μg/ml and left to incubate for four hours at 37°C. The medium 
was then aspirated and fresh PBS was added. Cells were then observed under a
fluorescent microscope and photographed on a confocal microscope.
2.22.3 VEGF challenge
UAECs grown to confluence in a 6-well plate were serum deprived
overnight. Next morning, VEGF-A165 protein (293-VE-010, R&D Systems) was
added to a well to yield a final concentration of 25μg/ml. Control wells were 
serum deprived overnight but not challenged with the VEGF-A165 protein. The
plate was returned to the 37°C incubator for 10 minutes, after which, the cells
were rinsed in cold PBS and protein extracted, as described below (Section 2.25).
The protein extract was probed with an antibody to phosphorylated-ERK Thr202
Tyr204 (1:1000, 9101, Cell Signaling Technology, Danvers, MA, USA) following
which the membrane was stripped and re-probed with an antibody to total ERK
(1:1000, 9102, Cell Signaling Technology) by western blotting. The secondary
antibody used was goat anti-rabbit IgG-HRP (1:8000, sc-2004, Santa Cruz
Biotechnology). Detailed protocol for western blotting is described in Section
2.27.2.
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2.23 Infection of UAECs with Adenovirus vectors
Cultured UAECs were seeded in a six well plate at a concentration of
3.5x105 cells/well as determined by an automated cell counter. Next day, the cells
were incubated for an hour with a minimal volume (1ml/well) of EBM containing
2% FBS. As FBS is very rich in growth factors, including VEGF, we wished to
reduce the concentrations of growth factors in the culture medium so that they do
not mask the effects of endogenously over-expressed VEGF. Ad.VEGF-A165,
Ad.VEGF-D or Ad.LacZ were then added to the medium at multiplicities of
infection of 0, 1, 10, 100, 1000 and 10000. Protein was extracted after 24 or 48
hours of infection for analysis by western blotting.
For cells that were incubated for 48 hours after infection with the
adenovirus, the medium was replaced with fresh EBM (containing 2% FBS) after
24 hours of infection.
2.24 Determination of infection efficiency by X-gal staining
An additional plate was infected with Ad.LacZ at increasing multiplicities
of infection (as described above). The medium was changed at 24 hours and fresh
medium was added. After 48 hours of incubation, 100% Ethanol was added to
each well for 20 minutes, in order to fix the cells. The wells were then washed in
PBS four times. 3ml of freshly prepared X-gal stain (composition described in
2.36) was then added to each well, and the plate was incubated in the dark
overnight on a shaking platform. Next morning, the cells were washed with PBS
and viewed under a light microscope. For each well, 10 high powered fields
(40X) were randomly selected and the number of stained cells and total cells were
counted to determine the infection efficiency.
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2.25 Protein extraction (from intact uterine arteries and
uterine artery endothelial cells)
Frozen tissues from the main, first, second and third branches of uterine
arteries, both left and right sides of the uterus were analysed from ewes injected
with Ad.VEGF-A165/Ad.VEGF-D and Ad.LacZ in vivo for both short and long-
term studies. Approximately, 30-50mg of tissue was pulverised in liquid nitrogen
using a metallic bijoux to extract protein for western blot analysis. After crushing,
1mL of Radio ImmunoPrecipitation Assay (RIPA) Buffer (R0278, Sigma Aldrich,
USA) containing Complete Protease Inhibitor Cocktail (11873580001, Roche,
Mannheim, Germany) and phosphatase inhibitor cocktail 1 and 2 (P5726 and
P2850, Sigma Aldrich USA), as per manufacturers’ recommended dosages, was
added to the powdered tissue. Samples were then homogenized for 30 seconds on
ice using a polytron in a 1.8ml cryovial (Nunc). The homogenised sample was
transferred to a 15ml falcon tube and centrifuged at 3000rpm for 10 minutes at
4°C. The supernatant was transferred to a 1.5ml Eppendorf tube and centrifuged
at 13000 rpm for 10 minutes at 4°C. The supernatant was then transferred to a
clean tube and stored at -20°C.
For protein extraction from cultured cells, the culture medium was
aspirated and the cells washed with cold PBS. The plate was kept on ice and
100μl of RIPA buffer (with protease and phosphatase inhibitors) was added to 
each well. The cells were then scraped off with a cell scraper (3010, Corning Life
Sciences, Amsterdam, Netherlands) and transferred to a 1.5ml eppendorf tube.
The tube was centrifuged at 13,000 rpm for 10 minutes at 4°C. The supernatant
was then transferred to a clean tube and stored at -20°C.
2.26 Determination of protein concentration
The concentration of each protein sample was determined using the Bio-
Rad Protein Assay Kit (Bio-Rad, Herts, UK), based on the method of Bradford.
The Bradford protein assay is a colorimetric assay based on the absorbance shift
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of the dye Coomassie Brilliant Blue G-250 under acid conditions when a redder
form of the dye is converted into a bluer form on binding to protein. The amount
of the blue-coloured complex in solution is a measure of protein concentration,
and can be quantified by means of an absorbance reading at 595 nm to determine
the protein concentration.
Protein standards were prepared using BSA (23209, Pierce,
Northumberland, UK) diluted in the same buffer in which protein extraction had
been performed. The following dilutions of BSA were prepared – 2.0, 1.5, 1.0,
0.5, 0.25, 0.125, 0.0625 and 0 mg/ml protein. The standard or sample (5 μl per 
well) was incubated with the dye reagent (200 μl per well) in a 96 well plate at 
room temperature for 15 minutes. The absorbance of the wells was then read on a
spectrophotometer (Tecan) at 595 nm. Every serial dilution or tissue sample was
tested on two wells and the final result taken as the average. The absorbance
values for the calibration dilutions were plotted against the standard
concentrations of BSA to produce a linear calibration curve (Figure 2.17) and the
protein concentration of the tissue samples was determined against it. Tissue
samples that gave a higher absorbance reading than that of the highest standard
(2.0 mg/ml) were re-diluted so that their absorbance fell within the linear range of
the assay.
Analysis was performed by Vedanta Mehta and Marie Buitendyk.
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Figure 2.17 – An example of a standard curve generated with BSA, used to
determine the concentration of protein extracts from uterine arteries and
UAECs.
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2.27 SDS-PAGE and Western blotting
SDS-PAGE separates proteins migrating through a gel under the influence
of an electric field. When coupled with antibody detection steps, the relative
abundance of a particular protein in two or more protein extracts can be
determined.
2.27.1 Principle of Western blotting
Heating of cell lysates with sodium dodecyl sulphate (SDS)- and
Dithiothreitol (DTT)- containing sample buffer denatures proteins, by reducing
protein disulphide bonds to thiol groups and covering the protein with SDS
molecules, forming a negatively-charged complex. Under the influence of an
electric field, proteins migrate through a gel whose pore size is determined by the
concentration of acrylamide and cross-linker in the gel. Larger proteins are
obstructed more than smaller proteins, resulting in a separation of proteins largely
based on molecular size. During transfer, the protein/SDS complex is transferred
out of the gel onto a protein-binding membrane under the influence of an electric
field. For antibody detection, protein-binding sites on the membrane are blocked
by incubating with a protein solution such as 5% milk or 3% BSA, and the protein
of interest is then specifically bound with an antibody. This primary antibody is
then detected with a secondary antibody conjugated to an enzyme, often a
peroxidase. A liquid substrate is then added, which in the presence of the
peroxidase enzyme emits light in a chemiluminescent reaction, and this light is
detected using photographic film.
Western blotting is often described as a semi-quantitative technique, with
the amount of protein originally present in the lysate proportional to the amount
of peroxidase enzyme bound to protein on the membrane, and thus the amount of
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light generated and area and intensity of the band present on the film. For routine
western blotting, samples were protein assayed before loading. Blotting with an
antibody such as GAPDH, total ERK, α-tubulin or β-actin serves as a loading 
control and helps to visually confirm comparable protein loading.
2.27.2 Western Blot Analysis
25μg of extracted protein (from either intact uterine arteries or transduced 
uterine artery endothelial cells) was assayed for levels of eNOS, iNOS,
phosphorylated eNOS (Ser1177) by Western blotting. The protein samples were
reduced with 4x Laemelli reducing buffer (NP007, Invitrogen) by boiling at
100°C for 5 minutes. The reduced samples were run on a 4-12% Bis-Tris Gel
(NP0335BOX, Invitrogen) in MOPS-SDS Running buffer (NP0001, Invitrogen)
alongside Rainbow Molecular Weight Marker (RPN800E, GE Healthcare, Bucks,
UK), at 200V for 50 minutes.
The protein was then transferred to a PVDF membrane (LC2005,
Invitrogen) using a wet transfer apparatus in 1x NuPAGE transfer buffer
(NP00061, Invitrogen) containing 10% methanol. The transfer was performed at
40V for 1.5 hours. Following the transfer, the membrane was blocked using 5%
skimmed milk in PBST for one hour at room temperature. The primary antibody
was diluted in 5% milk at an appropriate dilution (Table 2.5). Following the
blocking step, the membrane was incubated with the primary antibody overnight
at 4°C on a shaking platform.
Next morning, the membrane was washed three times with PBST. This
was followed by an incubation with the appropriate secondary antibody (diluted
in 5% milk) for one hour at room temperature. The membrane was washed again
three times with PBST and then dried. The protein bands were visualized using
the Enhanced Chemiluminescence Plus Reagent Detection system (RPN2132, GE
Healthcare). The hyperfilm was scanned using the HP Deskscan system and
densitometric analysis was performed on the bands using the software Image J.
After probing with one antibody, the membrane was stripped using the Re-blot
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Plus Strong solution (2504, Millipore, Watford, UK) as per manufacturer’s
instructions, and re-probed with another antibody.
Table 2.5 – Antibodies used for western blotting
Target antigen Primary and secondary antibodies
eNOS 1° = monoclonal mouse anti-eNOS
(1:3000, 610296, BD Biosciences,
Oxford, UK)
2° = sheep anti-mouse IgG-horseradish
peroxidase (1:3000, RPN 4201, GE
Healthcare, Bucks, UK)
iNOS 1° = monoclonal mouse anti-
iNOS(1:3000, 610328, BD
Biosciences, Oxford, UK)
2° = sheep anti-mouse IgG-horseradish
peroxidase (1:3000, RPN 4201, GE
Healthcare, Bucks, UK)
phosphorylated eNOS (Ser1177) 1° = monoclonal rabbit anti-p-
eNOS(Ser1177) (Cell Signaling
Technology, Danvers, MA, USA)
2° = donkey anti-rabbit IgG-
horseradish peroxidase (1:8000, Santa
Cruz Biotechnology, Heidelberg,
Germany)
2.28 ELISA for VEGF-A165 and VEGF-D
2.28.1 Principle of the VEGF Assay
This assay employs the quantitative sandwich enzyme immunoassay
technique. A monoclonal antibody specific for VEGF has been pre-coated onto a
microplate. Standard and samples are pipetted into the wells and any VEGF
present is bound by the immobilized antibody. After washing away the unbound
substances, an enzyme-linked polyconal antibody specific for VEGF is added to
the wells. The unbound substances are again washed away, followed by the
addition of a chromogenic substrate. The colour developed is proportional to the
161
amount of VEGF bound in the initial step. The colour development is stopped
after an appropriate time and the absorbance of the wells is measured to determine
VEGF concentration.
2.28.2 Method
A commercially available kit was used to quantify the levels of VEGF-
A165 (DVE00, R&D Systems, Minneapolis, MN, USA) or VEGF-D (DVED00,
R&D Systems) expression as per manufacturer’s instructions. The sensitivity of
this assay falls in the range of 5.0 – 10.0 pg/ml of VEGF. The protein extraction
and estimation were performed as has been described previously (Sections 2.25
and 2.26).
Tissue samples were diluted so that the absorbance of the sample fell
within the linear range of the VEGF assay (usually at a protein level of less than
1000 pg/ml). The VEGF assay consisted of a microtiter plate containing 12 x 8
wells precoated with a monoclonal mouse antibody to VEGF (-A165 or –D). The
VEGF protein standard dilutions were prepared to obtain a calibration curve. To
each well was added 50 μl of assay diluent (provided as part of the kit) and 200 μl 
of the calibration dilution or tissue extract containing 300 ng protein and the plate
was incubated for 2 hours at room temperature. The plate was washed three times
with washing solution and then incubated with ‘Conjugate’ solution (polyclonal
antibody against VEGF conjugated to horseradish peroxidase) for 2 hours at room
temperature. The wells were again washed three times with washing solution and
the bound peroxidase revealed by incubation with the ‘Substrate’ solution
(containing the chromogen tetramethylbenzidine) for 20 minutes at room
temperature yielding a blue coloured reaction product. The reaction was quenched
by the addition of ‘Stop’ solution (containing 2N Sulphuric acid). On addition of
the ‘Stop’ solution, the blue colour in the wells turned yellow. The absorbance of
the wells was measured at 450 nm with wavelength correction at 560 nm using a
microplate reader (Tecan). Every serial dilution or sample was tested on two wells
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and the final result taken as the average. The absorbance values for the calibration
dilutions were plotted against the standard concentrations of VEGF to produce a
nearly linear calibration curve and the VEGF concentration in tissue samples was
determined against it.
Analysis was done by Vedanta Mehta, Khalil Abi-Nader, Alison Evans and
Rikesh Patel.
2.29 Guinea Pig Experiments
Guinea Pigs of Dunkin Hartley breed were used. Female virgin guinea
pigs were purchased from Harlan Animal Research Laboratory, UK and housed in
groups of 2-3 in cages. The cages carried a card with an identification number for
each guinea pig. The guinea pigs housed within the same cage were distinguished
by making different coloured marks on the back of their heads. The room in
which the guinea pig cages were placed had a 12 h : 12 h light : dark cycle, at a
constant temperature of 25°C.
All procedures on animals were conducted in accordance with UK Home
Office regulations and the Guidance for the Operation of Animals (Scientific
Procedures) Act (1986) under Project Licence number 70/6546 titled ‘Fetal gene
therapy in utero’.
2.29.1 Guinea Pig Diet
The guinea pigs had ad lib access to food. They were fed a commercially
available guinea-pig/rabbit ration (Appendix 1). Tap water supplemented with
Vitamin C (400mg/L) was available ad lib.
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2.30 Timed Mating of Guinea Pigs
In order to time mate guinea pigs, their vaginas were visually observed
every day to check for the rupture of hymen. The guinea pig estrus cycle lasts
approximately 16 days. A pro-estrus of approximately 36 hours is characterized
by vaginal swelling, increased sexual activity and rupture of the vaginal
membrane.
The membrane remains open for 2-3 days, covering the period of
ovulation. Estrus lasts 8-12 hours and is characterized by the copulatory reflex
(lordosis), an open vaginal membrane and vaginal congestion. Estrus most
commonly occurs at night.
On finding the hymen ruptured and vagina open, female guinea pigs were
deemed to be in estrus and placed with a male for 3 nights. After 3 nights, the
male was separated from the female. The occurrence of coitus during this period
is usually marked by a copulatory plug, containing hardened semen. However,
even if a copulatory plug was not found, mating was presumed to have occurred
during these 3 days. The middle day of this 3-day period was considered to be day
0, and the next day was considered to be 1 day post-conception (dpc).
Guinea pigs were scanned at 22-24 dpc to confirm pregnancy. They were
restrained by a trained animal technician (Figure 2.18) and scanned using a 7-10
MHz probe (Siemens, Bracknell, United Kingdom). If a fetus was detected, an
attempt was made to get a measurement of BPD, and this was compared with
published data to confirm the gestational age (Turner AJ and Trudinger BJ, 2000).
Pregnant guinea pigs were used for surgeries subsequently.
In some cases, guinea pigs were mated but were not pregnant when
scanned. In such cases, a re-scan was performed one week later. If a fetus was still
not detected after one week, the non-pregnant guinea pigs were returned to the
routine of daily hymen examination for re-mating.
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Figure 2.18 – Restraint of a guinea pig in preparation for ultrasound
scanning
2.31 Creating Growth-Restricted Guinea Pigs (Method
adapted from Roberts CT et al 2001)
Virgin female guinea pigs were divided into two groups, with the
members of the two groups having similar body weights. One group was
maintained on the ad lib diet, while the other group was fed 70% of the ad lib
intake. The body weights of all animals were measured three times/week, as was
the food in the hopper of the ad lib fed animals before feeding each day to
determine the amount of food consumed per gram body weight. The nutrient
restricted group was fed 70% of the ad lib intake per gram body weight. The
guinea pigs were maintained on this control (normal) or nutrient-restricted diet for
approximately 4 weeks. During this period, the routine vaginal checks were
carried, as described in the preceding section.
After 4 weeks, the female guinea pigs were placed with a male for 3 nights
on the day they were deemed to be in estrus, that is, had a ruptured vaginal
membrane. The guinea pigs were scanned at 22-24 dpc to confirm pregnancy. If a
fetus was detected by ultrasound scanning, the nutrient restricted animals were
continued to be fed 70% of the ad lib intake per gram body weight until day 34
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post-conception, and from day 35 onwards, food was increased to 90% of the ad
lib intake. If a fetus was not detected, a re-scan was performed 1 week later. If the
uterine horns were found to be ‘empty’ on the second re-scan, the guinea pig was
returned to the original diet (control or nutrient-restricted) until the next estrus 16
days later, at which time she was mated again with a male.
2.32 Guinea Pig Anaesthesia
Surgery was performed at either 30 or 45 dpc in pregnant guinea pigs.
Before surgery, guinea pigs were starved overnight with free access to water to
reduce the volume of stomach contents during surgery, thereby reducing the risk
of regurgitation/aspiration. General anaesthesia was induced with Diazepam,
Atropine and Ketamine. Atropine (0.5mg/kg, Martindale Pharmaceuticals, Essex,
UK) and Diazepam (5mg/kg, Hameln Pharmaceuticals, Gloucester, UK) were
administered by the sub-cutaneous route. Following a 20 minute wait, Ketamine
(40 mg/kg, Hameln Pharmaceuticals, Gluocester, UK) was administered by the
intra-muscular route to the sedated animal.
A face mask was then applied to the animal, through which Isoflurane
(Isoflurane-vet, Merial Animal Health Ltd., Essex, UK) was administered.
General anaesthesia was maintained with 1.5-2.0% isoflurane in oxygen. The
animal was placed supine on a heated operating table for rodents. A diathermy
pad was placed underneath the animal.
Once anaesthetized, the fur was clipped from the guinea pig’s abdomen
and a detailed ultrasound examination of the uterus and its contents was
performed using a 7-10 MHz probe. Fetal measurements were collected, namely
biparietal diameteter, occipito-snout length, abdominal circumference, femur
length, placental length and thickness and crown-rump length.
The abdominal surface of the guinea pig was scrubbed with ‘Hibiscrub’
(Chlorhexidine gluconate 4% w/v, Regent Medical, Manchester, UK) followed by
‘Povidone’ (1% w/w Iodine solution, Vetasept Animal Care Ltd., York, UK), and
then exposed with sterile drapes.
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A pulse oximeter (5250 RGM, Ohmeda) placed on the guinea pig’s ear
was used to monitor oxygen saturation and pulse rate and this data was
documented every 15 minutes together with respiration rate, isoflurane
concentration and level of anaesthesia. Maternal blood was taken for pre-
operative haematological and biochemical analysis. Blood was collected into BD
Vacutainer tubes (BD Vacutainer systems, Plymouth, UK) containing 0.105 M
sodium citrate for plasma (9C, blue topped bottle), silica clot activator polymer
gel for serum and potassium EDTA (K3EDTA) for whole blood.
The guinea pig anaesthesia was performed by Mr. Michael Boyd. The fetal
measurments by ultrasound scanning were initially collected by Dr. Anna David.
During the course of the work for this thesis, she trained Vedanta Mehta to collect
fetal measurments by ultra-sound scanning, who performed all ultrasound
analysis in the latter part of the project.
2.33 Guinea Pig Surgery
To begin with, all surgeries were carried out on pregnant guinea pigs at 30
dpc and under direct vision. However, because of the difficulties associated with
finding the uterine arteries, we moved to pregnant guinea pigs at 45 dpc and
began operating under a surgical microscope - Discovery V8 Stereomicroscope
(Carl Zeiss Ltd., Herts UK).
A midline lower abdominal incision was made in the skin using a number
10 blade (Swann-Morton, Sheffield, UK). The edges of the skin incision were
injected with a 10% solution of Lidocaine hydrochloride (0.5ml, Hameln
Pharmaceuticals, Gloucester, UK) to provide local anaesthesia. The rectus sheath
was incised and the peritoneal cavity was opened carefully by blunt dissection.
This is primarily because the rectus sheath in a guinea pig is very thin, and it is
easy to accidentally rupture the bowel when using sharp surgical instruments to
gain access to the peritoneal cavity. Once inside the peritoneal cavity, the bowel
was packed to one side by either using sterile damp gauze or being retracted by a
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surgical assistant. The utero-placental circulation was transduced with Ad.LacZ or
Ad.VEGF-A165 by four different methods, which are described below.
2.33.1 Direct injection into uterine arteries
Experiments began by attempting to directly inject the vector into the
uterine arteries. The uterine arteries in a pregnant guinea pig at 45 dpc have a very
small diameter, ~200-350 μm and are deeply embedded in fat. To locate the 
uterine artery, the perivascular fat tissue was gently lifted up. A strong light was
shone directly across the fat pad from back to front, so that the bright red coloured
uterine artery could be visualized inside it. Once the precise location of the uterine
artery had been determined, the fat was very gently dissected using a small
straight vannas scissors (103102, John Weiss and Company, Milton Keynes, UK)
to expose the uterine artery. In case of any accidental bleeds while cutting through
the highly vascularized fat, haemostasis was achieved by electrical cauterization
(VIO 300D Electrosurgical Generator, ERBE, Georgia, USA). During this
surgery, it was sometimes necessary to deliver the uterus outside the body cavity
in order to gain easy access to the uterine artery. In such cases, the uterus and its
contents were kept warm by wrapping them up in sterile gauze soaked in warm
saline solution.
Once the uterine artery had been cleared of surrounding fat and just before
injecting the vessel, the uterine artery segment proximal to the injection site was
occluded using a microvascular clip (610195, Harvard Apparatus, Kent, UK). The
injection (1x1010 viral particles of Ad.LacZ in a volume of 0.5-1.3 ml PBS) was
then administered distal to the occlusion over approximately 1 minute. Initially a
31 gauge Hamilton needle was used, but this was too large for some of the uterine
artery vessels. A custom made 34 gauge needle was then used, with a catheter
attached, made by Dr. Simon Waddington (Lecturer, Institute for Women’s
Health, UCL) which helped in improving the injection technique.
A second microvascular clip was then placed over the injection site once
the needle was removed to compress the injection site, for a minimum of 3
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minutes (Figure 2.19). After this time both occluders were removed and the
vessel was carefully observed for bleeding. On some occasions re-occlusion of the
vessel was necessary to achieve haemostasis. Additionally, adrenaline (Hameln
Pharmaceuticals, Gluocester, UK) was applied to the vessel to achieve
haemostasis when further occlusion had been unsuccessful.
Figure 2.19 – A microvascular clip placed around a uterine artery at the site
of injection
After injection of Ad.LacZ to the uterine arteries of pregnant guinea pigs, a microvascular clip was
placed over the injection site to compress it, for a minimum of 3 minutes. After this time, the clip
was removed and the vessel was carefully watched for bleeding. If haemostasis was not achieved,
the clip was placed for longer duration and adrenaline was administered over the site of bleeding.
A successful injection was defined as the vector seen moving down the
vessel during injection. Failed injections were due to vector being inadvertently
injected into the vessel wall, leaking out of the vessel or coming out the other side
of the vessel, opposite the injection site. In case of failed injections, 1-2 re-
attempts were made to inject the uterine artery. As the uterine artery is very
unsupported within the fat, it is quite difficult and technically challenging to inject
it reliably.
The post-mortem examination was scheduled 3-5 days post-surgery to
achieve good transgene expression, unless necessitated earlier because of
maternal death or miscarriage.
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2.33.2 External transduction of uterine and radial arteries
The effect of external gene transfer to the uterine and radial arteries was
also studied in some animals. In some cases, these were animals in which
attempts to inject the uterine artery vessel were unsuccessful either because the
vessel was deemed to be too small to be injected, or because the injection attempt
failed. The vector dose administered on each side (left or right) was 1x1010 viral
particles of Ad.LacZ in a total volume of 0.5-1.0 ml PBS. For uterine artery gene
transfer the vector was either injected alongside the vessel as it ran within the fat
(6 uterine arteries) or dropped onto the exposed vessel within the fat (2 uterine
arteries) and left to transduce for 5 minutes. Vector was also dropped onto the
radial arteries as they ran within their mesentery (2 uterine horns) and left for 5
minutes before the uterus was subsequently mobilized. During this 5 minute time
period the uterine horn was kept warm and moist by wrapping it in a sterile gauze
soaked with warm saline. No vessel occlusion was used in this technique. The
radial arteries were kept as flat as possible during transduction to avoid vector
running off, but this did occur in all cases.
2.33.3 Injection of internal iliac arteries
The internal iliac artery gives off 6 branches in a guinea pig. These are
umbilical (which further forms the superior vesical artery that sends numerous
branches to the upper bladder and ureter), inferior vesical artery (supplying the
lower bladder and also forming the middle rectal artery supplying the rectum),
cranial gluteal (supply the dorsolateral wall of pelvis), internal pudendal artery
(supplying the external genitalia), vaginal and uterine arteries. Hence, we
believed that intra-arterial injection of adenovirus in the internal iliac, which is
more easily accessible than the uterine artery would also lead to transduction of
the latter. Figure 2.20 shows the vessels given off from the internal iliac artery
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before the uterine artery origin in a guinea pig. As can be seen, the uterine artery
is one of the most distal branches of the internal iliac artery, an approximate
distance of 3.5cm from the origin of the internal iliac artery.
Figure 2.20 – Distal branches of the internal iliac artery in a guinea pig
The internal iliac artery was easily identified running with a neurovascular
bundle along the pelvic side wall beneath the posterior aspect of the peritoneum at
the level of the cervix (Figure 2.21). Careful dissection of the peritoneum with a
small straight vannas scissors revealed the prominent internal iliac vein, and
behind it lay the smaller sized artery. The vessel is 200 – 250 m in diameter and
runs transversely from its origin at the common iliac artery towards the cervical
parametrium. Its first branch, the cranial gluteal artery was occasionally seen
after dissection of the fat within the cervical parametrium.
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Figure 2.21 – The internal iliac artery of the guinea pig
1 = The internal iliac artery of a guinea pig running along the pelvic wall; 2= pelvic neurovascular
bundle running adjacent to the internal iliac artery.
We initially performed the internal iliac injections with a 31 Gauge
Hamilton needle, but moved to the 34 Gauge needle thereafter as it is easier to
use. The vector dose injected was 1x1010 viral particles in 1.0-1.5 ml of PBS. All
animals were injected at 45 – 47 days of gestation.
The internal iliac artery segment proximal to the injection site was
occluded using a microvascular clip, and the injection was administered distal to
the occlusion over approximately 1 minute. On 2 occasions, the internal iliac
artery distal to the origin of the cranial gluteal artery was dissected out and
injected, when attempts at injection at sites on the internal iliac artery proximal to
this failed.
Following the administration of the vector, a second micro-vascular clip
was placed over the injection site once the needle was removed to compress the
injection site, for a minimum of 3 minutes. After this time both clips were
removed and the vessel was carefully observed for bleeding. On some occasions
re-occlusion of the vessel was necessary to achieve haemostasis. Additionally,
adrenaline was applied to the vessel to achieve haemostasis when further
occlusion had been unsuccessful.
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A successful injection was defined as the vector fluid seen moving down
the vessel during injection. Failed injections were due to vector being
inadvertently injected into the vessel wall, leaking out of the vessel or coming out
of the other side of the vessel, opposite the injection site. In case of failed
injections, 1-2 re-attempts were made to inject the internal iliac artery. After this
time the vessel was so constricted that it could not be injected.
Animals were left for a maximum of 4 days to achieve good transgene
expression after which they were put down, and vessels, maternal and fetal tissues
dissected out. The post-mortem examination had to performed earlier when there
were peri-operative complications or maternal deaths post-operatively.
2.33.4 External Administration of Vector-Pluronic Gel
Combination
Pluronic F-127 is a thermo-sensitive polymer gel that is liquid when cold,
but gelatinizes when brought to room temperature. It has been used as a vehicle
for virus-mediated gene delivery (Iaccarino G et al., 1999;Khurana R et al.,
2004;Mallawaarachchi CM et al., 2005), but not to the utero-placental circulation.
2.33.4.1 Re-constitution of vector in pluronic gel
A 25% (w/v) solution of Pluronic F-127 (P2443, Sigma Aldrich, USA)
was prepared by dissolving the powder in cold double distilled de-ionized water.
The solution was placed on a rotating platform overnight at 4°C to ensure the
polymer was homogenously mixed.
Next morning, the vector (Ad.LacZ, 1x1010 viral particles) was re-
constituted in 1 ml of Pluronic gel and mixed by gently pipetting up and down, on
ice. The vector was re-constituted just before the time of its administration.
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2.33.4.2 Surgery for pluronic gel-vector administration
A mid-line laparotomy was performed under general anaesthesia as above.
For administration on the uterine artery, the fat either side of the lower uterine
horns was exposed. A light (KL 1500 LCD, Schott, Mainz, Germany) was shone
through from the far side of the fat as it was held up to visualize the uterine artery.
The uterine artery was gently cleared of surrounding fat and exposed. On each
side, 1 ml of the vector-Pluronic gel combination was applied to the uterine artery
with a 1ml micro-pipette. The pluronic gel solidified as soon as it came in contact
with the guinea pig tissues. It was allowed to remain in place for at least 5
minutes, to ensure maximal tissue transduction. The procedure was repeated on
the contra-lateral side.
For radial artery gene transfer, the uterine horn on one side was moved
across to expose the arteries as they ran within the uterine parametrium.
Occasionally the uterine horn needed to be lifted out of the peritoneal cavity to
expose the radial arteries adequately and in these cases the uterus was kept warm
by wrapping in sterile gauze soaked in warm saline.
Sometimes, it was not possible to transduce the uterine artery and radials
at the same time because of difficulties in exposing all these vessels together. In
such instances, the uterine artery was transduced first. After a 5 minute wait, the
radials were exposed and transduced. Thereafter, the uterine horns and artery
were gently returned to the body cavity and the incision closed.
2.33.5 Closure of incision
After vector administration (by either of the four methods described
above), the abdomen was closed in layers. The rectus sheath was closed with
continuous 2-0 Vicryl with Tapercut needle (Ethicon, St. Stevens-Woluwe,
Belgium) to prevent herniation of the abdominal contents. The subcutaneous
tissue and skin were closed with continuous 2-0 Vicryl with Tapercut needle
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(Ethicon, St. Stevens-Woluwe, Belgium) and continuous 2-0 Vicryl with Cutting
needle (Ethicon, St. Stevens-Woluwe, Belgium) respectively. A 10% solution of
lidocaine hydrochloride (0.5ml) was again administered subcutaneously just
before closing the skin to provide local anaesthesia.
No antibiotics were administered intra-peritoneally prior to closing the
incision. There are only few antibiotics that are well-tolerated in guinea pigs and
many of those commonly used such as Penicillin-streptomycin kill the symbiotic
gut flora of the guinea pig, thereby interfering with their digestion. In extreme
cases, administration of antibiotics can even be lethal for guinea pigs. The
antibiotic regimen included intra-muscular administration of Baytril (2.5% w/v
Enrofloxacin, Bayer Health Care, Kiel, Germany), which is deemed safe to use in
guinea pigs.
The post-operative analgesia included administration of 0.1 mg/ml
Vetergesic (Buprenorphine, Alstoe Animal Health, York, UK) and Carprofen
(5mg/kg, Pfizer Animal Health, Kent, UK) sub-cutaneously. The guinea pig was
then allowed to recover and placed in her cage which was pre-warmed with a hot
water bottle. She was kept under close observation and not returned to the home
cage until she regained the righting reflex (ability of rodents to regain footing
when placed with the back down on a flat surface) and showed some slight
movements within the cage.
2.34 Post-operative care
Guinea pigs were closely observed for 3-4 days post-operatively for any
signs of miscarriage or distress. This included observations such as withdrawal
from food and water, loud vocalization in the form of squealing, sitting in one
corner of the cage and none or little movement when stimulated by touch. The
analgesic regimen (as described above) was administered once daily for 2-3 days
post-operatively, or for longer if needed.
Guinea pigs are well known for their lack of appetite post-operatively. In
order to promote their eating, they were fed commercially available probiotic
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yoghurts, baby food formulations and ‘Lectade’ Oral Rehydration Therapy for
small animals (Pfizer Animal Health, Kent, UK). All of these are known to
function as appetite stimulants for guinea pigs.
2.35 Post-mortem
The post-mortem examination was performed 4-7 days after the
administration of the vector, unless necessitated earlier by miscarriage or maternal
distress. The animal was put down with 3.5 ml of Euthatal (sodium
pentobarbitone, Rhône Merieux, Essex UK) by intra-peritoneal or intra-cardiac
administration. Once death was confirmed by cessation of breathing and heart
movement, an abdominal incision was made. The uterine and radial arteries
running alongside the uterus were harvested in one piece, along with all the
surrounding fat and placed in cold Kreb’s Ringer solution for subsequent
pharmacological analysis. Small sections of the uterine and radial arteries were
also preserved for histological studies, DNA, RNA and protein extraction.
The uterus was opened and amniotic fluid was collected with a 21G needle
attached to a 2ml syringe. Fetal blood was sampled for biochemistry and
haematological analysis from the umbilical vein and fetal heart. Maternal and
fetal organs were sampled widely according to a standard proforma (Appendix
V), and fetuses and organs were weighed. Fetal parameters were measured with a
calipers (biparietal diameter, occipito-snout length, crown rump length and femur
length). Placental weight, diameter and thickness were also noted down.
Samples from each tissue were snap-frozen in liquid nitrogen for future
nucleic acid/protein extraction. One sample from each tissue was placed in a
histology cassette and dropped into 4% paraformaldehyde (pH 7.4) overnight
before transfer into 70% ethanol. Some tissues (uterine and radial arteries, uterus,
cervix, placentae, bladder, pelvic muscles, maternal and fetal liver, heart, kidney,
lung, adrenal, spleen and gonad) were analysed by X-gal histochemistry to
determine transgene expression.
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2.36 Detection of β-galactosidase transgene expression by 
X-gal histochemistry
Tissue samples were placed in 100% ethanol at post-mortem and fixed for
atleast 2 hours before washing with PBS. Samples were then incubated in X-gal
staining solution containing 40mM potassium ferrocyanide, 40mM potassium
ferricyanide, 1mM MgCl2 in PBS and 5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-gal, B4252, Sigma Aldrich) dissolved in DMSO (D2650,
Sigma Aldrich) at 40mg/ml overnight in a rotary shaker protected from the light.
Next morning, the stained samples were washed in PBS and photographed with a
camera attached to a microscope (Discovery V8 Stereomicroscope, Carl Zeiss
Ltd., Herts UK and Canon Powershot A620 digital camera).
2.37 Wire Myography
2.37.1 Principle
Wire myography is an in vitro technique that allows examination of
functional responses and vascular reactivity of isolated small arteries (with
internal diameter 60 μm to 3 mm). The basic principle of wire myography is very 
similar to that described previously for an organ bath. It involves the mounting of
small vessels as ring preparations by threading them onto two stainless steel wires
and securing the wires to two supports. One support is then attached to a
micrometer, allowing control of vessel circumference, while the other support is
attached to a force transducer for measurement of tension development. The
whole vessel preparation is kept in a chamber with physiological salt solution at
37°C, bubbled with oxygen (Figure 2.22). Vessels are viable for many hours
while maintained in the myography chamber.
During the experiments, the circumferences of the vessels are kept
constant, i.e., the vessels are examined under isometric conditions. Different
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agonists are then added directly to the chamber and vessel tension is monitored
for possible contractile or relaxant effects.
Figure 2.22 – Principle of wire myography
A small segment of a blood vessel is suspended between two stainless steel wires in a myograph
chamber. The chamber is filled with Kreb’s buffer through which carbogen gas (95% O2, 5% CO2)
is constantly bubbled. The solution in the chamber is maintained at 37°C. Agonists added directly
into the myograph chamber cause the vessel ring to either contract or relax. The change in the
tension of the vessel is measured by a force transducer and recorded on an acquisition computer as
a real-time trace.
2.37.2 Procedure
The uterine and radial arteries were transported from the BSU Camden to
the Pharmacology Lab at the Rayne Institute, UCL in freshly prepared cold
Kreb’s buffer solution. At UCL, the guinea pig uterine and radial arteries were
cleared of surrounding fat and connective tissue under a dissection microscope
and cut into 1mm long ring segments. Each vessel ring was gently threaded
between two stainless steel wires (40μm thick) with the minimum possible 
manipulation, to preserve endothelial integrity. Each wire was secured to a stable
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support, one of which is connected to a force transducer for measurement of
tension development.
In these experiments, dual chamber wire myographs were used (DMT
410A, Danish Myotechnology, Aarhus, Denmark) which allow the analysis of
two vessel preparations simultaneously. Each chamber was filled with 5ml of
Kreb’s Ringer solution (supplemented with 2.5mM CaCl2). The Kreb’s buffer
was bubbled with carbogen gas (95% oxygen, 5% carbon dioxide) to maintain a
physiological pH of 7.4, and the temperature was maintained at 37°C.
Following mounting, the vessels were allowed to equilibrate for one hour,
with washing every 15 minutes. Each vessel was then normalized to determine the
maximum active tension development using the automatic feature on the
acquisition software. This allows the standardization of initial experimental
conditions, an important consideration when examining pharmacological
differences between vessels.
After one hour of equilibration, the vessels were challenged with 48mM
Potassium chloride (KCl) to test for viability and also determine the maximum
contractility. They were then washed 3 times with Kreb’s buffer, and challenged
again after 20 minutes. In all, the vessels were challenged 3-4 times with KCl,
until the maximum contractile response generated was equal to the previous
response (+5%). A contraction greater than 1.5g (14.7 mN) was considered
viable.
The vessels were allowed to rest for 30 minutes to recover, during which
time they were washed 3 times with Kreb’s buffer. They were then challenged
with a bolus dose of L-phenylephrine (1 μm, L-1286 Sigma Aldrich), and made to 
relax with a bolus dose of Acetycholine (1 μM, A7725, Sigma Aldrich). Only 
those segments which relaxed >70% (and therefore had an intact endothelium)
were used for subsequent analysis.
Following the endothelial integrity test, a dose response curve to L-
phenylephrine was generated (10-9 to 3x10-5M). The next higher dose of L-
phenylephrine was added only after the contraction induced by the previous dose
had stabilized and reached a plateau.
179
The vessels were again allowed to rest for 30 minutes, during which time
they were washed 4-5 times with Kreb’s buffer until they attained the pre-
contraction basal tone. They were then contracted sub-maximally with L-
phenylephrine (1μm) so that they attained ~70% of the maximum contractile 
response. Once the contraction had stabilized, they were made to relax with
increasing doses of Acetylcholine (10-9 to 3x10-5M).
The real-time traces were acquired using Myodaq software (MyoDaq
V.2.01, Danish Myo Technology, Aarhus, Denmark) and analysed using
Myoview software (Danish Myo Technology). The extracted data was plotted in
the form of a points-only graph with non-linear regression using GraphPad Prism
5.0, and statistical significance was assessed using two-way ANOVA.
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Chapter 3
Results: The Effects of Local Over-expression of VEGF on
the Uterine Arteries of Pregnant Sheep
This chapter describes the effects of adenovirus-mediated over-expression
of VEGF-A165 on uterine arteries from pregnant sheep 30-45 days after
administration of the vector. We studied the effects of VEGF-A165 on various
physiological parameters which included uterine artery blood flow, vascular
reactivity, neovascularization, maternal and fetal blood pressure and eNOS levels.
The rationale behind carrying out these studies was to determine if local over-
expression of VEGF in pregnant uterine arteries can be of potential therapeutic
benefit in treating FGR.
In this study, sixteen pregnant Romney ewes underwent surgery to implant
telemetric flow probes, followed by injection four to seven days later of an
adenovirus containing the VEGF-A165 gene (Ad.VEGF-A165) into one uterine
artery and the LacZ gene (Ad.LacZ) in the contralateral uterine artery (n=11), or
the VEGF-DΔNΔC gene (Ad.VEGF-DΔNΔC) into one uterine artery and Ad.LacZ in
the contralateral uterine artery (n=5). A sub-set of these pregnant sheep had
blood-pressure sensitive catheters implanted in their maternal carotid artery (n=4
for Ad.VEGF-A165 group) or fetal carotid artery (n=4, Ad.VEGF-A165 group) to
monitor maternal and fetal blood pressure, respectively. Each sheep was
monitored to give a mean daily reading of the uterine blood flows, maternal/fetal
blood pressure and maternal/fetal heart rate before and after injection until a few
days before expected delivery.
181
The results of the analysis performed on the sheep have been described in
the following chapter. In twin pregnancies, both the uterine horns carried a fetus
each and have been referred to as ‘gravid’. In singleton animals, the uterine horn
carrying a fetus has been referred to as the ‘gravid’ horn, and the contra-lateral
horn not carrying a fetus has been referred to as the ‘non-gravid’ horn. We found
the uterine artery supplying the gravid horn was generally more developed and
larger in size than the uterine artery supplying the non-gravid horn. The baseline
blood flow values were also always higher in the uterine artery supplying the
gravid horn.
Each sheep underwent surgery approximately 90-110 days into the
pregnancy. As the ewes were time-mated, this date was very accurate and
ultrasound scanning confirmed the gestation. The details of the analysis
performed on the Ad.VEGF-A165 sheep has been described in Table 3.1. A similar
table (Table 3.13) has been presented for the Ad.VEGF-DΔNΔC sheep later in this
chapter.
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Table 3.1 – Details of experimental analysis performed on sheep injected with
Ad.VEGF-A165 and Ad.LacZ contra-laterally
Animal Fetal
No.
GA at
probe
placement
(days)
GA at
vector
injection
(days)
GA at
PM
(days)
UABF MBP FBP
Organ
Bath
vWF RT-
PCR
eNOS
UA7 1 102 108 139 + - - + - - -
UA8 2 102 109 140 + - - + - - -
UA9 1 90 95 137 + - - + - - -
UA10 1 89 93 144 + - - + - - -
UA11 2 97 104 139 + - - + + - -
UA12 1 95 102 140 + - - + - - -
UA13 2 80 87 139 + + - + + + +
UA14 2 80 90 137 + + - + + + +
UA15 1 80 88 136 + + - + - + -
UA16 2 96 103 136 + + - + + - +
UA18 1 89 97 136 + - - - - - -
UA20 2 101 109 115 - - + + - - -
UA25 1 101 107 111 - - + + - - -
UA26 1 101 108 138 - - + + - - -
UA29 1 102 110 4
mths
PN
- - + + - - -
UA22* 1 78 84 134 - + - + + - -
UA24* 2 84 97 133 - + - + + - -
* indicates uterine artery injection with PBS bilaterally; GA=gestational age; UABF =
measurement of uterine artery blood flow; MBP = measurement of maternal blood pressure; FBP=
measurement of fetal blood pressure; vWF = adventitial vessel enumeration by anti-vWF
immunohistochemistry; PM: post mortem examination; mths: months; PN: postnatal
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3.1 Uterine artery injection of Ad.VEGF-A165 has a minimal
long term fetal and maternal morbidity and mortality rate
In the group of fetuses that underwent telemetric fetal haemodynamic
monitoring (n=4), two fetal deaths occurred 7 and 10 days after vector injection.
One ewe developed a haematoma underneath the site of skin button placement on
the flank. There were no other cases of maternal or fetal morbidity or mortality.
One ewe gave birth to a healthy lamb on the day of scheduled post mortem
examination, 2 days earlier than expected. The delivery was uncomplicated
without any postpartum haemorrhage or retained placenta. The ewe and lamb
were monitored for 4 months until weaning and showed no adverse development
or abnormal growth velocity. Gross examination at the time of post-mortem of all
ewes, fetuses and the one lamb did not reveal any pathology.
3.2 Ad.VEGF-A165 transduction of uterine arteries in the
pregnant sheep results in long-term increase in uterine
artery blood flow
Uterine artery blood flow (UABF) was measured successfully long term in
ten (6 singletons and 4 twins) out of 11 pregnant ewes in the Ad.VEGF-A165
group. In the sheep where UABF failed, the flow probe had a manufacturing fault
and no long-term UABF data could be obtained. In all other cases, UABF data
was available within 48 – 72 hours of flow probe placement.
The telemetric flow probes used in this study permitted measurements of
the blood flow to be collected over periods of time while allowing the ewe to
remain in her usual environment and without the need to restrain her to connect
up implanted flow probes. Flow probes were implanted bilaterally up to a week
before vector injection and uterine artery blood flow was measured for 1 hour
each day, at the same time of the day to avoid diurnal variation. Before
administration of the vector, the measured uterine artery blood flow was averaged
over three consecutive days to derive a baseline value. The daily measurements of
blood flow post-injection for each uterine artery were compared with this baseline
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value and converted into a percentage increase from baseline. Figure 3.1 depicts
the absolute values of uterine blood flow for one sheep. Figure 3.2 shows the
uterine blood flow data from the same animal expressed as a percentage increase
from baseline, while Figure 3.3(a) shows this data averaged for all 10 animals in
the cohort. Figure 3.3(b) depicts the UABF data in terms of conductance (blood
flow/pressure), which has greater physiological relevance for whole animal
studies as it is dependent on both uterine blood flow and mean arterial pressure.
Figure 3.1 – Representative graph for daily uterine artery blood flow in a
singleton pregnant sheep
Pregnant sheep underwent a laparotomy at mid-gestation to implant transit-time flow probes
around their uterine arteries. Uterine artery blood flow was measured for one hour each day at the
same time in the morning, before and after the administration of Ad.VEGF-A165 and Ad.LacZ
contralaterally. The daily uterine artery blood flow values for each uterine artery were plotted on a
graph. In this particular animal represented (UA9), the left uterine artery (injected with Ad.LacZ)
supplied a gravid horn, while the opposite uterine artery supplied a non-gravid horn. As can be
observed from the graph, the uterine artery blood flow in the vessel supplying the gravid horn is
higher at all time points, compared to the vessel supplying the non-gravid horn.
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Figure 3.2 – Representative graph for percentage increase in uterine artery
blood flow from baseline in a singleton pregnant sheep
Pregnant sheep underwent a laparatomy at mid-gestation to implant transit-time flow probes
around their uterine arteries. Uterine artery blood flow was measured for one hour each day at the
same time in the morning, before and after the administration of Ad.VEGF-A165 and Ad.LacZ
contralaterally. The post-injection values were compared with a pre-injection baseline, which was
obtained by averaging the values of uterine artery blood flow obtained for 3 consecutive days
before the administration of the vector. In this graph, the percentage increase in uterine artery
blood flow from baseline is greater in the Ad.VEGF-A165 transduced uterine artery compared to
the Ad.LacZ transduced uterine artery.
There was a slight fall in UABF from baseline directly after vector
administration, that reached a nadir at days 2-4 after vector injection and
recovered completely by days 5-7. The percentage fall in UABF from baseline to
the nadir at days 2-4 after vector injection was not significantly different in the
Ad.VEGF-A165 (n=10) compared with the Ad.LacZ (n=9) injected uterine arteries
(mean -10.85%+ SD16.94% v/s mean -8.42%+SD15.69%, p=0.74). This slight
but non-significant fall in UABF just after vector injection was most likely due to
trauma during vector delivery into the uterine artery lumen and the resultant
vasoconstriction.
As anticipated, UABF increased as gestation advanced. The extent of
increase in UABF in the last trimester of pregnancy, as noted in our study was
similar to what has been reported by other authors (Wallace JM et al., 2008). For
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each animal (n=10), the maximum increase in blood flow from baseline was
calculated at 4 different time points - 7 days, 14 days, 21 days and 28 days post-
vector injection. The UABF percent change at each time-point was calculated
using the average of 3 consecutive daily mean UABF measurements. The gradient
of the percentage increase in blood flow from baseline in each uterine artery was
calculated for the same time points. A two-way general linear model (GLiM) was
used to compare the UABF percent change in Ad.VEGF-A165 and Ad.LacZ
injected uterine arteries at each time point and also the gradients of UABF
%change over the length of gestation (Table 3.2). The two factors accounted for
in the GLiM analysis were whether the uterine artery supplied a gravid or non-
gravid horn and whether Ad.VEGF-A165 or Ad.LacZ vector was injected.
Figure 3.3 – Percentage increase in uterine artery blood flow from baseline
and gradient of percentage increase in uterine blood flow from baseline in 10
pregnant sheep injected with Ad.VEGF-A165 and Ad.LacZ contra-laterally
Pregnant sheep underwent a laparotomy at mid-gestation to implant transit-time flow probes
around their uterine arteries. Uterine artery blood flow was measured for one hour each day at the
same time in the morning, before and after the administration of Ad.VEGF-A165 and Ad.LacZ
contralaterally. The post-injection values were compared with a pre-injection baseline, which was
obtained by averaging the values of uterine blood flow obtained for 3 consecutive days before the
administration of the vector. In this graph, the mean percentage increase in uterine artery blood
flow from baseline is significantly greater in the Ad.VEGF-A165 transduced uterine arteries
(36.53%) compared to the Ad.LacZ transduced uterine arteries (20.08%), p=0.02, n=10.
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Figure 3.3(b) – Percentage increase in uterine artery conductance from
baseline and gradient of percentage increase in uterine artery conductance
from baseline in 10 pregnant sheep injected with Ad.VEGF-A165 and
Ad.LacZ contra-laterally
Pregnant sheep underwent a laparotomy at mid-gestation to implant transit-time flow probes
around their uterine arteries. Uterine artery blood flow and mean arterial pressure were measured
for one hour each day at the same time in the morning, before and after the administration of
Ad.VEGF-A165 and Ad.LacZ contralaterally. The post-injection values were compared with a pre-
injection baseline, which was obtained by averaging the values of uterine blood flow/mean arterial
pressure obtained for 3 consecutive days before the administration of the vector. In this graph, the
mean percentage increase in uterine artery conductance from baseline is significantly greater in the
Ad.VEGF-A165 transduced uterine arteries compared to the Ad.LacZ transduced uterine arteries.
Table 3.2 - Percentage change in uterine artery blood blow (UABF) and
Gradient of Percentage Change in UABF at one week intervals post-
Ad.VEGF-A165/Ad.LacZ injection to the uterine arteries of pregnant sheep
% Increase in UABF +
SEM
Gradient of %
Increase in UABFTime-point
after vector
injection
Ad.VEGF-
A165
(n=10)
Ad.LacZ
(n=9)
p
value
(GLiM)
Ad.VEGF-
A165
(n=10)
Ad.LacZ
(n=9)
p
value
(GLiM)
7
days
12.83+
4.76
-1.93+
4.23
0.02 1.00 -1.05 0.043
14 days 18.00+
5.62
6.19+
3.96
0.10 1.28 0.08 0.037
21 days 28.38+
6.36
12.81+
5.17
0.07 1.30 0.35 0.042
28 days 36.53+
4.51
20.08+
5.28
0.02 1.27 0.51 0.042
GLiM:General Linear Model
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Table 3.3 summarizes the maximum increase in blood flow from baseline
in each uterine artery at 28 days after the administration of the vector. The
maximum increase in blood flow in each uterine artery was seen only on the last
day of pregnancy, before post-mortem examination.
Table 3.3 – Percentage change in uterine artery blood flow from baseline 28
days after administration of Ad.VEGF-A165 or Ad.LacZ to the uterine
arteries of mid-gestation pregnant sheep.
Side of vector injection % change in UABF at
28d
Animal Fetal no.
Ad.
VEGF-A165
Ad.LacZ Ad.
VEGF-A165
Ad.LacZ
UA7 Singleton Gravid Non-
gravid
47.01 13.59
UA8 Twin Gravid Gravid 9.9 -8.8
UA9 Singleton Non-
gravid
Gravid 49.47 22.57
UA10 Singleton Non-
gravid
Gravid 42.35 16.96
UA11 Twin Gravid Gravid 27.82 NA
UA12 Singleton Non-
gravid
Gravid 28.55 11.56
UA13 Twin Gravid Gravid 44.33 32.52
UA14 Twin Gravid Gravid NA NA
UA15 Singleton Non-
gravid
Gravid 57.89 25.52
UA16 Twin Gravid Gravid 24.39 17.53
UA18 Singleton Gravid Non-
gravid
33.62 49.34
NA: data not available; UABF: Uterine artery blood flow
Considering singleton and twin gestations together, at 28 days post vector
injection, the mean increase in blood flow in the uterine arteries injected with
Ad.VEGF-A165 (n=10, 36.53% 4.51%) was significantly higher (p=0.02) than in
the uterine arteries injected with Ad.LacZ (n=9, 20.08%+5.28%). The difference
in UABF %increase was apparent and significantly different as early as 7 days
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after vector injection, although statistical significance was not reached at the 14
and 21 days post-injection time-points (Table 3.2). Also, the extent of increase in
UABF was highest when Ad.VEGF-A165 was injected on the non-gravid side in
singleton pregnancies (Table 3.4).
Table 3.4 - Percentage mean increase in UABF from baseline 28 days post-
injection in the different groups.
Max. increase in UABF at 28 days post injectionNo. of
fetuses
Side of
Ad.VEGF-
A165
injection
Ad.VEGF-A165 injected UtA Ad.LacZ injected UtA
Twins Gravid 26.61% n=4 13.75% n=3
Singleton Non-
gravid
44.56% n=4 19.15% n=4
Singleton Gravid 40.31% n=2 31.46% n=2
UtA = Uterine artery
Using GLiM analysis, the mean gradient of percentage increase in UABF
was significantly higher in the Ad.VEGF-A165 transduced vessels at all time
points analysed, that is, 7, 14, 21 and 28 days after vector injection (Table 3.2). Of
the two factors accounted for in the GLiM, only the vector played a significant
contribution towards the higher gradient in Ad.VEGF-A165 transduced vessels,
and not the pregnancy status of the uterine horn (i.e., gravid or non-gravid). That
is, the more rapid increase in uterine artery blood flow seen in the Ad.VEGF-A165
injected uterine arteries was significantly related to the effect of Ad.VEGF-A165
rather than to whether the vessel was supplying a gravid or non-gravid uterine
horn.
In two sheep, we measured UABF for 8 hours/day for 1 week after
administration of the vector, to see if there were any acute detrimental changes in
UABF. No acute adverse effects were observed on UABF.
In summary, local administration of Ad.VEGF-A165 to the uterine arteries
of pregnant sheep results in a sustained increase in uterine artery blood flow, that
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is apparent as early as 7 days post-injection and lasts for at least 28 days post-
injection.
3.3 Ad.VEGF-A165 transduction of uterine arteries in the
pregnant sheep results in a significant increase in fetal
weight compared to uninjected controls
Fetal weights from singleton pregnancies undergoing long-term UABF
monitoring (n=6) were measured at post-mortem examination and compared to a
historical singleton fetal control group from the same sheep breed (n=9) (David
AL, 2005, Ph.D Thesis). The gestational age of the two groups was not
statistically different (mean 139+3.1 days v/s mean 137.8+3.9 days, p=0.61,
unpaired t-test). The mean fetal weight in the experimental group was
significantly higher than that in the control group (5990+951 grams v/s
4698+1004 g, p=0.03, unpaired t-test). The relative fetal liver weights from the
experimental group (n=16) were compared to a historical fetal control group
(n=10). The mean gestational age of the two groups was not statistically different
(139+2.9 v/s 138.9+6.5 days, p=0.95, unpaired t-test). The relative fetal liver
weight was significantly higher in the experimental group (0.024 v/s 0.017g,
p=0.01). The relative fetal kidney weights were also significantly higher in the
treatment group (0.020 v/s 0.014, p=0.02). There was no significant difference in
the relative weights of other tissues and organs.
3.4 Local administration of Ad.VEGF-A165 to the uterine
arteries does not lead to significant changes in maternal
blood pressure
VEGF is known to have a vasodilatory and hypotensive effect (Henry TD
et al., 2003). We were concerned that uterine artery administration of Ad.VEGF-
A165 might lead to a sudden and detrimental drop in maternal blood pressure. In
order to assess the safety of adenoviral mediated VEGF gene transfer, maternal
haemodynamic parameters were monitored telemetrically continuously 3 days
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before and 4 to 7 days after Ad.VEGF-A165 vector injection in 4 animals. For
these experiments, a PhysioTel® Implantable Transmitter with a blood-pressure
sensitive catheter (PA-D70 device, Data Sciences International Tilburg,
Netherlands) was inserted into the maternal carotid artery just before placement of
flow probes around the uterine arteries. Blood pressure and heart rate were
measured for 3 days before vector injection in order to derive baseline values (to
compare the post-injection values with) and to examine the diurnal variation.
Measurements were then taken continuously round the clock after vector injection
over the period that would coincide with the time of maximum gene expression,
which is normally from 12 hours post-infection to 1 week.
To study the long-term effects of Ad.VEGF-A165 vector injection, I also
recorded maternal haemodynamic parameters daily until the end of gestation.
Measurements were taken for 1 hour at the same time of the day in each animal to
avoid diurnal variation. It was not possible to continuously monitor all 4 animals
until the end of pregnancy because only one animal could be monitored at one
time.
There was no significant change in maternal mean arterial pressure (MAP)
from pre-injection baseline values in the time period immediately following the
vector injection. Five days after vector injection, the MAP had fallen from
92.78+6.34 mmHg to 90.41+8.05 mmHg (n=4, paired t-test p=0.28). In normal
ovine pregnancy, there is a small non-significant fall in MAP during the third
trimester (105-136 days) (Kitanaka T et al., 1989). Maternal HR was not
significantly different and changed from 106+9.4 beats per minute (bpm) to
108+8.6 bpm (p=0.46) in the five days following Ad.VEGF-A165 administration.
The MAP and heart rate at term were not significantly different than the values at
vector injection. The following figures (3.4-3.7) summarize the changes in MAP
and heart rate short term and long term after the administration of the vector.
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Figure 3.4 – Diurnal variation in maternal blood pressure before and after
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries of
pregnant sheep
A blood pressure-sensitive haemodynamic catheter was implanted in the carotid artery of mid-
gestation pregnant sheep. The uterine arteries were injected with Ad.VEGF-A165 and Ad.LacZ
contra-laterally one week later. The maternal blood pressure was monitored continuously day and
night for 2-5 days before, and 3-7 days after the administration of the vector. There was no
significant acute change in maternal blood pressure in the period following the vector injection.
Purple = Systolic blood pressure, Green = Mean arterial pressure; Red = Diastolic pressure
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Figure 3.5 – Daily variation in maternal blood pressure before and after
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries of
pregnant sheep
A blood pressure-sensitive haemodynamic catheter was implanted in the carotid artery of mid-
gestation pregnant sheep. The uterine arteries were injected with Ad.VEGF-A165 and Ad.LacZ
contra-laterally one week later. The maternal blood pressure was monitored for one hour each
morning at the same time of the day, before and after the administration of the vector, until term.
There was no significant change in maternal blood pressure following the vector injection. Purple
= Systolic blood pressure, Green = Mean arterial pressure; Red = Diastolic pressure
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Figure 3.6 – Diurnal variation in maternal heart rate before and after
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries of
pregnant sheep
A blood pressure-sensitive haemodynamic catheter was implanted in the carotid artery of mid-
gestation pregnant sheep. The uterine arteries were injected with Ad.VEGF-A165 and Ad.LacZ
contra-laterally one week later. The maternal heart rate was monitored continuously day and night
for 2-5 days before, and 3-7 days after the administration of the vector. There was no significant
acute change in maternal heart rate in the period following the vector injection.
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Figure 3.7 – Daily variation in maternal heart rate before and after
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries of
pregnant sheep
A blood pressure-sensitive haemodynamic catheter was implanted in the carotid artery of mid-
gestation pregnant sheep. The uterine arteries were injected with Ad.VEGF-A165 and Ad.LacZ
contra-laterally one week later. The maternal heart rate was monitored for one hour each morning
at the same time of the day, before and after the administration of the vector, until term. There was
no significant change in maternal heart rate following the vector injection.
Overall this data shows that there was no statistically significant effect
seen on systemic maternal haemodynamics upon vector administration either
short-term or long-term, suggesting there is unlikely to be any acute or chronic
clinically important manifestation. A clinically important effect may be one
wherein the magnitude of difference may be 20 mm Hg or greater, as in the case
of severe haemorrhage. However, our experimental animals showed no
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detrimental signs of health. They resumed normal feeding a couple of hours after
surgery, were active and displayed no evident signs of distress.
3.5 Local administration of Ad.VEGF-A165 to the uterine
arteries does not lead to significant changes in fetal blood
pressure
In order to further assess the safety of Ad.VEGF-A165 administration to the
uterine arteries of pregnant sheep, fetal haemodynamic parameters were
monitored telemetrically (n=4). For these experiments, a PhysioTel® Implantable
Transmitter with two blood-pressure sensitive catheters (D70-PCTP device, Data
Sciences International Tilburg, Netherlands) was used, with one catheter being
chronically implanted in the fetal carotid while the other one was placed in the
amniotic cavity. This device can transmit in a range slightly exceeding one meter
and hence, we arranged our two receivers in a way to maximize free animal
movement while maintaining a good signal. The monitoring room set-up is
graphically illustrated in Figure 2.1. Fetal blood pressure and heart rate data were
transmitted telemetrically to the receivers which were in turn connected by cable
to a computer in the adjacent room. Uploaded traces were viewed using the
Dataquest software (Data Sciences International, Tilburg, Netherlands) then,
selected traces were copied onto a database (Microsoft Office Excel 2003
software, Microsoft Corporation, USA) for further analysis. The difference
between the fetal arterial and amniotic fluid pressure was used to calculate the
true fetal BP. Data were collected continuously for 3 days before and 7 days after
vector injection and then for 1 hour a day until the end of gestation (n=2 ewes).
During the monitoring schedule, short intermittent periods of signal loss
were initially noticed when the ewe strayed away from the receivers. After
repositioning of the receivers, this was kept to a minimum. Using this set-up, the
signal could be detected by one of the two receivers at any one time, providing
data for hourly monitoring in 100% of the diurnal and daily monitoring periods.
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3.5.1 Fetal blood pressure and heart rate can be measured
telemetrically long term
In the first procedure we performed, the catheter was placed into the
common carotid artery. Fetal BP and HR data were collected and appeared to be
in the normal range for the first 11 days after catheter placement. Adenovirus
vector injection was performed uneventfully 7 days after catheter placement. On
the 12th day after catheter placement, there was a sudden drop in BP and HR
followed by fetal death. Post-mortem examination performed 48 hours later
showed no fetal abnormality, haemorrhage or structural damage, and culture of
tissues from the uterus and fetus revealed no evidence of microbial invasion. The
tip of the catheter was found lying in the bicarotid trunk where it may have caused
a partial obstruction of blood flow to both common carotid arteries. As there is
some evidence that cannulation of the fetal sheep carotid arteries can result in
ischemic brain damage especially when bilateral obstruction has occurred (Dodic
M et al., 1998), we attempted to cannulate the second fetus through the femoral
artery as an alternative route. On examining the fetal femoral artery at
hysterotomy, this proved impossible to achieve at this gestational age due to the
discrepancy between the small diameter of the femoral artery when compared to
the catheter tip. The second fetus was thus cannulated through the common
carotid artery as before. Fetal death again occurred suddenly, on the 8th day after
catheter placement, and one day after vector injection. The catheter tip was
observed at the bicarotid trunk in a similar way to the preceding fetus. There were
no abnormal findings at post mortem examination.
In the subsequent two procedures we adjusted our technique to thread the
catheter tip further upstream the carotid artery in an attempt to bypass the
bicarotid trunk and reach the descending aorta (Figure 3.8). We used the distance
between the point of insertion and the middle third of the sternum as an estimate
of the threading distance which was approximately 7cm in both fetuses. The
cannulation of the common carotid artery in these two fetuses was uncomplicated,
and both survived until the end of gestation. At scheduled post mortem
examination in one fetus (138 days of gestation), the catheter tip was found to be
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lying in the right common carotid artery just below the point of insertion. This
migration of the catheter tip might have been a result of fetal growth and
movement. We were not able to ascertain the position of the catheter tip in the
other fetus, which was unexpectedly born overnight on the day of the scheduled
post mortem at term (139 days of gestation). During birth the catheter was pulled
out from the carotid artery without obvious haemorrhage or structural damage to
the fetal neck. This lamb survived until planned post mortem examination at four
months of age.
Figure 3.8 – Vascular anatomy of the neck arteries of fetal sheep
1 – Position of blood pressure sensitive catheter tip in first two experiments (placement in the right
common carotid artery) which resulted in fetal death due to downward migration of catheter tip
and obstruction of the bicarotid trunk. 2 – Position of catheter tip in subsequent two experiments
(placement in the descending aorta) which allowed long-term monitoring of fetal haemodynamics.
Picture adapted and modified from
http://www.wikidoc.org/index.php/Image:Aortic_variations_truebovine.jpg
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3.5.2 Short-term and long-term changes in fetal blood pressure
There was no significant change in fetal MAP from baseline values in the time
period immediately following the vector injection. Three days after vector
injection, the fetal MAP had fallen from 38.29+3.17 mmHg at baseline to
37.97+3.72 mmHg (n=3, paired t-test, p=0.28). Fetal heart rate was not
significantly different and changed from 178+12.4 bpm to 171+10.9 bpm in the
three days following Ad.VEGF-A165 administration. In one fetal sheep, the change
in MAP and heart rate was investigated during vector injection and subsequent
occlusion. The fetal MAP and heart rate increased by a maximum of 8mm Hg and
14 bpm respectively 3 minutes after occlusion and remained elevated until 30
minutes after release of occlusion. Figure 3.9 summarize the changes in MAP and
heart rate short-term and long-term after vector injection.
Figure 3.9 – Representative figures showing changes in fetal blood pressure
and heart rate after administration of Ad.VEGF-A165 and Ad.LacZ to the
uterine arteries of one pregnant sheep (UA29)
A blood pressure-sensitive haemodynamic catheter was implanted in the carotid artery of fetal
sheep between 100-110 days gestational age (term=145 days). The maternal uterine arteries were
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injected with Ad.VEGF-A165 and Ad.LacZ contra-laterally one week later. The fetal blood
pressure and heart rate were monitored continuously round the clock for 3 days before and 5 days
after the administration of the vector (A and C respectively). Fetal blood pressure and heart rate
were also monitored for one hour each morning at the same time of the day, before and after the
administration of the vector, until term (B and D respectively). There were no significant or
detrimental changes in fetal haemodynamics following vector administration. Purple = Systolic
blood pressure, Green = Mean arterial pressure; Red = Diastolic pressure; Blue = Heart
Rate
Overall this data shows that there is no statistically significant effect seen
on systemic maternal haemodynamics upon vector administration either short-
term or long-term, suggesting there is unlikely to be any acute or chronic
clinically important manifestation.
3.6 Ad.VEGF-A165 transduction of uterine arteries in the
pregnant sheep results in long term changes in vascular
reactivity.
I investigated the vascular responses of uterine arteries transduced with
Ad.VEGF-A165 and Ad.LacZ long-term, approximately 30-45 days after local
administration of the adenovirus vector. At 4 – 7 days after adenovirus-mediated
gene transfer of VEGF to the uterine arteries, a significant reduction in the
contractile response and a significant enhancement of the relaxation response
were seen (David AL et al., 2008). We therefore studied both types of response in
these long term transduced vessels.
3.6.1 Local over-expression of VEGF-A165 in the uterine arteries
of pregnant sheep results in a diminished contractile response
in twin and singleton pregnancies.
Organ bath experiments were conducted on the 2nd and 3rd branches of the
main uterine artery. I initially studied all the four branches (main, 1st, 2nd and 3rd
branches). The magnitude of the contractile responses generated in the main
uterine artery and its 1st branch however were very large resulting in deformation
of the L-shaped pins of the organ bath. Hence, I studied only the 2nd and 3rd
branches for our pharmacology experiments. This is in keeping with published
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literature where most studies on sheep uterine arteries have studied only these
branches (Xiao D and Zhang L, 2002). Two-way analysis of variance (ANOVA)
was used to statistically compare the vascular responses of the Ad.VEGF-A165 and
Ad.LacZ transduced vessels, as it enables a variety of factors affecting uterine
artery vascular response to be considered such as the type of vector applied, and
whether the uterine artery was supplying a gravid or non-gravid horn.
We first studied twin pregnancies (n = 3) where a fetus was present in
each horn of the bicornuate uterus. Figure 3.10 shows that there was a significant
reduction in the mean contractile response to phenylephrine (PE) in vessels from
twin pregnancies transduced with Ad.VEGF-A165 (Emax 155.7+13.65) compared to
Ad.LacZ (Emax 180.7+10.39, p<0.001, two-way ANOVA). There was no
significant difference in the magnitude of the KCl responses between the
Ad.VEGF-A165 and Ad.LacZ treated sides (16.63±3.05g v/s 15.89±2.65g
respectively, p=0.92).
Figure 3.10 – Contractility of twin pregnant Ad.VEGF-A165 and Ad.LacZ
transduced uterine arteries to L-phenylephrine (PE) 30-45 days after gene
transfer.
At mid-gestation and in twin pregnancies (n=3), one uterine artery was injected with Ad.VEGF-
A165 and the contra-lateral uterine artery was injected with Ad.LacZ. The second and third
branches of the main uterine arteries were harvested 30-45 days after injection, cut into 3mm ring
segments and analysed on an 8-chambered organ bath system. Concentration response curves to
PE were constructed for each vessel in quadruplicate. The contractility of the vessel is expressed
as a percentage of the response to KCl. PE produced concentration-dependent contractions, which
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were of significantly lesser magnitude in Ad.VEGF-A165 transduced vessels compared to Ad.LacZ
transduced vessels. Error bars denote standard error of mean. * denotes p<0.005
We next investigated this in animals that had a singleton pregnancy (n=5).
Animals either received Ad.VEGF-A165 into the uterine artery supplying the non-
gravid horn (n=4, Figure 3.11) or the gravid horn (n=1, Figure 3.12).
Figure 3.11 – Contractility of singleton pregnant Ad.VEGF-A165 and
Ad.LacZ transduced uterine arteries to L-phenylephrine 30-45 days after
gene transfer (Ad.VEGF-A165 administered on non-gravid side).
At mid-gestation, the uterine artery supplying the non-gravid horn was injected with Ad.VEGF-
A165 and the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals
(n=4). The second and third branches of the main uterine arteries were harvested 30-45 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. The
contractility of the vessel is expressed as a percentage of the response to KCl. PE produced
concentration-dependent contractions, which were of significantly lesser magnitude in Ad.VEGF-
A165 transduced vessels compared to Ad.LacZ transduced vessels. Error bars denote standard error
of mean. * denotes p<0.005
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Figure 3.12 – Contractility of singleton pregnant Ad.VEGF-A165 and
Ad.LacZ transduced uterine arteries to L-phenylephrine 30-45 days after
gene transfer (Ad.VEGF-A165 administered on gravid side).
At mid-gestation, the uterine artery supplying the gravid horn was injected with Ad.VEGF-A165
and the contra-lateral uterine artery was injected with Ad.LacZ in a singleton pregnant animal
(n=1). The second and third branches of the main uterine arteries were harvested 31 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. The
contractility of the vessel is expressed as a percentage of the response to KCl. PE produced
concentration-dependent contractions, which were of lesser magnitude in Ad.VEGF-A165
transduced vessels compared to Ad.LacZ transduced vessels. Error bars denote standard error of
mean.
When Ad.VEGF-A165 was administered to the uterine artery supplying the
non-gravid horn, there was a significant reduction in the contractile response
compared to the Ad.LacZ transduced vessel (Emax 153.9 ± 9.23 v/s 178.3 ±12.59,
n=4, p<0.001, two-way ANOVA, Figure 3.11). Similarly when Ad.VEGF-A165
was administered to the uterine artery supplying the pregnant horn in a singleton
pregnancy, there appeared to be a reduced contractile response compared to the
Ad.LacZ transduced uterine artery (Emax 155.1 ±11.32 v/s 235.9 ± 19.62, Figure
3.12). The change in contractile response appeared to be more marked in this
configuration. No statistical analysis could be performed in this case because only
one animal which received this combination of factors was studied.
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Combining the data for the three different experimental groups described
above by two-way ANOVA (to factor in the effects of the vector and whether the
uterine artery was supplying a gravid or non-gravid horn), I observed there was a
significant reduction in the contractile response to phenylephrine in the
Ad.VEGF-A165 transduced vessels (Emax 154.1+6.95) when compared to the
Ad.LacZ transduced vessels (Emax 184.7+8.33, p=0.0001).
Table 3.5 summarizes the maximum contractile response (Emax) to
phenylephrine observed in singleton and twin experiments.
Table 3.5 – Maximum response (Emax) to L-phenylephrine in uterine arteries
from twin and singleton pregnant animals injected with Ad.VEGF-A165 and
Ad.LacZ contra-laterally.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the
main uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered
organ bath system. Concentration response curves to PE were constructed for each vessel in
quadruplicate. The contractility of the vessel is expressed as a percentage of the response to KCl.
The p value is for the contraction dose response curve.
Observed Emax %
(Mean+SEM)Number of
fetuses
Side of Ad.VEGF-
A165 vector injection
Number of
animals Ad.VEGF-A165
vector
Ad.LacZ
vector
p
value
Twins Gravid 3 155.7 ±13.65 180.7±10.39 0.0003
Singleton Non-gravid 4 153.9 ± 9.23 178.3±12.59 0.0009
Singleton Gravid 1 155.1 ±11.32 235.9±19.62 na
All 3 groups - 8 154.1 ± 6.95 184.7 ± 8.33 0.0001
Table 3.6 summarizes the EC50 with phenylephrine observed in singleton
and twin experiments. EC50 is the dose required to produce 50% of the maximal
effect. As was expected, the EC50 was higher for the Ad.VEGF-A165 transduced
vessels than for the Ad.LacZ transduced ones since the former are less contractile
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Table 3.6 – EC50 in response to L-phenylephrine in uterine arteries from twin
and singleton pregnant animals injected with Ad.VEGF-A165 and Ad.LacZ
contra-laterally.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the
main uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered
organ bath system. Concentration response curves to PE were constructed for each vessel in
quadruplicate. The contractility of the vessel is expressed as a percentage of the response to KCl.
EC50 was calculated by plotting a sigmoidal dose response curve. The p value is for the contraction
dose response curve.
EC50 (M)Number of
fetuses
Side of Ad.VEGF-
A165 vector injection
Number of
animals Ad.VEGF-A165vector
Ad.LacZ
vector
p
value
Twins Gravid 3 3.48 x 10-6 2.33 x 10-6 0.0003
Singleton Non-gravid 4 2.97 x 10-6 1.88 x 10-6 0.0009
Singleton Gravid 1 9.84 x 10-7 9.91 x 10-7 na
All 3 groups - 8 2.60 x 10-6 1.82 x 10-6 0.0001
In summary this data demonstrates that 30-45 days after local
administration of Ad.VEGF-A165 to the uterine arteries of mid-gestation pregnant
sheep, there is a significant reduction in uterine artery contractility compared to
Ad.LacZ transduced vessels.
3.6.2 Local over-expression of VEGF-A165 in the uterine arteries
of pregnant sheep has no significant effect on the relaxation
response to bradykinin 30-45 days after gene transfer
I next analysed the relaxation response to bradykinin in the uterine arteries
that had been transduced with Ad.VEGF-A165 or Ad.LacZ, approximately 30-45
days after vector injection. Data is first presented on twin gestations (n=3), in
which there was a fetus in each uterine horn. Figure 3.13 shows that there was no
difference in the relaxation response to bradykinin between the Ad.VEGF-A165
transduced side (Emax 62.16±1.84) and the Ad.LacZ transduced side (Emax
59.01±1.90).
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Figure 3.13 – Endothelium-dependent relaxation of twin pregnant
Ad.VEGF-A165 and Ad.LacZ transduced uterine arteries to bradykinin (BK)
30-45 days after gene transfer.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in twin pregnant animals (n=3). The second and third
branches of the main uterine arteries were harvested 30-45 days after injection, cut into 3mm ring
segments and analysed on an 8-chambered organ bath system. Concentration response curves to
BK were constructed for each vessel in quadruplicate. The relaxation of the vessel is expressed as
a percentage of inhibition of PE-induced contraction. There was no significant difference in the
relaxation response between the Ad.VEGF-A165 and Ad.LacZ transduced vessels (statistical
significance assumed at p<0.05). Error bars denote standard error of mean.
I investigated this similarly in 4 animals that had a singleton pregnancy,
all of which had Ad.VEGF-A165 injected into the vessel supplying the non-gravid
side. As in the case of twins, no significant difference was observed in the
endothelium-dependent relaxation to bradykinin between the Ad.VEGF-A165
transduced side (Emax 48.83+2.63) and Ad.LacZ transduced side (Emax 40.13+1.86,
Figure 3.14). In one singleton pregnant animal, Ad.VEGF-A165 was injected into
the vessel supplying the gravid horn, and Ad.LacZ into the uterine artery
supplying the non-gravid horn. However, the vessels from this animal failed the
endothelial integrity test, that is, they did not relax more than 30% in response to
a bolus dose of bradykinin (1 μm) suggesting  compromise of endothelial integrity 
(either during dissection or mounting). Hence, the results of this animal were
excluded from the analysis.
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
Ad.VEGF
Ad.LacZ
BK (log M)
%
R
el
ax
at
io
n
207
Figure 3.14 – Endothelium-dependent relaxation of singleton pregnant
Ad.VEGF-A165 and Ad.LacZ transduced uterine arteries to bradykinin 30-45
days after gene transfer (Ad.VEGF-A165 administered on non-gravid side).
At mid-gestation, the uterine artery supplying the non-gravid horn was injected with Ad.VEGF-
A165 and the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals
(n=4). The second and third branches of the main uterine arteries were harvested 30-45 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to BK were constructed for each vessel in quadruplicate. The
relaxation of the vessel is expressed as a percentage of inhibition of PE-induced contraction. There
was no significant difference in the relaxation response between the Ad.VEGF-A165 and Ad.LacZ
transduced vessels (statistical significance assumed at p<0.05). Error bars denote standard error of
mean.
Table 3.7 summarizes the maximum relaxation response (Emax) to
bradykinin from singleton and twin experiments.
Table 3.7 – Maximum response (Emax) to bradykinin in uterine arteries from
twin and singleton pregnant animals injected with Ad.VEGF-A165 and
Ad.LacZ contra-laterally.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the
main uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered
organ bath system. Concentration response curves to BK were constructed for each vessel in
quadruplicate. The relaxation of the vessel is expressed as a percentage of inhibition of PE-
induced contraction. The p value is for the relaxation dose response curve.
Observed Emax %
(Mean+SEM)Number of
fetuses
Side of Ad.VEGF-
A165 vector injection
Number of
animals Ad.VEGF-A165
vector
Ad.LacZ
vector
p
value
Twins Gravid 3 62.16±1.84 59.01±1.90 0.995
Singleton Non-gravid 4 48.83± 2.63 40.13±1.86 0.968
Both groups - 7 57.53± 1.55 52.25±1.47 0.954
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Table 3.8 summarizes the pD2 (-log EC50) to bradykinin from singleton
and twin experiments.
Table 3.8 – pD2 (-log EC50) in response to bradykinin in uterine arteries from
twin and singleton pregnant animals injected with Ad.VEGF-A165 and
Ad.LacZ contra-laterally.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the
main uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered
organ bath system. Concentration response curves to BK were constructed for each vessel in
quadruplicate. The relaxation of the vessel is expressed as a percentage of inhibition of PE-
induced contraction. pD2 was calculated by plotting a sigmoidal dose-response curve. The p value
is for the relaxation dose response curve.
pD2 (Mean+SEM)Number of
fetuses
Side of Ad.VEGF-
A165 vector injection
Number of
animals Ad.VEGF-A165vector
Ad.LacZ
vector
p
value
Twins Gravid 3 9.27 + 0.12 9.50 + 0.13 0.995
Singleton Non-gravid 4 9.83 + 0.25 9.97 + 0.25 0.968
Both groups - 7 9.43 + 0.11 9.61 + 0.12 0.954
To summarize, these results show that 30-45 days after local over-
expression of VEGF-A165 in the uterine arteries of pregnant sheep, there is no
significant difference in the relaxation response to bradykinin between uterine
artery segments transduced with either Ad.VEGF-A165 or Ad.LacZ. This is
observed in both twin and singleton pregnancies.
3.6.3 The long-term relaxation response to Bradykinin is
primarily mediated via the Nitric oxide Synthase (NOS) and
Endothelium Derived Hyperpolarizing Factor (EDHF) pathways
The reduced contractility associated with local VEGF-A165 over-
expression in uterine arteries long-term prompted me to examine the mechanisms
involved. To do this it was first established which mechanisms mediated
relaxation of uterine arteries using inhibitors of specific relaxation pathways.
Vessels from 3 animals (all twins) were used for these experiments. I used three
inhibitors known to affect different components of the relaxation pathway. L-
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NAME is an inhibitor of the NOS pathway, indomethacin blocks the action of
prostacyclins while apamin is a small conductance Ca2+ activated K+ channel
blocker which inhibits the functions of EDHF. Uterine arteries were incubated for
20 minutes (for L-NAME and indomethacin) or 30 minutes (for apamin) with the
inhibitor either individually or in combination, then pre-contracted with
phenylephrine, followed by a dose-response curve to bradykinin. The
concentrations used for the different inhibitors were L-NAME - 300μM, 
Indomethacin - 10 μM and Apamin - 1 μM. The vascular relaxation in uterine 
arteries (2nd and 3rd branches of the main uterine artery) was compared in vessels
exposed or unexposed to inhibitors.
Treatment with L-NAME reduced the relaxation response to bradykinin in
uterine artery segments (Figure 3.15, Table 3.9). L-NAME significantly reduced
relaxation relative to control vessels (not treated with L-NAME). There was no
significant difference however in the amount of reduced relaxation response in the
uterine arteries with L-NAME inhibition, between the Ad.VEGF-A165 and
Ad.LacZ transduced sides. Treatment with the cyclooxygenase inhibitor
Indomethacin did not change the endothelium dependent relaxation, indicating
that PGI2 does not modulate the relaxation in these vessels. The remaining
endothelium-dependent relaxation, that was resistant to inhibition by L-NAME
and Indomethacin, was significantly reduced by pre-treatment with apamin (the
Emax was lowered by 43.21% in Ad.VEGF-A165 transduced vessels v/s 48.26% in
Ad.LacZ transduced vessels, n=3). There was no significant difference in the
small amount of residual relaxation that remained after NOS, PGI2 and EDHF
inhibition between the Ad.VEGF-A165 and Ad.LacZ transduced sides (n=3).
Incubation with Indomethacin alone or Apamin alone also did not significantly
alter the bradykinin-induced relaxation (data not shown).
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Figure 3.15(a) – The endothelium-dependent relaxation to bradykin in the
presence of different inhibitors of the relaxation pathway in pregnant sheep
uterine arteries, 30-45 days after Ad.VEGF-A165 or Ad.LacZ transduction.
The contribution of nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived
hyperpolarizing factor (EDHF) on the relaxation response to BK were investigated in vessels
precontracted with PE. Cumulative relaxation curves of BK (10-11M to 10-6M) were constructed
under the following conditions: (1) control (no inhibitors); (2) in the presence of G -nitro-L-
Arginine-Methyl Ester (L-NAME, NO synthase inhibitor, 300 µM); (3) in the presence of L-
NAME and indomethacin (PGI2 inhibitor, 10 µM); (4) in the presence of L-NAME, indomethacin
and apamin (small-conductance Ca2+-activated K+ channel inhibitor, 1 µM). Relaxation was
expressed as a percentage of inhibition of PE-induced contraction. The mean relaxation response
of vessels from twin pregnant sheep (n=3) was calculated. Statistical significance was assumed at
p<0.05. The BK relaxant effect was not modified by indomethacin but reduced by L-NAME
(p<0.05, n=3). The remaining endothelium-dependent relaxation (Emax), that was resistant to
indomethacin and NO synthase inhibition, was significantly reduced by pretreatment with apamin
in both Ad.VEGF-A165 and Ad.LacZ treated arteries (P<0.05, n=3).
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Figure 3.15(b) – Partial contribution of NO-dependent and NO-independent
mechanisms to the endothelial-dependent relaxation
Values are the mean+SEM for the area under the curve (AUC) for BK-induced relaxation
(complete bar with positive SEM), the AUC for BK-induced relaxation following treatment with
L-NAME (NO-independent component, white bar), and the remaining AUC after BK with L-
NAME (NO-dependent component, black bar). No significant differences were observed in the
overall relaxation as well as NO-dependent and NO-independent relaxations between the treated
and control sides.
Table 3.9 -– Emax in response to bradykinin in uterine arteries from pregnant
sheep injected with Ad.VEGF-A165 and Ad.LacZ contra-laterally, in the
presence of different inhibitors of endothelium-dependent relaxation.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the
main uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered
organ bath system. Concentration response curves to BK were constructed for each vessel in the
absence and presence of different inhibitors of relaxation, namely, L-NAME, Indomethacin and
Apamin. The relaxation of the vessel is expressed as a percentage of inhibition of PE-induced
contraction. The p value indicates the significance of the effect of individual inhibitors on the dose
response curve.
Emax % (Mean +SEM)
Inhibitor Ad.VEGF-A165 transduced
side
Ad.LacZ trandsduced
side
p value
No inhibitor 54.73+2.36 56.52+2.15
L-NAME 39.66+4.96 31.03+4.40 p<0.05
L-NAME+
Indomethacin
32.89+3.74 35.88+4.65 p=0.2
L-NAME+
Indomethacin+ Apamin
11.52+2.01 8.26+1.65 p<0.05
In summary, this data demonstrates that the bradykinin-mediated
endothelium-dependent relaxation in pregnant sheep uterine arteries is mediated
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via NO and EDHF. Inhibition by L-NAME significantly reduces the relaxation
response compared to untreated vessels. There is a further significant attenuation
of relaxation when Apamin is added. Prostacyclins do not appear to play a
significant role in the bradykinin-mediated relaxation. In all cases, that is, both in
the presence and absence of different inhibitors, the vascular relaxation responses
in the Ad.VEGF-A165 and Ad.LacZ transduced uterine arteries were not
significantly different.
3.6.4 The long-term reduction in contractility to Phenylephrine
in Ad.VEGF-A165 transduced vessels is mediated via the Nitric
oxide Synthase (NOS) pathway
In order to investigate the mechanism behind the reduced contractility of
Ad.VEGF-A165 transduced vessels long-term, the contractility to phenylephrine
was studied in the presence of the NOS inhibitor, L-NAME. Uterine arteries from
twin pregnant sheep (n=3) were incubated with L-NAME (300 μM) for 20 
minutes, and a dose-response curve to phenylephrine was generated. The
contractile response in uterine arteries (2nd and 3rd branch) was compared in
vessels exposed or unexposed to L-NAME.
I observed a significant increase in the contractile response to
phenylephrine in the Ad.VEGF-A165 transduced vessels when pre-treated with L-
NAME (Emax 106.6+3.94 v/s 132.9+6.07, p=0.002). Vessels transduced with
Ad.LacZ also contracted in response to phenylephrine when pre-treated with L-
NAME, but the increase in contractility was less and was non-significant (Emax
124.6+8.51 v/s 131.9+8.69). With the inhibition of the NOS pathway by L-
NAME, the Emax in response to phenylephrine in both the Ad.VEGF-A165 and
Ad.LacZ transduced vessels were very similar. (Figure 3.16, Table 3.10)
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Figure 3.16 - The contractility to phenylephrine in the presence of L-NAME
in pregnant sheep uterine arteries, 30-45 days after Ad.VEGF-A165 (top) or
Ad.LacZ (bottom) transduction.
The effect of NOS inhibition on the contractile response to PE was investigated in uterine arteries
transduced with either Ad.VEGF-A165 or Ad.LacZ. Cumulative relaxation curves of PE (10-9M to
10-4M) were constructed under the following conditions: (1) control (no inhibitor); and (2) in the
presence of L-NAME (300 µM). The contractility of the vessel is expressed as a percentage of the
response to KCl. The mean contractile response of vessels from twin pregnant sheep (n=3) was
calculated. Statistical significance was assumed at p<0.05. The PE-produced contractility was
significantly enhanced in the presence of L-NAME in Ad.VEGF-A165 treated uterine arteries (top
graph), but there was no significant increase seen in the Ad.LacZ treated uterine arteries (bottom
graph).
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Table 3.10 -– Maximum response (Emax) in response to phenylephrine in
uterine arteries from pregnant sheep injected with Ad.VEGF-A165 and
Ad.LacZ contra-laterally, in the presence of L-NAME.
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in twin pregnant sheep (n=3). The second and third
branches of the main uterine artery were harvested 30-45 days after injection and analysed on an
8-chambered organ bath system. Concentration response curves to PE were constructed for each
vessel in the absence and presence of L-NAME. The contractility of the vessel is expressed as a
percentage of the response to KCl. The p value indicates the significance of the effect of addition
of inhibitor compared to control vessels (i.e., unexposed to inhibitors).
Emax % (Mean+SEM)
Inhibitor No inhibitor L-NAME
p value
Ad.VEGF-A165
transduced side
106.6+3.94 132.9+6.07 0.002
Ad.LacZ trandsduced
side
124.6+8.51 131.9+8.69 0.987
Thus, the reduction in phenylephrine-induced contractility in pregnant
sheep uterine arteries transduced with Ad.VEGF-A165 appears to be mediated by
NO. When the NOS pathway is blocked by pre-treatment with L-NAME, there is
no longer any difference in the maximum contractile response between the
Ad.VEGF-A165 and Ad.LacZ transduced uterine arteries.
3.7 There is no difference in the vascular reactivity of the
contra-lateral uterine arteries in sham-operated term
pregnant sheep
Uterine arteries from two sham-operated long-term sheep (one twin
pregnant and one singleton pregnant) that were injected only with the vehicle
(PBS) were examined on an organ bath 36-50 days after injection. I was interested
in investigating whether there are any inherent differences between the vascular
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reactivity of the contra-lateral uterine arteries in the absence of over-expression of
VEGF. Figure 3.17 and Figure 3.18 show that there was no difference in the
contractility or relaxation between the left and right uterine arteries.
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Figure 3.17 - Contractility of pregnant sheep uterine artery sham-injected
with phosphate buffered saline (PBS) 30 days after injection.
At mid-gestation, the uterine arteries of one twin pregnant sheep and one singleton pregnant sheep
were injected with PBS bilaterally. The second and third branches of the main uterine arteries
were harvested over 30 days after injection, cut into 3mm ring segments and analysed on an 8-
chambered organ bath system. Concentration response curves to PE were constructed for each
vessel in quadruplicate. The contractility of the vessel is expressed as a percentage of the response
to KCl. PE produced concentration-dependent contractions, which were no different between the
left and right sides. Error bars denote standard error of mean.
In response to phenylephrine, the Emax in the left uterine artery was
135.7+8.35 and that in the right uterine artery was 158.3+19.19. The p value for
difference in the dose-response curve to phenylephrine was 0.90 (Two-way
ANOVA).
The relaxation dose response curve to bradykinin was also not
significantly different between the left and right uterine arteries (p=0.96, Two-
way ANOVA, Figure 3.18). The Emax in the left uterine artery was 63.73+2.45,
while the Emax in the right uterine artery was 65.33+2.05.
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Figure 3.18 – Endothelium-dependent relaxation of pregnant sheep uterine
artery sham-injected with phosphate buffered saline (PBS) 30 days after
injection
At mid-gestation, the uterine arteries of one twin pregnant sheep and one singleton pregnant sheep
were injected with PBS bilaterally. The second and third branches of the main uterine arteries
were harvested over 30 days after injection, cut into 3mm ring segments and analysed on an 8-
chambered organ bath system. Concentration response curves to BK were constructed for each
vessel in quadruplicate. The relaxation of the vessel is expressed as a percentage of inhibition of
PE-induced contraction. BK produced concentration-dependent relaxation, which was not
different between the left and right sides. Error bars denote standard error of mean.
3.8 The vascular reactivity of sheep uterine arteries can not
be studied on a wire myograph
I was interested in examining the effects of Ad.VEGF-A165 transduction on
the vascular reactivity of smaller utero-placental blood vessels (which resemble
the diameter of the human spiral arteries more closely). Hence, the 4th and 5th
branches of the main uterine artery were dissected out for pharmacology
experiments. I attempted to study the vascular reactivity of these segments on an
organ bath set-up, but failed to do so because their internal diameter was too small
for the two L-shaped pins to pass through their lumen.
Next, I attempted to study their vascular reactivity on a wire myograph
using 40 μm thick stainless steel wires to mount them. However, the thick 
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muscular layer of the sheep uterine arteries resulted in the generation of excessive
contractions to KCl and PE. The magnitude of these contractile tensions was
beyond the limits of accurate measurement of the wire myograph. In addition, the
large force of contraction also deformed the delicate wires of the myograph,
making it impossible to continue with the experiment.
Hence, it was concluded that the vascular reactivity of the fourth and fifth
branches of pregnant sheep uterine arteries cannot be analysed on a wire
myograph.
3.9 Ad.VEGF-A165 transduction of uterine arteries in the
pregnant sheep does not lead to any significant difference
in the vascular reactivity of the umbilical vessels
I also investigated the changes in vascular reactivity of the umbilical
arteries and umbilical veins in the Ad.VEGF-A165/Ad.LacZ transduced sheep
long-term. This experiment was only performed in twin pregnant sheep (n=3) in
order to have appropriate internal controls from within the same animal.
The umbilical arteries and umbilical veins were cut into 3mm long
segments and mounted on the organ bath. Their contractility and relaxation was
studied with phenylephrine and bradykinin respectively, similarly to as was done
for the uterine arteries. I found no observable difference in the vascular responses
of the umbilical arteries and veins between the Ad.VEGF-A165 and Ad.LacZ
transduced sides (data not shown).
3.10 Local over-expression of VEGF-A165 in the uterine
arteries of pregnant sheep upregulates eNOS levels short-
term but not long-term
The organ bath pharmacology experiments described previously (David
AL et al., 2008) and above, suggest that eNOS plays an important role in the
altered uterine artery vascular reactivity associated with Ad.VEGF-A165
transduction. In order to verify this, protein extracts of uterine artery samples
from short-term studies (4-7 days after vector injection) and long-term studies
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(30-52 days after vector injection) were analysed for changes in eNOS levels by
western blotting. I observed an upregulation in the levels of eNOS in Ad.VEGF-
A165 transduced compared to Ad.LacZ transduced uterine arteries short-term
(Figure 3.19 A). However, this difference was not sustained long-term. There was
no difference in eNOS levels between the Ad.VEGF-A165 and Ad.LacZ
transduced uterine arteries obtained from pregnant sheep at term (Figure 3.19 B).
Figure 3.19 - Representative western blot showing upregulation of eNOS in
Ad.VEGF-A165 transduced uterine arteries compared to Ad.LacZ transduced
uterine arteries (A) 5 days after vector administration but not (B) 30 days
after vector administration
Uterine arteries from pregnant sheep were injected with Ad.VEGF-A165 and Ad.LacZ contra-
laterally at mid-gestation, and harvested either (A) 5 days post-injection; or (B) 30 days post-
injection. Protein extracts from the uterine artery tissue samples were analysed by western blotting
using a mouse monoclonal antibody to eNOS. Results are representative of 3 independent
experiments each at the short-term and long-term time points. GAPDH was used as a loading
control.
3.11 Microscopic examination of tissues from Ad.VEGF-
A165 transduced sheep does not reveal any significant
pathology.
Maternal and fetal tissues collected at post-mortem examination (complete
list of samples in post-mortem sheet in Appendix IV) from Ad.VEGF-A165
transduced sheep (n=5) were stained with H&E and observed microscopically
under the supervision of Dr. Elizabeth Benjamin.
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The uterine arteries did not show any evidence of edema, leucocyte
infiltration or inflammation. Sections of the maternal heart from three ewes
showed evidence of low-grade myocarditis (Figure 3.20). A similar cardiac
histology was observed in sham operated ewes which received only PBS and in
ewes which had no surgical intervention prior to post-mortem (used for uterine
artery endothelial cell extraction). Hence, it was concluded that the presence of
low-grade myocarditis was unrelated to the administration of the vector.
Nevertheless, none of these ewes demonstrated any symptoms of ill-health or
anomalous maternal haemodynamics.
All other maternal and fetal tissues examined, including the liver had an
unremarkable histology.
20X mag.
Figure 3.20 – H&E stained section of pregnant sheep heart 30 days after
administration of Ad.VEGF-A165 and Ad.LacZ to the uterine arteries at
mid-gestation
Maternal tissue samples collected at post-mortem examination were analyzed for routine
histology. Tissues were fixed in 4% paraformaldehyde overnight, transferred to 70% ethanol and
processed into paraffin. Sections were stained with hematoxylin and eosin for morphological
assessment. A mild inflammatory response (myocarditis) was observed in sections of the maternal
heart from n=3 sheep (arrow pointing at site of inflammation). The histology of all other maternal
and fetal specimens was unremarkable.
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3.12 Ad.VEGF-A165 transduction of uterine arteries in the
pregnant sheep results in long term changes in adventitial
angiogenesis
VEGF is known to have an angiogenic effect, that is, it leads to the
formation of new blood vessels from pre-existing ones. We hypothesized that this
may be one of the mechanisms of action of VEGF-A165 over-expression in
pregnant ovine uterine arteries, and therefore we studied the angiogenic response
to Ad.VEGF-A165 transduction in these vessels.
3.12.1 Vessel counting in H & E stained sections
We started by counting the number of blood vessels in the perivascular
adventitia of the uterine arteries in H&E stained sections. Twins (n=4) were used
for the analysis to avoid any inherent differences between the gravid and non-
gravid sides. Vessels were cut in cross-section so that the lumen, intima, media
and adventitia were all visible in the same field. The counting was done under a
light microscope by two observers independently and blinded to the vector given.
Ten high-powered fields per vessel section were counted. An example of a vessel
stained with H&E is given in Figure 3.21.
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Figure 3.21 – Adventitial vessel enumeration in H&E stained uterine artery
sections from pregnant sheep, 30-45 days after a local injection of Ad.VEGF-
A165 or Ad.LacZ.
Maternal uterine artery samples collected at post-mortem examination were analyzed for routine
histology. Tissues were fixed in 4% paraformaldehyde overnight, transferred to 70% ethanol and
processed into paraffin. Sections were stained with hematoxylin and eosin for morphological
assessment and adventitial vessel enumeration. No inflammatory inflammation or edema was
observed. Dotted arrows point to adventitial blood vessels. We observed a significant increase in
the number of adventitial blood vessels in uterine arteries transduced with Ad.VEGF-A165
compared to Ad.LacZ. Scale bar = 40µm.
A significant increase in the number of blood vessels in the perivascular
adventitia of the uterine arteries tranduced with Ad.VEGF-A165 (11.64+0.79) was
observed, when compared with the Ad.LacZ transduced side (8.75+0.83), n=28
sections, p<0.05 (Student’s t-test).
One of the drawbacks of vessel enumeration in H&E stained sections is
that it is quite subjective, leaving it to the discretion of the observer what structure
to identify as a blood vessel. Hence, it is not very reproducible or reliable.
3.12.2 Immunohistochemical staining of endothelial cells
In order to make our analysis more reliable and reproducible, a more
objective method was used to identify adventitial blood vessels, using tissue
sections stained immunohistochemically with markers of endothelial cells. It is
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important to note that only animals carrying twin pregnancies (n=4) were selected
for this experiment, so as to exclude any intrinsic confounding factors that may
exist between the uterine arteries supplying the gravid and non-gravid horns of the
uterus, which might influence adventitial neovascularization.
Slides were stained with endothelial specific markers, namely anti-von
Willebrand Factor (vWF) and anti-CD31. Unfortunately, the latter antibody failed
to cross-react with the sheep antigen and did not yield any results.
First, the optimum concentration of anti-vWF antibody to stain endothelial
cells was determined (Figure 3.22) and a dilution of 1:400 was observed to be the
most appropriate concentration to use. The total number of positively stained
adventitial blood vessels associated with a distinct lumen were then counted by
two observers independently and blinded to the vector given. The advantage of
this method over H&E staining is that it is much more objective as only the
endothelium is positively stained. This enables the experimenter to
unambiguously identify and count a blood vessel.
20X mag.
Figure 3.22 – Optimization of anti-von Willebrand Factor (anti-vWF)
staining in pregnant sheep uterine artery sections.
1:50 1:100 1:200
1:400 1:800
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(Continued from overleaf) Maternal uterine artery samples collected at post-mortem examination
were analyzed by anti-vWF immunohistochemistry. Tissues were fixed in 4% paraformaldehyde
overnight, transferred to 70% ethanol and processed into paraffin. Sections were stained with
primary rabbit anti-human vWF antibody immunohistochemically at different concentrations,
using the avidin-biotin-peroxidase system; 3,3`-diaminobenzidine was used as a substrate for
visualization. The optimum concentration of the primary antibody was determined to be 1:400.
The number of positively stained adventitial blood vessels (Figure 3.23)
was significantly greater in the uterine arteries transduced with Ad.VEGF-A165
compared to Ad.LacZ (141.56+14.61 v/s 92.75+9.64 respectively, n=16 sections
for each vector in duplicate, p=0.013, unpaired t-test), when data was averaged
over all the uterine artery branches counted. The data for the individual branches
has been presented in Table 3.11.
As mentioned, each uterine artery section was stained and counted in
duplicate by two observers. The inter-observer variability between both the counts
was 4.2%.
Figure 3.23 – Representative images of anti-vWF stained sections of pregnant
sheep uterine arteries.
Maternal uterine artery samples collected at post-mortem examination were analyzed by anti-vWF
immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight, transferred to 70%
ethanol and processed into paraffin. Sections were stained with primary rabbit anti-human vWF
antibody immunohistochemically at a concentration of 1:400, using the avidin-biotin-peroxidase
system; 3,3`-diaminobenzidine and a light hematoxylin counterstain were used as substrates for
visualization. The positively stained adventitial blood vessels with a distinct lumen were counted
under a light microscope. The number of adventitial blood vessels was found to be significantly
greater in Ad.VEGF-A165 transduced uterine arteries (A), compared to Ad.LacZ transduced uterine
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arteries (B). Arrows point to positively stained adventitial blood vessels with a distinct lumen.
Scale bar = 40 µm.
Table 3.11 – Number of adventitial blood vessels in different branches of the
uterine artery, determined by enumeration of anti-vWF stained sections
Maternal uterine artery samples collected at post-mortem examination were analyzed by anti-vWF
immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight, transferred to 70%
ethanol and processed into paraffin. Sections were stained with primary rabbit anti-human vWF
antibody immunohistochemically at a concentration of 1:400, using the avidin-biotin-peroxidase
system; 3,3`-diaminobenzidine and a light hematoxylin counterstain were used as substrates for
visualization. The positively stained adventitial blood vessels with a distinct lumen were counted
in the different branches of the uterine arteries under a light microscope.
Uterine artery
branch
Number of adventitial blood vessels p value
Ad.VEGF-A165 side
(Mean+SEM)
Ad.LacZ side
(Mean+SEM)
Main uterine artery 227.09+18.61
(n=4)
152.67+13.17
(n=4)
0.0001
1st branch 144.80+17.62
(n=4)
89.8+8.24
(n=4)
0.032
2nd branch 114.11+18.49
(n=4)
83.50+8.52
(n=4)
0.247
3rd branch 80.27+2.64
(n=4)
45.06+7.81
(n=4)
0.035
Average of all
branches
141.56+14.61
(n=16)
92.75+9.64
(n=16)
0.013
Thus, our vessel enumeration results showed that local administration of
Ad.VEGF-A165 to the uterine arteries of pregnant sheep results in significant
adventitial neovascularization compared to control uterine arteries transduced
with Ad.LacZ.
3.13 There is no detectable difference in the level of VEGF
expression at the protein level between the Ad.VEGF-A165
and Ad.LacZ transduced arteries long-term
Snap-frozen tissue samples collected at post-mortem examination were
used for protein extraction and analysed by VEGF-A165 ELISA (R&D Systems,
Minneapolis, MN, USA) to quantify the level of VEGF-A165 protein present 30-45
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days after vector injection (that is, at term). However, at the end of gestation,
human VEGF-A165 was not detectable by ELISA in any uterine artery, uterine
wall, or placentome samples of all pregnant ewes injected with Ad.VEGF-A165
(n=10). Similarly, blood samples obtained from the ewes before vector injection
as well as samples obtained from the ewes and fetuses at post-mortem
examination did not show any detectable human VEGF-A165 expression using
ELISA.
We also performed immunohistochemistry for VEGF-A165 in the uterine
artery sections from six sheep (4 twins and 2 singleton pregnancies). The stained
slides showed specific staining of VEGF around the adventitial blood vessels on
both the Ad.VEGF-A165 and Ad.LacZ treated sides, though there was no
difference in the level of expression quantitatively (around the blood vessels)
between both the sides (Figure 3.24).
Figure 3.24 - Representative images of anti-VEGF stained sections of
pregnant sheep uterine arteries , 30-45 days after local administration of (A)
Ad.VEGF-A165 or (B) Ad.LacZ.
Maternal uterine artery samples collected at post-mortem examination were analyzed by anti-
VEGF immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight, transferred
to 70% ethanol and processed into paraffin. Sections were stained immunohistochemically with a
mouse monoclonal antibody to VEGF-A165 at a concentration of 1:400, using the avidin-biotin-
peroxidase system; 3,3`-diaminobenzidine was used as a substrate for visualization. Positive
staining was observed around small blood vessels in the perivascular adventitia of the uterine
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artery. Though the number of adventitial vessels was significantly greater in the Ad.VEGF-A165
transduced segments (A) relative to Ad.LacZ transduced ones (B), we were not able to detect any
quantitative difference in the levels of VEGF expression between both the sides. Scale bar = 40
µm.
Hence, the ELISA and immunohistochemistry data suggest that there are
no detectable differences in the levels of VEGF protein expression between the
Ad.VEGF-A165 and Ad.LacZ injected sides in long-term transduced animals.
3.14 Local administration of Ad.VEGF-A165 to the uterine
arteries of pregnant sheep results in upregulation of
VEGFR-2 short-term
Uterine artery sections obtained from experimental animals (after 5 days
and 30 days of Ad.VEGF-A165 transduction) were stained immunohistochemically
for VEGFR-1, VEGFR-2 and Neuropilin-1. The stained slides showed the
presence of VEGFR-1, VEGFR-2 and Neuropilin-1 in the intimal and adventitial
endothelia (lining small blood vessels) (Figure 3.25). The presence of these three
receptors in the sheep uterine artery suggests that all of them may be mediating
the biological effects of VEGF-A165. There was an upregulation of VEGFR-2 in
the uterine arteries transduced with Ad.VEGF-A165 compared to Ad.LacZ, 4-7
days after injection (Figure 3.25). There was no detectable difference in the level
of any of the receptors at 1 month post-injection (Figure 3.26).
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Figure 3.25 - Representative images of short-term Ad.VEGF-A165/Ad.LacZ
transduced sheep uterine artery sections stained with antibodies to (A-B)
VEGFR-2, (D-E) Neuropilin-1, and (G-H) VEGFR-1. (C), (F) and (I) are
respective negative controls for the stainings.
Maternal uterine artery samples from sheep injected with Ad.VEGF-A165 and Ad.LacZ contra-
laterally at mid-gestation were collected at post-mortem examination 4-7 days later. Tissues were
fixed in 4% paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin.
Sections were stained immunohistochemically with antibodies to the three VEGF receptors,
namely (A-B) VEGFR-2, (D-E) Neuropilin-1, and (G-H) VEGFR-1 at a concentration of 1:50,
using the avidin-biotin-peroxidase system; 3,3`-diaminobenzidine and a light haematoxylin
counter-stain were used as substrates for visualization. (C), (F) and (I) are respective negative
controls obtained by omitting the primary antibody. Positive staining (pointed at by arrows) was
observed around small blood vessels in the perivascular adventitia of the uterine artery. We
detected the presence of all three receptors in the uterine arteries of pregnant sheep, and noted an
upregulation of VEGFR-2 in the Ad.VEGF-A165 transduced uterine artery segments. Scale bar =
40 µm.
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Figure 3.26 - Representative images of long-term Ad.VEGF-A165/Ad.LacZ
transduced sheep uterine artery sections stained with antibodies to (A-B)
VEGFR-2, (C-D) Neuropilin-1, and (E-F) VEGFR-1.
Maternal uterine artery samples from sheep injected with Ad.VEGF-A165 at mid-gestation were
collected at post-mortem examination 30-45 days later. Tissues were fixed in 4%
paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained immunohistochemically with antibodies to the three VEGF receptors, namely (A-B)
VEGFR-2, (C-D) Neuropilin-1, and (E-F) VEGFR-1 at a concentration of 1:50, using the avidin-
biotin-peroxidase system; 3,3`-diaminobenzidine and a light haematoxylin counter-stain were used
as substrates for visualization. Positive staining (pointed at by arrows) was observed around small
blood vessels in the perivascular adventitia of the uterine artery. We detected the presence of all
three receptors in the uterine arteries of long-term transduced pregnant sheep. Scale bar = 40 µm.
I also performed immunohistochemistry with an antibody specific for the
phosphorylated form of VEGFR-2. The tyrosine residues of this receptor are
known to be phosphorylated in response to VEGF stimulation and thus, I was
interested to investigate whether there were specific sites in the uterine artery of
receptor phosphorylation. Unfortunately, three antibodies used for the
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immunohistochemical detection of phosphorylated VEGFR-2 failed to cross-react
with ovine samples.
It is well known that the ligand-dependent phosphorylation of VEGFR-2 is
critical for mediating the wide spectrum of biological effects of VEGF (Ferrara N,
1999). Hence, the presence of phosphorylated (activated) VEGFR-2 in the uterine
artery was expected, especially because VEGF-induced effects on uterine blood
flow, vascular reactivity and neovascularization were evident long-term.
3.15 Local administration of Ad.VEGF-A165 to the uterine
arteries does not result in systemic vector expression
In order to assess the safety of intra-arterial Ad.VEGF-A165 administration
into the utero-placental vasculature long-term, I determined the extent of systemic
vector expression. I performed Reverse Transcriptase (RT)-PCR with primers
specific for Ad.VEGF-A165 on RNA isolated from a wide selection of maternal
and fetal tissues. The RNA extracts used for all experiments were of high quality,
as judged by an A260/A280 reading of 1.80-1.95 and production of a doublet band
on agarose gel electrophoresis (Figure 3.27).
Figure 3.27 – Representative image for agarose gel electrophoresis of total
RNA extract from sheep tissues.
1 – Ad.VEGF-A165 injected UtA; 2 – Ad.LacZ injected UtA; 3 – maternal heart; 4 – maternal
ovary; 5 – maternal liver; 6 – maternal adrenal; 7 – maternal spleen; 8 – 1kb+ DNA ladder
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I also performed RT-PCR for a sheep housekeeping gene, Tata-box
binding protein (TBP), GenBank reference L47974, to use as a positive control.
This has previously been shown to give no amplification signal from adenovirus
DNA alone (David AL, 2005, Ph.D Thesis).
The first round PCR with primers specific for Ad.VEGF-A165 was
negative in all maternal and fetal samples analysed, including the uterine arteries
that had been transduced with the adenovirus. The RT-PCR with primers specific
for TBP was positive in all maternal and fetal samples. This confirmed that good
quality RNA had been extracted from all sheep samples that could be reverse-
transcribed into cDNA and subsequently amplified.
We speculated that first round PCR might not be sensitive enough to
detect long term transgene expression, which might be at quite low levels.
Consequently, a semi-nested PCR was carried out wherein the forward primer
was identical to the first round PCR forward primer, but the reverse primer bound
to a sequence more internal to the complementary binding site of the first round
reverse primer. Three reverse primer candidates were designed and tested at
different annealing temperatures on HUVECs transduced with Ad.VEGF-A165
(positive control) (Table 3.12). We chose oligonucleotide 2 which worked
consistently at the highest annealing temperature, (54°C) as the reverse primer for
the second round of the semi-nested PCR. Even though oligonucleotide 3 gave a
positive amplification signal at a lower annealing temperature, the advantage of
using a primer that works at a higher annealing temperature is that it minimizes
the possibility of contaminating bands from non-specific amplification.
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Table 3.12 – Optimisation of semi-nested RT-PCR to determine Ad.VEGF-
A165 expression in maternal and fetal tissues, 30-45 days after gene transfer to
the uterine arteries.
Sequence of reverse primer
candidates for 2nd round of Semi-
nested RT-PCR to determine
Ad.VEGF-A165 expression
RT-PCR amplification at different annealing
temperatures
50°C 52°C 54°C 56°C
Oligonucleotide 1
5`-GATCCGCATAATCTGCA-3`
- - - -
Oligonucleotide 2
5`-GATCCGCATAATCTGCATGGT-3`
+ + + -
Oligonucleotide 3
5`-CGCATAATCTGCATGGTGAT-3`
+ - - -
‘+’: Positive amplification; ‘-’: No amplification
Using this approach, a positive band was observed in the Ad.VEGF-A165
transduced vessel but the Ad.LacZ transduced vessel was negative, as were all
other tissues (Figure 3.28). This indicated there was no systemic expression of
transgenic vegf long-term.
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Figure 3.28 – RT-PCR to determine transgenic vegf experession in maternal
and fetal tissues, 30-45 days after Ad.VEGF-A165 gene transfer.
(A) Semi-nested RT-PCR with primers specific for Ad.VEGF-A165 in sheep maternal and fetal
samples was positive only in the Ad.VEGF-A165 transduced vessel, but negative in all other
tissues. Gel pictures are representative from one sheep. 1 – Ad.VEGF-A165 injected UtA; 2 –
Ad.LacZ injected UtA; 3 – maternal heart; 4 – maternal ovary; 5 – maternal liver; 6 – maternal
adrenal; 7 – maternal spleen; 8 – maternal uterus; 9 – maternal placentome; 10 – fetal heart; 11-
fetal liver; 12 – fetal gonad. The positive control used is either human umbilical vein endothelial
cells (HUVECs, PC1) or sheep uterine artery endothelial cells (PC2) infected with Ad.VEGF-A165
and the negative control (NC) is uninfected HUVECs. The ladder used is 1kb+ DNA ladder
(Fermentas). (B) RT-PCR with primers specific for sheep housekeeping gene TATA-box Binding
Protein (TBP) is positive for all ovine samples.
3.16 Local administration of Ad.VEGF-A165 to the uterine
arteries of pregnant sheep results in reduced intima:media
ratios
Uterine artery sections from animals carrying twin pregnancies (n=4) were
stained with H&E and examined for changes in intimal thickness, medial
thickness and intima:media ratios. This was done by analyzing cross-sectional
photomicrographs of uterine artery segments in ImageJ software to obtain the
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relative lengths of the intimal and medial layers and their respective ratios. All
measurements were performed twice by the same observer, who was blinded to
the vector injected into the uterine artery. The results of this analysis have been
summarized in Figure 3.29 (a-c).
Figure 3.29(a) – intima/media ratios in the uterine arteries of twin pregnant
sheep 30-45 days after administration of Ad.VEGF-A165 and Ad.LacZ to the
uterine arteries at mid-gestation
Figure 3.29(b) – Relative intimal thickness in the uterine arteries of twin
pregnant sheep 30-45 days after administration of Ad.VEGF-A165 and
Ad.LacZ to the uterine arteries at mid-gestation
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Figure 3.29(c) – Relative medial thickness in the uterine arteries of twin
pregnant sheep 30-45 days after administration of Ad.VEGF-A165 and
Ad.LacZ to the uterine arteries at mid-gestation
Maternal uterine artery samples collected at post-mortem examination were fixed in 4%
paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained with hematoxylin and eosin for morphological assessment. Photomicrographs of
stained sections were analysed using ‘ImageJ’ to determine the relative thicknesses of the intimal
and medial layers and intima/media ratios. Analysis was conducted on twin pregnant sheep (n=4).
There was a reduction in the intima/media ratios and intimal thickness in Ad.VEGF-A165
transduced vessels compared to Ad.LacZ transduced segments. * indicates p<0.05
We observed there was a reduction in the intima:media ratios in the
Ad.VEGF-A165 transduced segments compared to Ad.LacZ transduced segments
in the main uterine artery and its subsequent three branches, though this
difference was significant only in 2nd and 3rd branches (n=4, p=0.03 and 0.05
respectively). The intra-observer variability of measurement was 5.2%.
The reduction in intima/media ratios appeared to be primarily on account
of a reduction in the intimal thickness rather than an increase in medial thickness,
as is evident from Figure 3.29 (b and c).
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3.17 Local administration of Ad.VEGF-A165 to the uterine
arteries of pregnant sheep results in normal postnatal
growth
One ewe gave birth to a healthy female lamb (Figure 3.30) on the day of
scheduled post mortem examination (139 days gestational age), 2 days earlier
than expected. The delivery was uncomplicated without any postpartum
haemorrhage or retained placenta. This animal (UA29) had undergone chronic
fetal catheterization to monitor fetal haemodynamics. During birth the catheter
was pulled out from the carotid artery without obvious haemorrhage or structural
damage to the fetal neck. The next morning, the small wound in the lamb’s neck
through which the catheter had pulled out was cleaned with povidone antiseptic
solution.
Figure 3.30 – Pictures of the lamb born to an ewe injected with Ad.VEGF-
A165 and Ad.LacZ at mid-gestation.
The lamb was unexpectedly born on the day of its scheduled post-mortem. These pictures were
taken at 4 months age.
After discussion with the local Home Office Inspector, the ewe and lamb
were allowed to continue being monitored and this was done for 4 months until
weaning. The lamb showed no adverse development or abnormal growth velocity.
The maternal and neonatal haematology, biochemistry, liver function tests as well
as the weight and blood oxygen saturation of the lamb were assessed at weekly
intervals for the first month and thereafter once a month until post-mortem
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examination. All haematological values and serum biochemistry were within the
normal ranges for both mother and lamb. The liver enzyme Glutamate
dehydrogenase (GLDH) was elevated in the lamb (range 19-37 U/l at different
time-points examined; normal levels <20 U/l), as were the Gamma-glutamyl
transferase (GGT) levels (range 85-100 U/l at different time points examined;
normal levels < 76 U/l). Previous studies in lambs born to control ewes which
have not had any intervention have shown levels of GLDH to be elevated
compared to the normal range quoted for adult sheep (20 U/l), thus suggesting
that the normal adult range cannot be applied to young lambs (Meyer DJ and
Harvey JW, 1998;David AL, 2005). GGT is present in colostrum and this may
have resulted in the elevation during the period the lamb is suckling. All other
liver enzymes were within the normal range.
The blood oxygen saturation of the lamb as measured by a pulse oximeter
was in the range of 97-99% at all time points examined.
Figure 3.31 shows the post-natal weight gain of the lamb compared to
Suffolk sheep (a sheep breed of similar size to Romneys) at regular intervals after
birth. Similar post-natal growth velocity data was not available for Romney breed
for comparison.
Figure 3.31 – Percentage increase in body weight (relative to birthweight) in
the new born lamb compared to Suffolk breed sheep
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At 4 months after birth, both mother and lamb were euthanized. Maternal
and fetal tissue samples collected at post-mortem were examined microscopically
after H&E staining. All tissue samples examined had an unremarkable histology.
Even though post-natal data was acquired for only one lamb in this study,
it indicates that the neonatal growth and development is normal following
Ad.VEGF-A165 administration to the uterine arteries at mid-gestation.
3.18 The effects of adenovirus-mediated over-expression
of VEGF-A165 in the uterine arteries at mid-gestation are not
sustained post-partum
As mentioned in the preceding section, sheep UA29 gave birth to a
healthy female lamb on the day of her scheduled post-mortem. Both mother and
lamb were kept alive for a further 4 months to monitor development. At post-
mortem examination, maternal and lamb samples were snap-frozen for subsequent
semi-nested RT-PCR analysis for vector expression. All samples analysed (listed
in post-mortem sheep, Appendix IV) were negative.
The vascular reactivity of the maternal uterine arteries was studied on an
organ bath set-up. The contractility and relaxation to increasing doses of
phenylephrine and bradykinin respectively were investigated (Figure 3.32 and
Figure 3.33 respectively).
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Figure 3.32 - Contractility of pregnant sheep uterine arteries injected with
Ad.VEGF-A165 and Ad.LacZ contralaterally at mid-gestation, 4 months
post-partum
At mid-gestation, one uterine artery was injected with Ad.VEGF-A165 and the contra-lateral
uterine artery was injected with Ad.LacZ in a singleton pregnant sheep. The second and third
branches of the main uterine arteries were harvested 4 months post-partum, cut into 3mm ring
segments and analysed on an 8-chambered organ bath system. Concentration response curves to
PE were constructed for each vessel in quadruplicate. The contractility of the vessel is expressed
as a percentage of the response to KCl. PE produced concentration-dependent contractions, which
were not different in magnitude between the Ad.VEGF-A165 transduced vessels and Ad.LacZ
transduced vessels (n=1). Error bars denote standard error of mean.
-12 -11 -10 -9 -8 -7 -6
0
10
20
30
40
50
Ad.VEGF
Ad.LacZ
BK (log M)
%
R
el
ax
at
io
n
Figure 3.33 -Relaxation of pregnant sheep uterine arteries injected with
Ad.VEGF-A165 and Ad.LacZ contralaterally at mid-gestation, 4 months post-
partum
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(Continued from overleaf) At mid-gestation, one uterine artery was injected with Ad.VEGF-A165
and the contra-lateral uterine artery was injected with Ad.LacZ in a singleton pregnant sheep. The
second and third branches of the main uterine arteries were harvested 4 months post-partum, cut
into 3mm ring segments and analysed on an 8-chambered organ bath system. Concentration
response curves to BK were constructed for each vessel in quadruplicate. The relaxation of the
vessel is expressed as a percentage of inhibition of PE-induced contraction. There was no apparent
difference in the relaxation response between the Ad.VEGF-A165 and Ad.LacZ transduced vessels
(n=1). Error bars denote standard error of mean.
There was no difference in the contractile and relaxation responses of the
uterine arteries that had received either Ad.VEGF-A165 or Ad.LacZ. Even though
we only have data from one animal, it shows that the effects of adenovirus-
mediated transgene expression on vascular reactivity are not sustained 5 months
post-administration. This is to be expected since the maximum duration of
adenovirus mediated gene transfer is usually believed to be 4 – 6 weeks after
transduction.
3.19 Local administration of Ad.VEGF-A165 to the uterine
arteries of pregnant sheep does not lead to haematological
and biochemical pathological changes.
Blood and serum samples were taken from experimental sheep (n=3) at
three different time points – vector injection, 1 week post-injection and post-
mortem examination. Fetal samples could only be collected at post-mortem. The
samples were sent to the Clinical Diagnostics Lab, RVC Hawkshead for routine
haematological, biochemical and liver function analysis and were compared with
standard normal ranges for adult and fetal sheep. All maternal and fetal
haematological and biochemical values examined were within the normal range.
240
3.20 Analysis of maternal and fetal liver function tests after
Ad.VEGF-A165 injection does not indicate any liver
pathology
The serum levels of liver enzymes can indicate whether hepatic disease is
present and assess its functional aspect. The diagnostic usefulness of particular
liver enzymes depends on the domestic animal species investigated and their age,
and this must be considered when interpreting results (Meyer DJ and Harvey JW,
1998). The serum levels of aspartate transaminase (AST) were within the normal
range in all samples examined. While abnormal levels of AST provide only a
general indicator of hepatic injury in ruminants, the serum concentration of the
liver enzyme GLDH is the most specific for hepatocellular injury. In ruminants,
GLDH is raised in hepatic necrosis and bile-duct obstruction (Kaneko JJ et al.,
1997).
Two of the three sheep examined showed elevated levels of GLDH in the
samples taken just before vector injection (UA25 – 108 U/l and UA26 – 184 U/l;
normal levels <20 U/l). However, when examined 1 week post-injection, the
levels of GLDH had fallen to within the normal ranges (UA25 – 13 U/l and UA
26 – 17 U/l). These levels were normal when examined again at the time of the
post-mortem examination. It is unlikely that administration of Ad.VEGF-A165 may
have played a role in restoring the normal levels of GLDH in pregnant ewes, but
the data at least suggests that vector administration does not appear to cause any
hepatocellular injury.
GGT and alkaline phosphatase (ALP) are markers of cholestasis, GGT
being associated with epithelial cells comprising the bile ductular system and
ALP associated with the canalicular membrane. GGT levels were within the
normal range for all maternal and fetal sheep samples analysed. Serum levels of
ALP fluctuate widely in normal ruminants and are not considered to be very
valuable in the evaluation of cholestatic disorders. ALP levels were therefore not
measured in our sheep.
Bilirubin was not raised in any of the maternal and fetal serum samples
analysed. The levels of alanine aminotransferase (ALT) were normal. There is
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only low level ALT activity in the hepatocytes of ruminants in contrast to rodent
hepatocytes and therefore the level of this liver enzyme in the serum is not
diagnostically useful.
Overall, these results suggest that administration of Ad.VEGF-A165 to the
uterine arteries of pregnant ewes does not cause any clinically important changes
in the levels of maternal and fetal liver enzymes.
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Section II – Experiments with Ad.VEGF-DΔNΔC
Following on from the encouraging results of the Ad.VEGF-A165 study,
we became interested in investigating the effects of another member of the VEGF
family, VEGF-DΔNΔC on the utero-placental circulation. VEGF-DΔNΔC is
angiogenic but may elicit a more restricted range of biological responses
compared with VEGF-A165 (Rissanen TT et al., 2003;Jia H et al., 2004). It may
also be less likely to cause unwanted side effects, such as making the vessels less
leaky/permeable as compared to VEGF-A165, and thus we felt it may be of greater
therapeutic benefit in treating FGR caused by vascular placental insufficiency.
For the current study, we used adenoviral vectors encoding the mature
(processed/truncated) form of the VEGF-D gene, i.e., VEGF-DΔNΔC (Achen MG
et al., 1998) to transduce the uterine arteries of pregnant sheep. Previous
experiments with the long-form of the VEGF-D gene were found to not alter
uterine blood flow or vascular reactivity in pregnant sheep (David AL et al.,
2008). Published studies have demonstrated that VEGF-DΔNΔC has a substantially
greater angiogenic effect and significantly increased affinity for VEGFR-2 than
the full length form (Rissanen TT et al., 2003;Stacker SA et al., 1999). For
simplicity, VEGF-DΔNΔC and Ad.VEGF-DΔNΔC have been referred to as VEGF-D
and Ad.VEGF-D respectively in this chapter.
Initially, the short-term effects of Ad.VEGF-D on uterine artery vascular
reactivity were studied. Long-term experiments requiring chronic implantation of
flow-probes are technically more difficult and intensive. Hence, I first wanted to
determine if Ad.VEGF-D transduction actually has any biological effect on the
uterine arteries short-term, before carrying out any long-term experiments. Two
kinds of short-term experiments were performed – (i) uterine artery injection of
Ad.VEGF-D or Ad.LacZ bilaterally (n=2 each); and (ii) uterine artery injection of
Ad.VEGF-D and Ad.LacZ contra-laterally within the same animal (n=6). The
rationale behind conducting these two experiments was that VEGF-D is believed
to be more highly soluble than VEGF-A165. We were thus initially concerned that
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VEGF-D protein from the transduced side would be carried systemically to the
contra-lateral side and influence its vascular reactivity, thereby eliminating any
differences in vascular responses in experiments wherein the two vectors were
injected contra-laterally (Seppo Yla-Hertulla, personal communication). Hence,
we designed experiments to test both the combinations - bilateral and unilateral
administration of Ad.VEGF-D/Ad.LacZ.
We then studied the long-term effects of Ad.VEGF-D transduction on
vascular reactivity, neovascularization, endothelial cell proliferation and UABF
(by chronic implantation of telemetric flow probes, n=5). UABF was measured
successfully in all 5 ewes.
Some sheep in this study (n=9) had an intravenous administration of 5-
Bromo-2′-deoxyuridine (BrdU) 48 hours before post-mortem. Uterine artery 
samples from these sheep were stained with an anti-BrdU antibody to assess cell
proliferation.
The details of the analysis performed on the Ad.VEGF-D sheep have been
described in Table 3.13.
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Table 3.13 - Details of experimental analysis performed on sheep injected
with Ad.VEGF-D and Ad.LacZ.
Animal Fetal
No.
Vector
injected
GA at
Probe
placement
GA at
Vector
injection
GA
at
PM
UABF Organ
Bath
vWF BrdU eNOS
analysis
UA17 2 Ad.VEGF-
D bilaterally
- 87 91 - + - - -
UA19 1 Ad.VEGF-
D bilaterally
- 96 100 - + - - -
UA21 2 Ad.LacZ
bilaterally
- 91 95 - + - - -
UA23 1 Ad.LacZ
bilaterally
- 95 99 - + - - -
UA31 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 83 87 - + - - -
UA32 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 108 114 - + - - -
UA34 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 109 116 - + + + -
UA36 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 82 89 - + + + +
UA37 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 108 113 - + + + +
UA41 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
- 95 99 - + + + +
UA38 2 Ad.VEGF-D/
Ad.LacZ
contralaterally
89 96 139 + + + + +
UA39 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
89 95 136 + + + + +
UA42 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
98 112 142 + + + + -
UA43 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
95 105 139 + + + + -
UA45 1 Ad.VEGF-D/
Ad.LacZ
contralaterally
82 95 140 + + + + +
GA=gestational age; UABF = measurement of uterine artery blood flow; vWF = adventitial vessel
enumeration by anti-vWF immunohistochemistry; BrdU = administration of 5`-bromo-2`-
deoxyuridine to measure endothelial cell proliferation
The detailed results of the analysis performed on the Ad.VEGF-D
transduced sheep have been described in the following section. There was no
maternal or fetal mortality in this study. Gross examination at the time of post-
mortem of all ewes and fetuses did not reveal any pathology.
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3.21 Ad.VEGF-D transduction of uterine arteries in the
pregnant sheep bilaterally results in short term changes in
vascular reactivity.
I investigated the vascular responses of uterine arteries transduced with
Ad.VEGF-D and Ad.LacZ bilaterally, 4 days after gene transfer. Both the
contraction and relaxation responses of the vessels were examined.
3.21.1 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep bilaterally results in a diminished contractile
response in twin and singleton pregnancies.
Organ bath experiments were conducted on the 2nd and 3rd branches of the
main uterine artery from 4 sheep – two carrying twin pregnancies (UA17 and
UA21) and two carrying singleton pregnancies (UA19 and UA23). One twin
pregnant and one singleton pregnant animal were injected with Ad.VEGF-D
bilaterally (UA17 and UA19 respectively), while the other twin and singleton
pregnant animal were injected with Ad.LacZ bilaterally (UA 21 and UA23
respectively). The post-mortem examination was performed 4 days after injection,
and the vascular contractility of the harvested uterine arteries was examined with
phenylephrine.
I observed a reduction in the vascular contractility of uterine arteries from
both the twin (Figure 3.34) and singleton (Figure 3.35) pregnant animals injected
with Ad.VEGF-D, compared to the corresponding controls which had received
Ad.LacZ. Table 3.14 summarizes the Emax and EC50 to phenylephrine in the
animals studied in this group.
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Figure 3.34 - Contractility of twin pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine (PE) 4 days after gene
transfer.
At mid-gestation, the uterine arteries of one twin pregnant sheep were injected with Ad.VEGF-D
bilaterally, and those of another were injected with Ad.LacZ bilaterally (n=1 animal each). The
second and third branches of the main uterine arteries were harvested 4 days after injection, cut
into 3mm ring segments and analysed on an 8-chambered organ bath system. Concentration
response curves to PE were constructed for each vessel in quadruplicate. The contractility of the
vessel is expressed as a percentage of the response to KCl. PE produced concentration-dependent
contractions, which were of lesser magnitude in Ad.VEGF-D transduced vessels compared to
Ad.LacZ transduced vessels. Error bars denote standard error of mean.
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Figure 3.35 - Contractility of singleton pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine (PE) 4 days after gene
transfer.
At mid-gestation, the uterine arteries of one singleton pregnant sheep were injected with
Ad.VEGF-D bilaterally, and those of another were injected with Ad.LacZ bilaterally (n=1 animal
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each). The second and third branches of the main uterine arteries were harvested 4 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. The
contractility of the vessel is expressed as a percentage of the response to KCl. PE produced
concentration-dependent contractions, which were of lesser magnitude in Ad.VEGF-D transduced
vessels compared to Ad.LacZ transduced vessels. Error bars denote standard error of mean.
Table 3.14 – Emax and EC50 in response to L-phenylephrine in uterine arteries
from twin and singleton pregnant sheep injected with Ad.VEGF-D or
Ad.LacZ bilaterally.
At mid-gestation, the uterine arteries of one twin and one singleton pregnant sheep were injected
with Ad.VEGF-D bilaterally, and those of another twin and singleton sheep were injected with
Ad.LacZ bilaterally. The second and third branches of the main uterine artery were harvested 4
days after injection and analysed on an 8-chambered organ bath system. Concentration response
curves to PE were constructed for each vessel in quadruplicate. The contractility of the vessel is
expressed as a percentage of the response to KCl.
Animal Number of
fetuses
Vector
injected
Number of
animals
Emax %
(Mean+SEM)
EC50
UA17 Twin Ad.VEGF-D 1 102.8+3.45 2.46x10-6M
UA21 Twin Ad.LacZ 1 131.8+10.09 1.73x10-6M
UA19 Singleton Ad.VEGF-D 1 126.1+7.62 4.34x10-8M
UA23 Singleton Ad.LacZ 1 235.5+17.60 2.16x10-8M
In summary, this data suggests that 4 days after local administration of
Ad.VEGF-D to the uterine arteries of mid-gestation pregnant sheep bilaterally,
there is a reduction in uterine artery contractility compared to Ad.LacZ transduced
vessels. Because only one animal was studied in each configuration, it was not
possible to do any statistical test on these results. However, if the data is analysed
from a different perspective so that the contractile response of the 3 sets of gravid
vessels transduced with Ad.VEGF-D (2 sets from the twin pregnant animal and 1
set from the singleton pregnant animal) is compared with the contractile response
of the 3 sets of gravid vessels transduced with Ad.LacZ, the contractile response
of the former is significantly lesser than the latter (Emax 108.3+3.83 v/s 144.1+
10.22, n=3, p=0.013, Figure 3.36).
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Figure 3.36 - Contractility of gravid Ad.VEGF-D and Ad.LacZ transduced
uterine arteries to L-phenylephrine (PE) from one twin and one singleton
pregnant animal 4 days after gene transfer.
At mid-gestation, the uterine arteries of one twin and one singleton pregnant sheep were injected
with Ad.VEGF-D bilaterally, and those of another twin and another singleton pregnant sheep were
injected with Ad.LacZ bilaterally. The second and third branches of the main uterine arteries
supplying the gravid uterine horn were harvested 4 days after injection, cut into 3mm ring
segments and analysed on an 8-chambered organ bath system. Concentration response curves to
PE were constructed for each vessel in quadruplicate. The contractility of the vessel is expressed
as a percentage of the response to KCl. PE produced concentration-dependent contractions, which
were of significantly lesser magnitude in Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced vessels. Error bars denote standard error of mean. * denotes p<0.05
3.21.2 Studies on the uterine artery relaxation response after
local over-expression of VEGF-D in the uterine arteries of
pregnant sheep bilaterally are inconclusive.
I also studied the endothelium-dependent relaxation to bradykinin in the
uterine arteries from sheep that had been injected with Ad.VEGF-D or Ad.LacZ
bilaterally. I observed an enhancement in the relaxation of uterine arteries from
the twin pregnant animal (Figure 3.37), though the uterine arteries from the
singleton pregnant animals did not yield any conclusive results (Figure 3.38)
Table 3.15 summarizes the Emax and pD2 to bradykinin in the animals studied in
this group.
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Figure 3.37 – Endothelium-dependent relaxation to bradykinin in twin
pregnant Ad.VEGF-D and Ad.LacZ transduced uterine arteries 4 days after
gene transfer.
At mid-gestation, the uterine arteries of one twin pregnant sheep were injected with Ad.VEGF-D
bilaterally, and those of another were injected with Ad.LacZ bilaterally (n=1 animal each). The
second and third branches of the main uterine arteries were harvested 4 days after injection, cut
into 3mm ring segments and analysed on an 8-chambered organ bath system. Concentration
response curves to BK were constructed for each vessel in quadruplicate. The relaxation of the
vessel is expressed as a percentage of inhibition of PE-induced contraction. BK produced
concentration-dependent relaxation, which was of greater magnitude in Ad.VEGF-D transduced
vessels compared to Ad.LacZ transduced vessels. Error bars denote standard error of mean.
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Figure 3.38 – Endothelium-dependent relaxation to bradykinin in singleton
pregnant Ad.VEGF-D and Ad.LacZ transduced uterine arteries 4 days after
gene transfer.
At mid-gestation, the uterine arteries of one singleton pregnant sheep were injected with
Ad.VEGF-D bilaterally, and those of another were injected with Ad.LacZ bilaterally (n=1 animal
250
each). The second and third branches of the main uterine arteries were harvested 4 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to BK were constructed for each vessel in quadruplicate. The
relaxation of the vessel is expressed as a percentage of inhibition of PE-induced contraction. BK
produced concentration-dependent relaxation, which was not different between the Ad.VEGF-D
transduced segments and Ad.LacZ transduced segments. Error bars denote standard error of mean.
Table 3.15 – Emax and pD2 in response to bradykinin in uterine arteries from
twin and singleton pregnant sheep injected with Ad.VEGF-D or Ad.LacZ
bilaterally.
At mid-gestation, the uterine arteries of one twin and one pregnant singleton sheep were injected
with Ad.VEGF-D bilaterally, and those of another twin and singleton sheep were injected with
Ad.LacZ bilaterally. The second and third branches of the main uterine artery were harvested 4
days after injection and analysed on an 8-chambered organ bath system. Concentration response
curves to BK were constructed for each vessel in quadruplicate. The relaxation of the vessel is
expressed as a percentage of inhibition of PE-induced contraction.
Animal Number of
fetuses
Vector
injected
Number of
animals
Emax %
(Mean+SEM)
pD2
UA17 Twin Ad.VEGF-D 1 68.54+3.01 9.29+0.15
UA21 Twin Ad.LacZ 1 45.51+3.37 10.20+0.36
UA19 Singleton Ad.VEGF-D 1 47.28+4.99 8.97+0.28
UA23 Singleton Ad.LacZ 1 48.33+7.99 9.34+0.51
Because we only studied one animal in each configuration, it was not
possible to do any statistical test on these results and make definite conclusions
about the effects of Ad.VEGF-D on uterine artery relaxation. This study was
limited by animal numbers, and a greater number of animals are warranted to
come to any definite conclusion. However, if the data is analysed from a different
perspective so that the relaxation response of the 3 sets of gravid vessels
transduced with Ad.VEGF-D (2 sets from the twin pregnant animal and 1 set from
the singleton pregnant animal) is compared with the relaxation response of the 3
sets of gravid vessels transduced with Ad.LacZ, the endothelium-dependent
relaxation response of the former is significantly greater than the latter (Emax
66.07+2.03 v/s 41.50+3.40, n=3, p=0.036, Figure 3.39).
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Figure 3.39 – Relaxation of gravid Ad.VEGF-D and Ad.LacZ transduced
uterine arteries to bradykinin (BK) from one twin and one singleton
pregnant animal 4 days after gene transfer.
At mid-gestation, the uterine arteries of one twin and one singleton pregnant sheep were injected
with Ad.VEGF-D bilaterally, and those of another twin and another singleton pregnant sheep were
injected with Ad.LacZ bilaterally. The second and third branches of the main uterine arteries
supplying the gravid uterine horn were harvested 4 days after injection, cut into 3mm ring
segments and analysed on an 8-chambered organ bath system. Concentration response curves to
BK were constructed for each vessel in quadruplicate. The relaxtion of the vessel is expressed as a
percentage of inhibition of PE-induced contraction. BK produced concentration-dependent
relaxations, which were of significantly greater magnitude in Ad.VEGF-D transduced vessels
compared to Ad.LacZ transduced vessels. Error bars denote standard error of mean. * denotes
p<0.05
3.22 Ad.VEGF-D transduction of uterine arteries in the
pregnant sheep unilaterally results in short term changes
in vascular reactivity.
We also performed experiments wherein we injected the uterine arteries
with Ad.VEGF-D and Ad.LacZ contra-laterally in the same animal. The animals
were sacrificed 4-7 days post-injection, and the contractility and relaxation of
their vessels was studied in an organ bath set-up. The vascular reactivity of
uterine arteries depends on a number of factors, which include weight of the
animal, age and gravidity status. We therefore considered that an intra-animal
comparison (between both the uterine arteries of animals that had been injected
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with two different vectors) was likely to be more informative than an inter-animal
comparison (between animals injected bilaterally with the same vector) to
elucidate the effect of the vector. More importantly, we felt this data would give
us a better opportunity to put the results in perspective and compare with our
previous data from Ad.VEGF-A165 injected sheep (all of whom had received
Ad.VEGF-A165 and Ad.LacZ contra-laterally).
3.22.1 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep results in a diminished contractile response
The uterine arteries from mid-gestation pregnant sheep were injected with
Ad.VEGF-D and Ad.LacZ contra-laterally (n=6). All of the sheep used in this
study carried singleton pregnancies. In half of the animals (n=3), Ad.VEGF-D
was injected into the uterine artery supplying the gravid horn, while in the other
half (n=3), Ad.VEGF-D was injected into the uterine artery supplying the non-
gravid horn.
The results for contractility to phenylephrine have been presented
individually for each group first and then combined for both the groups. Two-way
ANOVA was used to statistically compare the vascular responses of the
Ad.VEGF-D and Ad.LacZ transduced vessels.
Injection of Ad.VEGF-D into the uterine artery supplying the gravid horn
significantly reduced the contractile response to phenylephrine when compared to
injection of Ad.LacZ vector on the non-gravid side (Figure 3.40). The Emax in the
Ad.VEGF-D transduced vessels was 115.1+7.81 v/s 158.7+11.75 in Ad.LacZ
transduced vessels (n=3, p<0.001, two-way ANOVA).
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Figure 3.40 - Contractility of singleton pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine 4-7 days after gene transfer
(Ad.VEGF-D administered on gravid side).
At mid-gestation, the uterine artery supplying the gravid horn was injected with Ad.VEGF-D and
the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals (n=3).
The second and third branches of the main uterine arteries were harvested 4-7 days after injection,
cut into 3mm ring segments and analysed on an 8-chambered organ bath system. Concentration
response curves to PE were constructed for each vessel in quadruplicate. The contractility of the
vessel is expressed as a percentage of the response to KCl. PE produced concentration-dependent
contractions, which were of significantly lesser magnitude in Ad.VEGF-D transduced vessels
compared to Ad.LacZ transduced vessels. Error bars denote standard error of mean. * denotes
p<0.005
Injection of Ad.VEGF-D into the uterine artery supplying the non-gravid
horn resulted in no differential response between the Ad.VEGF-D and Ad.LacZ
transduced vessels (Figure 3.41). The Emax in the Ad.VEGF-D transduced vessels
was 163.2+17.87 v/s 173.3+30.05 in Ad.LacZ transduced vessels (n=3, p=0.863,
two-way ANOVA).
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Figure 3.41 - Contractility of singleton pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine 4-7 days after gene transfer
(Ad.VEGF-D administered on non-gravid side).
At mid-gestation, the uterine artery supplying the non-gravid horn was injected with Ad.VEGF-D
and the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals
(n=3). The second and third branches of the main uterine arteries were harvested 4-7 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. The
contractility of the vessel is expressed as a percentage of the response to KCl. PE produced
concentration-dependent contractions, which were no different between the Ad.VEGF-D
transduced segments and Ad.LacZ transduced segments. Error bars denote standard error of mean.
When contractility data from these experiments was combined, analysis
using two-way ANOVA to control for factors such as the injection side and the
vector demonstrated that Ad.VEGF-D transduced vessels were significantly less
contractile to phenylephrine compared to Ad.LacZ transduced vessels (Figure
3.42). Table 3.16 and 3.17 summarize the Emax values and EC50 respectively, in
response to L-phenylephrine, observed in the animals in this cohort.
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Figure 3.42 - Contractility of singleton pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine 4-7 days after gene transfer
(combined data).
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=3) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=6). The second and third branches of the main uterine arteries were
harvested 4-7 days after injection, cut into 3mm ring segments and analysed on an 8-chambered
organ bath system. Concentration response curves to PE were constructed for each vessel in
quadruplicate. The contractility of the vessel is expressed as a percentage of the response to KCl.
PE produced concentration-dependent contractions, which were of significantly lesser magnitude
in Ad.VEGF-D transduced vessels compared to Ad.LacZ transduced vessels. Error bars denote
standard error of mean. * denotes p<0.005
Table 3.16 - Emax in response to L-phenylephrine in uterine arteries from
singleton pregnant animals injected with Ad.VEGF-D and Ad.LacZ contra-
laterally.
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=3) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=6). The second and third branches of the main uterine artery were
harvested 4-7 days after injection and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. The
contractility of the vessel is expressed as a percentage of the response to KCl. The p value is for
the contraction dose response curve.
Observed Emax %
(Mean+SEM)Number of
fetuses
Side of Ad.VEGF-D
vector injection
Number of
animals Ad.VEGF-D
vector
Ad.LacZ
vector
p
value
Singleton Gravid 3 115.1+7.81 158.7+11.75 0.0001
Singleton Non-gravid 3 163.2+17.87 173.3+30.05 0.863
Singleton
Gravid and non-
gravid data combined
6
126.6+7.54 159.9+10.96
0.0001
*
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Table 3.17 – EC50 in response to L-phenylephrine in uterine arteries from
singleton pregnant animals injected with Ad.VEGF-D and Ad.LacZ contra-
laterally.
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=3) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=6). The second and third branches of the main uterine artery were
harvested 4-7 days after injection and analysed on an 8-chambered organ bath system.
Concentration response curves to PE were constructed for each vessel in quadruplicate. EC50 was
determined by plotting a sigmoidal dose response curve. The p value is for the contraction dose
response curve.
EC50 (M)Number of
fetuses
Side of Ad.VEGF-D
vector injection
Number of
animals Ad.VEGF-Dvector
Ad.LacZ
vector
p
value
Singleton Gravid 3 2.49x10-6 2.53x10-6 0.0001
Singleton Non-gravid 3 4.08x10-6 4.52x10-6 0.863
Singleton
Gravid and non-
gravid data combined
6
2.86x10-6 2.87x10-6
0.0001
To summarize, these results show that 4-7 days after adenovirus-mediated
local over-expression of VEGF-D and LacZ in the uterine arteries of pregnant
sheep contra-laterally, there is a significant reduction in the contractile response to
L-phenylephrine in the Ad.VEGF-D transduced vessel segments. We have
demonstrated that the reduction in contractile response was only seen when
Ad.VEGF-D was injected into the gravid side uterine artery, but not when it was
injected into the non-gravid uterine artery. Nevertheless, the overall data obtained
by combining the results of the gravid and non-gravid side still shows a trend
towards a significant reduction in contractile response for the Ad.VEGF-D
transduced vessel segments.
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3.22.2 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep results in a significantly enhanced relaxation
response
We also investigated the endothelium-dependent relaxation to bradykinin
in the uterine arteries of pregnant sheep (n=6) which had received an Ad.VEGF-D
injection and Ad.LacZ injection contra-laterally. As in the preceding section, the
results for each group (Ad.VEGF-D injection on gravid side and Ad.VEGF-D
injection on non-gravid side) have been presented individually, followed by the
combined results for both groups. Two-way ANOVA was used to statistically
compare the vascular responses of the Ad.VEGF-D and Ad.LacZ transduced
vessels.
The uterine arteries from one sheep (UA41) which had received
Ad.VEGF-D on the non-gravid side failed the endothelial integrity test (the vessel
segments relaxed less than 10% to a bolus dose of bradykin). Consequently, the
relaxation data from this animal had to be excluded from our analysis.
Administration of Ad.VEGF-D to the uterine artery supplying the gravid
horn resulted in a significant enhancement of relaxation (Figure 3.43). The Emax in
the Ad.VEGF-D transduced vessels was 77.76+3.90 v/s 44.42+3.87 in Ad.LacZ
transduced vessels (n=3, p=0.010, two-way ANOVA)
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Figure 3.43 – Endothelium-dependent relaxation to bradykin in singleton
pregnant Ad.VEGF-D and Ad.LacZ transduced uterine arteries 4-7 days
after gene transfer (Ad.VEGF-D administered on gravid side).
At mid-gestation, the uterine artery supplying the gravid horn was injected with Ad.VEGF-D and
the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals (n=3).
The second and third branches of the main uterine arteries were harvested 4-7 days after injection,
cut into 3mm ring segments and analysed on an 8-chambered organ bath system. Concentration
response curves to BK were constructed for each vessel in quadruplicate. The relaxation of the
vessel is expressed as a percentage of inhibition of PE-induced contraction. BK produced
concentration-dependent relaxation, which was of significantly greater magnitude in Ad.VEGF-D
transduced vessels compared to Ad.LacZ transduced vessels. Error bars denote standard error of
mean. * denotes p<0.05
Administration of Ad.VEGF-D to the uterine artery supplying the non-
gravid horn indicated a trend towards increased relaxation on this side (Figure
3.44), even though the Emax values for both the sides were very similar –
38.75+2.24 (Ad.VEGF-D) v/s 37.71+1.61 v/s (Ad.LacZ). No statistical test was
performed on this group of results because of the small number of animals (n=2).
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Figure 3.44 – Endothelium-dependent relaxation to bradykin in singleton
pregnant Ad.VEGF-D and Ad.LacZ transduced uterine arteries 4-7 days
after gene transfer (Ad.VEGF-D administered on non-gravid side).
At mid-gestation, the uterine artery supplying the non-gravid horn was injected with Ad.VEGF-D
and the contra-lateral uterine artery was injected with Ad.LacZ in singleton pregnant animals
(n=2). The second and third branches of the main uterine arteries were harvested 4-7 days after
injection, cut into 3mm ring segments and analysed on an 8-chambered organ bath system.
Concentration response curves to BK were constructed for each vessel in quadruplicate. The
relaxation of the vessel is expressed as a percentage of inhibition of PE-induced contraction. BK
produced concentration-dependent relaxation, which demonstrated a trend towards enhancement
in the Ad.VEGF-D transduced segments compared to the Ad.LacZ transduced segments. Error
bars denote standard error of mean.
When the data for both these groups was combined (using two-way
ANOVA), the relaxation response in the Ad.VEGF-D transduced vessels was
significantly greater than the Ad.LacZ transduced vessels (p=0.052, Figure 3.45,
Table 3.18). Table 3.18 and 3.19 summarize the Emax values and pD2 in response
to bradykinin observed in the animals in this cohort.
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Figure 3.45 – Endothelium-dependent relaxation to bradykin in singleton
pregnant Ad.VEGF-D and Ad.LacZ transduced uterine arteries 4-7 days
after gene transfer (combined data)
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=2) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=5). The second and third branches of the main uterine arteries were
harvested 4-7 days after injection, cut into 3mm ring segments and analysed on an 8-chambered
organ bath system. Concentration response curves to BK were constructed for each vessel in
quadruplicate. The relaxation of the vessel is expressed as a percentage of inhibition of PE-
induced contraction. BK produced concentration-dependent relaxation, which was of significantly
greater magnitude in Ad.VEGF-D transduced vessels compared to Ad.LacZ transduced vessels.
Error bars denote standard error of mean. * denotes p<0.05
Table 3.18 - Emax in response to bradykinin in uterine arteries from singleton
pregnant animals injected with Ad.VEGF-D and Ad.LacZ contra-laterally.
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=2) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=5). The second and third branches of the main uterine artery were
harvested 4-7 days after injection and analysed on an 8-chambered organ bath system.
Concentration response curves to BK were constructed for each vessel in quadruplicate. The
relaxation of the vessel is expressed as a percentage of inhibition of PE-induced contraction. The p
value is for the relaxation dose response curve.
Observed Emax %
(Mean+SEM)Number of
fetuses
Side of Ad.VEGF-D
vector injection
Number of
animals Ad.VEGF-D
vector
Ad.LacZ
vector
p
value
Singleton Gravid 3 77.76+3.90 44.42+3.87 0.010
Singleton Non-gravid 2 38.75+2.24 37.71+1.61 na
Singleton
Gravid and non-
gravid data combined
5 62.50+3.25 41.89+2.49 0.052
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Table 3.19 – pD2 in response to bradykinin in uterine arteries from singleton
pregnant animals injected with Ad.VEGF-D and Ad.LacZ contra-laterally.
At mid-gestation, the uterine artery supplying the gravid horn (n=3) or non-gravid horn (n=2) was
injected with Ad.VEGF-D and the contra-lateral uterine artery was injected with Ad.LacZ in
singleton pregnant animals (n=5). The second and third branches of the main uterine artery were
harvested 4-7 days after injection and analysed on an 8-chambered organ bath system.
Concentration response curves to BK were constructed for each vessel in quadruplicate. pD2 was
determined by plotting a sigmoidal dose response curve. The p value is for the relaxation dose
response curve.
pD2Number of
fetuses
Side of Ad.VEGF-D
vector injection
Number of
animals Ad.VEGF-Dvector
Ad.LacZ
vector
p
value
Singleton Gravid 3 8.86+0.13 8.82+0.23 0.010
Singleton Non-gravid 2 9.42+0.17 8.95+0.11 na
Singleton
Combined data from
both groups above
5 9.05+0.14 8.87+0.16 0.052
To summarize, these results demonstrate that 4-7 days after adenovirus-
mediated local over-expression of VEGF-D and LacZ in the uterine arteries of
pregnant sheep contra-laterally, there is a significant increase in the endothelium-
dependent relaxation response to bradykinin in the Ad.VEGF-D transduced
vessels. The extent of enhancement of endothelium-dependent relaxation was
greater when Ad.VEGF-D was injected into the gravid uterine artery rather than
the non-gravid uterine artery.
3.22.3 The endothelium dependent relaxation in the uterine
arteries of pregnant sheep transduced with Ad.VEGF-D short-
term is mediated via NO and EDHF
The relaxation response to bradykinin was investigated in the presence of
different inhibitors of relaxation, to examine the mechanism of action of local
VEGF-D expression in uterine arteries short-term. Vessels from 5 singleton
pregnant animals (which had a good relaxation response) were used for this study.
These experiments were performed using the same methodology described in
Section 3.6.3, the only difference being that in place of Indomethacin, an
alternative COX-2 inhibitor, NS-398 (10 μM) was used. NS-398 is a specific 
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inhibitor of the COX-2 enzyme, a key mediator in the synthesis of PGI2 (Kawabe
J et al., 2010). Indomethacin, on the other hand is a non-selective inhibitor of both
COX-1 and COX-2 pathways and thus blocks the synthesis of Thromboxane-A2 (a
vasoconstrictor) and PGI2 (a vasodilator). As we intended to investigate only the
contribution of PGI2 towards endothelium-depend relaxation in uterine arteries
transduced with Ad.VEGF-D, use of a more specific inhibitor, such as NS-398,
was considered to be more appropriate.
Treatment with L-NAME significantly reduced the relaxant effect to
bradykinin in uterine artery segments from both the Ad.VEGF-D and Ad.LacZ
transduced vessels. Even though the Emax values in the presence of L-NAME were
not significantly different from that of vessels unexposed to this inhibitor (Table
3.20), addition of L-NAME resulted in a significant shift of the dose-response
curve to the right (Figure 3.46).
Further addition of NS-398 (with L-NAME) did not result in any
significant change in the endothelium dependent relaxation, even though there
was a trend towards a reduction in the relaxation response in the Ad.VEGF-D
transduced segments. Pre-treatment with Apamin (in the presence of L-NAME
and NS-398) resulted in a further significant attenuation of the endothelium-
dependent relaxation. The residual relaxation that was resistant to the cumulative
inhibition by all three inhibitors was significantly greater in the Ad.VEGF-D
transduced vessels (19.57%) compared to Ad.LacZ transduced vessels (9.21%,
n=5, p=0.05). NS-398 and Apamin alone had no significant influence on
relaxation (data not shown). Table 3.20 summarizes the results of the relaxation
response in the presence of different inhibitors.
263
Figure 3.46(a) - The endothelium-dependent relaxation to bradykin in the
presence of different inhibitors of the relaxation pathway in pregnant sheep
uterine arteries, 4-7 days after Ad.VEGF-D or Ad.LacZ transduction.
The contribution of NO, PGI2 and EDHF on the relaxation response to BK were investigated in
vessels precontracted with PE. Cumulative relaxation curves of BK (10-11M to 10-6M) were
constructed under the following conditions: (1) control (no inhibitors); (2) in the presence of L-
NAME (300 µM); (3) in the presence of L-NAME and NS-398 (COX-2 inhibitor, 10 µM); (4) in
the presence of L-NAME, NS-398 and apamin (1 µM). Relaxation was expressed as a percentage
of inhibition of PE-induced contraction. The mean relaxation response of vessels from singleton
pregnant sheep was calculated (n=5). Statistical significance was assumed at p<0.05. The BK
relaxant effect was not significantly modified by NS-398 but reduced by L-NAME (p<0.05, n=5).
The remaining endothelium-dependent relaxation (Emax), that was resistant to NS-398 and NO
synthase inhibition, was significantly reduced by pretreatment with apamin in both Ad.VEGF-D
and Ad.LacZ treated arteries (P<0.05, n=5). The residual relaxation that was resistant to the
cumulative addition of all three inhibitors was significantly greater in the Ad.VEGF-D transduced
segments compared to Ad.LacZ transduced segments.
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Figure 3.46(b)- Partial contribution of NO-dependent and NO-independent
mechanisms to the endothelial-dependent relaxation
Values are the mean+SEM for the area under the curve (AUC) for BK-induced relaxation
(complete bar with positive SEM), the AUC for BK-induced relaxation following treatment with
L-NAME (NO-independent component, white bar), and the remaining AUC after BK with L-
NAME (NO-dependent component, black bar). A significant reduction in the overall relaxation as
well as NO-dependent and NO-independent relaxations was observed between the treated and
control sides (p<0.05).
Table 3.20 - Emax in response to bradykinin in uterine arteries from pregnant
sheep transduced short-term with Ad.VEGF-D and Ad.LacZ contra-
laterally, in the presence of different inhibitors of endothelium-dependent
relaxation.
At mid-gestation, one uterine artery was injected with Ad.VEGF-D and the contra-lateral uterine
artery was injected with Ad.LacZ in singleton pregnant sheep (n=5). The second and third
branches of the main uterine artery were harvested 4-7 days after injection and analysed on an 8-
chambered organ bath system. Concentration response curves to BK were constructed for each
vessel in the absence and presence of different inhibitors of relaxation, namely, L-NAME, NS-398
and Apamin. The relaxation of the vessel is expressed as a percentage of inhibition of PE-induced
contraction. The p value indicates the significance of the effect of individual inhibitors on the dose
response curve.
Emax % (Mean+SEM)
Inhibitor Ad.VEGF-A165 transduced
side
Ad.LacZ trandsduced
side
p value
No inhibitor 62.50+3.25 41.79+3.09
L-NAME 66.00+6.17 39.12+2.29 p<0.05
L-NAME + NS-398 49.55+6.25 30.45+2.11 p=0.2
L-NAME + NS-398 +
Apamin
19.57+1.49 9.21+3.92 p<0.05
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Overall, this data demonstrates that NO and EDHF play a significant
contribution in mediating the endothelium-dependent relaxation in both
Ad.VEGF-D and Ad.LacZ transduced vessels. PGI2 may play a role as well in
Ad.VEGF-D transduced vessels, but our results currently show this contribution is
non-significant. The residual relaxation that remains after blocking all the three
pathways is significantly greater in the Ad.VEGF-D transduced vessels compared
to Ad.LacZ transduced vessels.
3.23 Ad.VEGF-D transduction of uterine arteries in the
pregnant sheep results in long-term changes in uterine
artery blood flow.
We were interested in investigating whether the short-term changes in
uterine artery vascular reactivity observed in response to VEGF-D over-
expression resulted in any long-term changes in UABF. The UABF was
measured long-term in 5 pregnant ewes which were injected with Ad.VEGF-D
and Ad.LacZ contra-laterally. Telemetric flow probes were implanted around the
uterine arteries of these sheep (Table 3.22) up to a week before vector injection
and uterine artery blood flow was measured for 1 hour each day. Before the
administration of the vector, the measured uterine artery blood flow was averaged
over three consecutive days to derive a baseline value. The daily measurements of
blood flow post-injection for each uterine artery were compared with this baseline
value and converted into a percentage increase from baseline.
We were aware that if Ad.VEGF-D had a similar effect in magnitude to
Ad.VEGF-A165 on utero-placental perfusion, we would need to measure uterine
artery blood flow in at least 10-11 ewes to reach statistically significant results.
However, we were more interested in investigating if Ad.VEGF-D had a
biological effect on uterine blood flow, rather than aiming for significance per se.
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Hence, a smaller number of animals were used for this study as compared to the
Ad.VEGF-A165 study.
As was seen with the Ad.VEGF-A165 injected ewes, there was a slight fall
in UABF from baseline for the first 1-3 days after vector injection, but it had
recovered completely by day 4 in all cases. The mean percentage fall in UABF
from baseline 1-3 days after vector injection was not significantly different in
Ad.VEGF-D (n=5) compared with Ad.LacZ (n=5) injected uterine arteries
(9.01+5.95% v/s 9.14+23.50%, p=0.99).
Figure 3.47 shows the average increase in blood flow from baseline in all
5 pregnant ewes, calculated in the same way as described earlier in Section 3.2.
Figure 3.47 - Percentage increase in uterine artery blood flow (UABF) from
baseline and gradient of percentage increase in UABF from baseline in 5
pregnant sheep injected with Ad.VEGF-D and Ad.LacZ contra-laterally
Pregnant sheep underwent a laparotomy at mid-gestation to implant transit-time flow probes
around their uterine arteries. UABF was measured for one hour each day at the same time in the
morning, before and after the administration of Ad.VEGF-D and Ad.LacZ contralaterally. The
post-injection values were compared with a pre-injection baseline, which was obtained by
averaging the values of UABF obtained for 3 consecutive days before the administration of the
vector. In this graph, the mean percentage increase in UABF from baseline is greater in the
Ad.VEGF-D transduced uterine arteries (50.58%) compared to the Ad.LacZ transduced uterine
arteries (26.94%), though statistical significance was not reached, most probably because of the
limited animal numbers.
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For each animal (n=5), the maximum increase in blood flow from baseline
was calculated at 4 different time points - 7 days, 14 days, 21 days and 28 days
post-vector injection. The UABF percent change at each time-point was
calculated using the average of 3 consecutive daily mean UABF measurements.
The gradient of the percentage increase in blood flow from baseline in each
uterine artery was calculated for the same time points. A two-way GLiM was used
to compare the UABF percent change in Ad.VEGF-D and Ad.LacZ injected
uterine arteries at each time point and also the gradients of UABF %change over
the length of gestation (Table 3.21). The two factors accounted for in the GLiM
analysis were whether the uterine artery supplied a gravid or non-gravid horn and
whether Ad.VEGF-D or Ad.LacZ vector was injected.
Table 3.21 - Percentage change in uterine artery blood blow (UABF) and
Gradient of Percentage Change in UABF at one week intervals post-
Ad.VEGF-D/Ad.LacZ injection to the uterine arteries of pregnant sheep
(n=5)
% Increase in UABF
+ SEM
Gradient of %
Increase in UABFTime-
point after
vector
injection
Ad.VEGF-
D
Ad.LacZ
p
value
(GLiM)
Ad.VEGF-
D
Ad.LacZ
p
value
(GLiM)
7 days 28.86+
8.23
20.91+
5.28
0.496 3.32 0.99 0.145
14 days 41.93+
8.70
24.41+
10.04
0.223 3.25 1.68 0.224
21 days 52.09+
9.83
29.11+
6.52
0.102 2.70 1.34 0.093
28 days 50.58+
15.81
26.94+
7.84
0.152 2.05 1.00 0.058
GLiM :General Linear Model
Table 3.22 summarizes the maximum increase in blood flow from baseline
in each uterine artery at 28 days after the administration of the vector.
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Table 3.22 - Percentage change in uterine artery blood flow (UABF) from
baseline 28 days after administration of Ad.VEGF-D or Ad.LacZ to the
uterine arteries of mid-gestation pregnant sheep.
Side of vector injection % change in UABF at
28 days post-injection
Animal Fetal no.
Ad.
VEGF-D
Ad.LacZ Ad.
VEGF-D
Ad.LacZ
UA38 Twin Gravid Gravid 23.60 21.23
UA39 Singleton Non-
gravid
Gravid 66.14 47.86
UA42 Singleton Gravid Non-
gravid
24.77 4.48
UA43 Singleton Non-
gravid
Gravid 32.65 19.85
UA45 Singleton Non-
gravid
Gravid 105.76 41.32
As anticipated, UABF increased with advancing gestation (Figure 3.47).
Considering singleton and twin gestations together, at 28 days post vector
injection, the mean increase in blood flow in the uterine arteries injected with
Ad.VEGF-D (50.58+15.81%, n=5) was higher than in the uterine arteries injected
with Ad.LacZ (26.94+7.84%, n=5). This increase was however not significant
(p=0.152, GLiM Test), most probably because of the limited number of animals
in this study.
At 28 days post-injection, it is encouraging to note that even with the
limited number of animals, the difference in gradient of the %increase in UABF
from baseline, between the Ad.VEGF-D and Ad.LacZ transduced sides (2.05 v/s
1.00 respectively) is close to significance (p=0.058).
These results propose that Ad.VEGF-D is playing a role in enhancing
utero-placental perfusion long-term. This is also supported by the data presented
in Table 3.22 which shows that the percentage increase in UABF from baseline in
the Ad.VEGF-D transduced uterine artery was always higher than the contra-
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lateral Ad.LacZ injected uterine artery. However, it must be emphasized that this
trend is not significant (most probably on account of the limited number of
experimental animals), thereby preventing us from making any firm conclusions.
Experiments in greater number of animals are warranted to obtain statistically
meaningful results.
3.24 The effect of Ad.VEGF-D transduction of uterine
arteries in the pregnant sheep on fetal weights
Fetal weights from singleton pregnancies undergoing long-term uterine
artery blood flow monitoring (n=4) were measured at post-mortem examination
and compared to a historical singleton fetal control group from the same sheep
breed (n=9) (David AL, 2005, Ph.D Thesis). The mean gestational age of the two
groups was not statistically different (139.3+2.5 days v/s 137.8+3.9 days, p=0.97,
unpaired t-test). The mean fetal weight in the experimental group was not
significantly different than that in the control group (4863+492 grams v/s
4698+1004 grams, p=0.45, unpaired t-test).
Fetal liver weights from the experimental group (n=4) were compared to a
historical singleton fetal control group from the same sheep breed (n=10). The
mean gestational age of the two groups was not statistically different (139.3+2.5
days v/s 138.9+6.5 days, p=0.68, unpaired t-test). Mean fetal liver weight was
higher in the experimental group (123.60+24.67 grams vs 106.10+21.18 grams),
although this increase was not significant (p=0.20).
Although statistical significance was not reached, there was a trend
observed, and higher numbers of experimental animals may have enabled a
significant difference to be observed.
270
3.25 Ad.VEGF-D transduction of uterine arteries in the
pregnant sheep results in long term changes in vascular
reactivity
The results described in the previous section demonstrate that Ad.VEGF-
D infection significantly alters uterine artery vascular reactivity 4-7 days after
administration. I was interested in investigating if these short-term findings were
sustained until term, and therefore examined the vascular reactivity of uterine
arteries from long-term transduced sheep (30-45 days post-injection) on an organ
bath. At 4 – 7 days after adenovirus gene transfer, changes in the contractile and
relaxation response had been seen. I therefore studied both types of responses in
these long term transduced vessels.
3.25.1 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep results in a diminished contractile response
long-term
Five mid-gestation pregnant sheep were used for this experiment, only one
of which was pregnant with twins. Of the four singleton pregnant ewes, three had
Ad.VEGF-D injected into the uterine artery supplying the non-gravid horn while
one had Ad.VEGF-D injected into the uterine artery supplying the gravid horn
(the operators were blinded to the vector injected at the time of surgery). At post-
mortem examination 30-45 later, the uterine arteries were carefully dissected out
and their vascular reactivity was studied with escalating doses of phenylephrine.
Two-way ANOVA was used to statistically compare the vascular responses of the
Ad.VEGF-D and Ad.LacZ transduced vessels.
Two of the study groups (twin pregnant animals and singleton pregnant
animals with Ad.VEGF-D injected into the gravid uterine artery) had only animal
each, making their results ineligible for any statistical assessment and logical
conclusion. Hence, data from all 5 animals has been presented together to get
statistically meaningful results. The statistical test used (two-way ANOVA)
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factors in not only the effect of the vector but also whether the uterine artery is
supplying a gravid or non-gravid horn.
I observed a significant reduction in the contractile response to
phenylephrine in the Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced vessels (Figure 3.48). The Emax and EC50 in the Ad.VEGF-D
transduced vessels were 144.0+4.64 and 2.89x10-6 respectively v/s 184.2+8.58
and 2.63x10-6 in the Ad.LacZ transduced vessels, n=5, p=0.002. There was no
significant difference in the magnitude of the KCl responses between the
Ad.VEGF-D and Ad.LacZ treated sides (18.45±4.87g v/s 17.63±4.34g
respectively, p=0.87).
Figure 3.48 – Contractility of pregnant Ad.VEGF-D and Ad.LacZ
transduced uterine arteries to L-phenylephrine 30-45 days after gene
transfer.
At mid-gestation, one uterine artery was injected with Ad.VEGF-D and the contra-lateral uterine
artery was injected with Ad.LacZ in pregnant animals (n=5). The second and third branches of the
main uterine arteries were harvested 30-45 days after injection, cut into 3mm ring segments and
analysed on an 8-chambered organ bath system. Concentration response curves to PE were
constructed for each vessel in quadruplicate. The contractility of the vessel is expressed as a
percentage of the response to KCl. PE produced concentration-dependent contractions, which
were of significantly lesser magnitude in Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced vessels. Error bars denote standard error of mean. * denotes p<0.005
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3.25.2 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep does not significantly change the
endothelium-dependent relaxation long-term
The uterine arteries from 5 mid-gestation pregnant sheep (described
above) were also examined for changes in endothelium-dependent relaxation to
bradykinin. Data from all 5 animals has again been presented together and
analysed using two-way ANOVA.
I observed no significant changes in the vascular relaxation between the
Ad.VEGF-D and Ad.LacZ transduced vessel segments (Figure 3.49). The Emax
and pD2 in the Ad.VEGF-D transduced vessels were 48.39+2.66 and 9.19+0.18
respectively v/s 43.92+2.99 and 9.12+0.22 respectively in the Ad.LacZ
transduced vessels, n=5, p=0.163.
Figure 3.49 - Endothelium-dependent relaxation of pregnant Ad.VEGF-D
and Ad.LacZ transduced uterine arteries to bradykinin 30-45 days after gene
transfer.
At mid-gestation, one uterine artery was injected with Ad.VEGF-D and the contra-lateral uterine
artery was injected with Ad.LacZ in pregnant sheep (n=5). The second and third branches of the
main uterine arteries were harvested 30-45 days after injection, cut into 3mm ring segments and
analysed on an 8-chambered organ bath system. Concentration response curves to BK were
constructed for each vessel in quadruplicate. The relaxation of the vessel is expressed as a
percentage of inhibition of PE-induced contraction. There was no significant difference in the
relaxation response between the Ad.VEGF-D and Ad.LacZ transduced vessels (statistical
significance assumed at p<0.05). Error bars denote standard error of mean.
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3.25.3 The endothelium dependent relaxation in the uterine
arteries of pregnant sheep transduced with Ad.VEGF-D long-
term is mediated via NO and EDHF
Similar to the short-term experiments described in section 3.22.3, the
relaxation response of long-term transduced uterine arteries was investigated in
the presence of different inhibitors of relaxation. Treatment with L-NAME
significantly reduced the relaxant effect to bradykinin in uterine artery segments
from both the Ad.VEGF-D and Ad.LacZ transduced vessels; there was no
differential response between the two kinds of vessels. Addition of NS-398 did
not result in any significant alterations in the relaxation response. Pre-treatment
with Apamin (in the presence of L-NAME and NS-398) resulted in a further
significant attenuation of the endothelium-dependent relaxation. The residual
relaxation that was resistant to the cumulative inhibition by all three inhibitors
was not significantly different between the Ad.VEGF-D and Ad.LacZ transduced
sides (Figure 3.50). Table 3.23 summarizes the results of the relaxation response
in the presence of different inhibitors.
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Figure 3.50(a) -The endothelium-dependent relaxation to bradykin in the
presence of different inhibitors of the relaxation pathway in pregnant sheep
uterine arteries, 30-45 days after Ad.VEGF-D or Ad.LacZ transduction.
The contribution of NO, PGI2 and EDHF on the relaxation response to BK were investigated in
vessels precontracted with PE. Cumulative relaxation curves of BK (10-11M to 10-6M) were
constructed under the following conditions: (1) control (no inhibitors); (2) in the presence of L-
NAME (300 µM); (3) in the presence of L-NAME and NS-398 (10 µM); (4) in the presence of L-
NAME, NS-398 and apamin (1 µM). Relaxation was expressed as a percentage of inhibition of
PE-induced contraction. The mean relaxation response of vessels from n=5 pregnant sheep was
calculated. Statistical significance was assumed at p<0.05. The BK relaxant effect was not
modified by NS-398 but reduced by L-NAME (p<0.05, n=5). The remaining endothelium-
dependent relaxation (Emax), that was resistant to NS-398 and NO synthase inhibition, was
significantly reduced by pretreatment with apamin in both Ad.VEGF-D and Ad.LacZ treated
arteries (P<0.05, n=5). There was no difference in the small amount of residual relaxation between
the Ad.VEGF-D and Ad.LacZ transduced vessels.
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Figure 3.50(b) - Partial contribution of NO-dependent and NO-independent
mechanisms to the endothelial-dependent relaxation
Values are the mean+SEM for the area under the curve (AUC) for BK-induced relaxation
(complete bar with positive SEM), the AUC for BK-induced relaxation following treatment with
L-NAME (NO-independent component, white bar), and the remaining AUC after BK with L-
NAME (NO-dependent component, black bar). No significant differences were observed in the
overall relaxation as well as NO-dependent and NO-independent relaxations between the treated
and control sides.
Table 3.23 - Emax in response to bradykinin in uterine arteries from pregnant
sheep transduced long-term with Ad.VEGF-D and Ad.LacZ contra-laterally,
in the presence of different inhibitors of endothelium-dependent relaxation.
At mid-gestation, one uterine artery was injected with Ad.VEGF-D and the contra-lateral uterine
artery was injected with Ad.LacZ in pregnant sheep. The second and third branches of the main
uterine artery were harvested 30-45 days after injection and analysed on an 8-chambered organ
bath system. Concentration response curves to BK were constructed for each vessel in the absence
and presence of different inhibitors of relaxation, namely, L-NAME, NS-398 and Apamin. The
relaxation of the vessel is expressed as a percentage of inhibition of PE-induced contraction. The p
value indicates the significance of the effect of individual inhibitors on the dose response curve.
Emax % (Mean+SEM)
Inhibitor Ad.VEGF-A165 transduced
side
Ad.LacZ trandsduced
side
p value
No inhibitor 48.39+2.66 43.92+2.99
L-NAME 37.13+4.30 32.38+4.08 p=0.05
L-NAME + NS-398 33.74+5.76 28.73+4.25 p=0.48
L-NAME + NS-398 +
Apamin
10.47+1.84 9.52+2.33 p<0.05
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In summary, these results show that local over-expression of VEGF-D in
the uterine arteries of pregnant sheep at mid-gestation results in a significant
reduction in vascular contractility long-term, but no significant difference in
relaxation compared to Ad.LacZ transduced vessels. The vascular relaxation
response to bradykinin is primarily mediated by NO and EDHF in both the
Ad.VEGF-D and Ad.LacZ infected uterine arteries. There is no significant
difference between the small amount of residual relaxation in the presence of
NOS, PGI2 and EDHF inhibitors, between the Ad.VEGF-D and Ad.LacZ
transduced vessels.
3.26 Local over-expression of VEGF-D in the uterine
arteries of pregnant sheep upregulates eNOS levels short-
term but not long-term
Protein extracts of uterine artery samples from short-term studies (4-7
days after vector injection) and long-term studies (30-45 days after vector
injection) were analysed for changes in eNOS levels by western blotting. I
observed an upregulation in the levels of eNOS in Ad.VEGF-D transduced uterine
arteries compared to Ad.LacZ transduced uterine arteries short-term (Figure 3.51
A). However, this difference was not sustained long-term. There was no
difference in eNOS levels between the Ad.VEGF-D and Ad.LacZ transduced
uterine arteries obtained from term pregnant sheep (Figure 3.51 B)
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Figure 3.51 - Representative western blot showing upregulation of eNOS in
Ad.VEGF-D transduced uterine arteries compared to Ad.LacZ transduced
uterine arteries (A) 5 days after vector administration but not (B) 30 days
after vector administration
Uterine arteries from pregnant sheep were injected with Ad.VEGF-D and Ad.LacZ contra-laterally
at mid-gestation, and harvested either (A) 5 days post-injection; or (B) 30 days post-injection.
Protein extracts from the uterine artery tissue samples were analysed by western blotting using a
mouse monoclonal antibody to eNOS. Results are representative of n=3 independent experiments
each for the short-term and long-term time points. GAPDH was used as a loading control. There
was an upregulation in eNOS 5 days after gene transfer in the Ad.VEGF-D transduced vessels
compared to Ad.LacZ transduced vessels (the protein extracts run in lanes 1 and 2 are from the
contra-lateral uterine arteries of one sheep, similarly for lanes 3 and 4; and lanes 5 and 6).
This result is similar to what was observed in the Ad.VEGF-A165
transduced ewes.
3.27 Ad.VEGF-D transduction of uterine arteries in the
pregnant sheep results in changes in endothelial cell
proliferation and adventitial neovascularization
On examination of H&E stained uterine artery sections from short-term
transduced animals, we observed a dramatic proliferation of cells in the
perivascular adventitia (Figure 3.52). We speculated that these may be endothelial
cells which had been stimulated to proliferate by VEGF-D, a known mitogen. In
order to confirm this, we carried out immunohistochemistry with two antibodies
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on the same section – (i) anti-BrdU, a cell proliferation marker and (ii) anti-vWF,
an endothelium marker.
Figure 3.52 – Endothelial cell proliferation in the perivascular adventitia of
uterine arteries transduced with Ad.VEGF-D, 5 days after gene transfer.
Maternal uterine artery samples collected at post-mortem examination (5 days after vector
injection) were analyzed for routine histology. Tissues were fixed in 4% paraformaldehyde
overnight, transferred to 70% ethanol and processed into paraffin. Sections were stained with
hematoxylin and eosin for morphological assessment. Sections from uterine arteries injected with
Ad.VEGF-D showed distinct nodules of proliferating endothelial cells (A and B), pointed at by
arrows. These were not observed in sections from Ad.LacZ injected uterine arteries (C and D).
Scale bar = 40 µm (A and C); 20 µm (B and D).
The protocol for anti-BrdU immunohistochemistry was adapted from
David AL, Ph D Thesis, 2005 while the protocol for anti-vWF staining had
previously been optimized in our lab. Both these protocols were combined
together into a double immunofluorescent staining protocol, as described by
(Hristova M et al., 2010).
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3.27.1 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep short-term increases the number of
proliferating endothelial cells but does not significantly
increase the number of adventitial blood vessels.
Uterine arteries from 4 singleton pregnant animals which had received a
BrdU infusion 48 hours before post-mortem (Table 3.13) were used for
immunohistochemical analysis of endothelial cell proliferation. The double-
stained slides were observed under a fluorescent microscope and the number of
proliferating endothelial cells (anti-BrdU positive and anti-vWF positive) was
counted in 10 randomly selected high powered fields in all branches of the uterine
arteries. As the sections had been stained with anti-vWF, we were also able to
count the number of adventitial blood vessels in order to assess
neovascularization (Figure 3.53). The counting was done by two observers who
were blinded to the vector injected into the uterine artery. The inter-observer and
intra-observer variability were 6.0% and 4.8% respectively.
Figure 3.53 – Representative images of proliferating endothelial cells in the
perivascular adventitia of uterine arteries injected with Ad.VEGF-D, 5 days
after gene transfer.
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(Continued from overleaf) Maternal uterine artery samples collected at post-mortem examination
were analyzed by double labeling using anti-vWF and anti-BrdU fluorescent
immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight, transferred to 70%
ethanol and processed into paraffin. Sections were stained with primary rabbit anti-human vWF
and monoclonal mouse anti-BrdU antibodies, using the avidin-biotin-peroxidase system; Texas
Red (red) and Alexafluor-488 (green) were used for visualization of the sites of antibody binding
respectively. The sections were observed under a confocal microscope using excitation lasers of
the appropriate wavelength. A and E represent the nuclei (blue) stained with DAPI, B and F
represent proliferating nuclei that have been stained positively with anti-BrdU, C and G represent
clusters of endothelial cells stained positively with anti-vWF. D and H are obtained by merging
images of all three stainings A green nucleus surrounded by red cytoplasm represents a
proliferating endothelial cell (white arrows). The number of proliferating endothelial cells was
found to be significantly greater in Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced ones. Scale bar = 40µm.
We observed a significant increase in the number of proliferating
endothelial cells in Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced vessels and untransduced vessels from control sheep (used for
endothelial cell studies) at the same gestational age (p=0.013, n=4, Two-way
ANOVA). The ANOVA showed that the vector type had a significant effect on
the number of proliferating endothelial cells but pregnancy status (gravid or non-
gravid uterine horn) did not (p=0.563). There was no significant difference in the
number of adventitial blood vessels (p=0.301, n=4, Two-way ANOVA) between
the Ad.VEGF-D transduced vessels and Ad.LacZ transduced vessels. The mean
number of proliferating endothelial cells and adventitial blood vessels in the
Ad.VEGF-D/Ad.LacZ transduced uterine arteries and untransduced vessels is
summarized in Table 3.24.
Table 3.24 – Mean number of proliferating endothelial cells and adventitial
blood vessels in the uterine arteries of pregnant sheep transduced with
Ad.VEGF-D or Ad.LacZ (4-7 days after gene transfer) and uninjected sheep.
Treatment administered Mean no. of proliferating
endothelial cells (+SEM)
Mean no. of adventitial
blood vessels (+SEM)
Ad.VEGF-D 22.83+6.03* 55.10+6.82
Ad.LacZ 9.16+2.68 50.41+5.51
No treatment 7.75+1.89 47.68+5.40
* indicates p<0.05
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Overall, this data demonstrates that over-expression of VEGF-D in the
uterine arteries of pregnant sheep at mid-gestation leads to a significant increase
in the number of proliferating endothelial cells in the perivascular adventitia 4-7
days after injection, though there is no significant effect on adventitial vessel
number.
3.27.2 Local over-expression of VEGF-D in the uterine arteries
of pregnant sheep long-term increases the number of
adventitial blood vessels but does not significantly increase the
number of proliferating endothelial cells.
The pregnant sheep used to study the long-term effects of VEGF-D over-
expression (n=5) were also administered an intravenous BrdU infusion 48 hours
before post-mortem examination. In one animal (UA38) which was pregnant with
twins, part of the uterine artery adventitia was lost during histology processing
and sections from this animal were therefore not used for vessel enumeration or
cell proliferation studies. We only used tissues from the other 4 singleton animals
(UA39, UA42, UA43 and UA45) for this study.
The double immunofluorescent stained sections (with anti-BrdU and anti-
vWF) were observed under a fluorescent microscope as before. Proliferating
endothelial cells and adventitial blood vessels were counted blinded in 10
randomly selected high-powered fields (Figure 3.54-3.56).
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Figure 3.54 – Representative images of proliferating endothelial cells and
adventitial blood vessels in the perivascular adventitia of uterine arteries
injected with Ad.VEGF-D, 30 days after gene transfer.
Maternal uterine artery samples collected at post-mortem examination were analyzed by double
labeling using anti-vWF and anti-BrdU fluorescent immunohistochemistry. Tissues were fixed in
4% paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained with primary rabbit anti-human vWF and monoclonal mouse anti-BrdU antibodies,
using the avidin-biotin-peroxidase system; Texas Red (red) and Alexafluor-488 (green) were used
for visualization of the sites of antibody binding respectively. The sections were observed under a
confocal microscope using excitation lasers of the appropriate wavelength. A represents the nuclei
(blue) stained with DAPI, B represents proliferating nuclei that have been stained positively with
anti-BrdU, C represents adventitial blood vessels stained positively with anti-vWF. D has been
obtained by merging images of all three stainings A green nucleus surrounded by red cytoplasm
(pointed at by white arrows) represents a proliferating endothelial cell. The number of adventitial
blood vessels was found to be significantly greater in Ad.VEGF-D transduced vessels compared to
Ad.LacZ transduced ones. Scale bar = 100µm.
C
DAPI BrdU vWF Merged
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Figure 3.55 – Representative images of proliferating endothelial cells and
adventitial blood vessels in the perivascular adventitia of uterine arteries
injected with Ad.VEGF-D, 30 days after gene transfer (high power).
Maternal uterine artery samples collected at post-mortem examination were analyzed by double
labeling using anti-vWF and anti-BrdU fluorescent immunohistochemistry. Tissues were fixed in
4% paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained with primary rabbit anti-human vWF and monoclonal mouse anti-BrdU antibodies,
using the avidin-biotin-peroxidase system; Texas Red (red) and Alexafluor-488 (green) were used
for visualization of the sites of antibody binding respectively. The sections were observed under a
confocal microscope using excitation lasers of the appropriate wavelength. A and E represent the
nuclei (blue) stained with DAPI, B and F represent proliferating nuclei that have been stained
positively with anti-BrdU, C and G represent adventitial blood vessels stained positively with anti-
vWF. D and H have been obtained by merging images of all three stainings A green nucleus
surrounded by red cytoplasm (pointed at by white arrows) represents a proliferating endothelial
cell. The number of adventitial blood vessels was found to be significantly greater in Ad.VEGF-D
transduced vessels compared to Ad.LacZ transduced ones. Scale bar = 40µm.
A B C D
E F G H
DAPI BrdU vWF Merged
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Figure 3.56 – Representative images of adventitial blood vessels in the
perivascular adventitia of uterine arteries injected with Ad.LacZ, 30 days
after gene transfer.
Maternal uterine artery samples collected at post-mortem examination were analyzed by double
labeling using anti-vWF and anti-BrdU fluorescent immunohistochemistry. Tissues were fixed in
4% paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained with primary rabbit anti-human vWF and monoclonal mouse anti-BrdU antibodies,
using the avidin-biotin-peroxidase system; Texas Red (red) and Alexafluor-488 (green) were used
for visualization of the sites of antibody binding respectively. The sections were observed under a
confocal microscope using excitation lasers of the appropriate wavelength. A represents the nuclei
(blue) stained with DAPI, B represents proliferating nuclei that have been stained positively with
anti-BrdU, C represents adventitial blood vessels stained positively with anti-vWF. D has been
obtained by merging images of all three stainings. Note the absence of any proliferating nuclei in
panel B in Ad.LacZ transduced vessels. Scale bar = 40µm.
We observed an increase in the number of proliferating endothelial cells in
the Ad.VEGF-D transduced vessels compared to Ad.LacZ transduced and
uninfected vessels, though this increase was not significant. (p=0.159, n=4, Two-
way ANOVA). However, the number of adventitial blood vessels was
significantly greater in the Ad.VEGF-D transduced vessels compared to Ad.LacZ
transduced and uninjected vessels (p=0.043, n=4, Two-way ANOVA). The
ANOVA showed that the vector type played a significant effect on the number of
adventitial blood vessels but whether the uterine artery was supplying a gravid or
non-gravid uterine horn did not (p=0.436). The mean number of proliferating
endothelial cells and adventitial blood vessels in the Ad.VEGF-D/Ad.LacZ
transduced uterine arteries and untransduced vessels is summarized in Table 3.25.
DAPI BrdU vWF Merged
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Table 3.25 – Mean number of proliferating endothelial cells and adventitial
blood vessels in the uterine arteries of pregnant sheep transduced with
Ad.VEGF-D or Ad.LacZ (30-45 days after gene transfer) and untransduced
vessels.
Treatment administered Mean no. of proliferating
endothelial cells (+SEM)
Mean no. of adventitial blood
vessels (+SEM)
Ad.VEGF-D 23.47+6.16 77.91+6.76*
Ad.LacZ 15.5+4.37 58.06+5.78
No treatment 7.8+3.74 54.33+7.26
* indicates p<0.05
In summary, this data demonstrates that in uterine arteries transduced
long-term with Ad.VEGF-D, there is a significant increase in the number of
adventitial blood vessels, but the number of proliferating endothelial cells is not
significantly different compared to controls.
3.28 Local administration of Ad.VEGF-D to the uterine
arteries of pregnant sheep leads to increased levels of
VEGF-D protein expression short-term
Protein extracts of uterine arteries, uterus and placentomes from 2 short-
term transduced, 2 long-term transduced and one control uninjected sheep were
used to detect levels of VEGF-D protein by ELISA. An ELISA to detect VEGF-
A165 protein in tissues from sheep which had been injected with Ad.VEGF-A165
has previously been optimized in our lab. We used the same protocol for the
VEGF-D ELISA, keeping all buffers (for protein extraction and plate washes) the
same.
To estimate the VEGF-D and total protein concentrations in the samples,
calibration curves to rhVEGF-D and bovine serum albumin (BSA) were
constructed respectively. These were unique to each assay, so a calibration was
performed for each experiment. Using these standard curves and optical density
measurements of the protein extracts, the concentration of the unknown sample
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could be determined using the ‘Linear Regression’ and ‘Interpolate Unknowns
from Standard’ feature in GraphPad Prism 5.0.
The values obtained for protein concentrations were used to calculate
equal amounts of protein to add to each well of the ELISA plate (0.3 μg in 200 μl 
buffer). Each protein extract needed to be appropriately diluted to achieve this.
The ELISA protocol was followed as per manufacturer’s instructions.
Table 3.26 summarizes the VEGF-D protein levels in each sample from
the short-term transduced sheep as determined by ELISA.
Table 3.26 – Amount of VEGF-D protein detected by ELISA in uterine
artery, uterus and placentome samples 4-7 days after injection of
Ad.VEGF-D or Ad.LacZ vectors
Sample VEGF-D protein concentration (pg/ml)
UA 34 left uterine artery (main) -
UA34 left uterine artery (1st branch) -
UA34 left uterine artery (2nd branch) -
UA34 left uterine artery (3rd branch) -
UA34 left uterus sample -
UA34 left placentome sample -
UA34 right uterine artery (main) -
UA34 right uterine artery (1st branch) 335.58
UA34 right uterine artery (2nd branch) 429.61
UA34 right uterine artery (3rd branch) 228.46
UA34 right uterus sample 358.16
UA34 right placentome sample -
UA 36 left uterine artery (main) 632.96
UA36 left uterine artery (1st branch) 577.53
UA36 left uterine artery (2nd branch) -
UA36 left uterine artery (3rd branch) 269.76
UA36 left uterus sample -
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UA36 left placentome sample -
UA36 right uterine artery (main) -
UA36 right uterine artery (1st branch) -
UA36 right uterine artery (2nd branch) -
UA36 right uterine artery (3rd branch) -
UA36 right uterus sample -
UA36 right placentome sample -
Samples in italics are from the side injected with Ad.VEGF-D. ‘-’ indicates a negative result.
Even though not all the expected branches had detectable levels of protein
in this assay, it shows that there was no VEGF-D protein detected in the uterine
artery branches contra-lateral to the side that had been injected with Ad.VEGF-D.
VEGF-D could also not be detected in maternal or fetal blood samples obtained at
vector injection and post-mortem (in short-term experiments).
For long-term transduced ewes and sham controls, human VEGF-D was
not detectable by ELISA in any uterine artery, uterine wall, or placentome
sample. Similarly, blood samples obtained from the ewes before vector injection
as well as samples obtained from the ewes and fetuses at post-mortem
examination did not show any detectable human VEGF-D expression using
ELISA.
In summary, VEGF-D protein was detectable by ELISA only in the
Ad.VEGF-D injected uterine arteries of the short-term transduced sheep. It was
not detectable in the Ad.LacZ injected uterine arteries. Likewise, it could also not
be detected in any sample from the long-term transduced or uninjected ewes.
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3.29 Local administration of Ad.VEGF-D to the uterine
arteries of pregnant sheep results in upregulation of
VEGFR-2 short-term
Uterine artery sections obtained from experimental animals injected with
Ad.VEGF-D/Ad.LacZ contra-laterally (both at the short-term and long-term time
points) were stained immunohistochemically for VEGFR-1, VEGFR-2 and
Neuropilin-1. The stained slides showed the presence of VEGFR-1, VEGFR-2
and Neuropilin-1 in the intimal and adventitial endothelia (lining small blood
vessels). Similar to our findings in the Ad.VEGF-A165 transduced sheep, I
observed an upregulation of VEGFR-2 in the uterine arteries transduced with
Ad.VEGF-D compared to Ad.LacZ, 4-7 days after injection (Figure 3.57). There
was no detectable difference in the level of any of the receptors at 1 month post-
injection between the Ad.VEGF-D and Ad.LacZ transduced vessels (data not
shown).
Figure 3.57 - Representative images of short-term Ad.VEGF-D/Ad.LacZ
transduced sheep uterine artery sections stained with an antibody to
VEGFR-2.
Maternal uterine artery samples from sheep injected with Ad.VEGF-D/Ad.LacZ at mid-gestation
were collected at post-mortem examination 4-7 days later. Tissues were fixed in 4%
paraformaldehyde overnight, transferred to 70% ethanol and processed into paraffin. Sections
were stained immunohistochemically with an antibody to VEGFR-2 at a concentration of 1:50,
using the avidin-biotin-peroxidase system; 3,3`-diaminobenzidine and a light haematoxylin
counter-stain were used as substrates for visualization. (C) is a negative control obtained by
omitting the primary antibody. Positive staining was observed around small blood vessels in the
perivascular adventitia of the uterine artery. We noted an upregulation of VEGFR-2 in the
Ad.VEGF-D transduced uterine artery segments compared to Ad.LacZ transduced ones. Scale bar
= 40 µm.
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3.30 Microscopic examination of tissues from Ad.VEGF-D
transduced sheep does not reveal any significant
pathology.
Maternal and fetal tissues collected at post-mortem examination (complete
list of samples in post-mortem sheet in Appendix) from Ad.VEGF-D transduced
sheep (n=3 short-term experiments and 3 long-term experiments) were stained
with H&E and observed microscopically under the supervision of Dr. Elizabeth
Benjamin.
The uterine arteries from all three short-term transduced sheep showed a
dramatic proliferation of cells in the perivascular adventitia of the Ad.VEGF-D
transduced segments relative to Ad.LacZ transduced segments (Figure 3.52). We
performed further staining with anti-BrdU and anti-vWF antibodies to confirm the
identity of these cells (Section 3.27), and found most of them to be proliferating
endothelial cells.
There were no inflammatory responses observed in the uterine arteries
from the short-term or long-term transduced sheep. Two sections of the maternal
heart from the short-term transduced sheep and one from the long-term
transduced sheep showed evidence of low-grade myocarditis, but this was
believed to be unrelated to the administration of the vector.
All other maternal and fetal tissues examined, including the liver had an
unremarkable histology.
3.31 Local administration of Ad.VEGF-D to the uterine
arteries of pregnant sheep does not lead to any
pathological haematological and biochemical changes.
Blood and serum samples were taken from experimental sheep (n=3) at
three different time points – vector injection, 1 week post-injection and post-
mortem. Fetal samples could only be collected at post-mortem. The samples were
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sent to the Clinical Diagnostics Lab, RVC Hawkshead for routine haematological
and biochemical analysis.
All maternal and fetal haematological and biochemical values examined
were within the normal range.
3.32 Analysis of maternal and fetal liver function tests after
Ad.VEGF-D injection does not indicate any liver pathology
The serum levels of liver enzymes were analysed to assess for functional
hepatocellular injury in 3 short-term transduced and 3 long-term transduced
animals. Maternal samples were collected from the former group before vector
injection and at post-mortem, while for the latter group, an additional time point –
1 week post injection was included. Fetal samples could only be obtained at post-
mortem.
The levels of maternal AST and GLDH were within the normal range in
all samples examined. Levels of fetal AST were below normal in one short-term
sheep UA19 (15 U/l; normal range 48-156 U/l) and both the fetuses of one long-
term twin pregnant sheep UA38 (14 U/l and 18 U/l). Abnormal levels of AST are
only a general indicator of hepatocellular injury in ruminants, with GLDH being
the most reliable indicator.
The levels of fetal GLDH were elevated in 2 short-term and 2 long-term
sheep. This is summarized in Table 3.27:-
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Table 3.27 – Levels of glutamate dehydrogenase (GLDH) in sheep fetuses at
post-mortem examination, after administration of Ad.VEGF-D to the
maternal uterine arteries.
GLDH levelsSheep
Number
Duration of
experiment
Number of
fetuses
1st fetus 2nd fetus
UA17 Short-term Twin 17.0 U/l 25.0 U/l
UA19 Short-term Singleton 24.0 U/l -
UA38 Long-term Twin 36.0 U/l 31.0 U/l
UA45 Long-term Singleton 31.0 U/l -
Short-term experiment = 4-7 days after gene transfer; long-term experiment = 30-45 days after
gene transfer; values indicated in red are above the normal range (<20U/l)
The normal range for GLDH in adult sheep is < 20 U/l. The GLDH levels
for fetal sheep are not very well known. In our study, fetal GLDH levels from
ewes which had only been injected with PBS were in the range of 39.0 – 54.0 U/l,
thus suggesting that the normal adult range cannot always be applied to fetal
sheep.
Bilirubin was not raised in any of the serum samples analysed. The levels
of alanine aminotransferase (ALT) were normal in all samples examined.
Overall, these results suggest that administration of Ad.VEGF-D to the
uterine arteries of pregnant ewes does not cause any clinically important changes
in the levels of maternal and fetal liver enzymes.
To conclude, the data presented in this section suggest that over-
expression of VEGF-D affects UABF, uterine artery vascular reactivity, eNOS
levels and adventitial neovascularization in a similar way to VEGF-A165.
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Discussion
The effects of local adenovirus-mediated over-expression of two members
of the VEGF gene family – VEGF-A165 and VEGF-D on the utero-placental
circulation of pregnant sheep have been explored in this chapter. The effects of
Ad.VEGF-A165 were only examined long term, at least 30 days after transduction
since data on the short term effect, 4 – 7 days after transduction, has been
previously published by our group (David AL et al., 2008). The effects of
Ad.VEGF-D have been studied both short-term and long-term.
3.33 Adenovirus-mediated over-expression of vegf in
uterine arteries results in a local upregulation of transgenic
vegf gene and protein short-term; however, in long-term
transduced vessels, only an upregulation of vegf mRNA
level is detectable.
In this thesis, VEGF (-A165 and -D) expression in maternal and fetal
samples was evaluated using a variety of techniques; at the mRNA level by RT-
PCR and at the protein level by ELISA and immunohistochemistry. Overall, it
was demonstrated that in short-term transduced vessels, VEGF expression was
upregulated at the protein level (both by ELISA and immunohistochemistry) and
at the transcriptional level (by RT-PCR) (David AL et al., 2008). In contrast, in
long-term transduced vessels, vegf upregulation was detectable only at the
transcriptional level, but not at the protein level.
Using ELISA for analysis of uterine artery, uterus and placentomes from
the short-term transduced animals, rhVEGF-D was primarily detected in the
uterine arteries that had been injected with Ad.VEGF-D. The contra-lateral
uterine artery (which had received Ad.LacZ) and all other samples were negative.
These findings are similar to the ELISA analysis of tissues from the short-term
transduced animals that were administered Ad.VEGF-A165 (David AL et al., 2008)
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in two important ways – (i) short-term expression of VEGF-D was restricted to
the uterine artery that had been injected with Ad.VEGF-D and (ii) there was no
expression of VEGF-D in the contra-lateral uterine artery (that had been injected
with Ad.LacZ). ELISA was unable to detect any VEGF-D (or VEGF-A165) in the
long-term transduced uterine arteries.
Immunohistochemical analysis for VEGF-A165 in the uterine arteries
showed specific staining of VEGF around the adventitial blood vessels on both
the Ad.VEGF-A165 and Ad.LacZ treated sides, though there was no difference in
the level of expression quantitatively between both the sides in long-term
transduced vessels. In our previously published short-term experiments, we noted
increased expression levels of VEGF in the adventitia of Ad.VEGF-A165
transduced uterine artery segments (David AL et al., 2008). A limitation of both
VEGF immunohistochemistry and ELISA is that the antibody is not able to
discriminate between endogenous and transgenic VEGF. I speculate that the
positive staining was due to endogenous VEGF while the lack of any differential
staining between both the sides was on account of low levels (or absence) of
transgenic VEGF being expressed long-term
Vegf-A165 expression at the messenger RNA level was investigated in a
number of maternal and fetal tissues by RT-PCR. The advantage of this technique
over protein/antigen analysis is that the primers can be customized to span the
vector-transgene boundary, thus enabling the amplification of only adenoviral
expressed vegf. Using this method, the first round RT-PCR was negative in all
maternal and fetal tissues sampled 30 days after gene transfer including the
uterine arteries that had been transduced with Ad.VEGF-A165. In order to make
the technique more sensitive, second round PCR was performed using a semi-
nested approach. This yielded a positive band only in the Ad.VEGF-A165
transduced vessels, but not in any other tissue. A similar result was obtained in
short-term transduced vessels, sampled 4-5 days after gene transfer, wherein a
positive band was only present in the Ad.VEGF-A165 transduced uterine arteries.
However, an important difference is that a second-round amplification step was
not required to detect transgene expression in the short-term samples, as the first
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round was sensitive enough to detect adenoviral expressed vegf, suggesting higher
levels of VEGF expression at the short term time point. This is to be expected,
given the short term nature of expression mediated by adenovirus vectors.
It is of note that the technique of RT-PCR is based on the principle of
reverse transcription of mRNA to cDNA, which then gets amplified in a PCR.
This means that only actively transcribed genes can be detected by RT-PCR.
During the toxicology studies conducted by Ark Therapeutics Ltd. for another
adenoviral gene therapy candidate (Trinam), simple PCR detected the presence of
viral DNA (and transgene) in the liver and spleen of pigs a few days after intra-
vascular administration. However, RT-PCR was not able to detect any expression
in these tissues. It was hypothesized that these viral particles were in a quiescent
state, and may not have infected any cells so that they were not actively
transcribing (Tim Farries, Ark Therapeutics Ltd., personal communication). This
highlights the importance of conducting both PCR and RT-PCR to detect vector
spread and vector expression respectively, in maternal and fetal tissues.
Knowledge of global distribution of the vector is important for safety assessment,
as even quiescent viral particles could mount a strong immune and inflammatory
response. These PCR experiments are currently being performed in collaboration
with Ark Therapeutics Ltd.
Notably, we were not able to detect any transgene expression in the
maternal liver either short-term or long-term. Administration of viral vectors in
rodents inevitably leads to strong transgenic expression in the liver, possibly
because of the very high density of Coxsackievirus Adenovirus Receptors in this
organ. I have observed this in guinea pig studies described elsewhere in this
thesis. These varying results may be due to the different animal models being
studied. Alternatively the injection technique used in combination with occlusion,
may be restricting the virus primarily to the utero-placental vasculature.
In summary, I have shown that within the first week of vector injection,
VEGF (-A165/-D) levels are upregulated in the Ad.VEGF transduced uterine
arteries as determined by ELISA and immunohistochemistry. However, there is
no detectable difference in VEGF protein levels when analysed at more than a
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month after injection. In the long-term transduced vessels, any differential
expression of the transgenic vegf between Ad.VEGF-A165 and Ad.LacZ
transduced segments is only detectable at the transcriptional level by semi-nested
RT-PCR.
3.34 Adenovirus mediated over-expression of VEGF in the
uterine arteries of pregnant sheep results in an
upregulation of VEGFR-2 short-term, but this difference is
not sustained long-term
Using immunohistochemistry and western blotting techniques, expression
of the VEGF receptors VEGFR-1, VEGFR-2 and Neuropilin-1 was evaluated in
Ad.VEGF-A165/Ad.VEGF-D/Ad.LacZ transduced uterine arteries short-term and
long-term. Immunohistochemistry showed presence of all three receptors in the
endothelium of the uterine artery lumen and adventitial blood vessels, whether
transduced with Ad.VEGF-A165/Ad.VEGF-D/Ad.LacZ.
I observed an upregulation in the level of only VEGFR-2 in short term
Ad.VEGF-A165 and Ad.VEGF-D transduced vessels (compared to Ad.LacZ
transduced vessels). However, there were no detectable differences in the level of
receptor expression (by immunohistochemistry) between the Ad.VEGF-A165,
Ad.VEGF-D and Ad.LacZ injected vessels long-term. The lack of any detectable
difference after long term adenovirus mediated gene transfer is likely to be
because the analysis was performed at a time-point when adenovirus-mediated
VEGF expression had decreased.
Exogenous VEGF treatment has been shown to upregulate levels of
VEGFR-1 mRNA in HUVECs from 1-24 hours after treatment (Barleon B et al.,
1997a); and also levels of VEGFR-2 in cultures of mouse cerebral slices from 6-
24 hours after treatment (Kremer C et al., 1997). Later time points were not
analysed in these studies.
The fact that I observed an upregulation of VEGFR-2 levels in the short-
term transduced vessels (coinciding with the peak of VEGF expression) is not
surprising. The pattern of VEGFR-2 expression has been shown to resemble that
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of VEGF expression very closely. Both are upregulated during developmental
angiogenesis, downregulated in adult tissue and upregulated in adult pathological
conditions like malignant tumours. It is therefore possible that a common
mechanism may regulate the expression of VEGF and VEGFR-2 (Kremer C et al.,
1997;Plate KH et al., 1993). Reduced VEGFR-2 expression is a characteristic of
atherosclerotic arteries, and may be associated with the development of
vasculopathies and their complications (Belgore F et al., 2004). It has also been
demonstrated that there is a significant reduction in the maternal serum levels of
soluble (s) VEGFR-2 in women whose pregnancies are complicated by FGR
(Wallner W et al., 2007). As VEGFR-2 is primarily derived from the vascular
endothelial cells, it is possible that the enhanced endothelial expression of
VEGFR-2 observed in this study may be of benefit in an FGR situation.
I did not observe any change in the level of VEGFR-1 and Neuropilin-1 in
the short-term or long-term transduced vessels. Although VEGFR-1 and VEGFR-
2 have been reported in ovine uterine artery endothelial cells (Grummer MA et
al., 2009), I am the first to document the presence of Neuropilin-1 in the ovine
uterine artery.
It is important to note that VEGFR-1 functions primarily as a decoy
receptor of VEGF, rendering it less available to VEGFR-2 to prevent excessive
VEGF signaling. Neuropilin has no known signaling activity alone, but acts as a
co-receptor that potentiates VEGF cell signaling through VEGFR-2. VEGFR-2 is
believed to be the major signaling receptor for VEGF, mediating most of its
biological activity. Its upregulation in the short-term transduced tissue provides
evidence of enhanced VEGF signaling and a possible explanation for the changes
in endothelial cell proliferation, vasodilatation, eNOS upregulation and UABF
that were observed in this study.
Western blotting is likely to be a more informative and reliable technique
than immunohistochemistry to detect any differences in the levels of the receptors
quantitatively. However, our western blot analysis did not yield any conclusive
results – either there were multiple bands and it was impossible to correctly
identify the VEGFR band, or there was no band at all. Previously published work
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has identified specific antibodies which cross-react with sheep VEGFR-1 and
VEGFR-2 (Grummer MA et al., 2009), but all these studies were carried out on
sheep endothelial cells rather than intact tissue. We tried these and a few other
antibodies on protein extracts from intact uterine artery tissue, both short-term and
long-term, but had no success.
In summary, I have shown the presence of all three receptors – VEGFR-1,
VEGFR-2 and Neuropilin-1 in the uterine arteries of pregnant sheep by
immunohistochemistry. VEGFR-2, but not VEGFR-1 or Neuropilin-1, is
upregulated in the short-term transduced uterine arteries in response to VEGF-
A165 and VEGF-D over-expression. However, there is no difference in the levels
of either of the VEGF receptors in the long-term transduced uterine arteries.
3.35 Adenovirus mediated gene transfer of VEGF to the
uterine arteries of mid-gestation pregnant sheep leads to
long-term changes in uterine blood flow
In this study we showed a statistically significant increase in UABF
apparent as early as 7 days after Ad.VEGF-A165 injection, and significantly
different at 28 days post-injection at which point the mean maximum increase in
UABF from baseline was 37% compared to 20% on the Ad.LacZ injected side. A
similar trend was observed in the Ad.VEGF-D injected ewes, although
significance was not demonstrated within the limited number of experimental
animals.
This observation is similar to our previously published finding of a
significant increase in utero-placental perfusion as measured by Doppler
sonography, seen 4-7 days after delivery of Ad.VEGF-A165 into the uterine
arteries of mid-gestation pregnant ewes. However, the importance of this new
result as compared to the previously published short term data is that the increase
in blood flow is maintained over at least 4 weeks, a critical finding that implies a
possible therapeutic potential for our intervention. Importantly, the use of the
‘gold standard’ transit time flow probes, instead of Doppler ultrasonography
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(David AL et al., 2008), provides a far more reliable and accurate estimate of the
true increase in UABF (Abi-Nader KN et al., 2010), and thus, unequivocally
confirms an effect for local over-expression of VEGF-A165 on UABF.
Perivascular transit-time technology, which uses piezoelectric transducers
positioned around a vessel during surgery, is considered a highly accurate method
for volume blood flow estimation and has been already evaluated in vitro (Lundell
A et al., 1993) and in vivo (Sokol GM et al., 1996). On the contrary, estimation of
uterine artery blood flow by colour Doppler is subjective and prone to large
errors. Although Doppler readings correlate well with those obtained using
transit-time flow probes in mid-gestation pregnant sheep (Acharya G et al., 2007),
use of Doppler derived blood volume flow data is too inaccurate in this kind of
study, where relatively minor differences in blood flow may be of significance.
For volume blood flow estimation, colour Doppler requires the use of
pulsed-wave Doppler (an ultrasound imaging technique that can detect moving
liquids). For accurate velocity measurements, it is essential that the pulsed-wave
Doppler insonation angle should be as close to zero as possible because angles of
insonation less than 30° will underestimate the maximal velocity (Palmer SK et
al., 1992) by less than 15%, while large insonation angles can induce substantial
errors in the measurement of maximal velocity (Dickerson KS et al., 1993).
Factors that can limit the accuracy of pulsed-wave Doppler in estimating blood
velocity also include nonlaminar flow, vessel shape, and estimation of mean
velocity (Taylor KJ and Holland S, 1990). In the sheep the error in blood volume
flow data changes as pregnancy advances. The uterine artery in mid-gestation
pregnant sheep follows a relatively tortuous pathway (compared to late gestation)
and corrections in the angle of insonation that are required for Doppler derived
blood flow measurements, would not be adequate enough to accurately reflect the
direction of blood flow.
There are also inaccuracies inherent in the pulsed-wave Doppler technique
because these systems are designed to achieve high spatial resolution rather than
uniformity of insonation. There is also overweighting of the higher velocity
components at the center of the vessel, resulting in flow overestimation (Ho SS et
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al., 2002). When measuring vessel diameter, the blooming effect is common to
both color and power Doppler, which results in overwriting of the vessel walls in
an attempt to maximize vessel filling. Errors in measuring vessel diameter have a
large impact on the calculated uterine artery blood flow since the measurement is
squared when calculating the vessel area A = π(D/2)2. In the sheep, our group
observed a larger relative error in vessel diameter estimation associated with the
smaller vessel diameter at mid-gestation when compared to late gestation
measurements (Abi-Nader KN et al., 2010).
Another important advancement in our method of uterine blood flow
monitoring was the use of a telemetric set-up. While transit-time flow probes have
been used previously to measure uterine blood flow in sheep (Wallace JM et al.,
2008;Miller SL et al., 2009), they involved connecting the sheep by cables to an
acquisition set-up. In order to do so, the sheep had to be restrained to a small pen
or cart. Our telemetric set-up for uterine blood flow monitoring allows the
pregnant ewe unrestricted movement in her pen. Thus, the animal is relatively
unstressed during monitoring, which is an important cornerstone of the principle
of 3Rs – Reduction, Refinement and Replacement, advocated by the UK Home
Office for experimental work with animals (Robinson V, 2005).
Uterine blood flow is known to be highly variable between animals. To
allow for this inter-animal variation, it is common practice to compare post-
treatment uterine blood flow data with a pre-treatment baseline (Miller SL et al.,
1999;Miller SL et al., 2009). In this study, baseline blood flow values were
acquired for 3 days before vector injection. The post-injection uterine blood flow
measurements were then compared with the pre-injection baseline to obtain a
value for percentage change in blood flow from baseline. Thus, using an objective
and reliable method of haemodynamic monitoring, we have shown a significant
increase in uterine blood flow for at least 4 weeks following Ad.VEGF-A165
injection.
We have shown an increase in blood flow in both gravid and non-gravid
uterine arteries, though the maximum increase was seen when Ad.VEGF-A165 was
injected into the non-gravid uterine artery in singleton pregnancies. This might be
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explained by the fact that non-gravid uterine arteries have undergone less vascular
remodeling than gravid vessels in animals that have a bicornuate uterus, such as
sheep and rodents (Osol G and Mandala M, 2009), which may make them more
susceptible to the effects of VEGF over-expression. During normal pregnancy, the
utero-placental vascular bed is significantly developed and the vascular channels
are dilated to facilitate the maximal supply of substrates and oxygen to the
developing fetus (Barry JS and Anthony RV, 2008). In cases of FGR or PET
where utero-placental perfusion is impaired, it is possible that VEGF expression
may provide an even greater enhancement of perfusion than is seen here.
The drop in UABF observed during the first few days after vector
injection was limited to approximately 10% of the pre-injection baseline UABF,
and may be due to the vessel occlusion during injection and subsequent trauma to
the vessel itself. UABF recovered in all treated sheep by days 5-7 after vector
injection. However, this is still a point of concern if our protocol is to be applied
in the clinical setting, where growth restricted fetuses are frequently hypoxemic
(Akalin-Sel T et al., 1994). In the last trimester of pregnancy, fetal PO2 as
determined by sampling blood from the umbilical vein under ultrasound guidance,
has been found to be significantly lower in growth-restricted fetuses
(median=2.70 kPa; range=1.71-3.51 kPa) than control fetuses (median=6.10 kPa;
range 4.47 – 7.58 kPa) (Nicolini U et al., 1990). A minimally invasive technique
such as trans-femoral uterine artery catheterization (Delotte J et al., 2009) would
reduce uterine artery trauma and post-injection constriction, and has been used to
inject the uterine arteries for embolization of fibroids in clinical practice. The
procedure itself, and in particular the temporary occlusion of the lumen, could
reduce the oxygen supply to the fetus, particularly if the other uterine artery
supply was significantly compromised. Hypoxaemic FGR fetuses may have little
reserve to tolerate further compromise of the uteroplacental circulation during the
catheterisation procedure. This could result in immediate death of the fetus, or
brain damage. On the other hand, they may be more tolerant of a temporary
interruption to the uteroplacental circulation, since they are already tolerant to it.
Data from sheep studies (Skillman CA et al., 1985) suggest that the uterus of the
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pregnant sheep is perfused to sufficient excess to protect the fetus during short-
term reductions of less that 50% UABF. In addition during the surgeries described
in this thesis, the operators did not observe any deleterious effects on fetal blood
pressure and heart rate following short-term occlusion of the uterine artery.
Although there is a risk of profound fetal hypoxaemia or even death during the
procedure, with pre-oxygenation of the mother, and sonographic fetal heart rate
monitoring via the mother’s abdomen this risk will be minimised. The alternative
option, of not treating the fetus, carries a high risk of intra-uterine death; therefore
the risk is considered acceptable. Further experiments to determine the optimal
vector dose and whether extra-luminal administration of vector results in equally
efficient gene delivery are required.
Some of the other therapeutic candidates being investigated with the aim
of reversing FGR include sildenafil citrate, an inhibitor of type 5 phospho-
diesterase (PDE5). This enzyme is responsible for the degradation of cGMP to
guanosine monophosphate. Administration of sildenafil delays the breakdown of
cGMP and increases vasodilatation. In myometrial arteries taken at Caesarean
delivery from women whose pregnancies were complicated by FGR, sildenafil
citrate reduced vasoconstriction and enhanced vasodilatation (Wareing M et al.,
2005). This and other studies on utero-placental vascular reactivity in human
pregnancy often employ myometrial arteries as a surrogate for investigations on
uterine arteries (Ashworth JR et al., 1996;Robinson NJ et al., 2008), because of
the extreme difficulty in obtaining the latter tissue. For instance, at University
College London Hospital, a tertiary referral centre with a high throughput of
deliveries (approximately 5500 per annum), there are not more than 1-2 cases of
uterine artery removal in pregnant women in a year (David AL, personal
communication). These primarily occur in cases of cervical cancer during
pregnancy or of massive obstetric haemorrhage.
Miller et al examined the effects of intra-venous administration of
sildenafil citrate on utero-placental circulation in normal pregnant and FGR
pregnant sheep at 0.7 gestation (110-115 days). The FGR was induced by single
umbilical artery ligation (SUAL) which is known to reduce uteroplacental
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perfusion and produce fetal hypoxemia, acidemia and asymmetric growth
restriction as observed in severe human FGR secondary to placental insufficiency.
SUAL carried out at 105-110 days of gestation (0.7 gestation) reduces fetal body
weight by about 20% compared with control animals (Miller SL et al., 2007).
Contrary to expectation, sildenafil citrate infusion reduced uterine blood flow in
all animals, whether normal or FGR, and this was associated with a significant
deterioration in fetal well-being as evidenced by decreased fetal oxygenation,
increased fetal CO2 (as determined by analysis of fetal blood samples collected at
specific time-points after infusion), hypotension and tachycardia (Miller SL et al.,
2009). The unexpected poor outcome is hypothesized to result from the
vasodilatory effect of the sildenafil citrate on the maternal vasculature
systemically, which results in a “steal” of blood flow from the utero-placental
circulation to the systemic vascular circuit. Even in normal pregnant sheep where
there is no reduction in UABF and yet, infused sildenafil citrate had a detrimental
effect on fetal growth and wellbeing. It is possible that this effect is likely to be
exacerbated in a pregnancy where there is already reduced UABF.
In yet another pre-clinical study, it was demonstrated that site-specific
placental gene transfer of Angiopoietin-2 using an adenoviral vector resulted in a
significant increase in fetal weights in normal pregnant mice, compared to control
untreated mice. 1x108 pfu of the recombinant adenoviral vector was injected into
the placentae of pregnant mice at E14, and the fetuses were harvested at day 17 of
gestation (Katz AB et al., 2009). Vector spread and expression in this study was
not evaluated by PCR or RT-PCR, and is an important parameter to consider for
clinical translation of the therapy. Moreover, other transgenes evaluated in the
same study (Ang-1, bFGF, hepatocyte growth factor, IGF-1, PlGF, PDGF-B and
VEGF-A121) had no effect on fetal weight.
Eremia SC et al demonstrated that intra-amniotic IGF supplementation
improved growth rate in ovine fetuses with FGR caused by placental embolization
(Eremia SC et al., 2007). The IGF-1 was administered as an intra-amniotic
injection three times/week (dose of each injection = 120 µg). Treatment was
commenced from day 100 of gestation, and post-mortem examination was
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performed 28 days later. The IGF-1 treatment improved fetal weight at post-
mortem examination to values intermediate between control (not growth-
restricted) and saline-treated FGR fetuses. The liver weight, perirenal fat weight
and carcass growth were also significantly improved.
Even though all these studies appear to hold great promise for the
treatment of FGR, it is unlikely for them to be translated to the clinic. This is
primarily because their delivery requires chronic catheterization of the amniotic
cavity, which is likely to lead to infection and preterm birth with its inherent
morbidity and mortality. Furthermore, it is important to note that in human
pregnancy characterized by utero-placental insufficiency, fetal growth is retarded
by both nutrient and oxygen deprivation. While growth factor treatment may
enhance metabolism of nutrients, oxygen would still remain a limiting factor. The
importance of oxygen for prenatal growth has been demonstrated by Dino
Giussani in the chick model (Giussani DA et al., 2007). Hence, it is likely that a
therapy that reverses the utero-placental insufficiency and requires only a single
intervention rather than a chronically invasive procedure is likely to hold more
potential for translation to the clinic. The finding that the increase in uterine blood
flow was sustained through pregnancy in our studies is therefore of critical
importance.
In our experiments, we noted a significant increase in singleton fetal
weight compared to data from historical controls using the same sheep breed.
Even though encouraging at first sight, the results could have been affected by
other factors such as differences in fetal growth year by year for example. Further
studies on the effects of Ad.VEGF-A165 gene therapy on fetal growth and birth
weight in cohorts of sheep are currently ongoing. A single measure of fetal weight
at post-mortem is a much less sensitive measure of fetal growth than repeated,
direct and precise measures of growth rate. It is for this reason that we are
measuring uterine blood flow, growth velocity (by serial weekly ultrasound
scanning), birth weight, neonatal growth and development in an FGR sheep
model, induced by maternal over-nourishment (Wallace JM et al., 2008).
Preliminary data from these studies have indicated a significantly increased fetal
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and neonatal growth velocity in FGR lambs whose mothers received uterine
artery injection of Ad.VEGF-A165 bilaterally at mid-gestation compared with
injection of Ad.LacZ vector (Carr D and David AL, personal communication).
Individuals born after growth restricted pregnancies have an increased pre-
disposition to cardiovascular disorders and neurological damage. It is therefore
important to design experiments to evaluate whether Ad.VEGF-A165 gene therapy
is only limited to producing bigger individuals, or if it can also reverse the
adverse developmental programming associated with FGR. This information
would be best explored in a clinical trial, owing to the lack of availability of ideal
animal models.
In summary, we have shown that adenovirus-mediated over-expression of
VEGF-A165 in the uterine arteries of pregnant sheep leads to a sustained and
significant increase in utero-placental perfusion for at least 4 weeks post-
injection. This is associated with an improvement in fetal weight.
3.36 Local over-expression of VEGF in the uterine arteries
of mid-gestation pregnant sheep leads to changes in
vascular reactivity
Changes in uterine artery vascular reactivity were seen in response to
VEGF over-expression both short-term and long-term. Vessels transduced with
Ad.VEGF-D and examined 5-7 days later were significantly less contractile to
phenylephrine and relaxed significantly more to bradykinin than control vessels
transduced with Ad.LacZ vector. In previously published data (David AL et al.,
2008), a similar effect was observed with Ad.VEGF-A165 at the short term time
point after vector administration. However, vessels examined over 30 days later
(long-term), irrespective of whether transduced with Ad.VEGF-A165 or
Ad.VEGF-D, only showed a diminished contractile response, but no significant
difference in relaxation response when compared to Ad.LacZ transduced vessels.
While the long-term effects of Ad.VEGF-A165 and Ad.VEGF-D on
vascular contractility and relaxation were similar, VEGF-D appeared to have a
more profound effect on relaxation in the short-term transduced vessels, as can be
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noted in Table 3.18 and 3.19. The pD2 in response to bradykinin between the
Ad.VEGF-D and Ad.LacZ transduced sides differed by an order of magnitude.
VEGF stimulates endothelial cells to produce nitric oxide (Laitinen M et
al., 1997;van der Zee R et al., 1997) and PGI2 (Wheeler-Jones C et al., 1997) both
of which molecules are involved in vascular relaxation. VEGF-D has also been
shown to stimulate eNOS phosphorylation at Ser1177 (Jia H et al., 2004). Hence,
the effects of VEGF over-expression described above are not unexpected. The
lack of any detectable difference in the long-term relaxation response to
bradykinin could be explained by the fact that at term, the utero-placental blood
vessels are maximally dilated (Lumbers ER, 1997); hence, VEGF over-expression
may be unable to further enhance the relaxation of uterine arteries. It is possible
that over-expression of VEGF may enhance vasodilatation in term-pregnant
vessels from an FGR pregnancy characterized by utero-placental vascular
insufficiency, impaired vasodilatation and endothelial dysfunction, wherein there
exists the potential of enhancing vascular relaxation responses.
When term pregnant vessels were contracted with phenylephrine in the
presence of L-NAME, both Ad.VEGF-A165 and Ad.LacZ transduced vessels
demonstrated an enhancement of contractile response. This increase in
contractility was however significant only in the Ad.VEGF-A165 transduced
vessels and not in the Ad.LacZ transduced vessels. I also observed that with NOS
blockade, the Emax in the Ad.VEGF-A165 and Ad.LacZ transduced vessels was
similar. This supports the concept that NO is a key mediator in the differential
contractile response to phenylephrine between the Ad.VEGF-A165 and Ad.LacZ
transduced vessels.
The vascular relaxation responses of the uterine arteries were also studied
in the presence of different inhibitors of relaxation – L-NAME, Indomethacin/NS-
398 and Apamin. I observed that L-NAME, and Apamin (in the presence of NS-
398 and L-NAME), significantly attenuated the relaxation response, while PGI2
inhibitors did not play any significant role. While previous studies have
demonstrated that PGI2 plays an important role in the relaxation of pregnant ovine
uterine arteries compared to uterine arteries from non-pregnant ewes (Magness
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RR and Rosenfeld CR, 1993;Magness RR et al., 1996), our experiments are
different because we have only examined uterine arteries from pregnant ewes, that
were transduced with adenovirus vectors. PGI2 is a known to be an important
vasodilator in several vascular beds, which include the utero-placental, pulmonary
and cerebral circulations (reviewed by Moncada S and Vane JR, 1978). However,
the results presented in this thesis suggest that in response to VEGF over-
expression in pregnant ovine uterine arteries, the contributions of NO and EDHF
towards vascular relaxation are more important than PGI2.
When the vascular response of vessel segments was examined after pre-
treatment with Apamin alone, there was no change in the relaxation response.
Apamin is an inhibitor of small conductance Ca2+ activated K+ channels and
inhibits the actions of EDHF. While the identity of EDHF remains a topic of
much debate, it is largely accepted that EDHF is a mediator of endothelium-
dependent relaxation in the presence of NOS and COX inhibitors (Feletou M and
Vanhoutte PM, 2009). It is proposed that the continuous generation of NO by
endothelial cells counteracts the generation of EDHF and/or the mechanism of its
action, and that EDHF acts as a backup endothelium-dependent vasodilator when
NO production is compromised. Exogenously applied NO, at concentrations
comparable to those achieved after endothelial stimulation with different agonists,
attenuated EDHF-mediated relaxation responses in rabbit carotid and porcine
coronary arteries. This inhibitory effect most likely resulted from an interference
with the synthesis and/or release of EDHF rather than its mechanism of action
(Bauersachs J et al., 1996). In concurrence with these studies in other vascular
beds, our results too indicate that in the absence of NOS blockade, EDHF does
not play any significant contribution to the endothelium dependent relaxation.
The importance of EDHF-mediated relaxation in the utero-placental vascular bed
was demonstrated by Kenny LC et al (2002). The relative contributions of NO,
PGI2 and EDHF were investigated in myometrial blood vessels from non-
pregnant, pregnant and PET women, by using inhibitors of all three alone and in
combination. The non-pregnant and PET vessels showed minimal residual
relaxation in the presence of L-NAME, suggesting that NO is the prinicipal
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mediator of endothelium dependent relaxation in these vessels. COX and EDHF
inhibitors had no effect on relaxation. On the contrary, normal pregnant vessels
were able to compensate and relax via either an NO or EDHF dependent
mechanism. Hence, normal pregnancy is associated with the development of
parallel EDHF and NO pathways in the myometrial bed, ensuring that if one of
the pathways is malfunctional, there is a compensatory back-up mechanism in
place. This ‘back-up’ system is lacking in PET pregnancy, with the endothelium-
dependent relaxation solely being mediated via NO.
The residual relaxation that remained after cumulative inhibition with
inhibitors of all three relaxation pathways was significantly greater in the vessels
transduced short-term with Ad.VEGF-A165 or Ad.VEGF-D (compared to
Ad.LacZ). However, in the long-term transduced vessels, there was no significant
difference in the small amount of residual relaxation that remained after NOS,
COX and EDHF inhibition between the Ad.VEGF and Ad.LacZ transduced sides.
It is possible that VEGF over-expression is activating an as yet unknown pathway
of relaxation short-term, and this effect is not sustained long-term when transgene
expression is on the decline.
Previous studies investigating the effects of pregnancy on uterine artery
vascular reactivity found that pregnancy brings about a reduction in contractility
and increase in relaxation in ovine uterine arteries (Xiao D et al., 1999). These
alterations are primarily NO-dependent. Quantitative western blotting showed that
eNOS protein expression in term pregnant sheep UAECs (harvested at ~140 days
gestational age) was increased to 197% of non-pregnant values.
An important strength of our study design is that uterine arteries were
injected with Ad.VEGF and Ad.LacZ contra-laterally and their vascular reactivity
was compared within the same animal. This controlled for inter-animal variation
on account of factors such as maternal weight, age, parity, etc. As discussed
above, transgenic vegf expression was only detectable in the uterine arteries that
had been injected with Ad.VEGF, and never in the contra-lateral Ad.LacZ
injected uterine arteries, thereby validating our findings. In singleton pregnancies,
there was the obvious issue of one vessel supplying a gravid horn while the other
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supplying a non-gravid horn. However, two-way ANOVA analysis allowed for
this factor while determining the relative contribution of the different vectors
used, on the vascular response.
The most commonly used agonist to study endothelium-dependent
relaxation in vascular beds is acetylcholine (ACh). We used bradykinin for our
experiments however, as stimulation with ACh had no relaxant effect on ovine
uterine arteries. Other groups working on pregnant ovine uterine arteries obtained
similar results, and it is believed that these vessels lack muscarinic receptors
(Xiao D et al., 2001). In this respect, the sheep uterine artery differs from the
human uterine artery, as the latter has been shown to relax in response to ACh
stimulation (Jovanovic A et al., 1994).
Though sheep and human pregnancy are quite different from each other,
the extent of increase in utero-placental perfusion, changes in uterine artery
dimensions and vascular reactivity in pregnancy are similar in both species.
During the latter half of gestation, uterine blood flow increases two and a half
times in humans (from 0.3 to 0.8 L/min) while in sheep, this increase is three fold
(0.4 to 1.2 L/min) (Konje JC et al., 2003;Meschia G, 1984). This is concomitant
with an increase in the supply of substrates and oxygen to the conceptus, failure
of which manifests as asymmetric FGR. The rates of oxygen and glucose
consumption in both near-term sheep and human fetuses are also similar, and
sheep are considered an ideal animal model for human reproductive physiology
(Barry JS and Anthony RV, 2008). I therefore believe that the magnitude of the
responses observed in ovine vessels would be reproducible and similar in the
human clinical scenario as well.
No difference was observed in the vascular reactivity of the umbilical
vessels between the Ad.VEGF and Ad.LacZ sides. The sheep placenta is
epitheliochorial and there are 6 maternal-fetal layers which would need to be
transgressed to reach the umbilical circulation from the maternal circulation,
compared to only a single trophoblastic layer in late human gestation. I thus
believe that the adenoviral vector or any VEGF protein released into the uterine
circulation in sheep is unable to cross the placenta and influence the umbilical
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circulation. In humans, the placenta has a high density of CAR that are capable of
sequestering adenovirus. CAR was found to be continuously expressed in
invasive cytotrophoblast (fetal side) but not in syncytiotrophoblast (outermost
fetal component), thus rendering the syncytiotrophoblast resistant to adenoviral
infection and limiting transplacental transmission (Koi H et al., 2001).
Nevertheless, in human pregnancy, limited amounts of VEGF protein may reach
the umbilical circulation and have therapeutic effects on umbilical vascular
reactivity, which may be of potential benefit in FGR.
Previous studies have demonstrated that the human placenta is capable of
synthesizing VEGF (Lash GE et al., 2002) and sVEGFR1 , which are released
into both the maternal and fetal circulations. Using the in vitro dually perfused
human placental lobule, it has been shown that the levels of VEGF and VEGFR1
secreted into the maternal circulation are greater than the fetal circulation. As
VEGFR1 is a decoy receptor for VEGF, it sequesters most of its ligand in the
uterine circulation, resulting in free VEGF being detectable only in the
fetoplacental circulation, where it is a potent vasodilator of the umbilical
vasculature (Brownbill P et al., 2007).
Using the same placental lobule perfusion model, it has been demonstrated
that the placental release of sVEGFR-1 into the maternal and fetal circulations is
significantly increased in pregnancies complicated by PET. This is concomitant
with a significant decrease in the levels of free VEGF in the umbilical circulation,
which probably contributes to a diminished vasodilatory response in vivo in this
disease. It is of interest to note that exogenous VEGF induced vasorelaxation in
the fetoplacental vasculature in perfused placental lobules from both normal and
PET pregnancies, but the magnitude of relaxation was significantly greater in PET
than in normal specimens. Furthermore, the recovery time from VEGF addition
was significantly longer in PET pregnancies than in normal pregnancies
(Brownbill P et al., 2008), thus proving that VEGF can induce vasodilatation and
consequently enhance perfusion in the umbilical vasculature.
Myometrial arteries from women with pregnancies complicated by FGR
are known to exhibit enhanced vasoconstriction and decreased endothelium-
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dependent vasodilatation (Wareing M et al., 2005). I therefore believe that the
alterations in uterine artery vascular reactivity brought about by VEGF over-
expression, presented in this thesis, are likely to confer a beneficial effect in
pregnancies complicated by FGR. These changes in vascular reactivity may also
partly explain the increase in uterine blood flow that was demonstrated in this
investigation.
3.37 Adenovirus mediated local over-expression of VEGF
in the uterine arteries of mid-gestation pregnant sheep
leads to elevated eNOS levels short-term but does not
affect eNOS levels 30 days after transduction
Levels of eNOS were examined in protein extracts of uterine arteries from
both short-term and long-term transduced animals by Western blotting. I observed
an upregulation in the level of eNOS in Ad.VEGF (-A165 and -D) transduced
vessels short-term compared to Ad.LacZ transduced vessels. However, this
difference was not sustained long term. These findings suggest two possible
mechanisms, of which either or both may be at work. Firstly continued significant
VEGF expression may be needed for long-term NOS upregulation and secondly,
upregulation of NOS at term in normal sheep pregnancy may already be at its
peak and cannot be upregulated further by VEGF overexpression.
VEGF phosphorylates KDR, resulting in phospholipase Cγ activation and 
inositol 1,4,5-triphosphate formation, which evokes an elevation in intra-cellular
Ca2+ levels and consequent eNOS activation (He H et al., 1999). In addition to the
calcium dependent pathway, VEGF can also bring about NO synthesis using a
Ca2+-independent pathway, perhaps using the phosphatidylinositol-3-OH-
kinase/Akt associated eNOS pathway, which is also stimulated by insulin and
shear stress (Fulton D et al., 1999).
The ability of adenovirus-mediated VEGF-A165 gene therapy to stimulate
upregulation of eNOS and NO and consequent increase in blood capillary density
and perfusion (at 7 days post-administration) has previously been demonstrated in
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a rat model of skin ischaemia (Huang N et al., 2006). The upregulation of eNOS
appears to be one of the underlying mechanisms of action of VEGF, by which it
produces therapeutic effects on vascular reactivity and blood flow.
Incubation of cultured HUVECs with VEGF protein has been shown to
upregulate eNOS and NO levels in both an acute (1 hour) and chronic (>24 hours)
manner (Hood JD et al., 1998), thus proving VEGF has an effect on human
endothelial cells. I therefore believe that the results obtained from sheep uterine
arteries presented in this thesis are likely to be similar to what we may expect
from human uterine arteries, if examined. However, it remains to be seen whether
chronic over-expression of VEGF in the uteroplacental circulation can upregulate
eNOS and NO levels in women with a pregnancy affected by severe FGR, where
there is evidence of endothelial dysfunction.
Even though I measured levels of eNOS protein in this study by Western
blotting, it would have been valuable to quantify the levels of eNOS activity
and/or NO levels. Increases in eNOS levels do not necessarily translate into
increased NO levels as the activation of eNOS is regulated by numerous post-
translational modifications and other processes, including protein-protein
interactions, phosphorylation, and subcellular localization.
Following activation, eNOS shuttles between caveolae and other
subcellular compartments such as the noncaveolar plasma membrane portions,
Golgi apparatus, and perinuclear structures. This subcellular distribution is
variable depending upon cell type and mode of activation and has a profound
effect on the ability of eNOS to produce NO as the availability of its substrates
and cofactors will vary with location (Fleming I and Busse R, 2003;Ostrom RS et
al., 2004). To this end, it has been demonstrated that in HUVECs obtained from
pregnancies complicated by FGR, there is an upregulation of eNOS protein levels
(1.7 fold) compared to cells obtained from normal pregnancies. In spite of this
increase, there is a dramatic reduction in eNOS activity (67+6%) and diminished
NO synthesis in HUVECs from FGR pregnancies, thus indicating that most of the
upregulated NOS is in its non-functional/dysfunctional conformation (Casanello P
et al., 2005;Casanello P and Sobrevia L, 2002). As mentioned further above, it is
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difficult to obtain pregnant uterine artery tissue for such experiments, but it is
possible that the mechanisms found to be operating in HUVECs may be operating
on the maternal side of the vasculature as well.
In summary, this data shows that VEGF over-expression results in
increased levels of eNOS in the short-term transduced vessels, but this increase is
not sustained long-term. Importantly, an increase in eNOS levels only, is not
sufficient to justify that this therapy would be of likely benefit in improving utero-
placental perfusion, and requires further investigation into levels of eNOS
activity/NO generation.
3.38 Local over-expression of VEGF in the uterine arteries
of mid-gestation pregnant sheep leads to changes in
endothelial cell proliferation and neovascularization
A significant increase in adventitial endothelial cell proliferation was
observed 4 – 7 days after transduction with Ad.VEGF-D vector in comparison
with control adenovirus vector. The number of proliferating endothelial cells
however was not significantly different between the Ad.VEGF-D and Ad.LacZ
transduced sides when vessels were analysed at 30 days after gene transfer. On
the other hand, the number of positively stained anti-vWF blood vessels was
significantly greater in uterine arteries examined 30 days after Ad.VEGF (-A165
and –D) transduction but not in vessels examined 4 – 7 days after adenovirus
gene transfer. We speculate that endothelial cells which are stimulated to
proliferate by relatively high levels of VEGF at the peak of adenovirus vector
expression (2-7 days) subsequently organize themselves into adventitial blood
vessels, which results in an increase in perivascular blood vessel number seen in
term pregnant uterine arteries.
The role of VEGF as a key regulator of angiogenesis has been very well
characterized in pre-clinical models. Site-specific arterial gene transfer with
plasmid vectors encoding VEGF-A165 cDNA leads to revacularization in a rabbit
model of hindlimb ischaemia, to an extent superior than that achieved with a
single intra-arterial bolus dose of the recombinant protein alone (Takeshita S et
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al., 1996a;Takeshita S et al., 1996b). The gene transfer in this case was performed
by transfecting the internal iliac artery of the ischemic limb with recombinant
plasmids percutaneously, using a hydrogel-coated balloon catheter. It has further
been demonstrated that an adenovirus vector encoding VEGF-A165 cDNA
stimulated a physiologically relevant angiogenic response that was adequate to
attenuate the detrimental effects of vascular occlusion in the setting of pre-
existing ischaemia in a rat model of hindlimb ischaemia. These results have been
used to propose that adenovirus-mediated VEGF expression may be useful in the
prevention of advancing arterial occlusive diseases (Mack CA et al., 1998). In
another recent study, cardiac fibroblasts engineered to express VEGF and
transplanted into the hearts of rats resulted in significant cardiac
neovascularization and attenuation of cardiac dysfunction, when compared to
control groups (Goncalves GA et al., 2010).
Based on these results, I believe that adenovirus-mediated VEGF gene
therapy to the utero-placental circulation, in the setting of pre-existing utero-
placental insufficiency, may be of potential benefit in improving utero-placental
perfusion. This is because the ability of VEGF to stimulate neovascularization
and improve collateral circulation, as demonstrated in the studies above, is likely
to enhance blood supply to the compromised fetus and overcome the detrimental
effects of FGR to some extent.
Nevertheless, it is important to note that even though the ability of VEGF
to promote therapeutic angiogenesis by stimulating proliferation, development
and survival of endothelial cells is well documented in diverse animal models,
compelling evidence that this translates to humans is so far lacking (Zachary I and
Morgan RD, 2011). The VIVA (VEGF in Ischemia for Vascular Angiogenesis)
phase II trial which investigated the effects of intracoronary and intravenous
infusions of rhVEGF in patients of exertional angina demonstrated no significant
improvements beyond that of placebo in exercise treadmill time, angina class and
quality of life assessments at 60 days post-treatment. At 120 days post-treatment,
there was only a significant improvement in angina class and modest
improvement in overall outcomes compared to placebo (Henry TD et al., 2003).
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These findings have been considered to be a huge setback for therapeutic
angiogenesis (Zachary I and Morgan RD, 2011).
The Kuopio angiogenesis trial evaluated the effects of Ad.VEGF-A165 on
restenosis and myocardial perfusion in patients with coronary heart disease,
compared with plasmids encoding VEGF-A165 or placebo; the vectors were
delivered by catheter during angioplasty and stent placement. The primary end
points of the study were minimal luminal diameter and percent diameter stenosis,
while the secondary end points included myocardial perfusion, exercise tolerance,
incidence of new cardiac events and working ability. At the 6-month follow-up,
there was no difference in the clinical restenosis rate and minimal luminal
diameter in the treated patients. Significant improvement was seen only in
myocardial perfusion in the Ad.VEGF-A165 treated patients (Hedman M et al.,
2003).
Despite the treatment of more than 2500 patients using angiogenic
cytokines, clinical trials have not demonstrated any long term beneficial
consequences of VEGF on cardiovascular disease. The findings of most of these
trials have been disappointing (Zachary I and Morgan RD, 2011), and the promise
shown by therapeutic angiogenesis in pre-clinical models yet remains to be
translated to the clinics. One of the reasons responsible for the poor clinical
outcomes of VEGF gene therapy is believed to be low transduction efficiency. It
is estimated that even using the most effective vectors, only 5-10% of the target
cell population can be transduced in humans, which is considerably less than the
transduction efficiency attained in smaller mammalian species (like mice and
rats), most commonly used to generate pre-clinical data.
An important limitation of our study is that it was performed in healthy
pregnant sheep, rather than in a model of FGR pregnancy. Normal human and
ovine pregnancies are characterized by elevated VEGF levels and increased utero-
placental angiogenesis that maximizes the supply of substrates and oxygen to the
developing fetus (McKeeman GC et al., 2004;Vonnahme KA et al., 2005).
Nevertheless, VEGF over-expression resulted in further angiogenesis, over and
above that demanded by the physiological changes in normal sheep pregnancy.
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Human pregnancies affected by FGR are characterized by lower baseline levels of
VEGF, dysfunctional endothelium and only partially re-modelled utero-placental
vasculature. We speculate that in human FGR pregnancy, VEGF over-expression
provided by recombinant protein or gene therapy will restore some if not all of the
deficient angiogenesis that characterizes this condition. While a short acute
exposure to VEGF treatment such as that provided by VEGF infusion, may be
insufficient, a chronic exposure to VEGF using gene therapy may potentially have
some therapeutic effects.
To determine the extent of adventitial neovascularization, I used two
endothelial markers to stain adventitial blood vessels – anti vWF and anti CD31.
Two previous studies have investigated anti-vWF antibody staining of endothelial
cells in sheep tissues; with good positive staining seen in one study (Bobryshev
YV et al., 2001), but only weak/unconvincing staining in the other (Preziuso S et
al., 2002). The immunohistochemical and fluorescent staining that we observed
with anti-vWF appeared to be specific and convincing. This may be on account of
the choice of antibody and methodology, particularly the antigen retrieval
technique which differed from the study wherein anti-vWF staining was weak. I
performed antigen retrieval using trypsin digestion, while the latter study
employed no antigen retrieval at all (Preziuso S et al., 2002). Bobyryshev YV et
al (2001) who also obtained good results with anti-vWF antibody used proteinase-
K for antigen retrieval. I did not observe any endothelial cell staining with the
anti-CD 31 antibody, in common with other authors (Preziuso S et al., 2002).
This is probably because of inter-species antigenic diversity and the consequent
inability of an antibody designed to rodent/human antigens to recognize the
corresponding ovine antigen.
The advantage of immunohistochemical evaluation of neovascularization
over other methods such as H&E staining is that it allows the researcher to
objectively identify and count a blood vessel. On H&E stained sections, it is
difficult to reliably identify a blood vessel as nerve fibers can appear very similar.
We observed that some of the positively stained blood vessels had small blood
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clots within their lumen, indicating there was blood flow through them and that
they were functional.
The number of proliferating endothelial cells was quantified by anti-BrdU
immunohistochemistry. H&E stained sections revealed dramatic cell proliferation
in the perivascular adventitia of uterine arteries that had been injected with
Ad.VEGF-D and these appeared to be proliferating endothelial cells. In order to
confirm this, it was necessary to perform double staining using a cell proliferation
marker (anti-BrdU) and an endothelial marker (anti-vWF). BrdU is a thymidine
analogue that is incorporated into dividing cells during DNA synthesis, and which
is passed down to daughter cells following division. Antibodies to BrdU thus stain
the DNA of actively dividing cells and BrdU immunohistochemsitry has often
been regarded as the ‘gold standard’ technique to determine cell proliferation. To
achieve results, the pregnant ewes received an intra-venous administration of
BrdU 48 hours before post-mortem which has the obvious disadvantages of a
stressful injection procedure for the animal and uncertain penetration of the
targeted cells with a uniform concentration of the compound. In contrast,
antibodies to endogenously expressed proliferation markers like Ki67 and
Proliferating Cell Nuclear Antigen (PCNA) stain protein antigens rather than
DNA.
Another sensitive technique to estimate cell proliferation is the use of
radiolabelled thymidine, which like BrdU, is incorporated during the S phase of
the cell cycle. The disadvantages of this technique include the need to use a
radioactive substance, and the fact that [3H]-thymidine is non-specifically
incorporated in several tissues. Thus, BrdU labeling appeared to be the optimum
method of assessing endothelial cell proliferation in this study.
As discussed further above, we again compared the effect of VEGF with
control vector on vessels from within the same animal. We observed significant
differences in the neovascularization data (long-term) and proliferation data
(short-term) provided by just 4-6 animals. The study is limited slightly because
sections from each branch of the uterine artery were obtained only at 1-2 levels. It
would have been more informative to examine sections from multiple levels of
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the utero-placental tree or from serial sections, and investigate if the rate of
adventitial neovascularization and endothelial cell proliferation is consistently
higher in all levels of all branches. The experimental protocol had to be limited to
only 2 levels at most because of the need to use large amounts of uterine artery
vessel tissue for organ bath analysis, DNA/RNA extraction and protein extraction.
We have demonstrated an increase in the number of adventitial blood
vessels in uterine arteries transduced with Ad.VEGF-A165/Ad.VEGF-D relative to
controls. We speculate that these adventitial blood vessels are vasa vasora. The
vasa vasora is a microvasculature network that originates primarily in the
adventitial layer of large arteries and supplies oxygen and nutrients to the outer
layers of the arterial wall (Heistad DD et al., 1981). Thus, increases in the vasa
vasora may augment the function of the uterine artery thereby enhancing uterine
perfusion.
There has been considerable debate about the role of adventitial
microvasculature/vasa vasora in the amelioration or deterioration of
vasculopathies. While some authors believe adventitial neovascularization may be
of therapeutic benefit, others are of the opinion that it may lead to progression of
vascular disease (Hoefer IE et al., 2007). Studies have demonstrated that
prolonged treatment with inhibitors of angiogenesis like endostatin and TNP-470
resulted in a reduction of intimal neovascularization and plaque growth in
apolipoprotein E-deficient mice (Moulton KS et al., 1999). Conversely, VEGF
administration (intra-peritoneally) in mice deficient in apolipoprotein E and
apolipoprotein B100, and fed on a cholesterol diet, resulted in a dramatic increase
in atherosclerotic plaque area (Celletti FL et al., 2001). Some animal studies have
shown increased neointima formation following VEGF delivery. Additionally,
VEGF and other markers of angiogenesis have been shown to be expressed in
atherosclerotic plaques (Inoue M et al., 1998).
Contrary to these results, other studies have demonstrated that VEGF-A
protein and adenoviral gene transfers of VEGF-A, VEGF-B, VEGF-C and VEGF-
D have no effects on atherosclerosis in hypercholesterolemic LDL-
receptor/ApoB48-deficient mice in which the lipoprotein profile and
318
atherosclerosis closely mimic the human disease (Leppanen P et al., 2005).
Furthermore, inhibition of VEGFR2 using an anti-Flk antibody has no effect on
plaque size and vessels in ApoE-deficient mice and did not halt disease
progression (Luttun A et al., 2002). Delivery of VEGF and other angiogenic
cytokines in patients with ischaemic heart disease did not promote or accelerate
atherosclerosis and any of its clinical complications (Zachary I and Morgan RD,
2011).
Even though the studies in this thesis were not performed in a model of
atherosclerosis, the increased adventitial neovascularization and chronic VEGF
exposure did not result in any adverse outcomes on the vascular health of the
uterine arteries. It has been demonstrated that hypertrophied vasa vasora have the
potential of revascularizing occluded atherosclerotic carotid arteries, by
developing a collateral circulation, in human patients (Colon GP et al., 1999).
Furthermore, it is believed that adventitial microvessels/vasa vasora in the utero-
placental and ovarian vascular beds play an important role in facilitating the
changes in blood flow in pregnancy (Zezula-Szpyra A et al., 1997).
I also measured the intima/media ratios in uterine arteries from twin
pregnant animals to examine if VEGF gene therapy altered the vessel
morphology. This was done by measuring the relative thickness of the intimal and
medial layers in H&E stained sections of uterine arteries that had been transduced
with Ad.VEGF-A165 or Ad.LacZ long-term. I observed a reduction in the
intima/media ratios of Ad.VEGF-A165 transduced uterine artery segments
compared to Ad.LacZ transduced segments in all branches examined, which was
significant in the two smallest branches of the main uterine artery that were
examined. It is likely that statistical significance would have been reached in the
main and first branch of the uterine artery as well, if a few additional twin
pregnant animals had been included in the study.
Studies in other vascular beds have demonstrated that an increase in the
intima/media ratios is associated with vasculoproliferative disorders such as
atherosclerosis and restenosis after angioplasty. It has further been demonstrated
that disruption of the function of vasa vasorum is associated with neointimal
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thickening. In pigs, ligation of the side branches of the femoral artery occludes
blood flow to the vasa vasora, and results in significant intimal hyperplasia. The
authors’ interpretation of these results was that occlusion of the vasa vasorum
promoted intimal thickening (Barker SG et al., 1993). Although oxygenation
measurements were not carried out following the ligation, they believed that
occlusion of the vasa vasorum would lead to a hypoxic environment, a condition
which would make the vessel prone to atherosis. Hence, intimal hyperplasia and
periadventitial blood flow may be inversely related.
Intimal hyperplasia observed in the uterine arteries of premenopausal
women is accompanied by impaired cyclic GMP production, and altered arginase
and NOS activities (Marinova GV et al., 2008). It has been demonstrated that
there exists a positive correlation between intima/media ratios and endogenous
NOS inhibitors in endothelial cells (like L-NMMA and ADMA), as well as
endothelin-1 within the vessel wall of perimenopausal human uterine arteries
(Beppu M et al., 2002). Accumulation of endogenous NOS inhibitors in
endothelial cells is known to be associated with diminished NO production and
intimal hyperplasia (Azuma H et al., 1995;Masuda H et al., 1999).
In another study, it was shown that uterine artery atherosclerosis may be
used as a surrogate marker for atherosclerosis in other critical vascular beds, like
the coronary and carotid arteries, as well as the development of cardiovascular
disease. Indeed other risk factors for the development of cardiovascular disease,
such as ECG abnormalities and cholesterol levels greater than 200 mg/dl (normal
range = 180-200 mg/dl) have been found to be associated with greater intimal
thickness and intima/media ratios in the uterine arteries (Crawford BS et al.,
1997). There is now strong evidence that developing both FGR and/or PET during
pregnancy confers an increased predisposition to cardiovascular disease (Smith
GC et al., 2001;Manten GT et al., 2007). The reduction in intima/media ratios we
observed in our study therefore may confer an arterioprotective effect on the
uterine arteries, which may potentially benefit FGR.
The importance of these findings has also been demonstrated in a study
investigating the effects of 17β-Estradiol (E2) in perimenopausal human arteries
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(Obayashi S et al., 2001). Incubation with E2 significantly augmented
endothelium-dependent relaxation, and was accompanied by significant increases
in cyclic AMP and GMP production, but only in uterine arteries that had normal
intima/media ratios. In perimenopausal human uterine arteries characterized by
intimal hyperplasia and increased intima/media ratios however, E2 failed to alter
the acetylcholine-induced relaxation as well as the cyclic nucleotide production.
NO is known to relax vascular smooth muscle through activation of soluble
guanylate cyclase, which in turn increases intracellular levels of cyclic GMP
(Ignarro LJ, 1989). PGI2 on the other hand, exerts its relaxation effect through
activation of soluble adenylate cyclase, which increases cyclic AMP levels
(Moncada S and Vane JR, 1978). Although this investigation was carried out
using uterine artery specimens from non-gravid women, the results underscore the
clinical importance of the intima/media ratio in this vascular bed.
3.39 Ad.VEGF administration to the uterine arteries does
not lead to detrimental changes in maternal and fetal
haemodynamics
In this study, we investigated changes in maternal and fetal
haemodynamics in response to Ad.VEGF-A165 injection to the uterine arteries
using implanted telemetric blood pressure sensitive catheters in the maternal or
fetal carotid arteries. We observed no significant difference in the maternal or
fetal blood pressure and heart rates in the week following vector injection. There
was a small non-significant drop in maternal blood pressure at term, but this is
normally observed in sheep (Kitanaka T et al., 1989). In one of the instrumented
fetuses, there was a rise in blood pressure at term. This too is a normal occurrence
in sheep. During the occlusion for vector administration, we observed a small and
non-signficant rise in fetal blood pressure and heart rate, which returned to
baseline levels within 30 minutes.
An intravenous injection of VEGF (250 µg/kg) has been shown to produce
transient tachycardia, hypotension and a decrease in cardiac output in conscious
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instrumented rats (Yang R et al., 1996). VEGF also caused a dose-dependent
reduction in mean arterial pressure and an associated increase in heart rate. Pre-
treatment with L-NAME significantly attenuated the depressor and tachycardic
responses to VEGF, suggesting that VEGF-induced hypotension is mediated by
NO. Conversely, drugs and antibodies that disrupt VEGF signaling are used to
treat cancer by inhibiting tumour growth, but are associated with significant
hypertension. The hypertension is believed to occur due to a decreased production
of NO in the wall of arterioles and other resistance vessels (Kamba T and
McDonald DM, 2007;Facemire CS et al., 2009).
The lack of a detectable systemic effect of VEGF expression suggests that
the technique of gene delivery used results in sustained over-expression only in
the uterine arteries and not in the systemic vasculature. This is borne out by the
RT-PCR data showing transgene expression only on the maternal side of the
placenta, as discussed above. VEGF is a large protein and is therefore unlikely to
be able to cross the epitheliochorial placenta of sheep to reach the fetal circulation
from maternal circulation and vice-versa (Vonnahme KA et al., 2005). However,
this is not the case in the human patient, where only a single syncytiotrophoblast
layer needs to be crossed in the third trimester of pregnancy to reach the fetal
circulation from the maternal circulation. Thus, there is a possibility of VEGF
protein entering the fetal circulation in humans and causing hypotension. An
appropriate way to assess if Ad.VEGF has any effects on fetal blood pressure in a
pre-clinical ovine model would be to inject the vector directly into the umbilical
vein, and then monitor fetal haemodynamics.
The technique of blood pressure monitoring we used has been regarded as
the ‘gold standard’ for measurement of haemodynamic parameters. Some
previously published studies on haemodynamic monitoring used chronic maternal
and/or fetal catheterization, and connection of the animal physically via the
catheters with a polygraph (Marsh AC et al., 2002). Furthermore, these catheters
need to be flushed with heparinised saline daily to prevent blood coagulation
around the pressure-sensitive tip, which would render the catheter useless. This
type of experiment involves space restriction and animal restraint, which is a
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significant stressor (Rivalland ET et al., 2007;Niezgoda J et al., 1993).
Refinement of animal experiments to reduce the potential for suffering and stress
and to enhance animal welfare improves the quality of the data obtained. It is also
one of the cornerstones of the 3Rs, a widely accepted ethical framework for
conducting scientific experiments using animals humanely (Robinson V, 2005).
We believe that telemetric monitoring of maternal or fetal blood pressure and
heart rate in the freely moving pregnant ewe would meet these expectations. One
of the advantages of traditional chronic catheterization using implanted
externalized catheters is that it permits access to the maternal/fetal circulation and
amniotic cavity for fluid sampling over time, which is not feasible using the
telemetric monitoring method described here.
As mentioned above, refinement of technique is associated with a
reduction in stress levels for the experimental animals. However, this project was
not designed to investigate this issue. For any true comparison to be made, the
same experiment would need to be repeated in animals monitored by traditional
methods. Comparing our data to those obtained by traditional methods in other
studies, we can only accurately compare the baseline (pre-intervention) data. In a
study investigating the effect of 50% reduction in maternal nutrient intake on fetal
blood pressure in sheep, the blood pressure of control fetuses was found to be
38+0.7 mm Hg at about 115 days of gestation (Edwards LJ and McMillen IC,
2001). In our study, the pre-injection baseline value of fetal blood pressure at
approximately 110-112 days of gestation was 38.29+3.17 mm Hg. Thus, even
though the values of fetal blood pressure in both the investigations are similar, it
is to be noted that this is only a snapshot comparison rather than a chronic long-
term one. Hence, little can be inferred about the difference in stress caused by the
two techniques of haemodynamic monitoring.
In animals that had maternal blood pressure catheters implanted, there was
no morbidity or mortality. However, in the four animals used for fetal telemetry
studies, there were 2 fetal deaths, that occurred 8 days and 12 days after catheter
placement. This is likely to have been due to displacement of the catheter as the
fetuses grew. In both cases the tip of the catheter was found lying in the bicarotid
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trunk at post-mortem, which may have resulted in obstruction of blood flow to
both common carotid arteries. Cannulation of the fetal sheep carotid arteries has
been shown to result in ischaemic brain damage especially when bilateral
obstruction has occurred (Dodic M et al., 1998). The insertion technique was
adjusted by threading the catheter tip further upstream the carotid artery in an
attempt to bypass the bicarotid trunk and reach the descending aorta, and the
problem was overcome. The two fetuses subsequently operated with this
adjustment were monitored successfully till term.
In summary, using a ‘gold standard’ technique of maternal and fetal
haemodynamic monitoring, we have demonstrated that local administration of
Ad.VEGF to the uterine arteries of mid-gestation pregnant sheep has no
detrimental consequences on maternal/fetal blood pressure and heart rate.
3.40 Administration of Ad.VEGF to the uterine arteries of
pregnant sheep is found to be safe in preliminary
investigations.
The preliminary analysis designed to assess the safety of Ad.VEGF gene
transfer in pregnant ewes suggested that there were no obvious signs of toxicity
from the viral vector. The ewes resumed normal feeding and behaviour the day
after vector injection and displayed no signs of suffering or distress. Analysis of
maternal blood and serum samples collected before vector injection, one week
after injection and at post-mortem; and fetal blood and serum samples collected at
post-mortem for routine haematology, biochemistry and liver function showed no
detectable abnormality. This further supports the safety of Ad.VEGF gene
transfer. Notably, there was no evidence of liver function abnormality despite the
high dose of vector injected. This is important because the liver is a major site of
Ad vector-induced inflammation and clearance in many experimental studies in
animals (Worgall S et al., 1997). In the study cited, the adenovirus vector was
administered intravenously. There are two possible explanations for the lack
hepatic toxicity – firstly the delivery technique restricts the vector to the uterine
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vasculature and does not allow it to leak into the systemic circulation; and
secondly, the vector preparations used in our studies were of a clinical-grade and
highly purified, in contrast to many experimental virus preparations which are
contaminated with replication-competent adenoviruses.
Gross examination of maternal and fetal tissues at post-mortem
examination or microscopic histology of H&E stained tissues did not reveal any
significant pathology. Some ewes showed evidence of low-grade myocarditis, this
was believed to be unrelated to the administration of viral vectors and is a
common finding in this breed of sheep (David AL personal communication and
PhD thesis). Sham operated ewes who received only the vehicle (PBS), also
showed evidence of myocarditis. All other tissues examined had an unremarkable
histology. The uterine arteries showed no evidence of oedema, inflammation or
leucocyte infiltration.
The sheep placentation is very different to that of humans, and therefore
the sheep is a relatively poor model in which to test for toxicity or safety. Work is
currently ongoing in another pre-clinical model, the FGR guinea pig, to assess
vector spread and expression in fetal tissue. The guinea pig placenta is very
similar to human placenta, and hence, this species can provide more valuable and
relevant data for pre-clinical assessment of safety.
More advanced toxicology studies are being conducted by Ark
Therapeutics to assess the safety of this potential therapy. These include
administration of very high doses of Ad.VEGF (2x1012 viral particles) to pregnant
rabbits to determine the LD50, as well as detailed microscopic histological
examination of maternal and fetal tissues from these experimental animals. In a
further series of experiments in collaboration with the University of Manchester,
in vitro studies with human placental villous explants exposed to Ad.VEGF have
been performed. Placental villous explants were grown in culture for 5 days, and
then infected with adenovirus at high concentrations or control material, and then
analysed 48 hours later. This exposure to adenovirus had no detrimental effect on
villous function as measured by hormone secretion or enzyme activity. Neither
was there any adverse effect on the cellular structure of the placental tissue.
325
Toxic effects such as the formation of vascular tumours, uncontrolled
angiogenesis and inflammation have been seen after unregulated myoblast-
mediated VEGF over-expression in murine hearts (Lee RJ et al., 2000). These
results underscore the need for regulated expression of a gene encoding such a
potent product. In contrast with these results, transient modes of VEGF gene
delivery based on the injection of an adenovirus or plasmid DNA have been
reported as safe to administer in animal models and human patients (Losordo DW
et al., 1998;Rosengart TK et al., 1999;Patel SR et al., 1999). Adenovirus-mediated
gene transfer peaks at 24 hours post-transduction, is maximum during the first one
week, after which it begins to decline, and there is only minimal residual
expression remaining after one month. This is considered to be a disadvantage of
adenoviral vector systems, and renders them useless for many therapeutic
applications which require long-term gene expression. However, in our study, the
short-term expression by adenoviral vectors makes their use highly desirable, as
therapeutic transgenic protein expression is required for only a few weeks of
gestation to achieve the desired beneficial outcome.
In summary, we have shown that adenovirus-mediated VEGF gene
transfer to treat utero-placental vascular insufficiency appears to be safe. More
advanced toxicology studies are currently being performed, which are pivotal
before clinical application can be contemplated.
3.41 Conclusion
The results presented in this chapter demonstrate that local adenovirus-
mediated VEGF-A165/VEGF-D over-expression in the pregnant sheep uterine
arteries at mid-gestation results in a significant long-term increase in UABF, a
reduction in uterine artery vascular contractility, increased adventitial
angiogenesis and increased fetal weight. It gives hope that impaired utero-
placental perfusion found in cases of FGR and pre-eclampsia may be potentially
reversed. Vector administration appears to be safe leading to no undesirable
vector expression, change in maternal or fetal haemodynamics, or pathology.
326
Studies in growth-restricted small and large animal models, optimization of the
delivery technique, and further safety evaluation will be required before clinical
application could be contemplated.
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Chapter 4
Results: The Effects of VEGF Over-expression on Pregnant
Uterine Artery Endothelial Cells
I was interested in elucidating the mechanism of action of VEGF in
pregnant ovine uterine arteries. To do this, experiments were carried out in
endothelial cells isolated from the uterine arteries of mid-gestation pregnant
sheep. The advantage of the uterine artery endothelial cell (UAEC) model is that
it provides an opportunity to investigate the response of the endothelium, which is
the first vascular layer infected by the adenovirus, to over-expression of the
transgenic protein. As the endothelium is believed to be the principal regulator of
the circulatory system, it is important to know how it reacts to different ligands,
such as VEGF in this case, to understand their mode of action and effects on
blood flow.
The UAEC model can be used to create several different experimental
conditions within a single culture plate, for instance, by altering the viral vector
dose or the incubation time post-infection. In addition, experimental conditions
can be controlled more clearly and experiments can be easily repeated. To carry
out such experiments in pregnant sheep would be technically demanding,
expensive and unethical. In contrast, endothelial cells can be isolated relatively
easily from sheep vessels by enzymatic digestion. It has been shown that these
cells retain their primary character and have similar responses to those of freshly
isolated UAECs, for up to 4 passages ex vivo (Bird IM et al., 2000).
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The following chapter describes the results of optimization of a technique
to isolate pure ovine UAECs, their characterization and their responses to
Ad.VEGF-A165 and Ad.VEGF-D infection. In order to obtain uncontaminated
cultures of endothelial cells from pregnant sheep uterine arteries, the first step was
to determine the optimum incubation time with collagenase. Following this, a
number of different methods were used to confirm the purity of our endothelial
cell preparation. This is primarily because it is easy to get contamination from
smooth muscle cells and fibroblasts in primary endothelial cell preparations.
Hence, confirming the purity of our primary cell cultures was critical to validate
our observations from subsequent experiments.
4.1 To extract uterine artery endothelial cells from pregnant
sheep, the optimum time for incubation of uterine arteries
with collagenase is 15 minutes.
In the first two experiments performed, endothelial cells were extracted in
accordance with the only previously published protocol (Bird IM et al.,
2000;Grummer MA et al., 2009), by incubating the uterine arteries with
collagenase for 55 minutes. Following this long incubation time, we observed that
our cell preparations did not consist of cobblestone-shaped cells, which is a
characteristic of endothelial cell morphology but instead, they had an elongated
and fibrous appearance, which is typical of smooth muscle cells. Following this,
the incubation time with collagenase was reduced to 15 minutes, as has been
suggested in papers for primary endothelial cell extraction from human blood
vessels (Crampton SP et al., 2007) which resulted in a pure culture of endothelial
cells. Immunofluorescent staining and other tests described below were used to
confirm these findings.
329
4.1.1. Immunofluorescent staining confirms that endothelial
cells can be extracted from the pregnant mid-gestation sheep
uterine artery
Anti-vWF, a marker specific for endothelial cells and megakaryocytes,
was first used to distinguish endothelial cells from other cell types. vWF is a
glycoprotein produced uniquely by endothelial cells and megakaryocytes (Zanetta
L et al., 2000) which forms a complex with coagulation factor VIII and is
involved in the formation of platelet plugs at the site of endothelial cell damage
(Mannucci PM, 1998). Its use as an endothelial cell marker has been well
established for several years (Zanetta L et al., 2000).
As was suspected, staining of cells isolated following a 55 minute
collagenase digestion, with anti-vWF antibody, showed that many nuclei lacked
any fluorescent staining (Figure 4.1A). This indicated contamination with other
cell types, most probably smooth muscle cells and macrophages.
Following this, the incubation time with collagenase was reduced to 15
minutes. Figure 4.1A depicts the photomicrograph of positive immuno-staining
with anti-vWF antibody on cells isolated after a reduced incubation time. The
vWF can be seen as a fluorescent green stain in the cytoplasm, specifically in the
Weibel-Palade bodies, and the nuclei are counterstained by DAPI, indicated by
blue dots. As is evident, all the blue dots are surrounded by green cytoplasm after
an incubation time of 15 minutes. This confirms that all the cells in the culture
preparation are of endothelial origin, and there is no contamination evident with
smooth muscle cells.
330
Figure 4.1 – Anti-vWF staining to optimize the incubation time of pregnant
sheep uterine arteries with collagenase to isolate pure endothelial cell
preparations
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(Continued from overleaf) Uterine arteries from mid-gestation pregnant sheep were incubated with
collagenase (5mg/ml) for either 55 minutes or 15 minutes to detach endothelial cells. Detached
cells were grown in culture for up to 4 passages and then stained with primary rabbit anti-human
von Willebrand Factor antibody (1:400), followed by a secondary Alexafluor-488 donkey anti-
rabbit IgG to confirm endothelial cell identity. The nuclei were counterstained with DAPI. The top
panel ‘A’ shows that digestion for 55 minutes resulted in contamination with other cell types,
which did not stain with anti-vWF. However, digestion for 15 minutes resulted in a pure culture of
endothelial cells, all of which were positively stained with anti-vWF. The bottom panel ‘B’ shows
anti-vWF staining on smooth muscle cells (negative control). Scale bar = 40µm
Staining with two additional antibodies anti-VE cadherin and anti-β-
catenin, was performed to verify the identity of cell types. VE cadherin and β-
catenin are essential for the early assembly of inter-cellular junctions in
endothelial cells (Lampugnani MG et al., 1995). Previous studies have described
their localization in areas of cell-to-cell contact in confluent cultured endothelial
cell monolayers. This indicates that these proteins may be used to recognize
endothelial cells (Lampugnani MG et al., 1995). While VE-cadherin is
specifically found in endothelial cells, β-catenin may also occur in the adherence 
junctions of other cell types. Nevertheless, staining with both these antibodies
would demonstrate the morphology of adherence junctions between cells. As seen
in Figure 4.2, the fluorescent green staining shows the adherence junctions
between the cells bearing a cobble-stone or pavement-stone like appearance,
which is characteristically seen in endothelial cells. Hence, this staining further
confirms the successful isolation of endothelial cells from ovine uterine arteries.
Smooth muscle cells were used as a negative control for all staining experiments
and gave no positive staining with any of the fluorescent antibodies.
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Figure 4.2 – Confirmation of the identity of pregnant sheep UAECs by
immunofluorescence and Ac-LDL staining
Uterine arteries from mid-gestation pregnant sheep were incubated with collagenase (5mg/ml) for
15 minutes to detach endothelial cells. Detached cells were grown in culture for up to 4 passages
and then stained with primary anti-VE cadherin (1:500) or anti-β-catenin (1:2000) antibodies, 
followed by the appropriate Alexafluor-488 conjugated secondary antibodies. These antibodies
stain the adherence junctions between endothelial cells, which give a cobblestone-like appearance.
Cultured cells were also incubated with acetylated LDL, a lipoprotein that endothelial cells
metabolize, that had been conjugated with Alexafluor-488. This resulted in a positive staining,
further confirming the endothelial origin of the cells. Blue dots (where present) represent the
DAPI-stained nuclei. Scale bar = 40µm
4.1.2 Staining with Ac-LDL confirms the isolation of pregnant
sheep uterine artery endothelial cells
Endothelial cells internalize and degrade Ac-LDL 7-15 times faster than
smooth muscle cells via the ‘scavenger cell pathway’ of LDL metabolism (Voyta
JC et al., 1984). This has enabled the identification of endothelial cells distinctly
from smooth muscle cells based on their increased metabolism of fluorescently
labeled Ac-LDL. Figure 4.2 shows the uptake of Ac-LDL by endothelial cell
specific receptor-mediated endocytosis into endosomes and lysosomes where it
will be metabolized. Smooth muscle cells were used as a negative control for all
staining experiments and gave no positive staining with Ac-LDL (data not
shown). As can be seen from the figure, all cells took up and metabolized the Ac-
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LDL to yield a fluorescent product, and are therefore endothelial in origin. There
is no contamination with smooth muscle cells.
4.1.3 Challenge with VEGF protein confirms the isolation of
pregnant sheep uterine artery endothelial cells
VEGF receptors are known to be present on the endothelium where they
bind VEGF and signal downstream activation of different signal transduction
pathways, including phosphorylation of ERK. Upregulation of the phosphorylated
form of ERK after challenge with VEGF-A165 protein was thus also used to
confirm that the isolated cells were of endothelial origin.
Western blotting with a phospo-ERK antibody was carried out on protein
extracts from cells challenged with VEGF-A165 for 10 minutes and unchallenged
cells. There was an observable increase in phospho-ERK levels as seen by a
denser band when compared with the band from unchallenged cells (Figure 4.3).
This further confirmed the endothelial origin of the isolated cells.
Figure 4.3 – Upregulation of phospho-ERK following challenge of pregnant
sheep uterine artery endothelial cells with rhVEGF-A165 protein
Uterine arteries from mid-gestation pregnant sheep were incubated with collagenase (5mg/ml) for
15 minutes to detach endothelial cells. Detached cells were grown in culture for up to 4 passages.
Prior to experimentation, cultured endothelial cells were serum-deprived overnight. Next morning,
they were challenged with rhVEGF-A165 protein (25 ng/ml, R&D Systems) for 10 minutes. Protein
extracts from challenged (V) and control (C) cells were analysed by western blotting for
phosphorylated (p) ERK and total-ERK levels. Upregulation of p-ERK following VEGF-A165
challenge indicates the endothelial origin of these cells.
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4.2 Adenovirus vector can infect pregnant ovine UAECs
To determine whether adenovirus vectors could infect the cultured ovine
UAECs, cells were infected with Ad.LacZ at increasing multiplicities of infection
(MOI, 0, 1, 10, 100, 1000 and 10000) in a 6-well plate. The culture medium was
replaced with fresh EGM (supplemented with 2% FBS) after 24 hours. After a
further 24 hours of incubation, the cells were fixed in 100% ethanol and stained
with X-gal staining solution. The percentage of positively stained cells in each
well was determined under a light microscope by direct counting in 10 randomly
selected high-powered fields. Figure 4.4 shows some representative images of
stained cells infected at different MOIs. The results of this analysis are shown in
Table 4.1.
20x mag.
Figure 4.4 – Improvement in transduction efficiency in sheep UAECs with an
increase in adenovirus vector MOI
Pregnant sheep UAECs were grown in culture for up to 4 passages, and then infected at increasing
multiplicities of infection (MOIs) with Ad.LacZ in 6-well plates. After 48 hours of infection, the
cells were fixed in 100% ethanol and stained with X-gal staining solution overnight. Infection
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efficiency was determined by counting the number of positively stained blue cells and unstained
cells in 10 randomly selected high powered fields.
Table 4.1 – Infection efficiency of pregnant sheep UAECs with Ad.LacZ
Multiplicity of Infection Percentage of cells positively stained in 10
randomly selected high powered fields
(Mean+SEM)
0 0
1 0.70+0.08
10 6.39+2.73
100 32.55+3.82
1000 63.12+1.79
10000 90.23+3.98
Thus, adenovirus vectors are capable of infecting pregnant ovine UAECS,
and the infection efficiency improves with increasing MOI.
4.3 eNOS, iNOS and phosphorylated eNOS (Ser1177) are
upregulated in cultured ovine UAECs 48 hours after
Ad.VEGF-A165 and Ad.VEGF-D transduction, but not after 24
hours of infection
In order to understand the mechanism of VEGF action on pregnant sheep
uterine arteries, I was interested in studying the effects of VEGF-A165 and VEGF-
D over-expression on eNOS, p-eNOS (Ser1177) and iNOS levels in pregnant sheep
UAECs. Ovine UAECs were passaged four times before seeding them in 6-well
plates. The cells in each plate were infected with Ad.VEGF-A165, Ad.VEGF-D or
Ad.LacZ at increasing multiplicities of infection (0, 1, 10, 100, 1000 and 10000).
After 24 hours of infection with either Ad.VEGF-A165 or Ad.LacZ, protein
was extracted from the cells and used for western blotting analysis with antibodies
specific to eNOS, iNOS and p-eNOS (Ser1177). Experiments were carried out three
times on cells from different sheep. I observed no change in the levels of any of
these proteins 24 hours after adenovirus infection (Figure 4.5). Similar results
were obtained with Ad.VEGF-D (data not shown).
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Figure 4.5 – Representative western blot showing no change in eNOS levels
24 hours after Ad.VEGF-A165 infection in pregnant sheep UAECs
Pregnant sheep UAECs were grown in culture for up to 4 passages, and then infected at increasing
multiplicities of infection (MOIs) with Ad.VEGF-A165 or Ad.LacZ in 6-well plates. Protein was
extracted from infected cells 24 hours later, and assayed for eNOS levels by western blotting.
There was no change in the levels of eNOS in Ad.VEGF-A165 or Ad.LacZ infected cells. Phospho-
eNOS (Ser1177) and iNOS levels were also analysed, and found to be unchanged (data not shown).
GAPDH was used as a loading control for gels.
These experiments were also carried out 48 hours after infection with
Ad.VEGF-A165, Ad.VEGF-D and Ad.LacZ at increasing MOIs (0, 1, 10, 100,
1000 and 10000). The medium was replaced with fresh culture medium (EGM
supplemented with 2% FBS) 24 hours post-infection.
After 48 hours of virus vector infection, protein was extracted from the
cells and used for western blotting analysis with antibodies specific to eNOS,
iNOS and p-eNOS (Ser1177). Experiments were performed three times on cells
from different sheep. I observed an upregulation in the levels of all three proteins
48 hours post-infection in the Ad.VEGF-A165 and Ad.VEGF-D infected cells.
There was no change in the levels of eNOS, iNOS or p-eNOS (Ser1177) in the
Ad.LacZ infected cells (Figure 4.6 and Figure 4.7).
While the levels of eNOS and iNOS appeared to increase in a dose-
dependent manner in response to Ad.VEGF (-A165/-D) infection, the levels of p-
eNOS (Ser1177) were significantly raised only at the highest MOI of Ad.VEGF-
A165/Ad.VEGF-D.
337
A.
B. Change in eNOS levels
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C. Change in p-eNOS levels
Figure 4.6 - Representative western blots showing an upregulation in eNOS
and phospho(p)-eNOS (Ser1177) levels 48 hours after Ad.VEGF (-A165/-D)
infection in pregnant sheep UAECs
Pregnant sheep UAECs were grown in culture for up to 4 passages, and then infected at increasing
multiplicities of infection (MOIs) with Ad.VEGF-A165, Ad.VEGF-D or Ad.LacZ in 6-well plates.
Protein was extracted from infected cells 48 hours later, and assayed for eNOS and p-eNOS
(Ser1177) levels by western blotting. (A) An increase in eNOS and p-eNOS (Ser1177) levels with
increasing MOI was observed in Ad.VEGF-A165 and Ad.VEGF-D infected cells, but not Ad.LacZ
infected cells. (B) Densitometric analysis was performed on the eNOS bands using Image J
software, after normalizing against the density of GAPDH bands. Results are representative of n=3
independent experiments. (C) Densitometric analysis was performed on the p-eNOS (Ser1177)
bands using Image J software, after normalizing against the density of GAPDH bands. Results are
representative of n=3 independent experiments. * indicates p<0.05 in comparison to the relative
density of the corresponding band from uninfected cells (MOI=0) by t-test.
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A.
B.
Figure 4.7 - Representative western blots showing an upregulation in iNOS
levels 48 hours after Ad.VEGF (-A165/-D) infection in pregnant sheep UAECs
Pregnant sheep UAECs were grown in culture for upto 4 passages, and then infected at increasing
multiplicities of infection (MOIs) with Ad.VEGF-A165, Ad.VEGF-D or Ad.LacZ in 6-well plates.
Protein was extracted from infected cells 48 hours later, and assayed for iNOS levels by western
blotting. (A) A dramatic increase in iNOS levels with increasing MOI was observed in Ad.VEGF-
A165 and Ad.VEGF-D infected cells, but not Ad.LacZ infected cells. (B) Densitometric analysis
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was performed on the iNOS bands using Image J software, after normalizing against the density of
GAPDH bands. Results are representative of n=3 independent experiments. * indicates p<0.05 in
comparison to the relative density of the corresponding band from uninfected cells (MOI=0) by t-
test.
In summary, these results demonstrate that adenovirus-mediated over-
expression of VEGF-A165 and VEGF-D in pregnant ovine UAECs results in an
upregulation of eNOS, iNOS and p-eNOS(Ser1177).
4.4 Western blotting for VEGF receptors in adenovirus
transduced pregnant ovine UAECs did not lead to any
conclusive results
Treatment with VEGF has been shown to upregulate the levels of its
receptors (Kremer C et al., 1997;Barleon B et al., 1997a). In order to investigate
how the levels of VEGF receptors were altered in ovine UAECs in response to
adenovirus-mediated over-expression, we performed western blotting on protein
extracts from infected cells with antibodies specific to VEGFR-1, VEGFR-2 and
Neuropilin-1. These antibodies (described in Section 2.16) have previously been
showed to react very well with sheep tissue by immunohistochemistry on
paraformaldehyde-fixed paraffin-embedded tissue sections. However, when these
and few other antibodies were used for western blotting on sheep endothelial cell
extracts, the results were disappointing. Either there was no band present at all, or
there were multiple bands and it was difficult to determine which one was the
actual receptor band.
Hence, it was not possible to come to any conclusion about changes in the
levels of the VEGF receptors in pregnant sheep UAECs in response to
adenovirus-mediated over-expression of VEGF-A165 or VEGF-D.
4.5 Discussion
This chapter describes the effects of Ad.VEGF-A165/Ad.VEGF-D gene
transfer on UAECs from mid-gestation pregnant sheep. UAECs were isolated by
collagenase digestion, grown in culture for up to 4 passages and then infected
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with Ad.VEGF-A165, Ad.VEGF-D or Ad.LacZ at increasing multiplicities of
infection. I observed an increase in the levels of eNOS, p-eNOS (Ser1177) and
iNOS in the Ad.VEGF-A165 and Ad.VEGF-D infected cells, but not in the
Ad.LacZ infected cells.
At the beginning of these experiments, collagenase digestion was
performed for 55 minutes to isolate endothelial cells from pregnant uterine
arteries, according to previously published work from Prof. Ian M. Bird’s group at
the University of Wisconsin (Bird IM et al., 2000;Grummer MA et al., 2009).
This is the only other group which has worked extensively on ovine UAECs, and
the isolation technique was discussed with them. However, we found that this
long incubation time resulted in extensive smooth-muscle cell contamination in
our cultures. It was therefore decided to reduce the incubation time to 15 minutes,
which is in conformity with other published studies for primary endothelial cell
isolation from human vessels (Crampton SP et al., 2007). Using this shorter
incubation time, we were able to obtain pure endothelial cell preparations. The
discrepancy in the results from the 55 minute incubation time between our studies
and those of Bird et al may be on account of differences in technique amongst
different operators, or perhaps the use of a different sheep breed.
The different results obtained lead us to use a variety of different
techniques to confirm the identity of the cells retrieved from the pregnant sheep
uterine arteries. I performed immunostaining with anti-vWF, anti-VE cadherin
and anti-β-catenin to confirm the identity of endothelial cells. While anti-vWF is a 
cytoplasmic stain, the latter two antibodies stain the adherence junctions between
endothelial cells. The pattern of staining observed with anti-VE cadherin and anti-
β-catenin antibodies had a cobblestone-like appearance, which is a characteristic 
of endothelial cells. In addition to the immunofluorescent staining, the cells were
also treated with fluorescently labeled Ac-LDL. Endothelial cells internalize and
degrade Ac-LDL 7-15 times faster than smooth muscle cells via the “scavenger
cell pathway” of LDL metabolism. This has enabled the identification of
endothelial cells distinctly from smooth muscle cells based on their different
metabolism of Ac-LDL (Voyta JC et al., 1984).
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Furthermore, serum-deprived cells were challenged with VEGF-A165
protein, and the levels of phosphorylated ERK examined. VEGF protein has been
shown to upregulate the phosphorylated form of ERK in endothelial cells (Bird
IM et al., 2000). I observed this trend in our primary cell cultures. Hence, all these
findings confirm that I had obtained pure cultures of endothelial cells.
It is important to note that all experiments in this investigation were
conducted at passage four. It has previously been shown that up to this passage,
ovine UAECs retain their primary in vivo characteristics. This means, expression
of key proteins and mRNA, as evident on the day of isolation, are sustained when
cells are maintained in culture up to passage four. In addition, levels of eNOS
protein and mRNA show higher expression in cells from pregnant ewes than in
cells from nonpregnant ewes at the fourth passage, indicating the retention of
characteristics present at the time of isolation (Bird IM et al., 2000;Gifford SM et
al., 2003). The retention of this primary character is important for the validation
of our results.
The UAEC model provided the opportunity to investigate the effects of
Ad.VEGF transduction, using multiple MOIs and incubation times post-infection,
while harvesting cells obtained from only a few animals. All the experiments
described in this chapter were performed on cells obtained from as few as 6
sheep. In addition, I was also able to prepare frozen stocks of cells for future
analysis. Carrying out such experiments directly on pregnant sheep would not
only be very expensive, but also unethical.
Previous studies have demonstrated that stimulation with VEGF-A165
protein for 24 hours results in an upregulation of eNOS and iNOS in cultures of
porcine aortic endothelial cells (Kroll J and Waltenberger J, 1998) and HUVECs
(Hood JD et al., 1998). VEGF also induces sustained eNOS activation in cultured
endothelial cells via PI-3-K dependent Akt-catalysed phosphorylation of eNOS at
Ser1177. This is the same site phosphorylated in response to shear stress (Dimmeler
S et al., 1999) and phosphorylation of this site renders eNOS active at resting Ca2+
concentrations.
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However, when uterine artery endothelial cells from pregnant sheep were
challenged with VEGF-A165 protein for 24 hours, there was no change in the level
of eNOS or iNOS (Bird IM, personal communication). A significant short-term
increase in NO release was observed in response to VEGF-A165 protein
stimulation for one hour in cultured pregnant UAECs (Bird IM et al., 2000), but
this could occur on account of increased activation of eNOS or enhanced iNOS
activity for a short duration, without any change in the levels of these proteins.
In contrast to these findings, we have shown upregulation of eNOS, p-
eNOS and the high-activity isoform iNOS in response to chronic VEGF exposure
resulting from Ad.VEGF transduction of pregnant sheep UAECs. These results
were visible 48 hours post-infection but there was no upregulation in the first 24
hours of infection. This is likely to be because transgene expression peaks during
the first 12-24 hours, and downstream signaling pathways are
activated/upregulated only following this period.
Levels of NO were not analysed in our study. The reason why we
observed a difference in eNOS and iNOS levels in response to adenovirus-
mediated over-expression, but the same was not noted by Bird IM, may be on
account of the method by which VEGF is presented to the cells, that is,
endogenous or exogenous. The prevailing view until recently had been that
endothelial cells do not produce VEGF (Maharaj AS et al., 2006). However, in a
report by Lee et al, it was demonstrated that endogenous VEGF produced by
endothelial cells is crucial for vascular homeostasis and maintenance (Lee S et al.,
2007). The authors specifically deleted VEGF in the endothelial cells and mature
haematopoietic cells of mice by using a vascular endothelial cadherin-driven Cre
recombinase system. Using this mouse model, it was shown that in the absence of
their own autocrine VEGF, endothelial cells undergo apoptosis, causing collateral
damage by blocking vascular traffic and initiating thrombosis. Accumulation of
these detrimental changes in the entire vascular network leads to haemorrhage,
endothelial cell rupture, neointimal hyperplasia, circulatory collapse and
consequent death of 55% of mice deficient in endothelial VEGF by 25 weeks of
age. Furthermore, in this mouse model, exogenous administration of VEGF was
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unable to compensate for the loss of endogenous VEGF in endothelial cells,
despite the fact that signaling through VEGFR-2 activated many cell signaling
pathways, including the PI3K/AKT pathway, which is essential for cell survival.
Extracellular inhibitors of VEGF (Avastin) are not known to affect the survival of
endothelial cells in culture, but a small molecular weight inhibitor of VEGFR-2
(SU4312), which blocks VEGF signaling at the intra-cellular level, has been
shown to be cytotoxic.
All these findings support the concept that endogenous/autocrine VEGF
signaling is essential for endothelial cell survival, and acts by a pathway that is
independent of exogenous/paracrine VEGF signaling.
A recent study has demonstrated that human pregnancies complicated by
FGR and early-onset PET are characterized by endothelial dysfunction, which
persists not only until term but also several weeks post-partum (Yinon Y et al.,
2010). This is manifested as an impaired vasodilatory response to shear-stress.
Extrapolating from the studies of Lee et al (2007), I believe that a therapy that
corrects the underlying endothelial dysfunction at the intra-cellular/endogenous
level rather than exogenous growth factor supplementation may be of potential
therapeutic benefit in FGR and early-onset PET. Though as already mentioned in
the previous chapter, this hypothesis is difficult to test in pregnant human uterine
endothelial cells because of the difficulty in procuring this tissue.
One of the limitations of this study was that levels of NO were not
measured. Even though upregulation of eNOS, p-eNOS (Ser1177) and iNOS would
suggest an increased release of NO, this may not necessarily hold true in every
case (as discussed in Chapter 3). It is therefore important to quantify the amount
of this gas to get a more reliable estimate of the amount of vasorelaxant effect that
can be expected. One of the commonly used techniques for NO estimation is the
use of a colorimetric assay, the Griess Method. Additionally, it would be helpful
to quantify the amount of VEGF protein released into the cell culture supernatant
and also the amount of intra-cellular VEGF, to get an estimate of the amount of
protein produced in response to adenovirus infection at the different MOIs. This
can be performed by ELISA on cell culture supernatants and UAEC protein
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extracts. I have preserved samples of cell culture supernatants and UAEC proteins
extracts, and intend to use them for estimation of VEGF and NO levels.
Further experiments in animal models of FGR characterized by utero-
placental insufficiency and endothelial dysfunction are warranted, to understand
the true mechanism of Ad.VEGF action and to explore the benefits of endogenous
VEGF treatment, if any, over exogenous VEGF treatment. To this end, we plan to
investigate the effects of adenovirus-mediated VEGF expression in UAECs
isolated from sheep with pregnancies complicated by FGR. Work alongside this
project is ongoing in the adolescent-overnourished ewe, a sheep model of FGR in
which there is mid-gestation reduction in uterine artery blood flow that correlates
with the reduction in fetal weight (Wallace JM et al., 2008). Additionally, using
siRNA technology we plan to knockdown VEGF expression in pregnant sheep
UAECs to mimic a dysfunctional endothelium (likely seen in FGR/PET), and then
investigate if Ad.VEGF infection can rescue the anomalous phenotype. The
rationale behind these experiments is to find out if Ad.VEGF infection and
consequent endogenous VEGF production can reverse the endothelial dysfunction
that characterizes utero-placental vascular insufficiency.
In this study, I attempted to measure the levels of VEGF receptors,
VEGFR-1, VEGFR-2 and neuropilin-1 in protein extracts from the infected
UAECs. However, we did not get any conclusive results in this study, due to the
poor quality of the western blots. Even though previous studies have shown the
presence of VEGFR-1 and VEGFR-2 in UAECs (Grummer MA et al., 2009) by
western blotting, we were unable to get clear results. It may be on account of an
inferior batch of antibodies that we used, or perhaps our choice of lysis buffer for
protein extraction, which is different to what was used by Grummer MA (2009). I
believe, however, the latter is unlikely to have played any role as our western
blots for eNOS, p-eNOS (Ser1177), iNOS and GAPDH were clean (showing only a
single band at the correct molecular weight). Nevertheless, we plan to repeat this
experiment using a fresh batch of antibodies and the same lysis buffer as was used
by Grummer MA. Another alternative to circumvent this problem would be to
extract RNA from the transduced UAECs, and use it for RT-PCR with primers
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specific for the different VEGF receptors. In this way, we would be able to
investigate changes in VEGF receptors at the messenger level, using a very
sensitive and reliable technique.
In these studies, it was noted that even at very high MOIs such as 104, the
infection efficiency only reached 90% and never 100% as would be anticipated at
this vector dose. It is unusual to have such a low infection efficiency with such a
high titre of adenoviral vector. It is possible that the titre of the virus provided was
over-estimated by Ark Therapeutics Ltd., which produced the virus, or that a
number of freeze-thaw cycles had been performed on the virus stocks, which can
lead to a reduction in infection efficiency. The titres were not re-checked in our
lab before experimentation, and in the future, this would be important to do.
The ex vivo experiments on uterine artery vascular reactivity using an
organ bath revealed that in addition to the NOS pathway, EDHF plays an
important role in the bradykinin-mediated endothelium-dependent relaxation in
pregnant sheep. However, the very identity of EDHF is unknown and there are no
known antibodies to recognize it currently. Hence, it was not possible to perform
any western blot analysis to investigate changes in EDHF levels in response to
Ad.VEGF infection in the UAEC model. But in future experiments, we intend to
measure the levels of small Ca2+ activated potassium (SK) channels by western
blotting on UAEC protein extracts. These channels mediate the effects of EDHF
in blood vessels and it would be of interest to see if there is any difference in their
level in response to chronic VEGF exposure.
In conclusion, I have demonstrated that Ad.VEGF transduction leads to an
upregulation in eNOS, p-eNOS and iNOS levels in pregnant ovine UAECs. This
may be one of the important mechanisms by which VEGF is able to mediate the
beneficial outcomes on uterine artery vascular reactivity and uterine blood flow.
Exogenous administration of VEGF protein has been shown to have no effect on
the different NOS isoforms analysed. It is possible therefore, that sustained local
endogenous over-expression of VEGF may be necessary to increase NOS levels
in the uteroplacental vasculature. Future experiments to investigate the receptors
involved and effects of Ad.VEGF infection on UAECs from an FGR sheep model
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may give insights into the potential of VEGF gene therapy to reverse utero-
placental insufficiency, and its mechanism of action.
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Chapter 5
Results: Optimisation of gene transfer to the utero-
placental circulation of pregnant guinea pigs
The work described in the previous chapters has shown that local
adenovirus-mediated over-expression of VEGF-A165 in the uterine arteries of
pregnant sheep brings about a significant increase in UABF. The effects appear to
be mediated by changes in vascular reactivity, eNOS upregulation and
neovascularization. It is well known that there exists a direct positive co-relation
between UABF and fetal size and weight (Lang U et al., 2003). A compromised
utero-placental circulation is known to limit the rate of fetal growth and produce
either SGA or FGR infants, but the converse of this has not been proven. Hence,
the next phase of this investigation logically progresses to study if an increase in
blood flow can actually translate into an increase in fetal growth. These
experiments were carried out in guinea pigs – an appropriate small animal model
for human pregnancy. The advantage of using guinea pigs is that they have a
haemomonochorial placentation, which is the most similar to human placentation
in an animal model, with the exception of some non-human primates. Thus,
experimental results obtained from pregnant guinea pigs as well as toxicology
studies conducted in this species are likely to hold more relevance for clinical
translation. Furthermore, they have a relatively long gestation (65 days) for a
small animal, in contrast to mice, rats and rabbits. This gives the opportunity to
administer therapy at mid-gestation, and study the effects of treatment for 30-35
days post-administration.
The following chapter describes the results of pilot experiments for this
project, firstly to set up the FGR model in pregnant guinea pigs and secondly to
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develop a method of targeting gene therapy to the utero-placental circulation of
pregnant guinea pigs. Most of these optimization experiments were carried out in
normal pregnant guinea pigs rather than nutrient-restricted ones, because they are
easier and quicker to obtain than FGR guinea pigs.
5.1 Timed mating of guinea pigs yields a good conception
rate when females are left with males for 3 nights
The model of FGR pregnancy that we chose to adopt was the peri-
conceptual under-nutrition model in guinea pigs (Roberts CT et al., 2001a).
Previous work developing this model showed that when males were left in the
same cage as nutrient restricted females for a single night (on the day the vaginal
membrane was found to be ruptured), conception rates were in the range of 50-
60% (Roberts CT, personal communication).
Initially we left males in with females only for a single night (on the day
the hymen was found to be open) so that mating could be timed accurately.
Unfortunately this resulted in a very low conception rate (Table 5.1) in our study
cohort. We considered that the most likely cause was that mating was occurring
outside the time period when we deemed the guinea pigs to be in estrus phase.
Even though the hymen remains open for 2-3 days, the estrus phase lasts only 8-
12 hours in the night, during which the female guinea pig is receptive to the male.
Table 5.1 – Conception rate in female guinea pigs left with a male for a single
night and 3 nights
Time male left in with female Conception rate
Overnight 2 out of 7 (28.57%)
3 days 6 out of 10 (60%)
3 days with new boar 7 out of 10 (70%)
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After discussion with Dr. Claire Roberts and her research group, Adelaide
University, South Australia, who originated this particular FGR model, it was
decided that the males be left in with the females for a longer period of time, to
ensure they were together during the receptive phase. This change boosted
conception rates as shown in Table 5.1. We have further improved the conception
rate in normal guinea pigs up to 70% in the most recent animals, by buying in
some new boars (Table 5.1).
5.2 Nutrient-restricted guinea pigs have a lower conception
rate than guinea pigs on ad lib diet
To develop the nutrient restricted diet that is known to generate pregnant
guinea pigs with FGR according to the protocol of Roberts CT et al (2001), the
daily dietary intake of normal pregnant guinea pigs was first determined. We
used virgin Dunkin Hartley guinea pigs at 5-7 months of age, that weighed at least
800 grams. Guinea pigs below this threshold weight showed a tendency towards
rapid weight loss when put on the nutrient restricted diet and nil conception rate.
The daily food intake and body weights of normal guinea pigs (n = 10) were
measured daily for 1 month before conception. Animals were then left in with the
male for 3 days, after which (assuming the animal got pregnant), the body weight
and food intake were measured throughout the length of gestation.
To create the FGR model, guinea pigs were nutrient restricted to 70% of
the normal intake for 4 weeks before conception until day 34 of pregnancy, and
then to 90% of the normal intake until the end of gestation. Normal pregnant
animals were found to be consuming an average of 0.6g of feed daily per 100g
body weight before and during early pregnancy. Animals on the growth restricted
diet were therefore fed 0.42g of feed daily (70%) per 100g body weight when put
on the under-nutrition regime.
Initially guinea pigs on a nutrient restricted diet failed to get pregnant,
even after being placed in the same cage as a male for over one month (n=6).
However, with the improved conception rates in normal pregnant animals, leaving
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males in with females for a longer duration during estrus and bringing in new
males into the breeding programme, we have currently started obtaining FGR
pregnancies with a success rate of 60-70%. This compares well with previously
published results (Roberts CT et al., 2001a), wherein the success rate of FGR
guinea pig pregnancy was 60%. Guinea pigs maintained on an ad lib diet
generally have conception rates >90%.
Guinea pigs that failed to get pregnant after being put on the nutrient
restricted diet were maintained on the same diet for a further 2-4 weeks (until the
next 1-2 estrus cycle) and re-mated. If they still failed to conceive after three
occasions to mate, they were returned to a normal diet for 4-6 weeks until they
regained their original baseline body weight, and then made to enter the under-
nutrition regime again.
5.3 It is possible to confirm pregnancy in guinea pigs by
ultrasound scanning
Guinea pigs were first scanned at 18-20 days post-conception, while
restrained by a trained animal technician, to confirm pregnancy. However, at this
gestational age, we were able to see a fetus and confirm pregnancy status in only
one-third of all animals scanned that were actually pregnant (n=12). When
scanned at a slightly later time point, that is, 24-25 days post-conception, we were
able to clearly see a fetus in all guinea pigs that were actually pregnant. Hence, it
was decided to scan all guinea pigs at this time point to confirm pregnancy.
In the initial scan during which the guinea pig was awake and restrained
by an animal technician, it was only possible to confirm pregnancy and determine
fetal number. Additionally, measurements of BPD could be taken to confirm
gestational age, by comparing with published data (Turner AJ and Trudinger BJ,
2000). It was often not possible to perform a more detailed ultrasound
examination and collect other fetal measurements in awake guinea pigs, as they
became restless quickly. These additional measurements (abdominal
circumference, femur length, placental thickness and placental diameter) could
however be easily obtained under general anaesthesia, at the time of vector
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injection for all guinea pigs. Initially, we also collected measurements of femur
length for the fetal guinea pigs, but because of the difficulty in accurately
identifying the femur, this parameter could not be acquired for all guinea pigs.
5.4 Growth-restricted guinea pigs have smaller abdominal
circumferences and show a trend towards brain sparing
compared to normal guinea pigs
Sonographic measurements of biparietal diameter, occipito-snout length
and abdominal circumference were compared between normal and growth-
restricted guinea pigs at 45 days gestational age (Figure 5.1). The results of these
are summarized in Table 5.2.
A.
B.
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C.
D.
Figure 5.1 – Representative images of fetal guinea pig ultrasound
measurements at 45 days of gestation.
‘A’ is a representative picture of femur length; measurement was taken between the two arrow
heads. ‘B’ is a representative picture of biparietal diameter; measurement was taken between the
two arrow heads. ‘C’ is a representative picture of abdominal circumference; measurement of the
abdominal perimeter was taken. ‘D’ is a representative picture of the placenta; measurement
between the arrow heads represents placental diameter, while measurement between the crosses
represents placental thickness.
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Table 5.2 – Sonographic estimation of guinea pig fetal measurements at 45
days gestational age (range 44-47 days)
DietSonographic
measurement
Normal ad lib
(Mean+SD)
Nutrient-restricted
(Mean+SD)
p
(unpaired t-
test)
Biparietal Diameter
(BPD, mm)
16.06+0.75
(n=13)
15.53+0.70
(n=10)
0.08
Occipito-Snout Length
(OSL, mm)
27.95+2.09
(n=10)
25.98+3.31
(n=9)
0.14
Head Circumference
(HC, mm)
69.09+4.44
(n=10)
65.17+4.11
(n=9)
0.03
Abdominal
Circumference (AC, mm)
84.25+9.25
(n=15)
71.21+11.09
(n=10)
0.004
BPD/AC 0.19+0.02
(n=13)
0.21+0.01
(n=10)
0.002
OSL/AC 0.33+0.05
(n=10)
0.36+0.04
(n=9)
0.25
HC/AC 0.82+0.09
(n=10)
0.92+0.08
(n=9)
0.07
To summarize, fetuses of guinea pigs on a nutrient restricted diet have a
significantly smaller abdominal circumference at 45 days gestational age than
fetuses of guinea pigs on an ad lib diet. BPD and OSL were also reduced in
growth-restricted fetal guinea pigs, though the difference did not reach
significance with the animal numbers that were analysed to date. There was a
significant reduction in the head circumference of nutrient restricted guinea pigs,
while the ratios of head to abdominal circumference demonstrated a trend towards
being increased in the fetuses of FGR guinea pigs. This suggests that maternal
nutrient restriction results in the onset of brain sparing in fetal guinea pigs.
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5.5 Fetuses from guinea pigs on the nutrient-restricted diet
weigh less than fetuses from guinea pigs on an ad lib diet
During the course of this Ph.D., 7 (out of 10) guinea pigs maintained on
the nutrient restriction diet to assess the degree of growth restriction achieved got
pregnant. Their fetuses were delivered at 44-47 dpc, and the fetal weights were
compared with the weights of fetuses born to sows on an ad lib diet, at the same
gestational age. The average fetal weight in the ad lib group was 35.05+3.75 g
(n=16), while the average fetal weight in the nutrient restricted diet was
20.54+1.16 g (n=22), p=0.01 (unpaired t-test). Thus, the fetuses of guinea pigs on
a nutrient restricted diet were 41.4% lighter than those of sows on an ad lib diet.
This compares well with previous data (Roberts CT et al., 2001a), which achieved
a 29% reduction in fetal weight at 30 days gestation and 35% reduction in fetal
weight at 60 days of gestation. The difference in fetal weights between nutrient-
restricted and control groups were not analysed at 45 days of gestation by this
author.
5.6 Fetuses from guinea pigs on the nutrient-restricted diet
have a smaller placenta than fetuses from guinea pigs on
an ad lib diet
Sonographic measurements of placental dimensions (thickness and
diameter) and placental weights at post-mortem were compared between the
nutrient-restricted and control groups. The placental thickness was taken at its
narrowest diameter for consistency, and the placental diameter was measured in
the same view. It was not possible to accurately obtain a view of the placenta in a
3rd plane due to the large number of fetuses present, and the relatively large size
of the ultrasound probe.
In animals that had an ultrasound examination at approximately 45 days of
gestation (range 44 to 47 days), the placental thickness in the nutrient restricted
group showed a trend to being smaller than the ad lib group. There was no,
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significant difference in the placental diameters or placental areas at 45 days of
gestation (Table 5.3).
Table 5.3 – Sonographic placental measurements in normal and FGR guinea
pigs at 45 days (range 44-47 days) gestational age
GroupMeasurement
Normal
(Mean+SD)
Nutrient-restricted
(Mean+SD)
p
(unpaired t-test)
Placental thickness
(mm)
13.00+1.41
(n=12)
9.18+0.97
(n=8)
0.056
Placental diameter
(mm)
23.65+1.21
(n=12)
22.24+0.88
(n=8)
0.399
Placental area
(mm2)
439.06+127 388.27+83.74 0.477
The placentae of animals that had a post mortem examination at 45 days
of gestation were significantly lighter in guinea pigs on the nutrient-restricted diet
(3.56+0.63g, n=10) than the ad lib diet control group (4.72+0.91, n=22), p=0.02
(unpaired t-test).
During laparotomy surgery, it was observed that the size of the uterine and
radial arteries were smaller in nutrient-restricted guinea pigs compared to normal
animals. The number of radial arteries supplying each placenta was also lesser in
the nutrient restricted guinea pigs.
5.7 Gene Targeting to the Utero-Placental Circulation of
Pregnant Guinea Pigs
5.7.1 The guinea pig uterine artery can be injected reliably only
under a dissection microscope
Initial attempts at injecting the uterine artery were carried out under direct
vision. However, the small size of the artery (300-400μm diameter, Figure 5.2) 
and the large amount of fat that surrounded it made it difficult to inject it reliably
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and repeatedly. The purchase of a dissecting microscope allowed better
visualisation of the uterine arteries of the guinea pig. By elevating the fat pad on
either side of the cervical canal and by shining a strong light through it, the course
of the uterine artery could be seen within the fat pad as a red line, before it gives
off the first radial artery branches. The uterine artery could then be seen running
more superficially within the fat pad giving off radial artery branches to the 3 to 5
fetal guinea pigs within the uterus. Once the course of the lower uterine artery
was identified, the fat pad was opened under an operating microscope to improve
visualization. The right uterine artery runs more towards the anterior aspect of the
fat pad making an anterior approach best. The left uterine artery runs more in the
posterior aspect of the fat pad, therefore on the left side the fat pad was turned
over to expose the posterior aspect and the uterine artery then dissected out. Intra-
arterial injections with the help of a dissecting microscope have proven to be
more accurate and reliable, as compared to injections under direct vision.
Figure 5.2 - Uterine and radial arteries in pregnant guinea pig at 45 days of
gestation
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5.7.2 The uterine arteries are more easily accessible at 45dpc as
compared to 30dpc
In the initial phase of this study, surgeries on guinea pigs were performed
at 30dpc (mid-gestation). However, the smaller size of the uterine arteries (150-
250µm) made it technically challenging not only to find them within the fat pad,
but also insert a needle (34 Gauge) within them to inject the vector. Hence, it was
decided to perform the optimization surgeries at 45dpc (3/4 gestation) when the
arteries are slightly larger (300-400µm, Figure 5.2). It was planned to operate on
30dpc animals after having gained some experience and skill at successfully
injecting 45dpc animals.
5.7.3 Morbidity and mortality in pregnant guinea pigs after
surgery is low
With experience we identified factors that improved fetal survival and
reduced maternal mortality. These include keeping the time for sonographic
measurement of fetuses to a minimum, rapidly accessing the abdomen,
minimising the time needed to identify and injecting the vessels, avoiding
removing the pregnant horns from the abdominal cavity, keeping the animal warm
throughout surgery and during recovery, minimizing blood loss and good
analgesia.
Deaths occurred initially with very long anaesthetic times (> 4 hours) due
to difficulties in identifying the uterine artery, and while developing the best set
up for the operating microscope. More recently, deaths have occurred when there
were multiple attempts to inject the internal iliac artery associated with excessive
blood loss (Table 5.4). At post mortem examination after maternal death, large
blood clots over the injection sites were identified, with associated peritonitis.
There is minimal bleeding after 3 minutes of occlusion over the injection site
whether it is the uterine artery or the internal iliac artery. However, in cases of
excessive bleeding, a longer occlusion time is required which is associated with a
higher maternal and/or fetal mortality rate.
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All maternal mortalities have been as a direct consequence of the surgery,
either during the surgery (n=2) or within the next 24 hours (n=3). There have been
no deaths attributed to the anaesthesia, and no problems with aspiration of
stomach contents, or the development of diarrhea, which is a common finding if
antibiotics are used. Recovery of the pregnant guinea pigs is good, and
miscarriage if it occurs, is usually by day 2 post-surgically. There have been no
hernias observed.
Table 5.4 - Maternal and fetal survival after surgery
Injection route Maternal
survival
Fetal survival Comments
Uterine artery near
cervix
6 out of 8 No fetal loss in mothers
that survived.
Early experiments. Complicated
by long anaesthetic time (>4 hrs),
excessive blood loss and
difficulty visualising uterine
artery
Uterine artery
injection or external
transduction
5 out of 6 1 mother died during a 4
hour surgery
Other mothers all had live
fetuses at PM
Shorter anaesthetic time when
extrernal gene transfer used
Internal iliac
injection
4 out of 6 No fetal loss in mothers
that survived.
Deaths occurred when the heating
pad failed, when there was
excessive blood loss and long
anaesthetic time (>4 hrs)
Pluronic gel
Administration
6 out of 6 One mother miscarried due
to excessive uterine
manipulation. No fetal
morbidity or mortality in
other mothers.
Simple and straightforward
technique, can be performed
relatively quickly compared to
other techniques.
5.8 Intra-arterial injections into the uterine arteries
5.8.1 Intra-arterial injections into the uterine arteries are
technically challenging even at 45dpc
We attempted Ad.LacZ injection into 16 uterine arteries from 8 pregnant
guinea pigs but were only successful in 7 vessels (Table 5.5), i.e. 44% of
attempts. The low success rate is primarily for two reasons – the uterine artery is
deeply embedded in fat and is unsupported. A successful injection was defined as
the vector seen moving down the vessel during injection. Failed injections were
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due to vector being inadvertently injected into the vessel wall, leaking out of the
vessel or coming out of the other side of the vessel, opposite the injection site.
The dose of vector injected per artery was 1x1010 vp. The volume ranged from
500μl to 1.3ml and the duration of injection ranged from 90-112 seconds. 
Following injection, the vessel was occluded with a vascular clip for up to 3
minutes. If haemostasis was not achieved, adrenaline was administered to the
vessel externally. Post mortem examination was carried out 2 to 5 days after
injection, the earlier time points were due to unexpected maternal death or
miscarriage.
Table 5.5: Uterine artery injection attempts in pregnant guinea pigs fed ad
lib
Number of
injection
attempts per
uterine artery
GP
no.
GA
(d)
Needle
size
(Gauge)
failed success
Volume
injected
(l)
Occlusion
time if
successful
injection
(min)
Adrenaline
used
Outcome
231 33 31 R(2),
L(4)
R(1),
L(0)
500 5.5 min Yes Maternal
death during
surgery due
to long
anaesthetic
time >4h
230 35 31 R(4),
L(4)
0 500 - No Fetuses alive
at PM (3d)
173 43 31 R(1),
L(4)
R(1),
L(0)
500 7 min Yes Fetuses alive
at PM (4d)
300 45 31 R(2),
L(4)
R(1),
L(0)
500 5 min Yes Fetuses alive
at PM (4d)
217 43 31 R(4),
L(2)
L(1),
R(0)
500 9 min Yes Maternal
death within
24h
218 45 34 R(3),
L(3)
0 500 5 min No 1 out of 3
fetuses alive
at PM (5d)
297 49 34 R(3),
L(3)
R(1),
L(1)
1000 8 min (L),
9.5 min (R)
Yes Fetuses alive
at PM (4d)
298 49 34 R(2),
L(4)
R(1),
L(0)
1300 5 min Yes Fetuses alive
at PM (4d)
Results are presented in the order that the experiments were performed. GP: guinea pig; d: days;
R: right uterine artery; L: left uterine artery; h: hours; d: days
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In summary, injection of uterine arteries is more successful when using the
smaller 34 Gauge needle, later in gestation and the right side is easier than the
left. It was only successful in 44% of attempts, and only on both sides in 1
animal. Fetal survival was good.
5.8.2 Intra-arterial injection into the uterine artery leads to
limited transgene expression in the utero-placental circulation
Injection of Ad.LacZ into the uterine arteries resulted in staining of the
cervical end of the uterine arteries, the cervical end radial arteries and the radial
arteries supplying fetuses in the middle of the uterus (Table 5.6 and Figure 5.3).
The maternal liver and uterus were also stained. The ovarian end uterine and
radial arteries were not stained.
The uterine arteries and the radial arteries to the first guinea pig fetus were
transduced when only 500 μl of vector was injected, but larger volumes (1.0 ml) 
were needed to reach the radial arteries supplying the middle fetus (if there are 3
on one side). However, even the maximum volume that was injected (1.3 ml) was
not successful in transducing the ovarian end of the uterine artery and ovarian end
radial arteries.
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Figure 5.3 – X-gal staining of guinea pig tissue after intra-arterial
administration of Ad.LacZ into the uterine arteries.
Pregnant guinea pigs received an injection of Ad.LacZ into their uterine arteries at 45 days of
gestation. Maternal and fetal tissues were harvested at post-mortem examination 2-5 days later and
analysed by X-gal staining. A and B – Positive expression distal to the site of injection and along
the origin of a radial artery; C – positive expression on the inside wall of the uterine artery; D –
positive staining on the external surface of a uterine artery; E – positive staining on the external
surface of a radial artery; F – strong β-galactosidase expression in the liver.  
Hence, intra-arterial administration of vector into the uterine arteries of
normal pregnant guinea pigs only leads to limited/partial transduction of the
utero-placental circulation that is confined to areas closest to the injection site.
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Table 5.6 : Transgene expression after intra-arterial injection into the
uterine artery
X gal staining
Ut Art Rad Art Uterine
horn
GP
no.
GA
(d)
Del-
ive-
ry
me-
thod
Vect-
or
vol-
ume
(l)
Cx
end
O
v
en
d
Cx
end
O
v
en
d
Place-
nta
Fe-
tus
Mater-
nal
liver Cx
en
d
O
v
en
d
Fat
of
ute-
rus
Oth-
er
tiss-
ues
231 33 $ Ut
Art
500 - - - - - - - - - - -
230 35 Ut
Art
500 - - - - - - + - - -
173 43 Ut
Art
500 ++ - + - - - ++ + + ++ Uteri
ne
vein
300 45 Ut
Art
500 +++
+
+ +++
+
- - - +++ ++ ++ ++ Uteri
ne
vein
217 43 $ Ut
Art
500 - - - - - - - - - - -
218 45 Ut
Art
500 - - - - - - ++ + + + -
297 49 Ut
Art
1000 +++ - + - - - +++ ++ + ++ Uteri
ne
vein
29 49 Ut
Art
1300 +++ - + - - - +++ ++ ++ ++ -
GP = Guinea pig; $ GP died during or shortly after surgery; GA = gestational age at
administration; d = days; Ut Art = Uterine artery injection; Cx=cervical, Ov=ovarian, number of
‘+’ signs indicates intensity of staining
5.9 External administration of Ad.LacZ to the uterine
arteries of pregnant guinea pigs is technically
straightforward
In those cases where repeated attempts to inject the uterine artery vessel
were unsuccessful, a decision was made to study the effect of external gene
transfer to the uterine and radial arteries (Table 5.7). The vector was injected into
the fat pad alongside the uterine artery (n=6 vessels). In cases where the vessel
could be completely exposed, the vector was dribbled upon it as it lay in the fat
pad (n=2 vessels). The vessels were left to transduce for 5 minutes. Vector was
also dribbled onto the radial arteries as they ran within their mesentery and left for
5 minutes before the uterus was subsequently mobilized. No vessel injection or
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occlusion was used in this technique, and hence it was much less traumatic and
easier to perform. We did observe however, that the vector ran off from the
intended vessels which was likely to lead to widespread gene transfer rather than
that local to the uteroplacental circulation.
Table 5.7: External gene transfer to uterine and radial arteries.
Uterine artery transductionGP
no.
GA
(days)
Needle
size
(Gauge)
External
administration
Injection
alongside vessel
Volume
applied to
vessel (l)
231 33 31 na L 500
230 35 31 na L, R 500
173 43 31 L na 500
300 45 31 L na 500
218 45 34 na L, R 500
298 49 34 na L 1000
All animals had a failed injection attempt into the uterine arteries before external vector
administration was tried. na: not attempted: The side not transduced by external administration of
the vector had been successfully injected by the intra-arterial route.
In summary injection alongside the vessel or dribbling the vector onto the
exposed vessel was technically easy to perform. It was also probably associated
with a lower morbidity and mortality when compared to intravascular injection,
although this aspect of the technique could not be examined here.
5.9.1 External administration of Ad.LacZ to the uterine and
radial arteries of pregnant guinea pigs leads to high expression
levels, but undesirable spread of transgene expression
systemically
External administration of the vector to the uterine and radial arteries
resulted in positive expression in all the vessels onto which the vector was
dribbled (Figure 5.4).  All radial arteries expressed β-galactosidase. There was 
also positive β-galactosidase expression in the fat surrounding the uterine arteries, 
the maternal liver and uterus (Figure 5.5). There was slight staining in the
placentae but none in the fetuses.
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Figure 5.4 – Transgene expression in the uterine and radial arteries of guinea
pigs after external administration of Ad.LacZ in PBS
The uterine and radial arteries of pregnant guinea pigs were transduced with Ad.LacZ at 45 days
of gestation by external administration. Maternal and fetal tissues were harvested at post-mortem
examination 2-7 days later and analysed by X-gal staining. A - Positive β-galactosidase expression 
in a uterine artery after Ad.LacZ was injected into the fat pad alongside the uterine artery; B –
Positive transgene expression in a uterine artery after Ad.LacZ was dribbled onto the exposed
vessel; C – Positive transgene expression on the inner luminal surface of a uterine artery after
vector was applied externally; D – positive transgene expression on a radial artery after Ad.LacZ
was dribbled on it.
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Figure 5.5 – Transgene expression in maternal tissues after external
administration of Ad.LacZ to the utero-placental vasculature
The uterine and radial arteries of pregnant guinea pigs were transduced with Ad.LacZ at 45 days
of gestation by external administration. Maternal and fetal tissues were harvested at post-mortem
examination 2-7 days later and analysed by X-gal staining. A and B – Transgene expression in the
uterine horns; C and D – Transgene expression in the fat pad surrounding the uterus
The outcome of external administration of vector to the uterine and radial
arteries has been summarized in Table 5.8.
In summary, external administration of the vector to the uterine artery
resulted in high levels of transgene expression in the uterine and radial arteries,
but there was also viral spread and expression in the liver.
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Table 5.8 : Transgene expression after external administration of vector to
the uterine arteries
X gal staining
Ut Art Rad Art Uterine
horn
GP
no.
GA
(d)
Del-
ive-
ry
me-
thod
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r
volu
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(l)
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en
d
O
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en
d
Cx
end
Ov
end
Placen
ta
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us
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d
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v
en
d
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of
uter
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r
tissu
es
231 33 $ Exte-
rnal
500 - - - - - - - - - - -
230 35 Exte-
rnal
500 + - + - - - + - - ++ -
173 43 Exte-
rnal
500 ++ - ++ ++ + - ++ ++ ++ ++ -
300 45 Exte-
rnal
500 ++ - +++
+
+++
+
+ - +++ ++ ++ ++ -
218 45 Exte-
rnal
500 + - + - - - ++ + + ++ -
298 49 Exte-
rnal
1300 ++ - ++ + - - +++ + + ++ -
GP = Guinea Pig; $ GP died during or shortly after surgery; GA = gestational age at
administration; d = days; Cx = cervical; Ov = ovarian The number of ‘+’ signs indicate the
intensity of staining.
5.10 Internal Iliac Injections
5.10.1 Vector injection into the internal iliac artery is more
straightforward than uterine artery injection
The internal iliac artery gives off the uterine artery as one of its distal
branches. Hence, we hypothesized that intra-vascular administration of vector into
the internal iliac artery would lead to transduction of the utero-placental
circulation, while being technically more easily achieved. We attempted to inject
the internal iliac arteries of 6 normal pregnant guinea pigs (12 vessels) at 45dpc
and achieved successful injection of both the internal iliac arteries of all 6 animals
(Table 5.9).
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Table 5.9 - Injection of the internal iliac artery: feasibility and survival (45 –
47 days of gestation)
Number of
attempts per
internal iliac vessel
GP
no.
Needle
Gauge
failed success
Volume
injected
(l)
Occlusion
time if
successful
injection
(min)
Adrenaline
used
Outcome
301 34 L(2),
R(3)
L(1),
R(1)
1000 2.5 min Yes Fetuses alive at
PM (4d)
302 34 R(2),
L(2)
R(1),
L(1)
R-400
L-1000
8 min Yes Fetuses alive at
PM (4d)
94 34 R(3),
L(4)
R(1),
L(1)
1500 5 min Yes Fetuses alive at
PM (3d)
331 34 R(3),
L(5)
R(1),
L(1)
1500 6.5 min Yes Fetuses alive at
PM (3d)
329 34 R(5),
L(6)
R(1),
L(1)
1500 6 min Yes Maternal death
within 24 hours
of surgery
330 34 R(6),
L(6)
R(1),
L(1)
1500 5 min Yes Maternal death
within 24 hours
of surgery
GP: Guinea pig; R: right uterine artery; L: Left uterine artery; d: days
As can be inferred from Table 5.9, the internal iliac artery injection was
more easily achieved than uterine artery injection, and we were able to inject the
vessel in all animals, eventually. Larger volumes of vector needed more attempts
to inject the vessel since the needle became dislodged from the vessel during the
1-2 minutes that were needed to deliver the volume intended, and a repeat
injection was often needed. Maternal survival was generally good, but two of the
four guinea pigs that received 1500 μl vector died.  This is probably related more 
to difficulties in injecting the vessel, since 5 or 6 attempts were needed on each
side to ensure that the full volume of vector was injected. This resulted in
bleeding rather than vector toxicity. Fetal survival was good in all other cases.
5.10.2 Injection of vector into the internal iliac artery does not
transduce the utero-placental circulation
Administration of Ad.LacZ into the internal iliac artery resulted in positive
X-gal staining in the internal iliac artery, the pelvic side wall muscles, bladder,
cervix and the maternal liver. There was no expression at all in the uterine/radial
369
arteries, the fat around the uterine arteries, the placentae or fetuses. Increasing the
volume of vector injected did not lead to positive expression in the uterine artery.
(Figure 5.6, Table 5.10)
Figure 5.6 - Transgene expression in maternal tissues after intra-arterial
administration of Ad.LacZ in the internal iliac arteries
Pregnant guinea pigs received an injection of Ad.LacZ into their internal iliac arteries at 45 days
of gestation. Maternal and fetal tissues were harvested at post-mortem examination 3-4 days later
and analysed by X-gal staining. A – Transgenic protein expression at the site of vector injection
but decline in expression distally; B – Transgenic protein expression in the urinary bladder; C and
D – Staining of pelvic side wall muscles from the left (C) and right (D) sides. The utero-placental
blood vessels showed no positive β-galactosidase expression (not shown). 
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Table 5.10: Gene transfer results after internal iliac artery injection
X gal staining
Ut Art Rad Art Uterine
horn
GP GA
(d)
Vector
volume
(l)
Cx
end
Ov
end
Cx
end
Ov
end
P F Maternal
liver
Cx
end
Ov
end
Ut
fat
Other tissues
301 45 1000 - - - - - - +++ - - - Pelvic muscles
302 45 R-400
L-1000
- - - - - - +++ - - - Pelvic muscles
94 47 1500 - - - - - - +++ - - - Pelvic muscles,
Urinary
bladder, cervix
331 45 1500 - - - - - - +++ - - - Pelvic muscles,
Urinary
bladder, cervix
329 45 $ 1500 - - - - - - - - - - -
330 45 $ 1500 - - - - - - - - - - -
For each animal there are two uterine horns and results are presented together.
GP: Guinea pig; $ GP died during or shortly after surgery; GA = gestational age at administration;
d= days; Cx = cervical; Ov = ovarian; P: placenta; F:fetus; Ut:uterine; Rad: radial; Art: artery; d:
days
Hence, injection of vector to the internal iliac artery is not a feasible option
to transduce the utero-placental circulation.
5.11 Pluronic Gel-Vector Combination
5.11.1 Administration of pluronic gel-vector combination is
technically the easiest and most reliable method to transduce the
utero-placental circulation
None of the intravascular injection routes so far investigated had provided
the ease, reproducibility or level of local gene transfer that would be required to
transduce the utero-placental circulation in the guinea pig. The easiest method of
gene transfer appeared to be external administration but this was associated with
high levels of systemic gene transfer, probably because the vector easily ran off
from the site of application. To avoid this we investigated combining the vector
with a substance that was less fluid. Pluronic gel provides such a system because of
its thermodynamic properties. This gel is liquid at 4°C, but becomes solid at body
temperature.
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Administration of Pluronic gel-vector combination involved exposing the
uterine and radial arteries by dissecting them out from the surrounding fat. The
Pluronic gel-vector combination was made up over ice until use and was then drawn
up into a 1ml syringe. It was then applied externally to the vessels and allowed to
remain in place for 5 minutes to allow sufficient time for transduction, before
mobilizing the uterine horns. In some cases parts of the uterine horns were lifted out
of the peritoneal cavity to allow better visualization of the radial arteries. The
uterine horns were kept warm during this time by wrapping them up in sterile gauze
soaked in warm saline. With experience we observed a higher rate of fetal loss
when the horn or part of it was lifted from the peritoneal cavity. To avoid this, a
larger laparotomy scar was made, to well above the umbilicus which allowed the
uterine horn to be manipulated to expose the radial arteries, while keeping it within
the peritoneal cavity. The feasibility of this technique is presented in Table 5.11.
We found that administration of the vector by this method is relatively
straightforward and quick to perform, shortening the duration of the surgery by
more than half (from 3-4 hours to only 1.5 hours). Within a few seconds of laying
the Pluronic gel-vector combination onto the vessel, it set to form a gelatinous
mass.
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Table 5.11 – Administration of vector using Pluronic gel as a vehicle: feasibility
and survival (45 – 47 days of gestation)
Number of
attempts at
administration
GP
no.
failure success
Vector
volume
delivered
(l)
Occlusion
time if
successful
(min)
Adrenaline
used
Outcome
339 L(0),
R(1)
L(1),
R(0)
1000 Not
required
No Mother
miscarried 24
hours after
surgery
375 L(0),
R(0)
L(1),
R(1)
1000 Not
required
No Fetuses alive at
PM (4 days)
413 L(0),
R(0)
L(1),
R(1)
1000 Not
required
No Fetuses alive at
PM (5 days)
415 L(0),
R(0)
L(1),
R(1)
1000 Not
required
No Fetuses alive at
PM (5 days)
319* L(0),
R(0)
L(1),
R(1)
1000 Not
required
No Fetuses alive at
PM (7 days)
320* L(0),
R(0)
L(1),
R(1)
1000 Not
required
No Fetuses alive at
PM (6 days)
* These animals only received the pluronic gel vehicle by itself, without any recombinant
adenovirus.
As can be inferred from the small number of attempts required to transduce
the vessels (Table 5.11), the administration of vector by this mode is technically
straightforward. In one case it was not possible to administer the vector to the right
uterine artery (guinea pig 339) because the vessel was very small and consequently
difficult to visualize within the fat pad. This guinea pig started to miscarry the next
morning, and the cause most likely was excessive manipulation of the uterine horn.
There was no evidence of peritoneal inflammation, bleeding or infection at post-
mortem examination.
5.11.2 Administration of vector using Pluronic gel as a vehicle
leads to very high levels of localized transgene expression
Administration of Ad.LacZ using Pluronic gel as a vehicle led to very high
levels of local transgenic protein expression in the uterine and radial arteries to
which the vector had been applied, both on the adventitial surface and the internal
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luminal surface (Figures 5.7-5.9). In fact, after X-gal histochemistry, some of the
vessels appeared as if they had been spray-painted blue. The liver and uterus had
minimal β-galactosidase expression in one animal and were not stained in any of the 
others. All other maternal and fetal tissues sampled (placentae, heart, kidney, lung,
gonad, bladder, brain and adrenal) were not stained (Table 5.12). Thus,
administration of Pluronic gel-vector combination achieves very high levels of
localized gene transfer and expression in the utero-placental circulation.
Administration of pluronic gel by itself without any Ad.LacZ in pregnant guinea
pigs (n=2) did not lead to any positive X-gal staining in any maternal/fetal tissue.
Figure 5.7 – Transgenic protein expression in the uterine arteries after
external administration of Ad.LacZ using Pluronic F-127 gel as a vehicle
The uterine and radial arteries of pregnant guinea pigs were transduced with Ad.LacZ at 45 days of
gestation using Pluronic F-127 as a vehicle. Maternal and fetal tissues were harvested at post-
mortem examination 1-4 days later and analysed by X-gal staining. A and B – Positive transgenic
protein expression in uterine arteries which had received the vector-pluronic gel combination; C –
No transgenic protein expression in a uterine artery which had only received pluronic gel without
Ad.LacZ.
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Figure 5.8 – Transgenic protein expression in the radial arteries after external
administration of Ad.LacZ using Pluronic F-127 gel as a vehicle
The uterine and radial arteries of pregnant guinea pigs were transduced with Ad.LacZ at 45 days of
gestation using Pluronic F-127 as a vehicle. Maternal and fetal tissues were harvested at post-
mortem examination 1-4 days later and analysed by X-gal staining. A-D – Positive transgenic
protein expression in radial arteries which had received the vector-pluronic gel combination.
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Figure 5.9 – Transgenic protein expression on the inner surface of a uterine
artery after external administration of Ad.LacZ using Pluronic F-127 gel as a
vehicle
The uterine and radial arteries of pregnant guinea pigs were transduced with Ad.LacZ at 45 days of
gestation using Pluronic F-127 as a vehicle. Maternal and fetal tissues were harvested at post-
mortem examination 1-4 days later and analysed by X-gal staining. The picture shows positive
transgenic protein expression on the inner surface of a uterine artery.
Table 5.12 – Gene transfer results after administration of the vector using
pluronic gel as a vehicle
X gal staining
Ut Art Rad Art Uterine
horn
GP
no.
G
A
(d)
Vect
or
volu
me
(l)
Cx
end
Ov
end
Cx
end
Ov
end
Placen
ta
Fet
us
Mater
nal
liver C
x
en
d
O
v
en
d
Fat
of
uter
us
Other
tissues
339 45 1000 +++
+
+++
+
+++
+
+++
+
- - + + - ++ No
expressi
on
375 46 1000 +++
+
+++
+
+++
+
+++
+
- - - - - ++ No
expressi
on
413 44 1000 +++
+
+++ +++
+
+++ - - - - - + No
expressi
on
415 47 1000 +++ +++ +++ +++ - - - - - - No
expressi
on
319
*
43 1000 - - - - - - - - - - No
expressi
on
320
*
46 1000 - - - - - - - - - - No
expressi
on
GP = Guinea Pig; GA = gestational age at administration; d = days; Cx = cervical; Ov = ovarian; *
these animals only received pluronic gel by itself, without any recombinant adenovirus; The number
of ‘+’ signs indicates the intensity of staining.
The primary objective of the study in pregnant guinea pigs was to
investigate how local over-expression of VEGF-A165 in the utero-placental
circulation affects the rate of fetal growth in normal and FGR guinea pigs. Having
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optimized the technique for gene targeting to the utero-placental circulation, we
started to examine the long term effect of gene transfer using Pluronic gel-
Ad.VEGF-A165 combination on the utero-placental vessels of FGR guinea pigs.
During the course of this Ph.D., an initial start was made by administering
Ad.VEGF-A165 to three FGR guinea pigs at 45 dpc. These studies were meant to be
long-term studies, with the animals being culled at 63 days (term=65 days).
Unfortunately, all 3 of these studies had to be terminated prematurely, within 7 days
post-administration of the vector because of experimental complications. In two of
the guinea pigs, the skin sutures snapped open at day 7, and hence they had to be
put down. We realized that the suture which we had been using to close the skin (3-
0 Vicryl) was not robust enough to last for more than a week, and hence we decided
to use 2-0 Vicryl for subsequent experiments. The third guinea pig had an eczema-
like skin condition pre-operatively. Post-surgically, the condition was exacerbated
and the animal appeared to in distress, having withdrawing from eating. In
accordance with the Home Office Regulations, the animal had to be euthanized.
5.12 Conclusion from Gene Targeting Experiments
Based on the results of the pilot experiments described above, it was decided
to administer gene therapy to the utero-placental circulation of guinea pigs using
Pluronic gel as a vehicle. The advantage of this method over other methods is that it
leads to very high levels of localized gene transfer and expression specifically at the
site of administration. There is none to minimal transgene expression in other
maternal and fetal tissues, as determined by X-gal histochemistry. It is technically
straightforward and atraumatic as there is no requirement of injecting any blood
vessel. External administration of the vector in pluronic gel also leads to transgene
expression on the inner luminal surface. There was no evidence of any edema or
inflammation at post-mortem examination. Hence, dilution of vector in Pluronic gel
appeared to be the most feasible approach to administer the vector to the utero-
placental circulation.
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5.13 The vascular reactivity of uterine arteries from pregnant
Guinea Pigs can be studied on a wire myograph
The uterine arteries from animals transduced with Ad.VEGF-A165/Ad.LacZ
were harvested and used for pharmacology analysis on a wire myograph. Initially, I
attempted to study the vascular pharmacology of these vessels on an organ bath, but
mounting on an organ bath damaged them because of their small size. This resulted
in no vascular reactivity (see Discussion). Analysis was performed on Ad.VEGF-
A165 and Ad.LacZ treated animals, who were administered the vector bilaterally at
44-47 days gestational age and terminated 2-7 days post-injection (n=3 each).
I observed a reduction in the contractile response and enhancement in
relaxation in Ad.VEGF-A165 transduced vessels compared to Ad.LacZ transduced
vessels. These results were however non-significant, probably on account of the
limited number of animals studied. The results of the myography experiments have
been summarized in Figures 5.10, 5.11 and Table 5.13.
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Figure 5.10 - Contractility of Ad.VEGF-A165 and Ad.LacZ transduced uterine
arteries from nutrient restricted pregnant guinea pigs 2-7 days after gene
transfer.
The uterine arteries of nutrient restricted pregnant guinea pigs were transduced with Ad.VEGF-A165
(n=3) or Ad.LacZ (n=3) at 43-47 days of gestation using Pluronic F-127 as a vehicle. The transduced
uterine arteries were harvested at post-mortem examination 2-7 days later, cut into 1mm ring
segments and analysed on a dual chambered wire myograph system. Concentration response curves
to PE were conducted for each vessel in duplicate. The contractility of the vessel is expressed as a
percentage of the response to KCl. PE produced concentration-dependent contractions, which were
of lesser magnitude in Ad.VEGF-A165 transduced vessels compared to Ad.LacZ transduced vessels.
Error bars denote standard error of mean.
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Figure 5.11 - Relaxation of Ad.VEGF-A165 and Ad.LacZ transduced uterine
arteries from nutrient restricted pregnant guinea pigs 2-7 days after gene
transfer.
The uterine arteries of nutrient restricted pregnant guinea pigs were transduced with Ad.VEGF-A165
(n=3) or Ad.LacZ (n=3) at 43-47 days of gestation using Pluronic F-127 as a vehicle. The transduced
uterine arteries were harvested at post-mortem examination 2-7 days later, cut into 1mm ring
segments and analysed on a dual chambered wire myograph system. Concentration response curves
to acetylcholine (Ach) were conducted for each vessel in duplicate. The relaxation of the vessel is
expressed as a percentage of inhibition of PE-produced contraction. Ach produced concentration-
dependent relaxation, which was of greater magnitude in Ad.VEGF-A165 transduced vessels
compared to Ad.LacZ transduced vessels. Error bars denote standard error of mean.
Table 5.13 – Vascular reactivity of uterine arteries from nutrient restricted
pregnant guinea pigs 2-7 days after adenovirus-mediated gene transfer of
VEGF-A165 (n=3) or β-galactosidase (n=3) 
Type of response Parameter Ad.VEGF-
A165
Ad.LacZ p
Emax
(Mean+SEM)
63.23+3.13
(n=3)
80.35+3.91
(n=3)Contractility
EC50 (M) 6.69x10-8 4.96x10-8
0.327
Emax
(Mean+SEM)
80.35+2.11
(n=3)
61.65+3.64
(n=3)Relaxation
pD2 9.93+0.08 9.82+0.19 0.223
In summary, the vascular reactivity of uterine arteries of pregnant guinea
pigs that have been transduced with Pluronic gel–Ad.VEGF-A165 combination can
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be studied on the wire myograph. The results show a trend towards diminished
vascular contractility and enhanced endothelium-dependent relaxation in vessels
transduced with Ad.VEGF-A165 as compared with Ad.LacZ transduced vessels.
Discussion
This chapter describes the optimization of a technique of gene targeting to
the utero-placental circulation of pregnant guinea pigs and analysis of vascular
reactivity in transduced vessels. Having shown that local over-expression of VEGF
in the utero-placental circulation of pregnant sheep leads to a sustained increase in
uterine blood flow, we were interested to examine if an increase in utero-placental
perfusion translated into an increase in fetal growth in FGR animal models. We
chose to carry out these studies on a well documented and validated FGR animal
model, the maternal nutrient restricted guinea pig (Roberts CT et al., 2001a). The
advantage of using guinea pigs is that they have a haemomonochorial placentation,
which is the most similar to human placentation in an animal model, with the
exception of some non-human primates. Thus, experimental results obtained from
pregnant guinea pigs as well as toxicology studies conducted in this species are
likely to hold more relevance for clinical translation. Furthermore, they have a
relatively long gestation (65 days) for a small animal, in contrast to mice, rats and
rabbits. This gives the opportunity to administer therapy at mid-gestation, and study
the effects of treatment for 30-35 days post-administration.
At the outset, to our knowledge, there had been no previous studies wherein
different drugs/substances have been locally administered to the guinea pig uterine
or radial arteries. There had been one published study which investigated the
vascular anatomy of the guinea pig utero-placental circulation in detail, by
administration of X-ray contrast medium into the utero-placental vessels after
gaining access through femoral artery catheterization (Egund N and Carter AM,
1974). The use of X-ray guidance was not available to us and we considered that it
would not be necessary, if intravascular injection under operating microscope vision
was feasible.
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The start of these experiments was hampered by a number of issues namely,
the low conception rate of the guinea pigs, the difficulty in visualizing the uterine
arteries, poor knowledge of the guinea pig utero-placental anatomy, and problems
of vascular injection in small vessels. However, with time we became more skillful
in the techniques needed, leading to a reduction in surgery time and improved
morbidity and mortality rates
We also faced problems in getting sufficient numbers of pregnant guinea
pigs when put on the nutrient restricted diet, and had to buy in some new stud boars
to boost our breeding programme. Once pregnant, there were cases where
pregnancy was missed on the ultrasound scan because we scanned them too early in
gestation. With experience, it was realized that the optimum gestational age to
confirm pregnancy by sonography was 24-25 days, at which a fetus can be reliably
and easily seen.
5.14 Gene Targeting to the Utero-Placental Vasculature of
pregnant Guinea pigs
In order to compare our findings in guinea pigs with results from pregnant
sheep, we first attempted to transduce the utero-placental vessels by direct intra-
arterial injections into the uterine artery, using a customized hand-made 34 gauge
needle. While the size of the uterine artery (between 250 and 400 µm) makes it
large enough for it to be injected, the vessel lies unsupported and deeply embedded
in fat with a surrounding network of tributaries which made this technique
extremely difficult. We were able to reliably inject the uterine artery in fewer than
half of all our attempts. Of more importance to the aims of this project however was
our finding that even when uterine artery injection was successful, the vector was
only able to transduce the cervical end and middle of the vessel, and the radial
arteries supplying the lower most fetuses. The more distal parts of the uterine artery
and ovarian end radial arteries were not transduced, meaning that this end of the
utero-placental vasculature would have to rely on the diffusion of transgenic VEGF
from further upstream for any therapeutic benefit to be realized. Increasing the
volume of vector delivered did not improve the extent of gene transfer. It is of note
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that because of the very fine gauge of the needle used for these injections, it took a
long time to inject 1.0-1.3 mls of vector solution, during which the needle tended to
dislodge. This further added to the difficulty of the procedures.
In an angiographic study to examine the vascular anatomy of guinea pig
uterine arteries, contrast medium injected into the uterine artery in vivo, at a rate
approximating to the rate of blood flow, failed to enter the most distal radial arteries
and placentae (Egund N and Carter AM, 1974). The same authors have shown that
the latter are preferentially served by the ovarian arteries. I did consider injecting
the vector into the ovarian arteries, but they were of even smaller diameter than the
uterine arteries. It is not surprising that substances administered into the uterine
artery are unable to reach the most distal radial arteries. The radial arteries follow a
devious and highly tortuous path, with several branches and anastomoses. Another
feature of the radial arteries is their progressive increase in caliber from their origin
to the placentae. These characteristics enhance the volume of blood within the
utero-placental circulation, but probably lead to the vector solution being channeled
only into the radial arteries that are close to the site of injection, and none remaining
to enter the distal radial arteries.
An alternative intravascular approach was used, injection of the internal iliac
artery, from which originates the uterine artery. We hypothesized that the larger
caliber of this vessel would improve the reliability of the intravascular injection
technique, facilitate the volume of vector to be delivered over a shorter time period,
and prevent needle dislodgement. The internal iliac artery in a guinea pig gives off
numerous branches in the following order – cranial gluteal artery (supplying the
dorsolateral wall of the pelvis and pelvic muscles), internal pudendal artery
(supplying the external genitalia), vesical artery (which branches to supply the
bladder, ureter and rectum), vaginal artery and uterine artery. The internal iliac
artery, though not much larger in diameter than the uterine artery, was found to be
easier and more reliable to inject because it is well supported on the pelvic side wall
musculature, and is easily identified. Nevertheless, the technique was associated
with significant fetal and maternal loss, most probably because of the long
anaesthetic time required to complete the procedure. Administration of vector to the
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internal iliac artery resulted in transgenic protein expression only in the pelvic
muscles and bladder, and none in the uterine and radial arteries. The uterine artery
is one of the most distal branches of the internal iliac artery and hence the vector
solution preferentially makes it way to the more proximal branches and the organs
these serve rather than the uterine and radial arteries. It was clear therefore, that the
intravascular injection route would not be able to achieve the aim of transducing the
uteroplacental circulation of the pregnant guinea pig.
In order to overcome this problem, it was decided to administer the vector
externally to the uterine and radial arteries, diluted in PBS. While this resulted in
good transduction of both cervical and ovarian ends of the uterine and radial
arteries, it also led to undesirable expression of the transgenic protein in the uterine
horns, the fat surrounding the uterus and maternal liver. We therefore decided to
adapt this local delivery technique to reduce the run off of the vector from the
vessels.
The approach adopted was to dilute the vector in Pluronic Gel, and
administer it to the external surface of the uterine and radial arteries. This resulted
in strong and local transgenic protein expression in the uterine and radial arteries,
on both the adventitial and luminal surfaces. There appeared to be no vector
expression systemically. This suggests that vector administration using Pluronic F-
127 as a vehicle may be the optimum method of gene targeting to the utero-
placental circulation of pregnant guinea pigs. It also resulted in shortening of the
surgery time by 1.0-1.5 hours compared to other methods, thereby lowering the risk
of morbidity and mortality.
Pluronics (also known as poloxamers), when dissolved in an aqueous
solution exhibit the feature of reversible thermal gelation (Schmolka IR, 1972).
They have the unique property of being liquid at 4°C and in a semi solid gel at
room or body temperature, thus providing an attractive platform for slow release of
drugs. The gelation mechanism of pluronics has been reviewed extensively (Jain NJ
et al., 1998;Bohorquez M et al., 1999) . Poloxamer gels display low toxicity at
therapeutically beneficial doses and do not increase serum triglycerides and
cholesterol in animal models (Blonder JM et al., 1999). Medical uses of pluronic
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F127 have included the controlled delivery of drugs to the eye (El-Kamel AH,
2002), nasal passage as well as parenteral and subcutaneous administration
(Barichello JM et al., 1999).
Pluronic gels have been used as a vehicle for local adenoviral gene delivery
previously (Iaccarino G et al., 1999;Khurana R et al., 2004;Mallawaarachchi CM et
al., 2005) and shown to be safe to administer. Pluronic gels increase the
transduction efficiency of adenoviral vector delivery to vascular cells in vivo
(Feldman LJ et al., 1997), probably because of the slower kinetics associated with
the longer term vector release from the gel or the closer proximity of viral vector to
the cell surface. Because of the thermo-responsive behaviour of pluronic F-127, the
gel is delivered in vivo over a short period of time before solidification. Our results
too indicate that using a localized pluronic gel based depot of slow viral vector
release facilitates greater transgene expression in comparison to other techniques.
Pluronic gel has been used to deliver Ad.LacZ to the carotid artery of rats. Five
days post-infection, the presence of the β-gal transgene was visualized throughout 
the arterial wall (Iaccarino G et al., 1999). As mentioned above, Pluronics have
previously been shown to have no toxic effects, and we too did not observe any
tissue edema or inflammation on gross examination at post-mortem. More detailed
microscopic examination on H&E stained sections had not been performed during
the course of this Ph.D., but is intended to be performed.
One of the animals that received the vector in pluronic gel suffered
miscarriage. We believe this was because of excessive manipulation of the pregnant
uterine horns while exposing the uterine and radial arteries, rather than the
administration of the gel. There were no miscarriages observed after we amended
our technique to minimize uterine manipulation.
In summary, we have shown that administration of recombinant
adenoviruses using pluronic gel as a vehicle leads to robust transgenic protein
expression in the utero-placental vessels, both on the adventitial and luminal
surfaces. There is no vector expression in other maternal and fetal tissues.
385
5.15 Peri-conceptual maternal under-nutrition leads to
growth restriction of fetal guinea pigs
As part of a larger project looking at the potential of local VEGF gene
therapy to treat FGR in a small animal model, we created FGR in guinea pigs using
a previously described method. In this model, guinea pigs are fed 70% of their ad
lib diet from 28 days before conception to day 34 of pregnancy, and 90% of their ad
lib diet thereafter, until term. This is reported to result in approximately 35%
reduction in neonatal weights and 30% reduction in placental weight at term
(Roberts CT et al., 2001a). Our findings compare very well with the findings of
Roberts CT et al, as we observed a 40% reduction in neonatal weights and 24%
reduction in placental weights (at 45 days of gestation). An important characteristic
feature of this model is reduced placental vascularity in FGR guinea pigs compared
to normal pregnant. This implies that the supply of both nutrients and oxygen to the
developing fetus is restricted, which closely mimics the human FGR condition
caused by vascular placental insufficiency.
Creating this model however, was not without problems. We observed that
in a number of cases, the guinea pigs on a growth-restricted diet failed to conceive
after 28 days of under-nutrition. This meant prolonging the period of restricted
feeding for a further 1-2 estrus cycles (each estrus cycle of guinea pig=14-16 days
days) until the hymen ruptured again. Consequently, some of the guinea pigs on the
growth-restricted diet became pregnant after 28 days of under-feeding, while others
became pregnant after approximately 42 or 56 days of under-feeding. One solution
to this would have been that guinea pigs which failed to conceive after the initial
period of nutrient restriction, were put on an ad lib diet for a few weeks until they
regained their normal body weights, and then made to enter the experiment again.
This would have increased the costs hugely, and would not have been feasible
experimentally. After discussion with the original authors of this FGR model, it was
decided that the most appropriate solution to this issue is to prolong the period of
pre-conceptual under-nutrition in female guinea pigs that did not get pregnant the
first time. They informed me that this was the strategy they adopted in their
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experiments too, even though this fact has not been mentioned in any of the
published papers from their group.
Thus, working with growth-restricted guinea pigs that have undergone
different periods of pre-conceptual under-nutrition is one of the limitations of this
model, which may influence the degree of growth restriction and the experimental
outcome. Nevertheless, this model is more advantageous to work with relative to
other models such as those created by uterine artery ligation. This is because the
latter would involve physically obstructing blood flow in a uterine artery, and then
trying to increase blood flow in it with gene therapy, which appears impossible to
achieve. A physiological model is likely to be more appropriate for the kind of
experiments we wish to pursue.
5.16 It is feasible to carry out fetal measurements on growth-
restricted guinea pigs
During the course of developing the FGR guinea pig model, all
experimental guinea pigs were scanned to collect fetal measurements by ultrasound.
To our knowledge, there has only been only one other study on fetal measurement
in guinea pigs by ultrasound (Turner AJ and Trudinger BJ, 2000). The authors of
this study scanned only normal pregnant animals and demonstrated that ultrasound
can be used successfully to study pregnancy in the guinea pig. They further showed
that measurements of BPD may be used to reliably estimate gestational age in this
species.
Using both normal pregnant and growth-restricted guinea pigs for our
experiments, we are developing a database of fetal measurements at different
gestational ages. Even with the small number of animals used so far, we observed a
significant reduction in abdominal circumference in growth-restricted guinea pigs at
45 days of gestation, compared to normally grown fetuses. The biparietal diameter
showed a strong trend towards reduction in the growth-restricted guinea pigs while
the ratio of head to abdominal circumference showed a strong trend towards being
increased in the FGR fetuses. With further animals, these parameters are likely to
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reach statistical significance. These data suggest that FGR guinea pigs created by
maternal nutrient restriction show evidence of brain sparing.
5.17 Transduction of guinea pig uterine arteries with
Ad.VEGF-A165 results in a reduction of contractile response
and enhancement of relaxation, compared to Ad.LacZ
transduced uterine arteries
Guinea pig uterine arteries transduced with Ad.VEGF-A165 or Ad.LacZ were
examined on a wire myograph to examine changes in vascular reactivity. I first
attempted to study their vascular responses on an organ bath, as has been described
previously by other groups (Weiner CP et al., 1992;Jovanovic A et al., 1997;White
MM et al., 2000). However, the organ bath set-ups in our lab are not designed to
experiment with any vessel smaller than a mouse aorta (~1mm in diameter). As the
guinea pig uterine artery is much smaller (~400 µm diameter at 45 days gestational
age), it is not unexpected that we were unable to measure its vascular reactivity on
an organ bath. However, when studied on a wire myograph, which can be used to
examine vessels as small as 100 µm in diameter, we were able to study the uterine
artery vascular responses easily.
I observed a reduction in the contractile response of the Ad.VEGF-A165
transduced uterine arteries compared to Ad.LacZ injected vessels and an increase in
the endothelium-dependent relaxation to acetylcholine. These results are similar to
what we had observed in the sheep uterine arteries that had been transduced short-
term. Statistical significance was not achieved in our results, most probably because
of the limited animal numbers. Further experiments to increase animal numbers are
currently in progress as part of the main project. A detailed discussion of the effects
of VEGF-A165 over-expression on uterine artery vascular responses has already
been made in Chapter 3.
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Conclusion
In summary, we have described the optimization of a technique of gene
targeting to the utero-placental circulation of pregnant guinea pigs using a thermo-
sensitive poloxamer gel. We plan to use this technique to study the effects of
VEGF-A165 over-expression on utero-placental vascular reactivity and fetal growth
rates in an FGR model of pregnancy. After a long period of improvisation of our
animal husbandry programme during which we honed our skills at time-mating of
nutrient-restricted guinea pigs, we have successfully recreated the nutrient
restriction FGR guinea pig model. This is characterized by reduced placental
vascularity and diminished supply of both nutrients and oxygen to the developing
fetuses. Experiments designed to study the effects of local Ad.VEGF-A165 gene
therapy on fetal growth rate in this model are currently in progress in our
laboratory.
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Chapter 6
General Discussion
The aim of the research undertaken in this thesis was to examine the effects
of local VEGF gene therapy on the utero-placental circulation, with the aim of
developing a potential therapy for Fetal Growth Restriction. A number of long term
physiological effects were seen in the normal sheep pregnancies examined, and the
mechanism of action was studied. In addition a technique to locally transduce the
uteroplacental circulation of the guinea pig was developed, with a view to studying
the efficacy of VEGF gene therapy to treat FGR.
6.1 Local over-expression of VEGF leads to long term
changes in uterine blood flow and vascular reactivity in
pregnant sheep uterine arteries.
In this study, we found that local adenovirus-mediated over-expression of
VEGF-A165 in the uterine arteries of mid-gestation pregnant sheep resulted in a
significantly higher increase in blood flow compared to transduction with a control
non-vasoreactive vector Ad.LacZ. A statistically significant increase in UABF was
apparent as early as 7 days after Ad.VEGF-A165 injection, and was maintained for at
least 28 days, where it reached a 37% increase over baseline compared to 20% on
the Ad.LacZ injected side. This increase was concomitant with a significant
reduction in uterine artery contractility and significant adventitial
neovascularization. There was an upregulation in the level of eNOS for up to 7 days
after the administration of Ad.VEGF-A165, but this increase was not evident at term.
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The importance of the findings presented in this thesis compared to our previously
published short-term data (David AL et al., 2008) is that the increase in blood flow
is maintained over at least 4 weeks, suggesting the potential for therapeutic use.
Importantly, the use of ‘gold standard’ transit time flow probes, instead of Doppler
ultrasonography (David AL et al., 2008), provided a more accurate and reliable
estimate of the true increase in UABF (Abi-Nader KN et al., 2010). To our
knowledge, this is the first report of a manipulation which leads to a sustained long-
term increase in uterine blood flow in pregnancy, with only a single intervention.
We also noted a significant increase in singleton fetal weight compared to data from
historical controls using the same sheep breed. Even though encouraging at first
sight, the results could have been affected by other factors such as differences in
fetal growth year by year for example. Further studies on the effects of Ad.VEGF-
A165 gene therapy on fetal growth and birthweight in cohorts of sheep with
contemporaneous controls are currently ongoing.
One longitudinal case control study showed that UABF was reduced by
12.5% at 20 weeks, and by 36.7% from 24 weeks of gestation until delivery in FGR
as compared to normal pregnancies (Konje JC et al., 2003). Thus, any therapy for
FGR based on increasing UABF to normal levels would need to achieve a 58%
increase in UABF. Even though the extent of increase in UABF in our study is less
than what is expected to achieve a normal utero-placental perfusion, it must be
emphasized that this treatment, if translated to the clinics, would potentially target
the most severely growth-restricted fetuses, that have a birthweight of 500 grams or
less. Even a small improvement in utero-placental perfusion may delay iatrogenic
delivery, enhance gestation by a few days, and translate into a small increase in
fetal weight. It has been shown that at the very extremes of pre-maturity, between
24-27 weeks of gestation, the median survival gained for each additional day in
utero is 2% (Baschat AA et al., 2007). Neonatal and long term morbidity is also
reduced, as gestational age and birthweight increases.
In this study, there was an acute drop in UABF in both the Ad.VEGF-
A165/Ad.VEGF-D and Ad.LacZ injected sides 1-3 days after vector injection. This
reduction was most likely due to the vessel occlusion and trauma to the vessel wall
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during vector injection which would result in vasoconstriction. UABF recovered in
all experimental sheep by days 5-7 after vector injection. However, this is a point of
concern if this therapy is to be applied in a clinical setting. Growth-restricted
fetuses are known to be frequently hypoxemic (Akalin-Sel T et al., 1994). A
minimally invasive technique such as trans-femoral uterine artery catheterization
(Delotte J et al., 2009) would reduce uterine artery trauma and post-injection
constriction, and has been used to inject the uterine arteries for embolization of
fibroids in clinical practice. The procedure itself, and in particular the temporary
occlusion of the lumen, could reduce the oxygen supply to the fetus, particularly if
the other uterine artery supply was significantly compromised. Hypoxaemic FGR
fetuses may have little reserve to tolerate further compromise of the uteroplacental
circulation during the catheterisation procedure. This could result in immediate
death of the fetus, or brain damage. It may also be possible that they may be more
tolerant of a temporary interruption to the uteroplacental circulation, since they are
already exposed to it chronically. Further experiments to determine the optimal
vector dose and whether extra-luminal administration of vector (for instance,
pluronic gel-mediated delivery) results in equally efficient gene delivery are
warranted.
This thesis also investigated some of the mechanisms by which VEGF over-
expression results in an increase in utero-placental perfusion. There was an
upregulation in the level of eNOS short-term, while the long-term transduced
vessels demonstrated increased adventitial angiogenesis, reduced vasoconstriction
and reduced intima/media ratios in the Ad.VEGF transduced uterine arteries. All
these appear to confer an ‘arterioprotective’ effect and promote the health of the
uterine artery, which may be responsible for the increased uterine perfusion that we
observed (discussed in ‘Discussion’ of Chapter 3). Experiments in endothelial cells
isolated from the uterine arteries of mid-gestation pregnant sheep and infected with
adenovirus vectors in vitro showed that infection with Ad.VEGF-A165 and
Ad.VEGF-D, but not Ad.LacZ resulted in an increase in the levels of eNOS, iNOS
and the phosphorylated (activated) form of eNOS. This further demonstrates that
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VEGF over-expression contributes to increased levels of vasodilators, which is
probably responsible for the increase in UABF that was observed.
This study was designed with clinical relevance in mind and was performed
in sheep because many aspects of sheep fetal and vascular physiology are similar to
the human. The ovine fetus is similar in size to the human fetus and has a good
tolerance to in utero manipulations, allowing the surgical placement of catheters in
both the maternal and fetal vasculature (Jellyman JK et al., 2004;Abi-Nader KN et
al., 2011). The increase in uterine blood flow that occurs through the latter half of
gestation is very similar for humans and sheep, increasing two and a half times in
humans (from 0.3 to 0.8 L/min) while in sheep, this increase is three fold (0.4 to 1.2
L/min) (Konje JC et al., 2003;Meschia G, 1984). This increase in uterine perfusion
results in an increase in the supply of substrates and oxygen to the conceptus,
failure of which manifests as asymmetric FGR. The rates of oxygen and glucose
consumption in both near-term sheep and human fetuses are also similar (Barry JS
and Anthony RV, 2008).
However, one of the important limitations of this investigation was that it
was conducted in normal pregnant and healthy sheep, rather than in an animal
model of FGR. There is a possibility that young and otherwise healthy animals are
able to mount an effective endogenous angiogenic response which can be further
maximized by an additional stimulus like VEGF. But human patients with FGR
characterized by utero-placental insufficiency and endothelial dysfunction (Yinon Y
et al., 2010) would probably have a less pronounced response. A brief exposure to
VEGF may be insufficient for a therapeutic effect, but chronic exposure as in the
case of adenovirus-mediated over-expression may provide therapeutic benefit.
It is also important to note that the primary etiological factor for human
FGR caused by utero-placental insufficiency is an inadequate remodeling of the
myometrial spiral arteries, because of defective trophoblast invasion of these
vessels. As a result, the uteroplacental circulation remains in a state of high
resistance which causes generalized endothelial cell injury. In our studies, we have
shown a significant increase in utero-placental perfusion in response to local
VEGF-A165 over-expression, possibly on account of changes in vascular reactivity,
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eNOS levels, neovascularization and uterine artery remodeling (in terms of changes
in intima/media ratios). However, it is difficult to predict if the replication of similar
effects in human utero-placental vessels would be sufficient to overcome the effect
of inadequate trophoblast invasion to any therapeutically beneficial extent.
Furthermore, normal spiral artery remodeling by trophoblast invasion is not
regulated by a single member of the VEGF family in humans. The invasive
cytotrophoblasts release a number of signaling factors that play an important role in
uterine invasion, including VEGF-C, PlGF and angiopoietin-2 (Zhou Y et al.,
2003a). It is therefore uncertain whether over-expressing only a single molecule
using local gene therapy can be of any benefit in improving a compromised uterine
circulation caused by defective physiological re-modelling.
Experiments in animal species where pregnancy-induced changes in utero-
placental vessels mimic the human situation would be of value. In Old World
monkeys, there is remodeling of the spiral arteries following trophoblast invasion
(Blankenship TN and Enders AC, 2003). The initial stages of implantation, as well
as the process of invasion by the trophoblast through the uterine epithelium, are
very similar in Old World monkeys and man (Enders AC, 1995). Interestingly,
there have even been reports of the occurrence of PET-like symptoms
spontaneously in Old World monkeys (Palmer AE et al., 1979) but it is not known
whether naturally occurring FGR caused by inadequate trophoblast invasion occurs
spontaneously in this species. Non-human primates are important as experimental
models of human pathological pregnancy and they may be the most suitable model
in which to study toxicology prior to first-in-man studies. Research in non-human
primates is costly and intensive however, and would not be appropriate for the
initial work up of a potential therapy, as has been explored here. Additionally, there
are ethical concerns about working with them because of their very close
phylogenetic relationship to humans.
Mice have the advantage of offering several transgenic models of FGR to
study. These include the placental-specific Igf2-knockout mouse (Constancia M et
al., 2002) and eNOS-knockout mouse (Hefler LA et al., 2001). Unfortunately, the
mouse serves as a less than optimal physiological model for the development of
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human utero-placental vessels. The extent of trophoblast invasion is relatively
shallow in the utero-placental blood vessels of pregnant mice. In fact,
transformation of the uterine arteries is more dependent on maternal factors,
particularly uterine natural killer cells, rather than trophoblast invasion per se
(Carter AM, 2007;Greenwood JD et al., 2000).
Before taking any therapy into man, its safety needs to be critically
examined in pre-clinical and ex vivo models. Preliminary studies from our lab
suggest that this treatment is safe to administer. There were no detrimental changes
in maternal and fetal blood pressure following local VEGF over-expression.
Histological examination of uterine artery sections showed no evidence of edema,
leucocyte infiltration or inflammation. RT-PCR was not able to detect any
undesirable vector expression in maternal and fetal tissues.
Further toxicology studies, including the risk of transplacental transmission
are being carried out by Ark Therapeutics Ltd who manufacture the vector. These
include investigating the transmission of the virus across the placental barrier in the
isolated perfused human placenta, in collaboration with the Maternal and Fetal
Health Research Centre, University of Manchester. The administration of very high
doses of the adenoviral construct to the uterine artery of pregnant rabbits is also
being performed, to determine the LD50 dose and to determine what toxic effects, if
any, might be important.
In summary, the data presented in this thesis give hope that Ad.VEGF gene
transfer to the utero-placental circulation is capable of providing long-term
beneficial changes in UABF and vascular reactivity. Further work in FGR animal
models is needed to determine whether this will be of therapeutic benefit for
treating FGR caused by utero-placental vascular insufficiency.
6.2 It is possible to efficiently transduce the utero-placental
circulation of pregnant guinea pigs by pluronic gel mediated
adenoviral delivery
In the studies with pregnant sheep, an increase in fetal weight (compared to
historical controls) in response to Ad.VEGF-A165 over-expression in the uterine
arteries was apparent. However, as mentioned above, it would be more helpful to
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evaluate the effects of Ad.VEGF-A165 gene transfer on fetal growth in an animal
model of FGR. We intend to investigate this in the maternal nutrient restricted
guinea pig, a species whose placentation is the closest to humans, after non-human
primates.
Chapter 5 of this thesis discusses the optimization of a technique of gene
targeting to the utero-placental circulation of pregnant guinea pigs. Initial attempts
at intra-vascular injection into the uterine arteries of pregnant guinea pigs had a low
success rate and low reproducibility. Vector delivery into the internal iliac artery
unfortunately did not result in gene transfer to the uteroplacental circulation. After
testing out different routes and modes of administration of the vector,
administration of the vector in Pluronic gel gave the best and most consistent results
in terms of local transduction efficiency. Importantly, the expression of the
transgene was limited to the utero-placental vessels and there was no transgene
expression in other maternal and fetal tissues. Pluronic gel has the unique property
of being liquid at 4°C and in a semi-solid form at room or body temperature. It thus
serves as a useful medium for the slow/controlled release of drugs over a prolonged
duration of time. Previous studies on administration of adenoviral vectors using
pluronic gel have shown that its use as a vehicle enhances the transduction
efficiency of adenoviral vector delivery to vascular cells (Feldman LJ et al., 1997).
This is believed to be because of the slower kinetics of vector release from the gel
or closer proximity of the viral vector to the cell surface. Our results are in
concurrence with these studies and also show that administration of the vector in
pluronic gel gave the strongest transgene expression, as compared to intravascular
delivery techniques. Pluronic gel at low doses has been shown to be safe to
administer in our investigation as well as other studies (Feldman LJ et al.,
1997;Blonder JM et al., 1999).
Having optimized a technique of gene targeting to the utero-placental
vessels, this technique will be used to investigate the effects of Ad.VEGF-A165 gene
transfer on fetal growth in FGR pregnant guinea pigs. During the course of this
Ph.D., growth restricted guinea pigs were successfully created. However, because
of the unanticipated and long duration of time it took to optimize the gene targeting
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technique, it was only possible to perform a few experiments on Ad.VEGF-A165
gene transfer during this Ph.D.
At the moment, it is not known whether pluronic gel may be an optimal
vehicle for gene transfer to human patients, if this therapy is translated to the clinic.
This decision, to a large extent, depends on the results that are obtained from the
guinea pig studies.
6.3 Insights into Prenatal Gene Therapy with VEGF to treat
pathological pregnancies – An epilogue
As mentioned above, to our knowledge, the work presented in this thesis is
the first report wherein a single intervention results in a sustained long-term
increase in uterine artery blood flow in pregnancy. There have been several
approaches to try to improve fetal growth in pathological pregnancies (Section 1.7),
and while some have shown to be promising in pre-clinical studies, none have so far
been of any therapeutic benefit in the clinic. There has been a general lack of
research into the treatment of pathological pregnancies, such as those affected by
FGR and PET. This may be because of the fear of potential risks to the developing
fetus by exposure to therapeutics.
Work by only a few other groups has explored the potential of gene therapy
to reverse FGR. For example, it has been demonstrated that site-specific placental
gene transfer of Angiopoietin-2 using an adenoviral vector resulted in a significant
increase in fetal weights in normal pregnant mice, compared to control untreated
mice (Katz AB et al., 2009). Further work is being planned by these authors to
study the effects of placental gene transfer on fetal growth in animal models of
FGR. It is of note that there is a general paucity of drugs for severe obstetric
conditions, in comparison to other health conditions. Only 17 drugs are under active
development for maternal health problems, which is less than 3% of the drugs in the
pipeline for cardiovascular disease and even fewer than for a single rare disease like
amyotrophic lateral sclerosis. Reasons for the lack of research and development of
new drugs for obstetric conditions like FGR and PET include factors such as the
high costs of reproductive toxicology studies, high risk of teratogenicity and the
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prohibitive expense of follow-up investigations on neonates, which need to be
carried out for a mean of 6 years. Additionally, the highest returns in the bio-
pharmaceutical industry typically comes from drugs taken life-long for chronic
diseases with a good life expectancy. In contrast, obstetric conditions are short-lived
and the number of children per woman is declining, which further limits allocations
of funding towards development of drugs for conditions like FGR (Fisk NM and
Atun R, 2008).
While the effects of VEGF-A165/VEGF-D on uterine artery blood flow or
fetal growth per se have not been examined before, VEGF-A121 gene or protein
therapy was found to be beneficial and alleviated some of the adverse symptoms,
including elevated blood pressure and proteinurea, in rodent models of PET (Woods
AK et al., 2011;Li Z et al., 2007). Use of gene therapy (or any newly developed
drug) to treat disorders of pregnancy is bound to remain a subject of controversy
and debate for many years to come.
One of the limitations of the current study design which involved injection
of Ad.VEGF-A165 and Ad.LacZ bilaterally in the same animal, was the fact that we
were unable to study modulation/alteration in vascular reactivity of the placental
microvasculature by VEGF. Diffusion of VEGF from the site of injection to
placental microvessesls is likely to have resulted in vasodilatation and reduction in
placental vascular resistance. Increased resistance in the placental microvessels is a
common feature of FGR as described previously. Hence, the apparent reduction in
downstream placental resistance is likely to have benefited perfusion in both the
Ad.VEGF-A165 and Ad.LacZ transduced uterine arteries, which means that the
differences in uterine blood flow that we detected between the treated and control
uterine arteries are likely to have been diluted. It is possible that if both the uterine
arteries of a pregnant ewe had been injected with the same vector, and an inter-
animal comparison performed, we may have been able to demonstrate a more
profound effect of Ad.VEGF transduction on uterine perfusion.
6.4 Ethics of Prenatal Gene Therapy
There are various ethical issues in relation to in utero gene therapy that need
to be addressed before such therapy could be applied clinically. There is a
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theoretical risk that the therapeutic gene product or vector could cause
developmental aberrations to occur. Any fetal therapy or procedure poses risks of
infection, immune reactions and the possibility of inducing preterm labour for the
fetus. An additional challenge for procedures performed for the benefit of the fetus
is that there exists the potential of risk for the mother. A conflict of interest can
arise since treating the fetus may not be in the mother’s best interest. In many
countries, a fetus has no legal rights per se. Attempts have been made to resolve this
moral ambiguity using the concept of ‘the fetus as a patient’. This aims to provide a
moral framework within which the fetus is reliably expected later to achieve the
status of becoming a child and eventually a person. ‘The fetus as a patient’ relies on
the mother’s decision to continue with the pregnancy and to present the fetus for
medical care (Chervenak FA and McCullough LB, 2002). However, it should be
emphasized that in many societies, presently the prospective mother has a right to
termination, even of a normal fetus, as well as the decision to terminate an
abnormal fetus or subject it to any clinical intervention. The availability of prenatal
gene therapy should not in any way infringe her autonomy in these decisions.
Currently used fetal treatments such as fetal blood transfusion for anaemia
are effective and carry a low risk for the mother such that the risk-benefit analysis
falls heavily on the side of treatment. For experimental prenatal gene therapy
procedures, the risk-benefit analysis is uncertain and it is therefore especially
important that the mother gives informed consent (Burger IM and Wilfond BS,
2000). This can be difficult since the decision to participate in a fetal gene therapy
trial will occur close to the time of prenatal diagnosis of the condition. The
professionals involved in counseling the parents must present the information in a
non-biased way and ensure that resources are set aside for long-term surveillance of
the mother and fetus after birth (David AL and Ashcroft R, 2009).
Currently some parents when faced with a severely growth-restricted baby,
decide to terminate the pregnancy in a procedure that is very safe for the mother and
totally effective. A prenatal gene therapy strategy will have to be extremely safe,
reliable and effective at treating the disease (Coutelle C and Rodeck C, 2002). For
parents who would not have continued with an affected pregnancy, a partial or no
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cure of an affected child resulting in a poor quality of life would be the worst case
scenario. There is a possibility to test the effectiveness of prenatal gene therapy (for
FGR) in utero, by examining uterine and umbilical artery Dopplers and performing
serial measurements of fetal parameters. This would give parents and clinicians the
opportunity to terminate the pregnancy if no therapeutic benefit can be detected.
One criticism leveled at prenatal gene therapy is a belief that couples
pregnant with an affected child would be unlikely to proceed with prenatal gene
therapy and would opt for a termination instead. There is almost no research in this
area however and the views of the general public and patient groups need to be
solicited as this technology comes closer to the clinic. The general public remains
concerned that ethical discussion about issues such as gene therapy, cloning and the
Human Genome Project are falling behind the technology (Brown P, 2000). It is
therefore important to provide adequate information that will allow the public to
understand the risks and benefits of these novel techniques and to enable an
educated involvement in the decision-making process along with health
professionals. This will also help individuals to give informed consent as these
procedures become used in clinical practice (David AL, 2005, Ph.D. Thesis).
6.5 Potential for clinical translation
If translated to the clinics, it is intended to administer this therapy to
pregnant women by X-ray guided catheterization of the uterine arteries through the
femoral artery. The procedure itself, and in particular the temporary occlusion of
the lumen, could reduce the oxygen supply to the fetus, particularly if the other
uterine artery supply was significantly compromised. Hypoxaemic FGR fetuses
may have little reserve to tolerate further compromise of the uteroplacental
circulation during the catheterisation procedure. This could result in immediate
death of the fetus, or brain damage. On the other hand, they may be more tolerant of
a temporary interruption to the uteroplacental circulation, since they are already
tolerant to it. Data from sheep studies (Skillman CA et al., 1985) suggest that the
uterus of the pregnant sheep is perfused to sufficient excess to protect the fetus
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during short-term reductions of less that 50% UABF. In addition during the
surgeries described in this thesis, the operators did not observe any deleterious
effects on fetal blood pressure and heart rate following short-term occlusion of the
uterine artery. Although there is a risk of profound fetal hypoxaemia or even death
during the procedure, with pre-oxygenation of the mother, and sonographic fetal
heart rate monitoring via the mother’s abdomen this risk will be minimised. The
alternative option, of not treating the fetus, carries a high risk of intra-uterine death;
therefore the risk is considered acceptable. Further experiments to determine the
optimal vector dose and whether extra-luminal administration of vector results in
equally efficient gene delivery are required.
6.6 Future Work
Having demonstrated the long term effect of local VEGF gene therapy on
UABF in pregnant sheep, future work aims to evaluate the efficacy of Ad.VEGF-
A165 gene therapy in an ovine model of FGR, created by overfeeding the ewes
during adolescence. This model is characterized by 40% reduction in UABF in mid-
gestation, prior to the onset of obvious changes in fetal growth. This gives the
opportunity to specifically examine the effects of Ad.VEGF-A165 gene therapy on a
compromised utero-placental circulation, and whether it benefits fetal growth
velocity. Long term outcomes in neonatal sheep born after VEGF-A165 gene
therapy prenatally will be examined, and will provide more safety data.
There are also plans to explore the mechanism of VEGF action further in
endothelial cells. We intend to knockdown the vegf expression in ovine UAECs by
siRNA technology and then compare the effects of exogenous VEGF treatment v/s
adenovirus-mediated over-expression on different signaling pathways, such as
eNOS, phospho-eNOS (Ser1177) and iNOS. The aim of these experiments is to study
if endogenous VEGF over-expression confers an advantage over exogenous VEGF
treatment, on the levels of vasodilators produced. We also intend to do similar
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experiments in endothelial cells from mice wherein vegf has been specifically
knocked out of the endothelium (Lee S et al., 2007). The importance of these
studies lies in the fact that there is endothelial dysfunction in pregnancies
complicated by PET and FGR (Yinon Y et al., 2010), and it is of interest to examine
if endogenous VEGF over-expression can be of any benefit in endothelial cells in
which cell signaling has been dysregulated because of low/absent levels of VEGF
family members. Exogenous VEGF treatment was found to be of no benefit in the
VEGF-knockout endothelial cells (Lee S et al., 2007).
In addition to endothelial cells, we would also like to investigate the
mechanism of action and test the proposed hypothesis in vivo. As the premise on
which this research is based is that local and sustained over-expression of VEGF in
the uterine arteries results in an increase in utero-placental perfusion, we would like
to evaluate this in pregnant sheep. This can be carried out by infusing an anti-VEGF
antibody or sFlt-1 (which binds to VEGF) systemically into pregnant sheep shortly
after Ad.VEGF/Ad.LacZ transduction of the uterine arteries. If we fail to see any
difference in the increase in blood flow between the treated and control uterine
arteries, it would prove that the effects on utero-placental perfusion observed are
indeed VEGF-mediated.
We would also like to test if the effects observed on uterine artery blood
flow are NO-mediated. This can be tested using an NO clamp. The NO clamp is a
well-established technique to block NO activity in vivo. It involves administration
of the NO synthase inhibitor L-NAME with the NO donor sodium nitroprusside to
block de novo synthesis of NO while compensating for the tonic production of the
gas, thereby maintaining basal vascular tone (Thakor AS et al., 2010).
One of the limitations of this work was that NO levels were not quantified in
culture supernatants from endothelial cells, that had been transduced with
Ad.VEGF-A165, Ad.VEGF-D or Ad.LacZ. The cell culture supernatants have been
preserved from all these experiments and are available for measurement of both NO
levels and secreted VEGF protein levels at the different MOIs in the future.
During the course of the experiments described in this Ph.D., the technique
of gene targeting to the utero-placental circulation of pregnant guinea pigs was
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optimised, using a thermo-sensitive pluronic F-127 gel. This method of delivery
will be used to study the effects of Ad.VEGF-A165 over-expression on fetal growth
in an FGR model of pregnancy. This is a large-scale project funded by Action
Medical Research, which aims to investigate the effects of different doses of
Ad.VEGF-A165 and different times of administration (mid-gestation and ¾
gestation) on fetal growth.
In addition to fetal growth, it would also be helpful to determine the effects
of VEGF-A165 over-expression on flow-mediated vasodilatory responses. As
pregnancies complicated by FGR and PET are characterized by impaired flow-
mediated vasodilatation (Yinon Y et al., 2010), we are interested in investigating if
chronic endogenous VEGF exposure can reverse the impaired flow-mediated
vasodilatory responses. We plan to do these experiments by perfusion myography,
in collaboration with Prof Lucilla Poston and Dr Rachel Tribe, Division of
Women’s Health, St. Thomas’ Hospital. We will use drugs that inhibit different
components of the relaxation pathway to further analyse their relative contributions
to the flow-mediated vasodilatation. L-NAME, NS-398 and Apamin would be used
individually and in combination to block the effects of NO synthase, prostacyclins
and EDHF respectively. NO levels will be measured in the perfusate using a
colorimetric assay (Griess Method).
In the studies carried out on pregnant sheep, we were unable to measure
vascular permeability of vessels transduced with Ad.VEGF-A165 because of
experimental design and limitation of animal numbers. VEGF-A165 is known to
profoundly increase vessel permeability leading to extravasation of leucocytes into
the surrounding tissue and localised edema. Even though we did not observe any
obvious changes or tissue edema at histological analysis of the maternal and fetal
tissues, we plan to carry out more detailed studies on measurements of vascular
permeability in the guinea pig model. These studies would be performed by
administering an intra-venous injection of Evan’s Blue Dye and tracking its
diffusion into various tissues, particularly those around the uterine artery (like
uterus and perivascular adipose tissue) (Gowen BB et al., 2010;Saria A and
Lundberg JM, 1983).
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Finally, before clinical application of this therapy can be contemplated,
further toxicology studies need to be completed in collaboration with Ark
Therapeutics Plc. These include investigating the potential of transplacental
transmission in the isolated perfused human placenta, determination of LD50 in
rabbits (a commonly used species for toxicology purposes), and the extent of vector
spread in sheep and guinea pig maternal and fetal tissues by quantitative PCR.
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Appendix 1 – Composition of sheep and guinea pig feed
Sheep Feed
Super Ewe & Lamb 6mm Pencils (Lillico Attlee Ltd., Surrey, UK)
This feed contains:-
Oil 5.0%
Fibre 9.0%
Selenium 0.30 mg/kg
Vitamin A 6,800 iu/kg
Vitamin D3 2,000 iu/kg
Vitamin E 30.0 iu/kg
Protein 18.0%
Ash 8.0%
The raw ingredients of this diet include:-
10-25% Wheat
Barley
Sunflower meal
Citrus pulp
Wheatfeed
10% Rape Meal
Palm Kernel Exp
Molasses
Sun Bean Meal
Amino Green
Limestone
Vegetable Oil
Salt
Sheep Vitamin/Minerals
Calcined Magnesite
Dicalcium phosphate
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Guinea Pig Feed
FD 1 (P) PL (Special Diets Services, Essex, UK)
Crude Fat 3.3%
Crude Protein 18.6%
Crude Fibre 9.7%
Crude Ash 8.8%
Vitamin A (retinol acetate) 3440 iu/kg
Vitamin D3 (cholecalciferol) 1960 iu/kg
Vitamin E (dl-a-tocopheryl acetate) 38iu/kg
Lysine 0.89%
Methionine 0.36%
Calcium 1.17%
Phosphorous 0.92%
Sodium 0.35%
Magnesium 0.33%
Copper 21mg/kg
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Appendix II – Composition of Kreb’s Ringer Solution used
for Pharmacology Experiments
118 mM NaCl
4.6 mM KCl
27.2 mM NaHCO3
1.2 mM KH2PO4
1.2 mM MgSO4
1.75 mM CaCl2
0.03 mM Na2EDTA
11.1 mM glucose
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Appendix III – Composition of cell culture medium used for
uterine artery endothelial cell experiments
The basic serum-free medium used was Endothelial Cell Basal Medium (EBM)
(CC3124, Lonza, Berkshire, UK).
For routine cell culture, EBM was supplemented with fetal bovine serum (FBS) and
growth factors. The supplemented medium was called Endothelial Cell Growth
Medium (EGM) and had the following composition:-
EBM 450ml
FBS (10500-056, Invitrogen, UK) 50ml
Growth supplements (CC4133,
Lonza, Berkshire, UK):
Bovine brain extract 2ml
Human Epidermal Growth Factor 0.5ml
Geneticin-Amphotericin 0.5ml
Fungizone (15290-025, Invitrogen, 3.75ml
Paisley, UK)
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Appendix IV – Sheep post-mortem form
Date: Animal No: Code:
Fetal measurements: Fetal Weight:
Crown Rump Length: Femur Length:
Biparietal Diameter: Abdominal Circumference:
Occipito-snout Length:
Post mortem findings:
Bloods taken: Maternal Serum Maternal Plasma
Tissue samples to be collected from the MOTHER: __
Tissue sample ________________code______N2 PFA
Right Uterine artery RU-A1  
Right Uterine artery 1st division RU-A2  
Right Uterine artery 2nd division RU-A3  
Right Uterine artery 3rd division RU-A4  
Right Uterus RU-T  
Right Placentome R-P  
Left Uterine artery LU-A1  
Left Uterine artery 1st division LU-A2  
Left Uterine artery 2nd division LU-A3  
Left Uterine artery 3rd division LU-A4  
Left Uterus LU-T  
Left placentome L-P  
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Lung E-AU  
Heart E-H  
Ovary E-G  
Liver E-L  
Adrenal E-D  
Kidney E-K  
Spleen E-X  
Brain E-NC  
Retina E-Retina  
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FETUS
Tissue samples to be collected from each FETUS:
Blood (serum & plasma) B
__Tissue _samples______________code______ N2 PFA__
Membranes Me  
Umbilical cord U  
Amniotic Fluid AF  
Lung AU  
Thymus T  
Heart H  
Spleen X  
Liver L  
Gonads Female Male G  
Adrenal glands D  
Kidney K  
Brain NC  
Retina Retina  
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Tissue samples collected for histology processing
Cassettes Tissues
1 Left UA1
2 Left UA2
3 Left UA3
4 Left UA4
5 Left uterus Left placentomes
6 Right UA1
7 Right UA2
8 Right UA3
9 Right UA4
10 Right uterus Right placentomes
11 Maternal ovary, liver, spleen
12 Maternal kidney, adrenal, heart, lung
13 Left membranes, Left umbilical vein
14 Left gonad, liver,
15 Left spleen, adrenal, kidney
16 Left heart, lung, thymus
17 Right membranes, umbilical vein
18 Right gonad, liver
19 Right spleen, adrenal, kidney
20 Right heart, lung, thymus
21 Ewe brain, retina
22 Fetal brain, retina
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Appendix V – Guinea Pig Post-mortem Form
Date: Animal No: Code:
Fetal measurements: Fetal Weight:
Brain Weight: Liver Weight:
Heart Weight: Kidney Weight:
Crown Rump Length: Femur Length:
Biparietal Diameter: Abdominal Circumference:
Occipito-snout Length:
Post mortem findings:
Bloods taken: Maternal Serum Maternal Plasma
Maternal Whole Blood
Tissue samples to be collected from the MOTHER:
_______________________________code______N2 PFA
Right Uterine artery RU-A1  
Right Radial artery (Cervical end 1) RR-A1  
Right Radial artery (Cervical end 2) RR-A2  
Right Radial artery (Cervical end 3) RR-A3  
Right Placenta (Cervical end 1) R-P1  
Right Placenta (Cervical end 2) R-P2  
Right Placenta (Cervical end 3) R-P3  
Right Uterus (Cervical end) R-UT1  
Right Uterus (Middle) R-UT2  
Right Uterus (Ovarian end) R-UT3  
Left Uterine artery LU-A1  
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Left Radial artery (Cervical end 1) LR-A1  
Left Radial artery (Cervical end 2) LR-A2  
Left Radial artery (Cervical end 3) LR-A3  
Left Placenta (Cervical end 1) L-P1  
Left Placenta (Cervical end 2) L-P2  
Left Placenta (Cervical end 3) L-P3  
Left Uterus (Cervical end) L-UT1  
Left Uterus (Middle) L-UT2  
Left Uterus (Ovarian end) L-UT3  
Lung E-AU  
Heart E-H  
Ovary E-G  
Liver E-L  
Adrenal E-D  
Kidney E-K  
Spleen E-X  
Brain E-NC  
Retina E-Retina  
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FETUS Cervical end____
Tissue samples to be collected from each FETUS:
Blood, serum & plasma B
_________________________ code____ __ N2 PFA
Membranes Me  
Umbilical cord U  
Amniotic Fluid AF  
Lung AU  
Thymus T  
Heart H  
Spleen X  
Liver L  
Gonads Female Male G  
Adrenal glands D  
Kidney K  
Muscle M  
Skin S  
Brain NC  
Bone Marrow BM  
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Tissue samples collected for histology processing
Cassettes Tissues
1 Left UA1
2 Left RA1, Left RA2, Left RA3
3 Left uterus, Left placentae (1,2,3)
4 Right UA1
5 Right RA1, Right RA2, Right RA3
6 Right uterus, Right placentae (1,2,3)
7 Maternal ovary, liver, spleen
8 Maternal kidney, adrenal, heart, lung, thymus
9 Maternal brain
10 Maternal bone marrow
11 Fetal spleen, adrenal, kidney
12 Fetal heart, lung, thymus
13 Fetal gonad, liver
14 Fetal brain
15 Fetal muscle, skin
16 Fetal bone marrow
